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A B S T R A C T
Background
Parenteral opioids (intramuscular and intravenous drugs including patient-controlled analgesia) are used for pain relief in labour in
many countries throughout the world. This review is an update of a review first published in 2010.
Objectives
To assess the effectiveness, safety and acceptability to women of different types, doses and modes of administration of parenteral opioid
analgesia in labour. A second objective is to assess the effects of opioids in labour on the baby in terms of safety, condition at birth and
early feeding.
Search methods
We searched Cochrane Pregnancy and Childbirth’s Trials Register, ClinicalTrials.gov, the WHO International Clinical Trials Registry
Platform (ICTRP) (11 May 2017) and reference lists of retrieved studies.
Selection criteria
We included randomised controlled trials examining the use of intramuscular or intravenous opioids (including patient-controlled
analgesia) for women in labour. Cluster-randomised trials were also eligible for inclusion, although none were identified. We did not
include quasi-randomised trials. We looked at studies comparing an opioid with another opioid, placebo, no treatment, other non-
pharmacological interventions (transcutaneous electrical nerve stimulation (TENS)) or inhaled analgesia.
Data collection and analysis
Two review authors independently assessed trials for inclusion and risk of bias, extracted data and checked them for accuracy. We
assessed the quality of each evidence synthesis using the GRADE approach.
Main results
We included 70 studies that compared an opioid with placebo or no treatment, another opioid administered intramuscularly or
intravenously or compared with TENS applied to the back. Sixty-one studies involving more than 8000 women contributed data to
the review and these studies reported on 34 different comparisons; for many comparisons and outcomes only one study contributed
data. All of the studies were conducted in hospital settings, on healthy women with uncomplicated pregnancies at 37 to 42 weeks’
gestation. We excluded studies focusing on women with pre-eclampsia or pre-existing conditions or with a compromised fetus. Overall,
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the evidence was graded as low- or very low-quality regarding the analgesic effect of opioids and satisfaction with analgesia; evidence was
downgraded because of study design limitations, and many of the studies were underpowered to detect differences between groups and
so effect estimates were imprecise. Due to the large number of different comparisons, it was not possible to present GRADE findings
for every comparison.
For the comparison of intramuscular pethidine (50 mg/100 mg) versus placebo, no clear differences were found in maternal satisfaction
with analgesia measured during labour (number of women satisfied or very satisfied after 30 minutes: 50 women; 1 trial; risk ratio
(RR) 7.00, 95% confidence interval (CI) 0.38 to 128.87, very low-quality evidence), or number of women requesting an epidural
(50 women; 1 trial; RR 0.50, 95% CI 0.14 to 1.78; very low-quality evidence). Pain scores (reduction in visual analogue scale (VAS)
score of at least 40 mm: 50 women; 1 trial; RR 25, 95% CI 1.56 to 400, low-quality evidence) and pain measured in labour (women
reporting pain relief to be “good” or “fair” within one hour of administration: 116 women; 1 trial; RR 1.75, 95% CI 1.24 to 2.47,
low-quality evidence) were both reduced in the pethidine group, and fewer women requested any additional analgesia (50 women; 1
trial; RR 0.71, 95% CI 0.54 to 0.94, low-quality evidence).
There was limited information on adverse effects and harm to women and babies. There were few results that clearly showed that one
opioid was more effective than another. Overall, findings indicated that parenteral opioids provided some pain relief and moderate
satisfaction with analgesia in labour. Opioid drugs were associated with maternal nausea, vomiting and drowsiness, although different
opioid drugs were associated with different adverse effects. There was no clear evidence of adverse effects of opioids on the newborn.
We did not have sufficient evidence to assess which opioid drug provided the best pain relief with the least adverse effects.
Authors’ conclusions
Though most evidence is of low- or very-low quality, for healthy women with an uncomplicated pregnancy who are giving birth at
37 to 42 weeks, parenteral opioids appear to provide some relief from pain in labour but are associated with drowsiness, nausea, and
vomiting in the woman. Effects on the newborn are unclear. Maternal satisfaction with opioid analgesia was largely unreported. The
review needs to be examined alongside related Cochrane reviews. More research is needed to determine which analgesic intervention
is most effective, and provides greatest satisfaction to women with acceptable adverse effects for mothers and their newborn.
P L A I N L A N G U A G E S U M M A R Y
Intramuscular and intravenous opioid pain relieving drugs in labour
What is the issue?
We set out to determine the effectiveness, side effects and acceptability to women of different opioids (pain killers), the doses used and
how they are given during labour. We were also concerned about the effects of the opioids on the baby in terms of its safety, alertness
at birth and early feeding.
Uterine contractions cause pain during labour, particularly as they reach their peak. The pain lessens as the contraction goes and the
uterus relaxes. As labour progresses the uterine contractions become stronger, more frequent and longer lasting; at the same time they
become more painful. The strongest, most frequent, and most intense uterine contractions generally occur at the end of the first stage
of labour as the cervix reaches full dilatation. The mother then has the urge to push or bear down, which assists the birth of the baby.
The severity of the pain varies considerably from woman to woman, and is influenced by mental and emotional factors. For example,
continuous support during labour can help women to cope with the pain and help with their overall satisfaction with the childbirth
experience.
Why is this important?
In many maternity units, intramuscular injections of opioid drugs are widely used for pain relief in labour. Options for intravenous
administrations, often controlled by the woman, may also be available. Injected opioids can make women drowsy and interfere with
their ability to engage in decision making about their care. They may also experience nausea and vomiting. Opioids can increase
variations in fetal heart rate during labour and depress breathing. A number of different opioid drugs are available. The increasing use
of epidural analgesia in resource-rich countries means that opioids are now less likely to be the drugs of choice in these settings. Yet in
many parts of the world and in midwifery-led settings epidural analgesia is not available, and injected opioids are still widely used. They
are relatively inexpensive. It is not clear how effective these drugs are, which opioid is best, and how adverse effects (such as vomiting
or sleepiness) or harm to women or their babies can be avoided. This review is an update of a review first published in 2010.
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What evidence did we find?
We searched for trials on 11 May 2017. We included 70 studies though only 61 studies involving more than 8000 women contributed
data to the review. All of the trials were conducted in hospital settings, on healthy women with uncomplicated pregnancies at 37 to
42 weeks’ gestation. The trials compared an opioid (intramuscular or intravenous) with placebo (dummy treatment), no treatment,
another opioid (or in three trials another medication or inhaled nitrous oxide) or transcutaneous electrical nerve stimulation (TENS)
in 34 different comparisons. There were few opportunities to pool the findings, and for many outcomes only one trial contributed
findings. The quality of the evidence was mainly assessed as low or very low for the outcomes of pain in labour and satisfaction with
analgesia. Many of the studies included insufficient numbers of women to detect differences between groups.
What does this mean?
Overall, our findings indicate that opioids provided some pain relief during labour, although substantial proportions of women still
reported moderate or severe pain. Opioid drugs were associated with nausea, vomiting and drowsiness, with different types of opioids
causing different side effects. We did not have sufficient evidence to assess which opioid drug provided the best pain relief with the least
adverse effects. Nor did we find clear evidence of adverse effects of opioids on the newborn. Maternal satisfaction with opioid analgesia
appeared moderate although it was often unreported or reported in different ways. We did not have sufficient evidence to assess which
opioid drugs women were most satisfied with.
In this review we did not examine the effectiveness and safety of intramuscular or intravenous opioids compared with other methods
of pain relief in labour such as epidural analgesia. The review needs to be examined alongside related Cochrane reviews. As injected
opioid drugs are so widely used it is important that more research is carried out so that women can make informed choices about pain
relief.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
IM pethidine compared to placebo for pain management for women in labour
Patient or population: women in labour
Setting: hospital sett ings in South Af rica and Hong Kong
Intervention: IM pethidine 50 mg/ 100 mg
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with IM pethidine
50 mg/100 mg
Risk with placebo
Maternal sat isfact ion
with analgesia mea-
sured during labour
(number of women sat-
isf ied or very sat isf ied
af ter 30 minutes)
Study populat ion RR 7.00
(0.38 to 128.87)
50
(1 RCT)
⊕©©©
VERY LOW 12
0 per 1000
(0 to 0)
0 per 1000
Maternal pain score
or pain measured in
labour (described as
good or fair af ter 1
hour)
Study populat ion RR 1.75
(1.24 to 2.47)
116
(1 RCT)
⊕⊕©©
LOW 13
724 per 1000
(513 to 1000)
414 per 1000
Maternal pain score
or pain measured in
labour (reduct ion in
VAS of at least 40 mm
af ter 30 minutes)
Study populat ion RR 25.00
(1.56 to 400.54)
50
(1 RCT)
⊕⊕©©
LOW 14
0 per 1000
(0 to 0)
0 per 1000
Addit ional analgesia re-
quired (epidural, pethi-
dine and Entonox)
Study populat ion RR 0.71
(0.54 to 0.94)
50
(1 RCT)
⊕⊕©©
LOW 13
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682 per 1000
(518 to 902)
960 per 1000
Epidural Study populat ion RR 0.50
(0.14 to 1.78)
50
(1 RCT)
⊕©©©
VERY LOW 12
120 per 1000
(34 to 427)
240 per 1000
* SEE ADDITIONAL Table 1FOR FURTHER GRADE COMPARISONS*
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: we are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: we have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Risk of bias: serious (ef fect est imate f rom single study with design lim itat ions)
2 Imprecision: very serious (wide conf idence interval crossing the line of no ef fect, few events, and small sample size)
3 Imprecision: serious (small sample size)
4 Imprecision: serious (small sample size and few events)
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B A C K G R O U N D
This review was last published in 2010 (Ullman 2010) as one of a
series of Cochrane reviews examining pain management in labour.
These reviews contributed to an overview of systematic reviews of
pain management for women in labour (Jones 2012), and shared
a generic protocol (Jones 2011). This current review is an update
from the previous version (Ullman 2010).
Description of the condition
Pain during labour is a physiological phenomenon, being one of
the few examples of pain which does not signal pathology or harm.
This does not make the experience of pain any less, but it may
alter the way pain is perceived, both by the labouring woman and
those providing her care.
Pain during labour is intermittent; it accompanies uterine contrac-
tions, particularly as they reach their peak with the activation of
oxytocin receptors around the cervix, and then diminishes as the
contraction goes and the uterus relaxes (Eisenach 2010). Between
contractions the uterus is at rest and there is usually no associated
pain. As labour progresses the uterine contractions grow stronger,
more frequent and longer lasting; at the same time they become
more painful. Typically, the strongest, most frequent, and most
intense uterine contractions occur at the end of the first stage of
labour as the cervix reaches full dilatation. While the vast majority
of women will describe at least some stages of labour as painful,
the severity of reported pain varies considerably (Jones 2011a).
Pain relief in labour - physiology and pain perceptions
Labour pain as perceived by women is a unique, subjective and
complex neuro-hormonal phenomenon, which involves the inter-
action of physiological and psychological factors (Genesi 1998a;
Genesi 1998b; Trout 2004). Several factors have been shown to
reduce pain experienced by women in labour. These include con-
tinuous support of a caregiver, attendance of a birth companion
and a relaxed birth environment (Bohren 2017; Hodnett 2012;
Sandall 2016). Additional key determinants that may influence
the pain that a woman experiences are feeling in control, level of
anxiety, her rapport with her caregivers and her birth companions,
and the care setting where she gives birth (Anim-Somuah 2018;
Klomp 2014; Lang 2006). Having more control fosters a woman’s
sense of self-belief and confidence in her capacity to labour and
give birth, which also affects her pain perception (Cook 2012;
Lowe 2002). The extent to which a woman can actively partic-
ipate in negotiating the care she receives has also been linked to
overall maternal satisfaction with the childbirth experience (Green
2003; Hodnett 2002). The degree to which a woman is satisfied
with the birth experience is not, therefore, solely associated with
the pain felt. From the clinical point of view, the management of
pain during labour involves much more than simply the provision
of a pharmacological intervention. It is important that decisions
for coping with the pain of labour are based on informed choice
(Green 2003; Hawkins 2003).
Practitioners’ attitudes tomaternal pain vary (Leap 2004). Charac-
teristics such as philosophical perspective, length of time in prac-
tice, knowledge and experience, care setting, cultural differences,
and beliefs may all influence the approach midwives will adopt
when caring for women during labour; some adopt a rescue posi-
tion to relieve the pain and recommend the use of analgesia, whilst
others facilitate the woman to optimise coping mechanisms, using
strategies involving breathing and/or relaxation techniques and
positions that offer her more comfort (Aziato 2016; Lally 2014;
Lamm 2007; Leap 2004; Williams 2013).
Women’s attitudes towards, and preferences for, intrapartum pain
relief vary widely.Whilst somewomen prefer to labour without the
use of pharmacological analgesia, others opt, for example, to use
epidural analgesia throughout labour. Good communication and
sensitive support from caregivers improves a woman’s experience
of labour, and her overall satisfaction with care, regardless of her
choice of pain relief or levels of reported pain (Hodnett 2002). It
is important that decisions for coping with the pain of labour are
based on informed choice (Green 2003; Hawkins 2003).
Description of the intervention
Pain relief in labour - the use of opioids
The use of pain-relieving drugs during labour is now standard
care in many countries throughout the world (Bricker 2002; Tveit
2009;Wong 2009). The extent of usage of parenteral (intramuscu-
lar and intravenous drugs including patient-controlled analgesia)
opioids during labour is unclear; however, most obstetric units in
middle- and high-income countries offer intramuscular opioids,
along with facilities for epidural analgesia. Opioids are relatively
inexpensive, and use of the opioid drugs pethidine, meptazinol or
diamorphine during labour is common midwifery and obstetric
practice in some countries. In other parts of the world, parenteral
opioids commonly used in labour include morphine, nalbuphine,
fentanyl and remifentanil (Evron 2007). Worldwide, pethidine
is the most commonly used opioid (Bricker 2002; Wong 2009).
Other opioids include: meperidine, butorphanol, buprenorphine,
pentazocine, tramadol, alfentanil and sufentanil. In theUK, amid-
wife can take responsibility for giving a woman an intramuscular
injection of either pethidine or diamorphine, without a prescrip-
tion from a medical practitioner, whether she is working in the
hospital or community care setting (MHRA 2007).
In the UK, data from a random sample of 4571 women who
gave birth over a two-week period during 2014 showed that 25%
used pethidine or a similar opioid during labour (Redshaw 2015).
This reflects a decreasing trend in parenteral opioid use from 33%
of women in a similar survey in 2006 (Redshaw 2007). In con-
trast, reported epidural/regional analgesia use has remained con-
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stant; 28% in 2006 (Redshaw 2007), and 29% in 2014 (Redshaw
2015). This latest survey indicates a higher proportion of nul-
liparous women using an opioid (with or without an epidural)
compared with multiparous women (Redshaw 2015). Studies in
New Zealand and the UK have revealed that more than 95% of
hospitals surveyed routinely offered intramuscular pethidine (Lee
2004; Saravanakumar 2007). In the UK study, approximately half
(49%) of the units surveyed offered patient-controlled intravenous
opioid analgesia for use in labour (Saravanakumar 2007).
Some maternity practitioners have voiced concerns about the use
of parenteral opioid analgesia during labour. These centre ondoubt
about analgesic effectiveness, and anxiety about the sedative effects
on women and babies. Concerns relating to maternal outcomes
include an impaired capacity to engage in decision making about
care, nausea and/or vomiting, and the slowing down of gastric
emptying, which increases the risk of inhalation of gastric contents
should a general anaesthetic be required in an emergency situation.
If a woman feels drowsy or sedated, she is less likely to mobilise
and adopt an upright position, and as a result this may lengthen
her labour, and make it more painful (Lawrence 2013). These
concerns are particularly relevant to midwives who are caring for
women inmidwifery-led community settingswhere strategies such
as mobilisation and water immersion are implemented to optimise
labour progress.
Effects on the baby
Opioids readily cross the placenta by passive diffusion, and
have been shown to compromise fetal well-being during labour
(Reynolds 2002; Sosa 2006). Pethidine has been shown to signif-
icantly affect fetal heart rate variability, accelerations and deceler-
ations during labour (Solt 2002). Changes in normal fetal heart
indices have consequences for the woman. She will be required
to have electronic fetal heart rate monitoring (EFM) if she is in
hospital, and transfer to hospital if she is in a community setting.
Results from observational studies have reported effects of opi-
oids on the newborn that include inhibited sucking at the breast
and decreased alertness, resulting in delayed effective breastfeeding
(Brimdyr 2015; Fleet2017; Jordan2005; Lind 2014;Nissen1995;
Ransjo-Arvidson 2001; Righard 1990). There is clear evidence
showing that early skin-to-skin contact and the successful onset
of early breastfeeding have major benefits for mothers and their
babies with far-reaching benefits into adulthood (Aghdas 2014;
Carberry 2013; Moore 2016; Victora 2016; Widstrom 2011). It
has been suggested that interventions which compromise this con-
tact and early suckling can impact on neonatal mortality (Edmond
2006). It is estimated that it can take a newborn three to six days
to eliminate pethidine, and its metabolite, norpethidine, from its
system (Hogg 1977).
How the intervention might work
Opioid drugs are narcotic drugs that work by binding to opi-
oid receptors in the brain and spinal cord, thereby inhibiting the
transmission of pain signals. A range of opioids have been used
to treat both acute and chronic pain, and they are often used to
control cancer pain. Opioids have mainly been used to treat mod-
erate and severe pain. Although opioids have been used to treat
pain in labour for many years, there have been concerns about
their use relating to their sedative effects, and questions have been
raised about their effectiveness in labour and about their safety for
women and babies (Lawrence 2013).
Why it is important to do this review
This review evaluates the effectiveness and safety of parenteral opi-
oids for analgesia in labour. The use of intramuscular injections
of opioid analgesia in labour became a traditional part of mid-
wifery practice without evidence from randomised controlled tri-
als demonstrating analgesic effectiveness, impact on labour out-
comes or acceptability to women. It is thought that the perceived
analgesic efficacy of parenteral opioids may be due, at least in part,
to their sedative effects rather than a true reduction in maternal
pain perception (NICE 2014; Wong 2009). There remains un-
certainty amongst practitioners as to which opioid provides the
most effective pain relief, and whether opioids used during labour
are acceptable to women. The most effective and acceptable mode
of administration also remains unknown. In addition, there are
concerns about the potential adverse effects associated with the
use of opioids in labour, particularly the effects on the newborn
in relation to infant feeding.
At present, the choice of opioid for analgesia in labour depends on
what is available in different hospitals. However, no matter what
facilities and drugs are available, women often have no choice as to
which drug is used, and healthcare professionals have little infor-
mation to guide decision-making. Whilst there have been previous
reviews on this topic (Bricker 2002; Elbourne 2006), this review
provides an up-to-date summary of existing knowledge.We aim to
provide best evidence to facilitate discussions between maternity
practitioners and women to enable them to make informed deci-
sions about their choice of analgesia during labour. This review is
an update of a review first published in 2010 (Ullman 2010).
O B J E C T I V E S
To assess the effectiveness, safety and acceptability to women of
different types, doses and modes of administration of parenteral
opioid analgesia in labour. A second objective is to assess the effects
of opioids in labour on the baby in terms of safety, condition at
birth and early feeding.
7Parenteral opioids for maternal pain management in labour (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials. Cluster-randomised trials were also
eligible for inclusion, although none were identified. We did not
include quasi-randomised or cross-over trials. Trials using a cross-
over design are not suitable for interventions in labour. We in-
cluded studies presented only in abstracts provided that there was
enough information to allow us to assess eligibility and risk of
bias; if there was insufficient information we attempted to contact
study authors.
Types of participants
Women in labour. We excluded studies focusing specifically and
exclusively on women in high-risk groups, or women in prema-
ture labour (before 37 weeks’ gestation), but have included studies
which include such women as part of a broader sample.
Types of interventions
Parenteral opioids (intramuscular and intravenous drugs, includ-
ing patient-controlled analgesia).
Drugs for comparison include pethidine ormeperidine,morphine,
nalbuphine, butorphanol, diamorphine, buprenorphine, meptazi-
nol, pentazocine, tramadol, alfentanil, sufentanil, remifentanil and
fentanyl.
The following comparisons were eligible for the review.
1. An opioid versus placebo using the same route of
administration.
2. An opioid versus another opioid using the same route of
administration.
3. An opioid plus an add-on drug versus another opioid plus
the same add-on drug using the same route of administration.
4. One opioid versus the same opioid but a different dose.
We planned to use trialists’ definitions of higher and lower doses
of the same drugs, as high and low doses are different for different
opioids.
Where different doses of the same drug were compared with the
same comparator (e.g. 40 mg pethidine versus placebo, and 80 mg
pethidine versus placebo), we planned to use subgroup analyses to
examine findings.
This previous version of this review was one in a series of Cochrane
reviews examining painmanagement in labour. These reviews con-
tributed to an overview of systematic reviews of interventions for
pain management in labour (Jones 2012), and shared a generic
protocol (Jones 2011). To avoid duplication, the different meth-
ods of pain management were listed in a specific order, from one
to 15. Individual reviews focusing on particular interventions in-
cluded comparisons with only the interventions above it on the
list. The current list is as follows.
1. Placebo
2. No treatment
3. Hypnosis (Madden 2016)
4. Biofeedback (Barragán 2011)
5. Intracutaneous or subcutaneous sterile water injection
(Derry 2012)
6. Immersion in water (Cluett 2009)
7. Aromatherapy (Smith 2011a)
8. Relaxation techniques (yoga, music, audio) (Smith 2018a)
9. Acupuncture or acupressure (Smith 2011b)
10. Massage, reflexology and other manual methods (Smith
2018b)
11. Transcutaneous electrical nerve stimulation (TENS)
(Dowswell 2009)
12. Inhaled analgesia (Klomp 2012)
13. Opioids (this review)
14. Non-opioid drugs (Othman 2012)
15. Local anaesthetic nerve blocks (Novikova 2011)
16. Epidural (including combined spinal epidural)
(Anim-Somuah 2018; Simmons 2012)
Accordingly, this review includes comparisons of an opioid with:
1. placebo/no treatment; 2. hypnosis; 3. biofeedback; 4. intracu-
taneous or subcutaneous sterile water injection; 5. immersion in
water; 6. aromatherapy; 7. relaxation techniques (yoga, music, au-
dio); 8. acupuncture or acupressure; 9. manual methods (massage,
reflexology); 10. TENS; 11. inhaled analgesia; or 12. another opi-
oid (as specified above).
Types of outcome measures
Primary outcomes
1. Maternal satisfaction with analgesia measured during labour
2. Maternal satisfaction with analgesia in labour measured
during the postnatal period
Secondary outcomes
For women
1. Maternal pain score or pain measured in labour
2. Additional analgesia required
3. Epidural
4. Maternal sleepiness during labour
5. Nausea and vomiting in labour
6. Caesarean section
7. Assisted vaginal birth
8. Postpartum haemorrhage (as defined by the trial authors)
9. Breastfeeding at discharge
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10. Breastfeeding in the postnatal period (four to six weeks)
11. Sense of control in labour (as defined by trialists)
12. Satisfaction with childbirth experience (as defined by
trialists)
13. Effect (negative) on mother/baby interaction
For babies
1. Fetal heart rate changes in labour (persistent decelerations
or tachycardia)
2. Naloxone administration
3. Neonatal resuscitation
4. Apgar score less than seven at one minute
5. Apgar score less than seven at five minutes
6. Apgar score less than seven at ten minutes
7. Admission to special care baby unit/neonatal intensive care
unit (as defined by trialists)
8. Newborn neuro-behavioural scores
9. Neurodevelopment outcomes during infancy
Other
1. Cost (as defined by trialists)
Search methods for identification of studies
The following search methods section of this review is based on a
standard template used by Cochrane Pregnancy and Childbirth.
Electronic searches
We searched Cochrane Pregnancy and Childbirth’s Trials Register
by contacting their Information Specialist (11 May 2017).
The Register is a database containing over 24,000 reports of con-
trolled trials in the field of pregnancy and childbirth. For full search
methods used to populate Pregnancy andChildbirth’s Trials Regis-
ter including the detailed search strategies for CENTRAL, MED-
LINE, Embase and CINAHL; the list of handsearched journals
and conference proceedings, and the list of journals reviewed via
the current awareness service, please follow this link to the edi-
torial information about the Cochrane Pregnancy and Childbirth
in the Cochrane Library and select the ‘Specialized Register ’ sec-
tion from the options on the left side of the screen.
Briefly, Cochrane Pregnancy and Childbirth’s Trials Register is
maintained by their Information Specialist and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Search results are screened by two people and the full text of
all relevant trial reports identified through the searching activi-
ties described above is reviewed. Based on the intervention de-
scribed, each trial report is assigned a number that corresponds
to a specific Pregnancy and Childbirth review topic (or topics),
and is then added to the Register. The Information Specialist
searches the Register for each reviewusing this topic number rather
than keywords. This results in a more specific search set that has
been fully accounted for in the relevant review sections (Included
studies; Excluded studies; Studies awaiting classification; Ongoing
studies).
In addition, we searched ClinicalTrials.gov and the WHO Inter-
national Clinical Trials Registry Platform ( ICTRP) for unpub-
lished, planned and ongoing trial reports using the methods de-
tailed in Appendix 1 (searched 11 May 2017).
Searching other resources
We searched the reference lists of background review articles and
the reference lists of papers retrieved by the search.
We did not apply any language or date restrictions.
Data collection and analysis
For methods used in the previous version of this review, seeUllman
2010.
For this update, the following methods were used for assessing the
70 reports that were identified as a result of the updated search.
The followingmethods section of this review is based on a standard
template used by Cochrane Pregnancy and Childbirth.
Selection of studies
In this update two review authors (A Cuthbert (AC), Lesley Smith
(LS) independently assessed for inclusion all the new reports iden-
tified as a result of the search strategy. We resolved any disagree-
ment through discussion or, if required, we consulted a third au-
thor (E Burns).
Data extraction and management
For eligible studies, two same two review authors extracted the
data using an agreed form. We resolved discrepancies through
discussion or, if required, we consulted the third review author.
Data were entered into ReviewManager software (RevMan 2014)
and checked for accuracy.
When information regarding any of the above was unclear, we
contacted authors of the original reports to provide further details.
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Assessment of risk of bias in included studies
Two review authors independently assessed risk of bias for each
study using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011a). Any disagree-
ment was resolved by discussion or by involving the third assessor.
(1) Random sequence generation (checking for possible
selection bias)
We described the method used to generate the allocation sequence
in sufficient detail to allow an assessment of whether it should
produce comparable groups.
For each included study we assessed the method as being at:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
For each included study we described the method used to con-
ceal allocation to interventions prior to assignment and assessed
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We assessed the methods as being at:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
For each included study we described the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered that studies
were at low risk of bias if theywere blinded, or if we judged that the
lack of blinding was unlikely to affect results. We assessed blinding
separately for different outcomes or classes of outcomes.
We assessed the methods as being at:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
For each included study we described the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received. We assessed blinding separately for different
outcomes or classes of outcomes.
We assessed methods used to blind outcome assessment as being
at:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
For each included study, and for each outcome or class of out-
comes, we described the completeness of data including attrition
and exclusions from the analysis. We stated whether attrition and
exclusions were reported and the numbers included in the analysis
at each stage (compared with the total randomised participants),
reasons for attrition or exclusion where reported, and whether
missing data were balanced across groups or were related to out-
comes. Where sufficient information was reported, or could be
supplied by the trial authors, we planned to re-include missing
data in the analyses that we undertook.
We assessed methods as being at:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomisation);
• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
For each included study we described how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as being at:
• low risk of bias (where it was clear that all of the study’s
prespecified outcomes and all expected outcomes of interest to
the review have been reported);
• high risk of bias (where not all the study’s prespecified
outcomes were reported; one or more reported primary
outcomes were not prespecified; outcomes of interest were
reported incompletely and so could not be used; study failed to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
For each included study we described any important concerns we
had about other possible sources of bias.
(7) Overall risk of bias
We made explicit judgements about whether studies were at high
risk of bias, according to the criteria given in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011a). With
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reference to (1) to (6) above, we planned to assess the likely mag-
nitude and direction of the bias and whether we considered it was
likely to have an impact on the findings. In future updates, we
will explore the impact of the level of bias through undertaking
sensitivity analyses (Sensitivity analysis).
Measures of treatment effect
Dichotomous data
For dichotomous data, we presented results as summary risk ratio
with 95% confidence intervals.
Continuous data
We used the mean difference if outcomes were measured in the
same way between trials. In future updates as appropriate, we
will use the standardised mean difference to combine trials that
measure the same outcome, but use different methods.
Unit of analysis issues
Cluster-randomised trials
We intended to include cluster-randomised trials in the analyses
along with individually-randomised trials, no cluster-randomised
trials were identified for inclusion in this version of the review.
If such trials are identified in future updates, we will adjust their
sample sizes using themethods described in theHandbook using an
estimate of the intracluster correlation co-efficient (ICC) derived
from the trial (if possible), from a similar trial or from a study of
a similar population. If we use ICCs from other sources, we will
report this and conduct sensitivity analyses to investigate the effect
of variation in the ICC. If we identify both cluster-randomised
trials and individually-randomised trials, we plan to synthesise the
relevant information. We will consider it reasonable to combine
the results from both if there is little heterogeneity between the
study designs and the interactionbetween the effect of intervention
and the choice of randomisation unit is considered to be unlikely.
We will also acknowledge heterogeneity in the randomisation unit
and perform a sensitivity analysis to investigate the effects of the
randomisation unit.
Cross-over trials
Trials using a cross-over design are not suitable for interventions
in labour and were not included.
Other unit of analysis issues
In this update, trials with more than two treatment groups only
contributed data into different comparisons and so unit of analysis
error was not an issue. In future updates, where necessary, we will
follow the methods as described in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011b, Section 16.5.4)
in order to avoid unit of analysis errors (combine groups to create
a single pair-wise comparison, divide the control group between
intervention arms to avoid double-counting or select one pair of
interventions and exclude others).
Dealing with missing data
For included studies, we noted levels of attrition. In future updates,
if more eligible studies are included in any of the comparisons,
we will explore the impact of including studies with high levels of
missing data in the overall assessment of treatment effect by using
sensitivity analysis.
For all outcomes, we carried out analyses, as far as possible, on an
intention-to-treat basis, i.e. we attempted to include all partici-
pants randomised to each group in the analyses. The denominator
for each outcome in each trial was the number randomised minus
any participants whose outcomes were known to be missing.
Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
the Tau², I² and Chi² statistics. We regarded heterogeneity as sub-
stantial if an I² was greater than 30% and either a Tau² was greater
than zero, or there was a low P value (less than 0.10) in the Chi²
test for heterogeneity. Had we identified substantial heterogeneity
(above 30%), we planned to explore it by pre-specified subgroup
analysis.
Assessment of reporting biases
In future updates, if there are 10 or more studies in the meta-
analysis we will investigate reporting biases (such as publication
bias) using funnel plots. We will assess funnel plot asymmetry
visually. If asymmetry is suggested by a visual assessment, we will
perform exploratory analyses to investigate it.
Data synthesis
We carried out statistical analysis using the Review Manager soft-
ware (RevMan 2014).We used fixed-effect meta-analysis for com-
bining data where it was reasonable to assume that studies were
estimating the same underlying treatment effect: i.e. where trials
were examining the same intervention, and the trials’ populations
and methods were judged sufficiently similar.
If there was clinical heterogeneity sufficient to expect that the un-
derlying treatment effects differed between trials, or if substan-
tial statistical heterogeneity was detected, we used random-effects
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meta-analysis to produce an overall summary if an average treat-
ment effect across trials was considered clinically meaningful. The
random-effects summary was treated as the average range of possi-
ble treatment effects and we discussed the clinical implications of
treatment effects differing between trials. If the average treatment
effect was not clinically meaningful, we did not combine trials.
Where we used random-effects analyses, we presented the results
as the average treatment effect with 95% confidence intervals, and
the estimates of Tau² and I².
Subgroup analysis and investigation of heterogeneity
We intended to conduct planned subgroup analysis using the
methods described by Deeks 2001 and set out in the Cochrane
Handbook for Systematic Reviews (Higgins 2011a).
We had planned to carry out the following subgroup analyses.
1. By parity (nulliparous versus multiparous women).
2. By spontaneous versus induced or augmented labour.
3. Term versus preterm birth.
4. Continuous support in labour versus no continuous
support.
Where different doses of the same drug were examined (e.g. pethi-
dine 40 mg or pethidine 80 mg versus a placebo), we separated
analyses into subgroups to examine the impact of different doses.
We planned to assess subgroup differences by interaction tests
available within RevMan (RevMan 2014) reporting the results of
subgroup analyses quoting the Chi² statistic and P value, and the
interaction test I² value. In this version of the review there were
too few studies contributing data to any particular comparison to
make such additional analyses worthwhile. If more data become
available in the future we will carry out planned subgroup analysis.
Sensitivity analysis
We planned to carry out sensitivity analyses to explore the effect
of risk of bias for important outcomes in the review. Where there
was risk of bias associated with a particular risk of bias domain
(e.g. inadequate allocation concealment), we planned to explore
this by temporarily excluding studies at high risk of bias to see if
this had any impact on the results. In this version of the review
we did not carry out this planned analysis due to too few studies
contributing data.
Summary of findings tables
For this update we assessed the quality of the evidence using the
GRADE approach as outlined in the GRADE handbook; we as-
sessed the quality of the body of evidence relating to the following
outcomes.
1. Maternal satisfaction with analgesia measured during labour
2. Maternal satisfaction with analgesia in labour measured
during the postnatal period
3. Maternal pain score or pain measured in labour
4. Additional analgesia required
Selecting the most important comparisons for GRADE and the
’Summary of findings’ tables was not simple, as different types and
routes of opioid drugs are used in different parts of the world and
in different settings. We therefore created a single table summaris-
ing findings for pain outcomes for all comparisons which involved
an opioid versus placebo/no treatment, or where comparisons in-
cluded pethidine as a control group. Whilst there are several other
comparisons between different opioids in the review, most were
reported in single studies which were of low quality.
We used the GRADEpro Guideline Development Tool to import
data from Review Manager 5.3 (RevMan 2014) in order to create
the ’Summary of findings’ tables. We produced a summary of the
intervention effect and a measure of quality for each of the above
outcomes using the GRADE approach. The GRADE approach
uses five considerations (study limitations, consistency of effect,
imprecision, indirectness and publication bias) to assess the quality
of the body of evidence for each outcome. The evidence can be
downgraded from ’high quality’ by one level for serious (or by
two levels for very serious) limitations, depending on assessments
for risk of bias, indirectness of evidence, serious inconsistency,
imprecision of effect estimates or potential publication bias.
R E S U L T S
Description of studies
Results of the search
See: Figure 1.
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Figure 1. Study flow diagram.
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We retrieved 656 citations from the updated search in May 2017.
We screened out 586 (not scope or not a trial), and assessed 70
trial reports which related to 54 new trials. We included 13 new
trials and excluded 34 trials. Two trials are awaiting classification
(Mohan 2015; Sereshti 2013), and five are ongoing (Kokki 2015;
Raheja 2016; Reyes 2013; Sahin 2012; Shen 2008).
Included studies
Altogther in this update we have included 70 studies, 61 of which
contributed data. The studies that contributed data involvedmore
than 8000 women (see Characteristics of included studies).
Trials with more than two arms may be included in more than
one comparison. Nine studies did not contribute any data to this
review: Fieni 2000; Kamyabi 2003; Kermani 2015; Lalooha 2017;
Lisboa 1997; Tharamas 1999; Wahab 1988; Wali 2012; Zhu
2013.
Design
All included studieswere randomised controlled trials although the
randomisation method was not always well described. All studies
involved two trial arms except for Douma 2010, Kainz 1992, and
Nelson 2005, which had three trial arms, and Liu 2015, which
had four although only three were relevant to this review.
All women were randomised in labour. Though most studies do
not report specifically when randomisation took place, 26 studies
reported that women were randomised when they requested pain
relief (Atkinson 1994; Campbell 1961; Frank 1987; Kainz 1992;
Khooshideh 2009; Lardizabal 1999; Li 1988; Mitterschiffthaler
1991; Morley-Forster 2000; Morrison 1987; Mowat 1970; Nel
1981; Nelson 2005; Nicholas 1982; O’Dwyer 1971; Osler 1987;
Prasertsawat 1986; Rayburn 1989a; Refstad 1980; Sekhavat 2009;
Sheikh 1986; Sliom 1970; Tsui 2004; Viegas 1993; Volikas 2001;
Wilson 1986).
Participants
All studies included healthy pregnant women in either induced
or spontaneous early labour. All women were classed as having a
’low-risk’ pregnancy. Most studies included both nulliparous and
multiparous women, or did not specify parity. Thirteen studies
included nulliparous women only (Direkvand-Moghadam 2014;
El-Refaie 2012; Hamann 1972; Kamyabi 2003; Keskin 2003;
Lalooha 2017; Levy 1971; Li 1988; Olofsson 1996; Tawfik 1982;
Tharamas 1999; Viegas 1993; Zhu 2013), and two included mul-
tiparous women only (Jahani 2013; Wahab 1988).
Interventions and comparisons
Most of the studies included in the review examined an opioid
drug administered intramuscularly (IM) and comparedwith either
a placebo, no treatment, or with another opioid. A smaller number
of studies examined opioid drugs administered intravenously (IV),
sometimes with a degree of patient control over the amount of
drug infused (patient-controlled anaesthesia; PCA). None of the
included studies examined subcutaneous administration of opi-
oids. Some of the studies compared opioids with other non-phar-
macological interventions such as transcutaneous electrical nerve
stimulation (TENS) (four studies).
IM comparisons
1. IM pethidine versus IM placebo (all studies used saline as
placebo) (four studies) (Direkvand-Moghadam 2014; Sekhavat
2009; Sliom 1970; Tsui 2004).
2. IM pentazocine versus placebo (saline placebo) (one study)
(Zafar 2016).
3. IM tramadol versus no treatment (one study) (Li 1994).
4. IM meptazinol versus IM pethidine (eight studies) (De
Boer 1987; Jackson 1983; Morrison 1987; Nel 1981; Nicholas
1982; Osler 1987; Sheikh 1986; Wheble 1988) (in the studies
by De Boer 1987 and Jackson 1983, women in both study
groups also received add-on drugs).
5. IM diamorphine + prochlorperazine versus IM pethidine +
prochlorperazine (one study) (Fairlie 1999).
6. IM tramadol versus IM pethidine (six studies) (Bitsch 1980;
Husslein 1987; Keskin 2003; Khooshideh 2009; Prasertsawat
1986; Viegas 1993). Fieni 2000 did not contribute any data.
7. IM tramadol + triflupromazine versus pethidine +
triflupromazine (one study) (Kainz 1992).
8. IM dihydrocodeine versus IM pethidine (one study) (Sliom
1970).
9. IM pentazocine versus IM pethidine (six studies) (Borglin
1971; Duncan 1969; Levy 1971; Moore 1970; Mowat 1970;
Refstad 1980).Refstad 1980 gave both group promazine -
subtotals only reported.
10. IM nalbuphine versus IM pethidine (three studies)
(Lardizabal 1999; Mitterschiffthaler 1991; Wilson 1986).
11. IM phenazocine versus IM pethidine (one study) (Grant
1970).
12. IM morphine or diamorphine versus pethidine (two
studies) (Prasertsawat 1986; Wee 2014).
13. IM butorphanol versus IM pethidine (one study) (Maduska
1978).
14. IM pentazocine versus a spasmolytic drug (Avacan ®) (one
study) (Hamann 1972).
15. IM pentazocine versus IM Pethilorphan® (one study)
(O’Dwyer 1971).
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16. IM pentazocine versus complementary and alternative
medicine (one study) (Zafar 2016).
17. IM pentazocine versus IM tramadol (one study) (Kuti
2008).
18. IM pethidine versus inhaled nitrous oxide (one study)
(Mobaraki 2016).
IV comparisons
1. IV pethidine versus placebo (one study) (El-Refaie 2012).
2. IV fentanyl versus no treatment (one study) (Jahani 2013).
3. IV fentanyl versus IV pethidine (one study) (Rayburn
1989).
4. IV nalbuphine versus IV pethidine (one study) (Giannina
1995).
5. IV phenazocine versus IV pethidine (one study) (Olson
1964).
6. IV butorphanol versus IV pethidine (three studies)
(Hodgkinson 1979; Nelson 2005; Quilligan 1980).
7. IV morphine versus IV pethidine (two studies) (Campbell
1961; Olofsson 1996).
8. IV alphaprodine (Nisentil) versus IV pethidine (one study)
(Gillam 1958).
9. IV fentanyl versus butorphanol (one study) (Atkinson
1994).
IV/PCA comparisons
1. PCA pentazocine versus PCA pethidine (one study)
(Erskine 1985).
2. PCA remifentanil versus PCA pethidine (three studies)
(Blair 2005; Douma 2010; Volikas 2001).
3. PCA nalbuphine versus PCA pethidine (one study) (Frank
1987).
4. PCA fentanyl versus PCA alfentanil (one study)
(Morley-Forster 2000).
5. PCA fentanyl versus PCA pethidine (one study) (Douma
2010).
IM/PCA comparisons
1. IM meptazinol PCA versus IM pethidine PCA
administration (one study) (Li 1988).
Opioids versus TENs
1. IV pethidine (50 mg) versus TENS to lower back
(Neumark 1978), IM pethidine (50 mg) versus TENS to back
(Tawfik 1982), IM tramadol (100 mg) versus TENS to back
(Thakur 2004), PCA ondansetron and tramadol versus Han’s
acupoint nerve stimulator (Liu 2015).
Outcomes
There are pain outcomes reported under most comparisons in-
cluding maternal satisfaction with analgesia, pain severity, or ad-
ditional analgesia required. The way that pain outcomes were re-
ported in studies were not consistent. Adverse effects, neonatal
outcomes, and costs were not reported in all the studies.
Setting
All studies took place in hospital settings. Most studies were con-
ducted in the USA (Atkinson 1994; Campbell 1961; Giannina
1995; Gillam 1958; Hodgkinson 1979; Levy 1971; Maduska
1978; Nelson 2005; Olson 1964; Quilligan 1980; Rayburn
1989a), or the UK (Blair 2005; De Boer 1987; Duncan 1969;
Fairlie 1999; Frank 1987;Grant 1970; Jackson 1983;Moore 1970;
Morrison 1987; Mowat 1970; Nicholas 1982; O’Dwyer 1971;
Sheikh 1986; Volikas 2001; Wee 2014; Wheble 1988; Wilson
1986). Eight were conducted in Iran (Direkvand-Moghadam
2014; Jahani 2013; Kamyabi 2003; Kermani 2015; Khooshideh
2009; Lalooha 2017; Mobaraki 2016; Sekhavat 2009), three each
in Germany (Bitsch 1980; Kainz 1992; Mitterschiffthaler 1991),
Egypt (El-Refaie 2012; Tawfik 1982; Wahab 1988), South Africa
(Erskine 1985; Nel 1981; Sliom 1970), and China (Li 1988; Li
1994; Liu 2015), and one in each of the Netherlands (Douma
2010), Italy (Fieni 2000), Austria (Husslein 1987), Turkey (Keskin
2003), Nigeria (Kuti 2008), Argentina (Lardizabal 1999), Brazil
(Lisboa 1997), Canada (Morley-Forster 2000), Sweden (Olofsson
1996), Denmark (Osler 1987), Thailand (Prasertsawat 1986),
Norway (Refstad 1980), India (Thakur 2004), Hong Kong (Tsui
2004), Singapore (Viegas 1993), and Pakistan (Zafar 2016).
Six studies did not explicitly state where they were conducted
(Borglin 1971; Hamann 1972; Neumark 1978; Tharamas 1999;
Wali 2012; Zhu 2013).
Dates of study
Hamann 1972 took place between 1969 and 1971; Bitsch 1980
in the 1970s; Prasertsawat 1986, Rayburn 1989a, and Wahab
1988 in the 1980s; Atkinson 1994, Fairlie 1999, Giannina 1995,
Lardizabal 1999, Li 1994, and Tharamas 1999 in the 1990s; El-
Refaie 2012, Khooshideh 2009, Kuti 2008, Sekhavat 2009, Tsui
2004, and Zafar 2016 in the 2000s; and Direkvand-Moghadam
2014, Liu 2015, and Mobaraki 2016 in the 2010s.
All other studies did not report study dates.
Funding
Smith and Nephew (Pharmaceutics) Ltd provided the marked
drug ampoules in Grant 1970; Bronovo Research Fund funded
Douma 2010; pentazocine was supplied by Bayer products in
Duncan 1969; Dupont (UK) Ltd funded Frank 1987; The Scien-
tific Achievement and Appropriate Technology Extension Project
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of Beijing Municipal Commission of Health and Family Planning
(TG-2014-12) funded Liu 2015; Bristol laboratories, Syracuse,
New York funded Maduska 1978; Ardabil Medical Sciences Uni-
versity funded Mobaraki 2016; Sterling Winthrop Research Di-
vision supplied the drugs in Mowat 1970; National Institutes of
Health, Bethesda,Maryland (grant No. NS41386) fundedNelson
2005; Karolinska Institute foundations and the Swedish Medical
ResearchCouncil fundedOlofsson 1996; Sterling-Winthrop com-
pany supplied trial drugs in Refstad 1980; Sekhavat 2009 reported
tonot be fundedbe any pharmaceutical company;Wyeth laborato-
ries supplied the coded ampoules of the trial drugs in Sheikh 1986;
BDH (South Africa) Pty Ltd supplied dihydrocodeine bitartrate
in Sliom 1970;Wee 2014 was independent research funded by the
National Institute for Health Research (NIHR) under its Research
for Patient Benefit (RfPB) Programme (Grant Reference Number
PB-PG-0407-13170) with additional support costs funded by the
Western Comprehensive Local Research Network; Medical Re-
search Council and Wyeth Research (UK) funded Wheble 1988;
and the Higher Education Commission (Pakistan) funded Zafar
2016.
All other studies did not report funding sources.
Conflicts of interest
Two studies declared to have no conflicts of interest (Direkvand-
Moghadam 2014; Wee 2014).
All other studies did not report whether or not there were conflicts
of interest.
Excluded studies
We have excluded 121 studies (see Characteristics of excluded
studies).
Reasons for exclusions (some of the studies were excluded formore
than one reason).
1. In 26 studies, the focus was on epidural analgesia (Camann
1992; El-Kerdawy 2010; Evron 2007; Evron 2008; Freeman
2012; Gambling 1998; Ginosar 2003; Grandjean 1979; John
2013; Karadjova 2016; Logtenberg 2017; Marshalov 2012;
McGrath 1992; Morris 1994; Nafisi 2006; Polley 2000; Rabie
2006; Sabry 2011; Samanta 2013; Solek-Pastuszka 2009; Stocki
2014; Stourac 2014; Volmanen 2008; Weissman 2006; Wiener
1979; Wong 2005). The use of epidural analgesia for pain
management in labour is covered in related Cochrane reviews
(Anim-Somuah 2018; Simmons 2012).
2. In 13 studies, women in both groups received the same
opioid and the focus of studies was on add-on drugs; so, for
example, both groups received pethidine with one group, in
addition, receiving a sedative. The focus of these trials was on the
effects of the add-on drug (Aiken 1971; Ballas 1976; De
Lamerens 1964; Hodgkinson 1978; Malkasian 1967; McQuitty
1967; Posner 1960; Powe 1962; Ron 1984; Roberts 1960;
Spellacy 1966; Wan 1965; Williams 1962).
3. Nineteen studies were not randomised trials, or it was not
clear that there was any random allocation to groups (Balcioglu
2007; Bredow 1992; Brelje 1966; Callaghan 1966; Chandnani
2013; Cincadze 1978; Cullhed 1961; Eliot 1975; MacVicar
1960; Moore 1974; Pandole 2003; Rowley 1963; Savage 1955;
Singh 2001; Soontrapa 2002; Suvonnakote 1986; Tripti 2006;
Vavrinkova 2005; Volmanen 2005).
4. In three studies, it was not clear that participants were in
labour (Chang 1976; Krins 1969; Tomlin 1965).
5. In three studies, the intervention was not an opioid
(Abd-El-Maeboud 2014; Bare 1962; Elhalwagy 2017).
6. In the study by Kaltreider 1967, the focus was on a high-
risk group (women in preterm labour) and post-randomisation
exclusions meant that results were difficult to interpret.
7. We excluded two studies as levels of attrition meant that
results were at high risk of bias. There were serious
methodological problems in the study by Robinson 1980 and
complete data were available for only approximately one-third of
those randomised. In the study by De Kornfeld 1964, data on
pain outcomes were available for less than half the sample at one
hour; results from this study were therefore very difficult to
interpret.
8. Five trials were reported in trial registers or in brief abstracts
and we were unable to assess risk of bias or extract results. We
attempted to contact authors for more information without
success (Goodlin 1988; Kalaskar 2007; Morgan 2004; Overton
1992; Taskin 1993).
9. The focus of four studies was not on pain relief, so women
may have received an opioid with the purpose of promoting
progress in labour (Sosa 2004; Tournaire 1980; Treisser 1981;
Von Vorherr 1963). In one of these studies, women were
specifically excluded if they complained of pain (Sosa 2004), and
in another, women in the two groups also received oxytocin with
each study group receiving a different dose (Von Vorherr 1963).
A further two studies did not focus on pain relief but rather on
newborn serum bilirubin (McDonald 1964) or platelet function
(Greer 1988).
10. Seven studies focused on drugs no longer in use, or drugs
not used nowadays for obstetric analgesia (Cahal 1960;
Cavanagh 1966; Eames 1964; Ransom 1966; Roberts 1957;
Sentnor 1966; Walker 1992).
11. In eight studies, the same opioid was given to women in
both arms of trials and the difference between groups was mode
of administration; (different modes of administration of
parenteral opioids will be considered in a separate Cochrane
review) (Balki 2007; Balki 2012; Isenor 1993; Khooshideh 2015;
McInnes 2004; Rayburn 1989; Rayburn 1991; Volmanen 2009).
12. In four studies, women in one arm of the trial, as well as
receiving an opioid, were also given another add-on drug that the
comparison group did not receive. In these studies results are
difficult to interpret, as any differences between groups may be
due to the add-on drug rather than the opioid (Busacca 1982;
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Calderon 2006; Dan 1991; Fernandez 2015).
13. In the studies by Brookes 2013, Calderon 2006, Evron
2005, Fleet 2015, Li 1995, Ng 2011, Nikkola 2000; Shahriari
2007, Thurlow 2002, and Wilson 2016, different drugs were
administered using different methods, and so it is difficult to
interpret results as any differences between groups may be due to
drug, method or both together.
14. In one study, the effect of the opioid analgesia was not
assessed during childbirth, but for second trimester labour
following termination of pregnancy (Castro 2004).
15. Opioid was compared with a non-opioid drug: IV
paracetamol (Abdollahi 2014; Alhashemi 2011; Ankumah 2016;
Bhatia 2013; Dahiya 2015; Elbohoty 2012; Gupta 2016;
Hashemiyan 2014; Kaur 2015; Lallar 2015), NSAIDs (El
Kinawy 2015b).
16. Four trials were cross-over trials (Easton 2016; Jost 2015;
Rahimi 2012; Volmanen 2005).
Risk of bias in included studies
See Figure 2; Figure 3.We have only described the 61 studies below
that contributed data to the review; Fieni 2000; Kamyabi 2003;
Kermani 2015; Lalooha 2017; Lisboa 1997; Tharamas 1999;
Wahab 1988; Wali 2012; Zhu 2013 are therefore not included in
the descriptions below.
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Sequence generation
Eighteen studies were assessed as having adequate random se-
quence generation: in 11 studies a computer-generated random
sequence was used (Atkinson 1994; Douma 2010; El-Refaie
2012; Giannina 1995; Khooshideh 2009; Kuti 2008; Lardizabal
1999; Nelson 2005; Tsui 2004; Wee 2014; Zafar 2016); two
used an external randomisation service (Morley-Forster 2000;
Rayburn 1989a); and five studies used random number ta-
bles (Direkvand-Moghadam 2014; Erskine 1985; Hamann 1972;
Kainz 1992; Liu 2015). The remaining 43 included studies were
unclear about how the randomisation sequence was generated.
Allocation concealment
Allocation concealment was not generally described in sufficient
detail to allow assessment of risk of bias; it was not always clear
at what stage randomisation took place, and whether or not the
person carrying out randomisation was aware of group alloca-
tion. Seven studies described using numbered opaque sealed en-
velopes to conceal allocation (El-Refaie 2012; Giannina 1995;
Khooshideh 2009; Kuti 2008; Tsui 2004; Volikas 2001; Zafar
2016). Thirteen studies describedusing identical codeddrugboxes
(although it may not have been clear who had access to the
code or when the code was broken) (Atkinson 1994; Campbell
1961; Douma 2010; Fairlie 1999; Gillam 1958; Grant 1970;
Lardizabal 1999; Maduska 1978; Morley-Forster 2000; Morrison
1987; Olofsson 1996; Olson 1964; Sheikh 1986). One trial used
two identical syringes labelled only with the trial number to con-
ceal group allocation and to ensure that if two doses were given,
the same opioid was given both times, which were prepared by
trial centre pharmacies (Wee 2014). One study appeared to ran-
domise at the time of a coin toss and did not attempt allocation
concealment (Jahani 2013), so was assessed to be at high risk of
selection bias. In the remaining studies it was not clear what steps
were taken to conceal allocation at the point of randomisation.
Blinding
Manyof the studieswere described as double-blind; in themajority
of these trials women in the control arms were given preparations
of similar appearance to those given to women in the experimental
arms (either a placebo or an indistinguishable comparison drug).
It was not always clear that blinding was effective; for example,
some IMdrugsmay appear similar, but different consistencies may
be apparent to experienced staff. It was also not generally clear at
what point blinding ended, and whether outcome assessors were
blind to group allocation.
Performance bias (participants and personnel)
In 25 studies it appears that adequate blinding of women and
caregivers was achieved with identical administration of placebo
or comparison drugs. Nine studies were at high risk of perfor-
mance bias: four administered study drugs of interventions via
different routes (Direkvand-Moghadam 2014; Mobaraki 2016;
Tawfik 1982; Thakur 2004); three compared the study drug with
no analgesia (Jahani 2013; Li 1994; Liu 2015); two did not blind
staff to the intervention (Rayburn 1989a; Refstad 1980). Blinding
of women and caregivers was unclear in 28 studies (Bitsch 1980;
Blair 2005; Borglin 1971; De Boer 1987; Duncan 1969; Erskine
1985; Frank 1987; Giannina 1995; Hamann 1972; Hodgkinson
1979; Husslein 1987; Jackson 1983; Kainz 1992; Keskin 2003;
Khooshideh 2009; Li 1988;Moore 1970;Mowat 1970; Nel 1981;
Neumark 1978; Nicholas 1982; O’Dwyer 1971; Olson 1964;
Osler 1987; Prasertsawat 1986; Quilligan 1980; Sliom 1970;
Wheble 1988). Some studies reported to be double-blind but did
not give details of blinding. The remaining studies blinded the
women and caregivers by using identical volumes and syringes.
Detection bias (outcome assessor)
Twenty studies reported blinding of outcome assessor (Atkinson
1994; Bitsch 1980; Campbell 1961; Douma 2010; Fairlie 1999;
Gillam 1958; Grant 1970; Keskin 2003; Khooshideh 2009;
Kuti 2008; Levy 1971; Morley-Forster 2000; Morrison 1987;
Prasertsawat 1986; Sekhavat 2009; Sheikh 1986; Viegas 1993;
Volikas 2001; Wee 2014; Zafar 2016). Nine studies did not blind
outcome assessors or likely used caregivers to record labour out-
comes (Direkvand-Moghadam 2014; Jahani 2013; Li 1994; Liu
2015; Mobaraki 2016; Rayburn 1989a; Refstad 1980; Tawfik
1982; Thakur 2004). In the remaining studies, it was unclear if
outcome assessors were blinded or not.
Incomplete outcome data
Assessing levels of attrition was very difficult in these studies, as
denominators were frequently absent from results tables. In addi-
tion, even where all women appeared to be accounted for at fol-
low-up, there were frequently missing data for specific outcomes.
Nineteen studies were assessed to be at high risk of bias. In 14
studies loss to follow-up or missing data were greater than 10%
(Bitsch 1980; Fairlie 1999; Hamann 1972; Levy 1971; Moore
1970; Mowat 1970; Wilson 1986), or greater than 20% (De Boer
1987; Frank 1987; Giannina 1995; Gillam 1958; Nicholas 1982;
O’Dwyer 1971; Refstad 1980). Jackson 1983 excluded on the
grounds of fetal distress andheart defects post randomisation. Four
studies (Duncan 1969; Keskin 2003; Mowat 1970; Nel 1981)
reported unexplained loss to follow-up. Sixty-five women were
19Parenteral opioids for maternal pain management in labour (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
excluded due to clerical errors or administration of wrong drug in
Morrison 1987.
In several studies there were missing data on pain outcomes. This
may have occurred because drugs were given at a late stage in
labour, so that women had already given birth before the first
scheduled pain assessment. For example, in Fairlie 1999 17%,
and in O’Dwyer 1971 and Refstad 1980 more than one-third of
women had given birth within an hour of drug administration.
These three studies were rated as high risk of bias.
In some studies women were explicitly excluded from the analysis
because of factors that may have related to study medication; in
Hamann 1972, 13% of women were excluded after randomisa-
tion because they had a long labour or a caesarean section, and in
Moore 1970, women were excluded because they received addi-
tional pain relief. Wilson 1986 excluded 10% of the sample be-
cause women reported that they received inadequate pain relief.
Mitterschiffthaler 1991 excluded women who reported insuffi-
cient pain relief. In the study by Nelson 2005, any woman un-
dergoing artificial rupture of membranes, commencing oxytocin
or requesting epidural was excluded after randomisation and were
replaced. Further, any women who reached 10 cm cervical dila-
tion within one hour of drug administration were also excluded
from the analysis; it was not clear how many women were lost and
replaced for these reasons.
Twenty-two studies reported little explained, or no loss to fol-
low-up. The remaining studies were assessed to be at unclear risk
of attrition bias (Atkinson 1994; Campbell 1961; Direkvand-
Moghadam 2014; Erskine 1985; Frank 1987; Giannina 1995;
Grant 1970; Jahani 2013; Kainz 1992; Kuti 2008; Li 1994; Liu
2015; Mobaraki 2016; Morley-Forster 2000; Neumark 1978;
Quilligan 1980; Sekhavat 2009; Sliom 1970; Wee 2014; Zafar
2016).
Selective reporting
Most of the studies were assessed to have unclear risk of reporting
bias as we had access only to study reports and without study pro-
tocols for most studies, it is difficult to assess whether all outcomes
have been accounted for. One study reported all outcomes pre-
specified in their protocol (Wee 2014). Four studies (Campbell
1961; De Boer 1987; Jahani 2013; Sekhavat 2009) did report all
the outcomes pre-specified in their methods and were at high risk
of reporting bias (see Characteristics of included studies).
We were not able to explore possible publication bias by using
funnel plots as too few studies were included in different compar-
isons.
Other potential sources of bias
Most of the studies reported that there was no apparent baseline
imbalance between groups although this was not always explicit,
and where tables describing characteristics of the two groups were
provided, they frequently included only a small number of ob-
stetric or demographic variables. In the study by Tsui 2004, there
was imbalance between groups in terms of the numbers of women
undergoing induction of labour in the two groups (20/25 in the
pethidine group and 12/25 in the placebo group), and this may
have had an impact on outcomes so this study was assessed to be
at high risk of other bias. In the study by Rayburn 1989a, women
were only recruited to the study at very limited times (weekdays
8am to 3pm), and while this may not put findings at high risk
of bias, it may mean that those recruited were not representative
of the population served by the study hospital. Most studies were
assessed to be at unclear risk of other bias due to lack of infor-
mation to adequately assess, or poor reporting. Thirteen studies
had no other apparent risk of bias and were assessed to be at low
risk (Atkinson 1994; Blair 2005; Borglin 1971; De Boer 1987;
Douma 2010; Fairlie 1999; Giannina 1995; Jahani 2013; Mowat
1970; Olson 1964; Prasertsawat 1986; Volikas 2001; Wee 2014).
In the Characteristics of included studies and ’Risk of bias’ tables,
we have set out more information which will assist in the inter-
pretation of results.
Effects of interventions
See: Summary of findings for the main comparison IM
pethidine compared to placebo for pain management in labour;
Summary of findings 2 Placebo and pethidine comparisons for
pain management in labour
In this section where several studies have contributed data to a
comparison, we have reported primary and secondary outcomes
separately. For some comparisons single studies provided data on a
very limited number of outcomes; for these comparisons we have
reported outcomes under one heading. We had planned subgroup
analysis by parity, by whether or not the labour was induced or
augmented, by gestational age (preterm versus term birth), and by
whether or not women had continuous support during labour. In
this version of the review we were unable to carry out this analy-
sis, as data were not provided by subgroups. In addition, we did
not carry out planned sensitivity analysis by risk of bias domains
because for most outcomes only one or two studies contributed
data.
Intramuscular opioids for pain relief in labour
1. IM pethidine 50 mg/100 mg versus placebo
Four studies with 486 women contributed data to this comparison
(Direkvand-Moghadam 2014; Sekhavat 2009; Sliom 1970; Tsui
2004), although formost outcomes only a single study contributed
data. Kamyabi 2003 did not contribute any data.
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Primary outcomes
Maternal satisfaction with analgesia measured during labour
One study involving 50 women (Tsui 2004) showed no clear
difference in maternal satisfaction 30 minutes after administra-
tion of study drug (risk ratio (RR) 7.00, 95% confidence inter-
val (CI) 0.38 to 128.87, very low-quality evidence); only three of
25 women receiving pethidine and none of the women receiving
placebo reported to be ’satisfied’ or ’very satisfied’ with analgesia
(Analysis 1.1).
Maternal satisfaction with analgesia in labour measured
during the postnatal period
No study reported this outcome.
Secondary outcomes
Maternal
Maternal pain score or pain measured in labour
One study involving 116 women (Sliom 1970), reported more
women in the pethidine group with “fair” or “good” pain relief
within an hour of receiving the drug (RR 1.75, 95% CI 1.24 to
2.47, low-quality evidence; Analysis 1.2).
Maternal pain relief 30 minutes after study drug administration,
defined as a reduction in visual analogue scale (VAS) score of at least
40 mm, was measured in one study with 50 women (Tsui 2004),
and was greater for pethidine 100 mg compared with placebo (RR
25.00, 95% CI 1.56 to 400.54, low-quality evidence) though the
CI for this estimate is very wide (Analysis 1.3).
Additional analgesia required
In one study (Tsui 2004), the majority of women in both groups
required additional analgesia (epidural, pethidine, and Entonox);
this applied to fewer women with pethidine 100 mg compared
with placebo (RR 0.71, 95% CI 0.54 to 0.94, low-quality evi-
dence; Analysis 1.4).However, 12/25 women in the placebo group
had pethidine at 30 minutes as rescue analgesia confounding in-
terpretation of reported outcomes after 30 minutes.
Epidural
There was no evidence of clear differences between groups the
number of women requiring an epidural (RR 0.50, 95% CI 0.14
to 1.78; 1 study, 50 women; very low-quality evidence; Analysis
1.5).
Maternal sleepiness during labour
More women reported sleepiness with pethidine 100 mg, with
half of those receiving pethidine feeling sedated compared with
11% of controls (RR 4.67, 95% CI 2.43 to 8.95; 2 studies, 166
women; Analysis 1.7).
There was no evidence of clear differences between groups in:
1. nausea and vomiting (RR 1.47, 95% CI 0.65 to 3.31; 2
studies, 166 women; Analysis 1.6);
2. caesarean sections (RR 0.71, 95% CI 0.36 to 1.37; 2
studies, 140 women; Analysis 1.9);
3. assisted vaginal births (RR 0.86, 95% CI 0.34 to 2.19; 1
study, 50 women; Analysis 1.8).
Postpartum haemorrhage (as defined by the trial authors), breast-
feeding at discharge, breastfeeding in the postnatal period (four
to six weeks), sense of control in labour (as defined by trialists),
satisfaction with childbirth experience (as defined by trialists), ef-
fect (negative) on mother/baby interaction, and cost (as defined
by trialists) were not reported for this comparison.
Neonatal
Neonatal resuscitation
The incidence of newborn resuscitation was low; no clear differ-
ences between groups was detected (RR 1.67, 95% CI 0.45 to
6.24; 1 study; 50 infants; Analysis 1.10).
Apgar score less than seven at one minute and Apgar score less
than seven at five minutes
The number of babies with Apgar scores of seven or less at one
minute did not differ between the placebo and pethidine groups;
for this outcome we used a random-effects model because of high
heterogeneity (average RR 1.64, 95% CI 0.52 to 5.18); 2 studies,
166 infants; (heterogeneity: I² = 61%, Tau² = 0.46, Chi² test for
heterogeneity P = 0.11) (Analysis 1.11). No babies had Apgar
scores less than or equal to seven at five minutes in two studies
that reported this outcome (200 infants; Analysis 1.11).
Admission to special care baby unit/neonatal intensive care
unit (as defined by trialists)
Admission to neonatal intensive care unit (NICU) was low; no
clear differences between groups was detected (RR 1.00, 95% CI
0.07 to 15.12; 1 study; 50 infants; Analysis 1.12).
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One study reported the incidence of fetal respiratory depression,
but the study drugs were given late in labour to assess maximum
fetal effect. Participants were not included in the analysis if birth
was less than 30 minutes or more than four hours after adminis-
tration of study drugs (Sliom 1970).
We were unable to include any results from one study that met the
inclusion criteria, as it was unclear when outcomes were measured
how they were defined and how many participants were included
in the analysis (Kamyabi 2003). In this study,mean Apgar scores at
oneminute were reported to be higher (P = 0.008) in the pethidine
75 mg group compared with placebo group (data not shown).
No other neonatal outcomes were reported.
2. IM pentazocine versus placebo
IM pentazocine versus placebo was reported by one three-armed
study involving 150 women (Zafar 2016). One hundred women
contributed to the data for this comparison.
Primary outcomes
No outcomes regarding maternal satisfaction were reported.
Secondary outcomes
Maternal
This small study reported no clear differences between groups for:
1. maternal pain scores measured during labour (measured on
a VAS) (mean difference (MD) -3.60, 95% CI -9.91 to 2.71; 1
study, 89 women; low-quality evidence;Analysis 2.1)
2. nausea and vomiting (no events reported in either group; 1
study, 89 women; Analysis 2.2);
3. caesarean section (RR 0.89, 95% CI 0.24 to 3.35; 1 study,
89 women; Analysis 2.3);
4. assisted vaginal births (RR 0.60, 95% CI 0.10 to 3.39; 1
study, 89 women; Analysis 2.4).
No other maternal or neonatal outcomes were reported.
3. IM tramadol versus no treatment
IM tramadol versus no treatment was reported by one small study
involving 60 women (Li 1994). This study reported one outcome
relevant to this review. Maternal satisfaction with analgesia was
reported as “analgesic effect” and was described as “satisfactory”
by 5/30 women in the tramadol group, and 0/30 in the no treat-
ment group (RR 11.00, 95% CI 0.64 to 190.53; very low-quality
evidence; Analysis 3.1). It is not clear from the trial report when
this outcome was measured.
4. IM meptazinol versus IM pethidine
IM meptazinol versus IM pethidine was evaluated in six studies
with 1898 women (Morrison 1987; Nel 1981; Nicholas 1982;
Osler 1987; Sheikh 1986; Wheble 1988), and in two additional
studies where women in both study groups also received add-
on drugs (De Boer 1987; Jackson 1983). These two studies are
reported at the end of this comparison.
Primary outcomes
Maternal satisfaction with analgesia measured during labour
and Maternal satisfaction with analgesia in labour measured
during the postnatal period
One study (Morrison 1987), involving 801 women showed no
evidence of a difference between meptazinol 100 mg to 150 mg
compared with pethidine 100 mg to 150 mg for assessment of
analgesic effect measured at three to five days postpartum (RR
1.01, 95%CI 0.91 to 1.12; low-quality evidence;Analysis 4.1). In
this study, more than half of the women receiving either of these
opioids reported that they received no or poor relief despite the
fact that women in both groups could also receive an additional
dose of study drug, epidural or nitrous oxide as required.
Secondary outcomes
Maternal
Maternal pain score or pain measured in labour
In two studies (Nel 1981; Sheikh 1986), involving 239 women,
there was no evidence of a difference between groups in pain in-
tensity one hour after administration of meptazinol 100 mg or
pethidine 100mg; more than two-thirds of women in both groups
were rating their pain as severe (four or five on a five-point scale) at
one hour (average RR 1.11, 95%CI 0.69 to 1.80 (random-effects;
heterogeneity: I² = 43%, Tau² = 0.08, Chi² test for heterogeneity
P = 0.18, very low-quality evidence; Analysis 4.2)).
Additional analgesia required
Two studies (Osler 1987; Wheble 1988), involving 233 women
found no evidence of a difference in requirement for additional
analgesia between those who received meptazinol compared with
pethidine (RR 1.03, 95% CI 0.88 to 1.20, very low-quality ev-
idence; Analysis 4.3). This outcome is difficult to interpret as
women in the study by Osler 1987 were allowed up to three doses
of study drug (meptazinol 100 mg or pethidine 75 mg). Over-
all, 56 women required a second dose and 15 a third dose, but
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the number per group was not reported. Whereas in the study by
Wheble 1988, women were allowed a second dose of study drug
(meptazinol 100 mg or 150 mg or pethidine 100 mg or 150 mg)
or epidural or nitrous oxide at the discretion of the caregiver. Addi-
tional analgesia relates to a pudendal block in the one study (Osler
1987), and a second dose of study drug in the other (Wheble
1988).
Epidural
The use of epidural analgesia was similar between meptazinol and
pethidine (RR 0.96, 95% CI 0.71 to 1.29, very low-quality evi-
dence) in four studies (Nicholas 1982; Osler 1987; Sheikh 1986;
Wheble 1988) involving 788 women (Analysis 4.4).
Maternal sleepiness during labour
Fewerwomen in themeptazinol group reported sleepiness (average
RR 0.55, 95%CI 0.28 to 1.07; 3 studies, 1590 women), although
there was moderate heterogeneity for this outcome (heterogeneity:
I² = 44%, Tau² = 0.18, Chi² test for heterogeneity P = 0.17) and
the CIs crossed the line of no effect (Analysis 4.5).
Nausea and vomiting in labour
Three studies each reported nausea and vomiting (Morrison 1987;
Nicholas 1982; Sheikh 1986). There was no evidence for a differ-
ence in nausea (RR 1.11, 95% CI 0.95 to 1.28; 3 studies, 1590
women; Analysis 4.6); however, more women reported vomiting
(RR 1.25, 95% CI 1.06 to 1.47; 3 studies, 1589 women; Analysis
4.6) with meptazinol compared with pethidine.
Caesarean section
There was no evidence of a difference in rates of caesarean section
between meptazinol and placebo. However, substantial hetero-
geneity was detected; therefore, we used a random-effects model
(average RR 0.56, 95%CI 0.16 to 2.00) (heterogeneity: I² = 75%,
Tau² = 0.84, Chi² test for heterogeneity P = 0.02; Analysis 4.7).
Assisted vaginal birth
Instrumental birth was reported in three studies (Morrison 1987;
Osler 1987;Wheble 1988) involving 1266 women, and rates were
similar between groups (RR 1.00, 95% CI 0.81 to 1.22; Analysis
4.8).
No other maternal outcomes were reported.
Neonatal
Fetal heart rate changes in labour (persistent decelerations or
tachycardia)
One study (34 women) (De Boer 1987) reported decelerations
during labour but found no clear difference between the meptazi-
nol or pethidine groups (RR 1.23, 95% CI 0.92 to 1.64; Analysis
4.10). One study compared IM meptazinol 1.8 mg/kg with IM
pethidine 1.8 mg/kg; all women also received promazine 25 mg
IM (Jackson 1983). A second study compared IM meptazinol 1.5
mg/kg with IM pethidine 1.5 mg/kg; all women also received
metoclopramide 10mg IM (De Boer 1987).Women could receive
a second dose of study drug after three hours in both studies. Both
studies were conducted to assess effects of the study drugs on the
newborn only. There was no evidence of difference in the number
of babies with fetal heart rate changes (decelerations).
Naloxone administration
We found no evidence of a difference between meptazinol com-
pared with pethidine for naloxone administration (RR 0.89, 95%
CI 0.77 to 1.02; 1 study, 998 infants; Analysis 4.11). In one study
(Morrison 1987), 40% of the babies were given naloxone, reflect-
ing local practice at the time rather than low Apgar scores; with
41% of the babies having Apgar scores greater than or equal to
eight at the time of administration.
Neonatal resuscitation
We found no evidence of a difference between meptazinol com-
pared with pethidine for newborn resuscitation before and after
36 weeks’ gestation (RR 1.00, 95% CI 0.95 to 1.05; 2 studies,
1356 infants; Analysis 4.12). In one study (Jackson 1983), three
babies in the meptazinol group and two in the pethidine group re-
quired resuscitation (RR 1.50, 95% CI 0.26 to 8.60; 100 infants;
Analysis 4.13).
Apgar score less than seven at one minute and Apgar score less
than seven at five minutes and Apgar score less than seven at
10 minutes
Six studies involving 791 women reported number of babies
with Apgar scores less than or equal to seven at one minute (De
Boer 1987; Jackson 1983; Nel 1981; Nicholas 1982; Osler 1987;
Wheble 1988), and three studies reported this outcome at five
minutes (Nel 1981; Nicholas 1982; Osler 1987). There was no
evidence of a difference between groups at one minute (RR 0.79,
95% CI 0.56 to 1.11; 6 studies; 791 infants; Analysis 4.14) or five
minutes (RR 0.49, 95% CI 0.05 to 5.37; 3 studies, 616 infants;
Analysis 4.15) with three babies with low scores at five minutes
reported in one study (Osler 1987), and none in the other two
(Nel 1981; Nicholas 1982).
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In the study by De Boer 1987, Apgar at five and 10 minutes were
reported as ’similar’ in both groups. No babies in either group had
Apgar scores less than or equal to seven at 10 minutes.
5. IM diamorphine + prochlorperazine versus IM pethidine +
prochlorperazine
One study involving 133women compared IMdiamorphine 5mg
with 7.5 mg versus IM pethidine 100 mg to 150 mg. All women
also received IM prochlorperazine 12.5 mg at the same time as the
study drug (Fairlie 1999).
Primary outcomes
Maternal satisfaction with analgesia in labour measured
during the postnatal period
Global assessment of pain relief was evaluated at 24 hours; there
was no evidence of a difference between groups in the number of
women reporting ’fair’ or ’poor’ as opposed to ’good’ pain relief,
with more than half of the women in both groups having inad-
equate relief (RR 0.88, 95% CI 0.67 to 1.16; very low-quality
evidence; Analysis 5.1). Maternal satisfaction was not measured
in labour.
Secondary outcomes
Maternal
Maternal pain score or pain measured in labour
More women reported pain intensity as moderate or severe one
hour post administration of study drug with pethidine compared
with diamorphine, though there was no evidence of a clear differ-
ence between groups, with the majority of women in both groups
reporting moderate or severe pain (RR 0.85, 95%CI 0.72 to 1.01;
very low-quality evidence; Analysis 5.2).
Additional analgesia required
There was no evidence for a difference between groups in the
number of women requiring additional analgesia (second dose of
study drug) (RR 1.35, 95% CI 0.53 to 3.40; very low-quality
evidence; Analysis 5.3).
Epidural
There was no evidence for a difference between groups in the
number of women requiring an epidural (RR 1.22, 95% CI 0.72
to 2.07; very low-quality evidence; Analysis 5.4).
Maternal sleepiness during labour
The number of women moderately drowsy or asleep one hour
after study drug administration was similar between groups (RR
0.93, 95% CI 0.52 to 1.66; Analysis 5.5). The attending midwife
measured sedation on a four-point scale where: 0 = alert; 1 =mildly
drowsy; 2 = moderately drowsy; 3 = asleep.
Nausea and vomiting in labour
The number of women vomiting was lower with diamorphine
comparedwith pethidine (RR0.39, 95%CI 0.17 to 0.86; Analysis
5.6).
Caesarean section
There was no evidence for a difference between groups in the
number of women who had a caesarean section (RR 0.52, 95%
CI 0.10 to 2.76; Analysis 5.7).
Assisted vaginal birth
There was no evidence for a difference between groups in the
number of women who had an assisted vaginal birth (RR 0.96,
95% CI 0.46 to 2.02; Analysis 5.8).
No other maternal outcomes were reported.
Neonatal
Neonatal resuscitation
There were no clear differences between groups for the number of
babies needing resuscitation (RR 1.21, 95% CI 0.73 to 2.02; 133
infants; Analysis 5.9).
Apgar score less than seven at one minute and Apgar score less
than seven at five minutes
Fewer babies had Apgar scores less than seven at one minute with
diamorphine compared with pethidine (RR 0.41, 95% CI 0.18 to
0.91; 133 infants; Analysis 5.10). However, there was no evidence
of a clear difference between groups at five minutes, with few
babies with an Apgar score less than seven in either group (RR
0.35, 95% CI 0.04 to 3.27; 133 infants; Analysis 5.11).
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Admission to special care baby unit/neonatal intensive care
unit (as defined by trialists)
There were no clear differences between groups for the number
of babies needing admission to NICU (RR 0.58, 95% CI 0.21 to
1.64; 133 infants; Analysis 5.12).
No other neonatal outcomes were reported.
6. IM tramadol versus IM pethidine
Seven studies involving 569 women compared IM tramadol versus
IM pethidine (Bitsch 1980; Fieni 2000; Husslein 1987; Keskin
2003; Khooshideh 2009; Prasertsawat 1986; Viegas 1993). Tra-
madol and pethidine doses varied between studies and were 50
mg, 75 mg or 100 mg.
Primary and secondary outcomes
Maternal
Women’s satisfaction with analgesia was not measured in any of
the studies.
Maternal pain score or pain measured in labour
Pain intensitywas defined indisparateways in the studies; however,
more women had poor pain relief with tramadol compared with
pethidine (RR 1.56, 95% CI 1.10 to 2.21; 4 studies, 243 women;
low-quality evidence; Analysis 6.1).
Additional analgesia required
In three studies which reported requirement for additional anal-
gesia, no evidence of a difference was detected (average RR 1.07,
95% CI 0.60 to 1.91; 3 studies, 295 women; very low-quality ev-
idence; Analysis 6.2). Bitsch 1980 administered second and third
doses of the study drug, Khooshideh 2009 offered a second dose,
and Prasertsawat 1986 gave a second dose but half the amount.
Maternal sleepiness during labour
More women in the pethidine group reported sleepiness although
heterogeneity was high and we used a random-effects model (av-
erage RR 0.57, 95% CI 0.33 to 0.97; 5 studies, 409 women) (het-
erogeneity I² = 72%, Tau² = 0.24, Chi² test for heterogeneity P =
0.007; Analysis 6.3).
Nausea and vomiting in labour
There was no evidence for a clear difference in incidence of nausea
and/or vomiting with tramadol compared with placebo (average
RR 0.97, 95% CI 0.34 to 2.76; 6 studies, 454 women; Analysis
6.4). There was a substantial level of heterogeneity detected for this
outcome (I² = 72%, Tau² = 1.09, Chi² test for heterogeneity P =
0.003) therefore we used a random-effects model for the analysis.
Caesarean section and assisted vaginal birth
There was no clear difference between the tramadol and pethidine
groups for incidence of caesarean section (RR 0.71, 95% CI 0.23
to 2.18; 3 studies, 260 women; Analysis 6.5) or assisted vaginal
birth (RR 0.56, 95% CI 0.12 to 2.56; 3 studies, 260 women;
Analysis 6.6).
Neonatal
Only two studies reported Apgar scores (Khooshideh 2009;
Prasertsawat 1986), and reported no babies in either group with
Apgar scores less than or equal to seven at one or five minutes, and
no babies requiring resuscitation (Analysis 6.8; Analysis 6.7).
One study (Keskin 2003), reported the incidence of respiratory
distress and admission to NICU which occurred more frequently
with tramadol 100 mg compared with pethidine 100 mg, though
CIs crossed the line of no effect for both outcomes (RR 2.26, 95%
CI 0.64 to 7.89; 1 study; 59 infants; Analysis 6.9 and RR 2.26,
95% CI 0.64 to 7.89; 1 study; 59 infants; Analysis 6.10).
No other maternal or neonatal outcomes were reported.
7. IM tramadol + triflupromazine versus IM pethidine +
triflupromazine
One study involving 66 women compared tramadol 500 mg with
pethidine 50 mg, and both groups also received triflupromazine
10 mg (Kainz 1992). A third study arm received tramadol 100
mg.
Primary and secondary outcomes
Maternal satisfaction with analgesia measured during labour or
maternal satisfaction with analgesia in labour measured during the
postnatal period was not reported.
Data for effects on pain were not reported (P values for the change
within groups were reported; not the between group differences;
data not shown).
Sleepiness was more frequently reported by women who received
tramadol, though CIs crossed the line of no effect (RR 2.86, 95%
CI 0.68 to 12.12; 1 study, 40women; Analysis 7.1). The incidence
of nausea or vomiting was reported and was infrequent, with no
evidence of differences between groups (RR 0.82, 95% CI 0.13
to 5.25 and RR 0.40, 95% CI 0.02 to 9.35, respectively; 1 study,
40 women; Analysis 7.2).
The authors report that there were no negative effects on the new-
born; though no data were presented.
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8. IM dihydrocodeine versus IM pethidine
One study involving 196 women compared a single dose of IM
dihydrocodeine 50 mg with IM pethidine 100 mg (Sliom 1970).
An additional study arm received placebo.
Primary and secondary outcomes
Maternal pain score or pain measured in labour
There was no evidence of a clear difference in pain relief between
groups with a substantial proportion of women in each group
reporting poor pain relief one hour after administration of study
drug (RR 1.09, 95% CI 0.64 to 1.86; 1 study, 138 women; very
low-quality evidence; Analysis 8.1).
Maternal sleepiness and nausea and vomiting in labour
There was no evidence of a difference between dihydrocodeine
and pethidine for nausea and vomiting (RR 0.87, 95% CI 0.40 to
1.88; 1 study, 138 women; Analysis 8.3), or sleepiness (RR 0.67,
95% CI 0.43 to 1.04; 1 study, 138 women; Analysis 8.2).
Apgar score less than seven at one minute
Fewer babies had Apgar scores less than or equal to seven at one
minute with dihydrocodeine compared with pethidine (RR 0.57,
95% CI 0.39 to 0.84; 138 infants; Analysis 8.4). Apgar score at
five minutes was reported as mean scores rather than number of
babies in each group: there was no clear difference between groups
reported (data not shown).
9. IM pentazocine versus pethidine
Five studies with 792 women compared IM pentazocine versus
pethidine (Borglin 1971; Duncan 1969; Levy 1971; Moore 1970;
Mowat 1970). One study with 85 women also compared IM pen-
tazocine versus pethidine but all women received promazine 25
mg IM before first injection (Refstad 1980).
Primary outcomes
Maternal satisfaction with analgesia measured during labour
Two studies reported on the numbers ofwomen ratingpain relief as
good or very good at birth (Borglin 1971;Mowat 1970), and there
was no clear difference between IM pentazocine or IM pethidine
without add-on drugs in either study, or when results were pooled
(RR 1.08, 95% CI 0.92 to 1.27; 253 women; very low-quality
evidence; Analysis 9.1).
Secondary outcomes
Maternal
Maternal pain score or pain measured in labour
Four studies reported poor pain relief (Duncan 1969; Levy 1971;
Moore 1970; Refstad 1980).More than half of the women in both
groups had only partial or poor relief and there was no clear dif-
ference between groups for women who received promazine (RR
1.53, 95% CI 0.66 to 3.58; 1 study, 85 women, very low-quality
evidence) or those who did not (average RR 1.23, 95% CI 0.74 to
2.05; 3 studies, 365 women; very low-quality evidence; Analysis
9.2). There was a substantial level of heterogeneity detected for
this outcome (I² = 83%, Tau² = 0.16, Chi² test for heterogene-
ity P = 0.003), therefore we used a random-effects model for the
analysis.
Additional analgesia required
The use of additional analgesic drugs (second dose of study drug)
was reported by two studies (Mowat 1970; Refstad 1980). There
was no clear difference between groups in either study (Analysis
9.3): pentazocine and pethidine alone (RR 0.91, 95% CI 0.50 to
1.65; 94 women, very low-quality evidence); and with promazine
(RR 1.67, 95% CI 0.73 to 3.84; 85 women, very low-quality
evidence).
There was no clear evidence of a difference between groups for:
1. maternal sleepiness in labour (Analysis 9.4)
i) pentazocine versus pethidine alone (RR 1.00, 95% CI
0.89 to 1.12; 3 studies, 391 women);
2. nausea in labour (Analysis 9.5)
i) pentazocine versus pethidine alone (RR 0.46, 95% CI
0.24 to 0.90; 3 studies, 391 women);
3. vomiting in labour (Analysis 9.5)
i) pentazocine versus pethidine alone (RR 0.92, 95% CI
0.27 to 3.14; 1 study, 73 women);
4. assisted vaginal birth (Analysis 9.6)
i) pentazocine versus pethidine alone (RR 5.22, 95% CI
0.63 to 42.97; 1 study, 94 women);
ii) pentazocine versus pethidine with promazine (RR
0.78, 95% CI 0.23 to 2.71; 1 study, 85 women).
No other maternal outcomes were reported.
Neonatal
There was no clear evidence of a difference between groups for:
1. naloxone administration (Analysis 9.7)
i) pentazocine versus pethidine with promazine (RR
0.49, 95% CI 0.09 to 2.53; 1 study, 85 infants);
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2. low Apgar score (less than seven) at one minute (Analysis
9.8)
i) pentazocine versus pethidine alone (average RR 1.39,
95% CI 0.06 to 32.97; 2 studies, 242 infants, I² = 67%, Tau² =
3.56; Chi² test for heterogeneity P = 0.08);
ii) pentazocine versus pethidine with promazine (RR
1.13, 95% CI 0.07 to 17.30; 1 study, 66 infants);
3. low Apgar score (less than seven) at five minutes (Analysis
9.9)
i) pentazocine versus pethidine alone (RR 0.23, 95% CI
0.01 to 4.54; 1 study, 62 infants);
ii) pentazocine versus pethidine with promazine (RR
0.38, 95% CI 0.02 to 8.88; 1 study, 66 infants).
No other neonatal outcomes were reported.
10. IM nalbuphine versus pethidine
Four studies with 486 women are included in this comparison
(Lardizabal 1999; Lisboa 1997; Mitterschiffthaler 1991; Wilson
1986).
Primary outcomes
Maternal satisfaction with analgesia measured during labour
and during the postnatal period
One study reported maternal satisfaction with analgesia at 24
hours (Wilson 1986). The majority of women receiving both nal-
buphine and pethidine thought that analgesia had been “min-
imally effective” (63% and 85% respectively), although fewer
women who received nalbuphine reported to be dissatisfied with
their analgesia (RR 0.73, 95% CI 0.55 to 0.96; 72 women, 1
study; low-quality evidence; Analysis 10.1). One study reported
the number of women that were free of pain (Mitterschiffthaler
1991); there was no clear difference between groups, with few
women in either group having no pain (RR 6.00, 95% CI 0.79
to 45.42; 1 study, 40 women; very low-quality evidence; Analysis
10.2).
Secondary outcomes
Maternal
Maternal pain score or pain measured in labour
Two studies reported pain intensity: one reported severe pain at
30 minutes (Lardizabal 1999), and the other VAS at 60 minutes
(Wilson 1986). There were no clear differences between groups
in either analysis (RR 0.86, 95% CI 0.59 to 1.26; 1 study, 295
women; very low-quality evidence; Analysis 10.3; and (MD -8.00,
95% CI -18.55 to 2.55; 1 study, 72 women; very low-quality
evidence; Analysis 10.4).
Additional analgesia required
One study reported the use of additional analgesia (second dose
of study drug) but found no difference between the groups (RR
1.26, 95% CI 0.49 to 3.27; 1 study, 72 women; very low-quality
evidence; Analysis 10.5).
Epidural
One study reported the use of epidural (Lardizabal 1999); there
was no clear difference between groups (RR 1.65, 95% CI 0.55
to 4.94; 307 women; low-quality evidence; Analysis 10.6).
Nausea and vomiting in labour
One study reported nausea and vomiting as separate outcomes
(Lardizabal 1999), and another reported nausea and vomiting as
a single outcome (Wilson 1986). Fewer women who received nal-
buphine reported nausea alone (RR 0.62, 95% CI 0.42 to 0.91,
301 women), or vomiting (RR 0.41, 95% CI 0.22 to 0.76; 301
women) compared with women who received pethidine. Like-
wise, fewer women who received nalbuphine reported nausea and
vomiting combined (RR 0.41, 95% CI 0.18 to 0.94; 72 women;
Analysis 10.8).
There was no evidence of clear differences between groups for:
1. maternal sleepiness (RR 3.78, 95% CI 0.86 to 16.60; 1
study, 72 women; Analysis 10.7);
2. caesarean section (RR 0.45, 95% CI 0.12 to 1.69; 1 study,
310 women; Analysis 10.9);
3. assisted vaginal births (average RR 0.98, 95% CI 0.25 to
3.85; 2 studies, 382 women; I² = 41%; Tau² = 0.50; Chi² test for
heterogeneity P = 0.19; Analysis 10.10).
No other maternal outcomes were reported.
Neonatal
Two studies reported neonatal outcomes (Lardizabal 1999;Wilson
1986).
There was no clear difference between groups for:
1. naloxone administration (RR 6.63, 95% CI 0.35 to
123.93; 1 study, 72 infants; Analysis 10.11);
2. Apgar score less than seven at one (average RR 1.18, 95%
CI 0.72 to 1.95; 2 studies, 382 infants; I² = 44%; Tau² = 0.07;
Chi² test for heterogeneity P = 0.18), and Apgar score less than
seven at five minutes (RR 0.47, 95% CI 0.04 to 4.99; 1 study,
72 infants; Analysis 10.12);
3. admission to NICU (RR 1.07, 95% CI 0.61 to 1.89; 1
study, 299 infants; Analysis 10.13).
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Newborn neuro-behavioural scores
One study reported a neonatal neuro-behavioural score two to
four hours following birth (Wilson 1986); babies of women who
received nalbuphine had lower scores than babies born to women
in the control group (MD -3.70, 95% CI -6.14 to -1.26; 72 in-
fants; Analysis 10.14).
No other neonatal outcomes were reported.
11. IM phenazocine versus pethidine
One study with 212 women (Grant 1970) compared IM
phenazocine versus IM pethidine.
Primary and secondary outcomes
This study reported only two outcomes: epidural and nausea and
vomiting in labour. There was no clear difference between groups
for epidural (RR 1.31, 95% CI 0.58 to 2.97; very low-quality evi-
dence; Analysis 11.1), but fewer womenwho received phenazocine
reported nausea and vomiting in labour (RR 0.39, 95%CI 0.20 to
0.78; Analysis 11.2) compared with those who received pethidine.
12. IM diamorphine/morphine versus pethidine
We included two studies with 619 women in this comparison
(Prasertsawat 1986; Wee 2014).
Primary outcomes
Maternal satisfaction with analgesia measured during labour
or during the postnatal period
One study (Wee 2014), found that more women in the diamor-
phine group reported to be ’satisfied’ or ’very satisfied’ with the
analgesia compared with the pethidine group (RR 1.13, 95% CI
1.02 to 1.26; 484 women; high-quality evidence Analysis 12.1).
However, the smaller study reported no clear difference between
groups in the number of women describing their pain relief as
poor (RR 1.22, 95% CI 0.56 to 2.66; 1 study, 90 women; very
low-quality evidence; Analysis 12.2).
Secondary outcomes
Maternal
Maternal pain score or pain measured in labour
Women in the diamorphine group reported less pain than the
pethidine group at 30 minutes (MD -0.80, 95% CI -1.24 to -
0.36; 1 study, 484 women; high-quality evidence; Analysis 12.3),
and at 60 minutes (MD -0.80, 95% CI -1.26 to -0.34; 1 study,
484 women; high-quality evidence; Analysis 12.4) after receiving
analgesia.
There was no clear difference between groups for:
1. additional analgesia required (RR 1.00, 95% CI 0.92 to
1.10; 2 studies, 574 women; moderate-quality evidence; Analysis
12.5);
2. maternal sleepiness during labour (RR 0.60, 95% CI 0.29
to 1.23; 1 study, 90 women; Analysis 12.6);
3. nausea and vomiting in labour (RR 1.00, 95% CI 0.21 to
4.69; 1 study, 90 women; Analysis 12.7);
4. caesarean section (RR 0.94, 95% CI 0.66 to 1.35; 1 study,
484 women; Analysis 12.8);
5. assisted vaginal birth (RR 1.28, 95% CI 0.91 to 1.80; 1
study, 484 women; Analysis 12.9).
Neonatal
There was no clear difference between morphine and pethidine
for:
• naloxone administration (RR 0.98, 95% CI 0.20 to 4.83; 1
study, 484 infants; Analysis 12.10);
• neonatal resuscitation (RR 0.96, 95% CI 0.66 to 1.41; 2
studies, 574 infants; Analysis 12.11). No babies received
resuscitation in Prasertsawat 1986;
• Apgar score less than seven at one minute (RR 1.15, 95%
CI 0.76 to 1.73; 2 studies, 574 infants; Analysis 12.12);
• admission to special care baby unit/neonatal intensive care
unit (RR 0.87, 95% CI 0.34 to 2.23; 1 study, 484 infants;
Analysis 12.13).
No other neonatal outcomes were reported.
13. IM butorphanol versus pethidine
One study with 80 women compared IM butorphanol with IM
pethidine (Maduska 1978).
Primary and secondary outcomes
This study did not report on the review’s primary outcomes. There
was no evidence of clear differences between groups for additional
analgesia required (second dose of study drug) (RR 0.89, 95% CI
0.55 to 1.45; very low-quality evidence; Analysis 13.1), nausea (RR
0.20, 95% CI 0.01 to 4.04; Analysis 13.2), or vomiting (RR 0.50,
95% CI 0.05 to 5.30; Analysis 13.3). Likewise, there was no clear
difference between groups for neonatal resuscitation (RR 0.33,
95% CI 0.01 to 7.95; Analysis 13.4) or naloxone administration
(RR 0.33, 95% CI 0.01 to 7.95; Analysis 13.5).
14. IM Avacan® versus IM pentazocine
We included one study with 185 women in this comparison (
Hamann 1972).
28Parenteral opioids for maternal pain management in labour (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Primary and secondary outcomes
This study did not report on either of our primary outcomes.
There were no clear differences between groups for additional
analgesia required (Entonox) (RR 0.92, 95% CI 0.53 to 1.63; 1
study, 160 women; Analysis 14.1). More women in the Avacan®
group received a pudendal-paracervical block (RR 2.02, 95% CI
1.16 to 3.53; 160 women; Analysis 14.2). There was no evidence
of a clear difference between groups for the number of women
having a caesarean section (RR 0.62, 95% CI 0.21 to 1.84; 184
women; Analysis 14.3), or babies born with an Apgar score less
than or equal to seven at birth ((RR 0.59, 95% CI 0.27 to 1.26;
160 women; Analysis 14.4). This study did not report on any
other maternal or neonatal outcomes.
15. IM pentazocine versus IM Pethilorfan®
One trial involving 98 women compared pentazocine with
Pethilorfan® (O’Dwyer 1971).
Primary and secondary outcomes
This trial reported maternal satisfaction with analgesia in labour
in the form of the number of women saying that they did not
obtain any relief frommedication at one hour. There were no clear
differences between groups for this outcome (RR 1.22, 95% CI
0.77 to 1.95; 69 women; Analysis 15.1).
No clear differences were reported for any of the secondary out-
comes recorded: additional analgesia required (second dose of
study drug) (RR 0.52, 95% CI 0.10 to 2.71; 98 women; Analysis
15.2), assisted vaginal birth (RR 1.04, 95% CI 0.07 to 16.19;
98 women; Analysis 15.3). Apgars scores less than seven were not
reported, however, Apgar scores less than eight were reported at
one minute (RR 5.71, 95% CI 0.72 to 45.39; 82 infants; Analysis
15.4), and at five minutes (no events in either group, 82 infants;
Analysis 15.5) finding no clear differences across groups.
16. IM pentazocine versus complementary and alternative
medicine (CAM)
One study (Zafar 2016) involving 150 women contributed to this
outcome, one control arm of 50 women were not included in
this comparison. The homeopathy group received 1 mL of saline
injection and oral homeopathic medicine prescribed by a qualified
homeopath.
Primary and secondary outcomes
No primary outcomes were reported.
There were no clear differences between the groups for: maternal
pain score during labour (MD -0.40, 95% CI -7.61 to 6.81; 89
women; Analysis 16.1), nausea and vomiting (RR 0.30, 95% CI
0.01 to 7.14; 89 women; Analysis 16.2), caesarean section (RR
0.89, 95%CI 0.24 to 3.35; 89women; Analysis 16.3), and assisted
vaginal birth (RR 0.89, 95% CI 0.13 to 6.07; 89 women; Analysis
16.4).
17. IM pentazocine versus IM tramadol
One study (Kuti 2008) involving 100 women reported this com-
parison.
Primary outcomes
Maternal satisfaction with analgesia measured during labour
or during the postnatal period
More women in the pentazocine group than the tramadol group
reported to be satisfied with their analgesia 30 minutes after re-
ceiving the injection (RR 2.40, 95%CI 1.28 to 4.48; 100 women;
Analysis 17.1), however this difference was no longer clear after 60
minutes had passed (RR 1.62, 95% CI 0.91 to 2.86; 100 women;
Analysis 17.2).
Secondary outcomes
Maternal
Maternal pain score or pain measured in labour
It appears that fewer women in the pentazocine group reported
moderate or severe pain 30 minutes following administration of
the drug however CIs cross the line of no effect so this result is
not certain (RR 0.75, 95% CI 0.55 to 1.02; 100 women; Analysis
17.3). At 60 minutes following administration there is not a clear
difference between the groups (RR 0.81, 95% CI 0.60 to 1.08;
100 women; Analysis 17.4) though results still appear to favour
pentazocine.
There were no clear differences between the groups for:
1. maternal sleepiness during labour (RR 1.67, 95% CI 0.66
to 4.24; Analysis 17.5);
2. nausea and vomiting during labour (RR 1.00, 95% CI 0.06
to 15.55; Analysis 17.6);
3. caesarean section (RR 1.50, 95% CI 0.45 to 4.99; Analysis
17.7);
4. assisted vaginal birth (RR 2.00, 95% CI 0.19 to 21.36;
Analysis 17.8).
No other maternal outcomes were reported.
Neonatal
There were no clear differences between the groups for:
1. Apgar score less than seven at one minute (RR 1.67, 95%
CI 0.42 to 6.60; 100 infants; Analysis 17.9);
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2. Apgar score less than seven at five minutes (RR 3.00, 95%
CI 0.13 to 71.92; 100 infants; Analysis 17.10);
3. admission to neonatal intensive care unit (RR 2.87, 95%
CI 0.12 to 68.47; 86 infants; Analysis 17.11).
No other neonatal outcomes were reported in this study.
18. IM pethidine versus inhaled nitrous oxide (Entonox)
One study (Mobaraki 2016) with 100 women reported this com-
parison.
Primary and secondary outcomes
Maternal pain score or pain measured during labour
This study only reported pain relief following analgesia using a
pain score; at 30 minutes women who received pethidine reported
better pain relief than those with inhaled nitrous oxide (MD 1.66,
95% CI 1.17 to 2.15; very low-quality evidence; Analysis 18.1).
After 60 minutes, there was not a clear difference in pain relief
reported by the groups (MD -0.36, 95% CI -0.85 to 0.13; very
low-quality evidence; Analysis 18.2), although interestingly, pain
relief reported in the pethidine group had dropped compared to 30
minute readings, whilst the pain relief in the nitrous oxide group
had risen.
Intravenous opioids for pain relief in labour
19. IV pethidine versus placebo
One study (El-Refaie 2012) with 240 women contributed data to
this comparison.
Primary and secondary outcomes
Maternal
This study did not report the primary outcomes.
Maternal pain score or pain measured in labour
Womenwho received IV pethidine reported lower pain scores than
those who received a placebo (MD -4.10, 95% CI -4.56 to -3.64;
moderate-quality evidence; Analysis 19.1).
Nausea and vomiting
Fewer women in the placebo group experienced nausea and vom-
iting in labour (RR 2.43, 95% CI 1.05 to 5.64; Analysis 19.2).
Caesarean section; assisted vaginal birth
There was no clear difference between the groups in number of
women who had a caesarean section (RR 0.88, 95% CI 0.46 to
1.68; Analysis 19.3) or assisted vaginal birth (RR 0.75, 95% CI
0.33 to 1.71; Analysis 19.4).
No other maternal outcomes reported.
Neonatal
There was no clear difference between the groups in number of
babies admitted to neonatal intensive care (RR 0.67, 95%CI 0.11
to 3.92; 240 infants; Analysis 19.5).
No other neonatal outcomes were reported.
20. IV fentanyl versus no treatment
One study (Jahani 2013) involving 70 women reported this com-
parison. It was not made clear in this study whether or not the
women in the control group were able to request pain relief. The
pain scores were noticeably worse in the control group with 31/
35 women reporting severe pain, and 0/35 reporting this in the
fentanyl group.
Primary and secondary outcomes
This study did not report the primary outcomes, many maternal,
or any neonatal outcomes.
Maternal pain score or pain measured in labour
IV fentanyl resulted in lower pain scores (MD -5.00, 95% CI -
5.47 to -4.53; very low-quality evidence; Analysis 20.1), and no
women reporting “severe pain” after 60minutes (RR0.02, 95%CI
0.00 to 0.25; very low-quality evidence; Analysis 20.2). There was
no clear difference between groups for the number of women who
had caesarean sections (RR 1.50, 95% CI 0.27 to 8.43; Analysis
20.3).
21. IV fentanyl versus IV pethidine
We included one study with 105 women in this comparison (
Rayburn 1989a). The study recruitedwomenonly during a limited
time period Monday to Friday and allocation was not blinded due
to the different half-lives of the treatment options.
Primary and secondary outcomes
The primary outcomes were not reported in this study.
Maternal
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Maternal pain score or pain measured in labour
Themeanmaternal pain scores for women allocated to the IV fen-
tanyl compared with those in the IV pethidine group were similar;
women inboth groups reportedmeanpain scores of approximately
six on a 10 mm scale (MD -0.20, 95% CI -1.18 to 0.78; low-
quality evidence; Analysis 21.1). It is not clear from the trial report
whether 0 or 10 equalled less pain. It is reported that both treat-
ments “took the edge off” the contraction pain (Rayburn 1989a).
Additional analgesia required
Women in the pethidine group required fewer doses than those in
the fentanyl group (MD 0.40, 95% CI 0.14 to 0.66; low-quality
evidence; Analysis 21.2).
Maternal sleepiness in labour
Maternal sedationwas lower inwomen allocated to the IV fentanyl
group compared with those in the IV pethidine group (RR 0.05,
95% CI 0.00 to 0.82; Analysis 21.3).
There were no clear differences for all other reported outcomes
including nausea and vomiting (RR 0.51, 95% CI 0.17 to 1.55;
Analysis 21.4), anti-emetic required (RR 0.09, 95% CI 0.01 to
1.52; Analysis 21.5), and caesarean section (RR 1.14, 95% CI
0.24 to 5.40; Analysis 21.6).
No further maternal outcomes were reported.
Neonatal
There were no clear differences for all neonatal outcomes reported:
1. naloxone required (RR 0.16, 95% CI 0.02 to 1.28; Analysis
21.7);
2. neonatal resuscitation/ventilatory support (RR 1.03, 95%
CI 0.46 to 2.32; Analysis 21.8);
3. Apgar score less than seven at one minute (RR 0.63, 95%
CI 0.23 to 1.77; Analysis 21.9);
4. Apgar score less than seven at five minutes (RR 0.38, 95%
CI 0.02 to 9.12; Analysis 21.10);
5. newborn neuro-behavioural score (one to two hours after
delivery) (MD 1.30, 95% CI 0.15 to 2.45; Analysis 21.11);
6. newborn neuro-behavioural score (two hours to 24 hours)
(MD 0.90, 95% CI -0.42 to 2.22; Analysis 21.12).
No other neonatal outcomes were reported.
22. IV nalbuphine versus IV pethidine
We included one study involving 28 women compared IV nal-
buphine with IV pethidine (Giannina 1995).
Primary and secondary outcomes
No outcomes relating to maternal pain during labour were re-
ported.
This study reported estimable data for only two relevant secondary
outcomes (caesarean section and Apgar score less than seven at one
and five minutes), neither of which showed any clear difference
between the two groups: caesarean section (RR 5.00, 95% CI
0.26 to 95.61; Analysis 22.1), Apgar scores less than seven at one
minute (RR 3.00, 95% CI 0.13 to 67.91; Analysis 22.2; no babies
had Apgar less than seven at five minutes; Analysis 22.3).
23. IV phenazocine versus IV pethidine
We included one study including 194 women compared IV
phenazocine with IV pethidine (Olson 1964).
Primary and secondary outcomes
Maternal
There was no clear difference between groups for maternal sat-
isfaction with analgesia measured during labour (comparing the
number of women with “fair” or “poor” pain relief one hour af-
ter administration) (RR 0.72, 95% CI 0.48 to 1.10; very low-
quality evidence; Analysis 23.1). No other primary outcomes were
reported.
Only one identified secondary outcome reported estimable data:
nausea with vomiting. There was no clear difference between the
two groups for this outcome (RR 0.40, 95% CI 0.08 to 2.01;
Analysis 23.2).
Neonatal
There were no babies that had an Apgar score less than seven at
one minute (Analysis 23.3; Analysis 23.4).
24. IV butorphanol versus IV pethidine
Three studies involving a total of 330 women compared IV bu-
torphanol with IV pethidine (Hodgkinson 1979; Nelson 2005;
Quilligan 1980), though most outcomes only include data from
single studies.
Primary outcomes
No outcomes relating to maternal satisfaction with analgesia were
reported.
Secondary outcomes
Maternal
Maternal pain score or pain measured in labour
One study (Quilligan 1980), involving 100 women (findings for
these primary outcomes reported for 80 women) included two
measures of women’s pain during labour; women’s reported pain
relief and pain score. Women’s mean pain relief score was higher
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for those in the group receiving butorphanol (MD 0.67, 95% CI
0.25 to 1.09; low-quality evidence; Analysis 24.1). This finding
was supported by data regarding reported pain scores one hour
after drug administration, which were lower for women in the bu-
torphanol group (MD -0.60, 95% CI -1.02 to -0.18; low-quality
evidence; Analysis 24.2). The clinical significance of a difference
of this magnitude (i.e. 0.6 on a 10-point scale) is more difficult to
determine.
Additional analgesia required
There was no clear difference between the groups for numbers of
women requesting second doses of analgesia (RR 0.96, 95% CI
0.63 to 1.45; very low-quality evidence; Analysis 24.3). The other
two studies comparing IV butorphanol with IV pethidine did not
report any outcomes relating to women’s pain during labour.
Epidural
Other secondary outcomes were reported by Hodgkinson 1979:
no clear differences between groups were shown (RR 1.00, 95%
CI 0.30 to 3.35; 200 women; very low-quality evidence; Analysis
24.4),
Nausea and vomiting
One study (Hodgkinson 1979) involving 200 women reported
a lower incidence of nausea and vomiting associated with butor-
phanol compared with pethidine (0/100 in the butorphanol group
versus 12/100 in the pethidine group; RR 0.04, 95% CI 0.00 to
0.67; Analysis 24.5).
Other secondary outcomes were reported by Hodgkinson 1979:
no clear differences between groups were shown for caesarean sec-
tion (RR 0.80, 95% CI 0.22 to 2.89; 200 women; Analysis 24.6),
and assisted vaginal birth (RR 1.30, 95% CI 0.60 to 2.83; 200
women; Analysis 24.7).
No other maternal outcomes were reported.
Neonatal
There was no clear difference between groups for the only neonatal
outcome reported: Apgar score less than seven at one (RR 0.50,
95% CI 0.15 to 1.61; 2 studies, 230 infants; Analysis 24.8) and
five minutes (RR 1.00, 95% CI 0.06 to 15.77; 2 studies, 230
infants; Analysis 24.9).
25. IV morphine versus IV pethidine
Two trials involving a total of 163 women compared IV morphine
with IV pethidine (Campbell 1961; Olofsson 1996).
Primary and secondary outcomes
One study involving 143 women reported maternal satisfaction
with pain relief assessed three days postpartum (Campbell 1961).
Fewer women allocated to receive IVmorphine during labour were
satisfied with pain relief than those allocated to receive pethidine
(RR0.87, 95%CI0.78 to 0.98; low-quality evidence; 141women;
Analysis 25.1), although the proportion of women who reported
that they were satisfied was high in both groups (60/72 and 66/
69).
Campbell 1961 also reported that women allocated to receive IV
morphine were more likely to request additional analgesia com-
pared with women allocated to receive IV pethidine (RR 3.41,
95% CI 1.90 to 6.12; 143 women; low-quality evidence; Analysis
25.2). This difference may simply reflect a lack of equivalence in
the study doses of analgesia given (pethidine initial dose = 100
mg; morphine initial dose = 8 mg) rather than true differences
between analgesic effects.
A second study which investigated this comparison (Olofsson
1996) included only 10 women in each trial arm. No clear dif-
ferences were found for each of the three secondary outcomes re-
ported: nausea (RR 0.17, 95% CI 0.02 to 1.14), vomiting (RR
0.25, 95% CI 0.03 to 1.86; Analysis 25.3), and caesarean section
(no events in either group; Analysis 25.4), although the incidence
of nausea was lower in the morphine group (6/10 pethidine versus
1/10 morphine).
26. IV Nisentil versus IV pethidine
One study including 395 women compared IV Nisentil with IV
pethidine (Gillam 1958).
Primary and secondary outcomes
The study did not report any outcomes relating to women’s pain
relief.
Women allocated to the Nisentil group were less likely to suffer
vomiting than those receiving pethidine (RR 0.38, 95% CI 0.22
to 0.66). There was also less risk of nausea in the Nisentil group,
although this difference was not clear (RR 0.71, 95% CI 0.33 to
1.52; Analysis 26.1).
The incidence of babies requiring resuscitation and/or ventilatory
support was higher in babies born to women in the Nisentil group
(14/185) compared to those in the pethidine group (8/210) (RR
1.99, 95% CI 0.85 to 4.63; Analysis 26.2). Although this differ-
ence is not clear due to wide CIs crossing the line of no effect, and
this finding may have occurred by chance, if this is a true reflection
of differences between groups then this degree of harmful effect
on newborn babies is not clinically acceptable.
27. IV fentanyl versus IV butorphanol
One trial involving 100 women compared IV fentanyl with IV
butorphanol (Atkinson 1994).
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Primary and secondary outcomes
The study did not report any outcomes relating to maternal sat-
isfaction with analgesia measured during labour or maternal sat-
isfaction with analgesia in labour measured during the postnatal
period.
Additional analgesia required
Women allocated to receive IV fentanyl weremore likely to request
additional doses (two or more) of the study analgesia compared
with women allocated to receive IV butorphanol (RR 1.39, 95%
CI 1.05 to 1.85; Analysis 27.1). The study author claims the study
doses of drug were equivalent (IV fentanyl 50 µg to 100 µg every
one to two hours; IV butorphanol 1 mg to 2 mg every one to two
hours).
Epidural
Additionally, women in the fentanyl group were twice as likely as
those in the butorphanol group to go on to request an epidural
(RR 2.00, 95% CI 1.00 to 4.02; Analysis 27.2).
Other maternal outcomes reported (maternal sleepiness during
labour and caesarean section) showed no clear difference between
study groups (RR 3.00, 95% CI 0.64 to 14.16; Analysis 27.3, and
RR 0.80, 95% CI 0.23 to 2.81; Analysis 27.4, respectively).
There were no clear differences observed between groups for any
of the neonatal outcomes reported:
1. naloxone administration (RR 1.75, 95% CI 0.81 to 3.80;
Analysis 27.5);
2. neonatal resuscitation (RR 11.00, 95% CI 0.62 to 193.80;
Analysis 27.6);
3. Apgar score less than seven at five minutes (RR 1.20, 95%
CI 0.39 to 3.68; Analysis 27.7);
4. newborn neuro-behavioural score at two to four hours
(MD 0.00, 95% CI -1.61 to 1.61; Analysis 27.8);
5. newborn neuro-behavioural score at 24 to 36 hours (MD -
0.50, 95% CI -1.62 to 0.62; Analysis 27.9).
No other outcomes were reported.
Intravenous patient-controlled opioids for pain relief
in labour
28. PCA pentazocine versus PCA pethidine
One trial involving 29 women compared PCA pentazocine with
PCA pethidine (Erskine 1985).
Primary and secondary outcomes
Maternal pan score or pain measured in labour
Women’s self-reported pain score during labour was found to be
lower for those allocated to the pentazocine group compared with
women in the pethidine group, although this difference was not
clear between the groups (SMD -0.76, 95% CI -1.62 to 0.09;
23 women; very low-quality evidence; Analysis 28.1), a difference
of 1.6 cm on a 10 cm pain scale might be considered clinically
important. Similar numbers ofwomen in the two treatment groups
rated their pain relief as goodone day after the birth (RR0.82, 95%
CI 0.51 to 1.32; 28 women; very low-quality evidence; Analysis
28.2).
None of the maternal and neonatal secondary outcomes studied
showed a clear difference between the two study groups with low
numbers of events recorded for a number of these outcomes:
1. epidural (RR 1.50, 95% CI 0.29 to 7.65; 28 women; very
low-quality evidence; Analysis 28.3);
2. maternal sleepiness during labour (not clear how this was
measured) (RR 0.21, 95% CI 0.01 to 4.09; 29 women; Analysis
28.5);
3. nausea and vomiting in labour (RR 0.10, 95% CI 0.01 to
1.61; 29 women; Analysis 28.4);
4. caesarean section (RR 0.36, 95% CI 0.02 to 8.07; 29
women; Analysis 28.6);
5. breastfeeding at discharge (RR 1.00, 95% CI 0.85 to 1.17;
23 women; Analysis 28.7);
6. Apgar score less than seven at five minutes (no events in
either group; Analysis 28.8).
29. PCA remifentanil versus PCA pethidine
Three trials involving a total of 161 women compared PCA
remifentanil with PCA pethidine (Blair 2005; Douma 2010;
Volikas 2001).
Primary
No primary outcomes were reported upon in these studies.
Secondary outcomes
Maternal
Maternal pain score or pain measured in labour
Two studies (Volikas 2001; Douma 2010), involving 122 women
reported women’s pain score during labour. In both studies pain
was assessed using a VAS ranging from 0 (“no pain”) to 10 cm
(“worst imaginable pain”). In both studies women were asked to
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mark the level of pain experienced every hour, starting before anal-
gesia was administered. Results for the Volikas 2001 study were
recorded in a graph and so values have been estimated from the
graph. There was no evidence of a clear difference in mean pain
scores at one hour between the remifentanil and pethidine groups
(average MD -8.59, 95% CI -27.61 to 10.44; 122 women; low-
quality evidence; Analysis 29.1). There was substantial hetero-
geneity for this outcome and so a random-effects model has been
used (heterogeneity I² = 62%, Tau² = 136.73, Chi² test for het-
erogeneity P = 0.10).
Additional analgesia required
Two included studies (Blair 2005; Volikas 2001) reported num-
ber of women requiring additional analgesia (Entonox®) as an
outcome, with most women in both study groups requiring ad-
ditional analgesia (22/29 versus 24/27; RR 0.86, 95% CI 0.69 to
1.08; 56 women; very low-quality evidence; Analysis 29.2).
Epidural
Two studies reported number of women crossing over to epidural
as an outcome (Douma 2010; Volikas 2001), with fewer women
in the remifentanil group requiring an epidural (RR 0.42, 95%
CI 0.20 to 0.89; 122 women; moderate-quality evidence; Analysis
29.3).
Maternal sleepiness during labour
Maternal sleepinesswas reported in one study (Douma 2010). This
outcome was assessed using an observer sedation score recorded
hourly (1, awake; 2, sleepy; 3 eyes closed, but rousable by vocal
stimuli; 4, eyes closed, but rousable by physical stimulus; and 5,
un-rousable). Mean hourly scores at inclusion and then at one,
two and three hours after analgesia were reported. There was no
evidence of a clear difference in mean sedation scores at one hour
between the remifentanil and pethidine groups (MD 0.40, 95%
CI 0.14 to 0.66; 105 women; Analysis 29.4).
There was no clear difference found between groups for any of the
other secondary outcomes reported:
1. nausea and vomiting (RR 0.95, 95% CI 0.61 to 1.49; 2
studies, 119 women; Analysis 29.5);
2. caesarean section (RR 1.81, 95% CI 0.60 to 5.46; 2 studies,
97 participants; Analysis 29.6);
3. assisted vaginal birth (RR 0.96, 95% CI 0.46 to 2.00; 2
studies, 97 participants; Analysis 29.7).
Satisfaction with childbirth experience
Satisfaction with childbirth experience was reported in one study
(Douma 2010). Two hours after delivery women were asked to
score their overall satisfaction on a 10-point scale (tool not speci-
fied). Women in the remifentanil groups had slightly higher mean
satisfaction scores (MD 1.10, 95% CI 0.46 to 1.74; 68 women;
Analysis 29.8).
Neonatal
There was no clear difference found between groups for any of the
neonatal outcomes reported:
1. naloxone administration (RR 0.30, 95% CI 0.01 to 6.47; 2
studies, 56 infants; Analysis 29.9);
2. Apgar score less than seven at five minutes (RR 0.13, 95%
CI 0.01 to 2.16; 1 study, 17 infants; Analysis 29.10); Douma
2010 provided mean and standard deviation (SD) values for
Apgar scores at five minutes and so these data could not be
included in an analysis;
3. admission to NICU (RR 0.30, 95% CI 0.01 to 6.47; 1
study, 17 infants; Analysis 29.11);
4. newborn neuro-behavioural scores - The Neurologic and
Adaptive Capacity Score (NACS) was recorded at 15 minutes
and two hours after delivery (MD 0.20, 95% CI -0.93 to 1.33; 1
study, 56 infants; Analysis 29.12; and MD 0.60, 95% CI -0.66
to 1.86; 1 study, 56 infants; Analysis 29.13; respectively). A
maximum score of 40 indicates the neonate scored “normal”
scores in all neuro-behavioural areas.
No other neonatal outcomeswere reported under this comparison.
30. PCA nalbuphine versus PCA pethidine
One trial involving 60 women compared PCA nalbuphine with
PCA pethidine (Frank 1987).
Primary outcomes
Maternal satisfaction with analgesia measured during labour
The included study did not report this outcome.
Maternal satisfaction with analgesia in labour measured
during the postnatal period
There was no clear difference between the groups for this out-
come (RR 1.29, 95% CI 0.88 to 1.89; very low-quality evidence;
Analysis 30.1). Similarly, there was no clear difference between the
groups in the frequency of women who reported that they would
use the same pain relief in future (RR 1.06, 95% CI 0.79 to 1.43;
59 women; very low-quality evidence; Analysis 30.2).
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Secondary outcomes
Maternal
Maternal pain score or pain measured in labour
Womenwho received PCAnalbuphine reported lower pain scores,
measured on afive-point scale, than thosewho receivedPCApethi-
dine (MD -0.40, 95% CI -0.79 to -0.01; 60 women; low-quality
evidence; Analysis 30.3).
Additional analgesia required
There was no clear difference between the groups for women re-
quired Entonox (RR 0.83, 95% CI 0.46, 1.48; 59 women; very
low-quality evidence; Analysis 30.4).
Nausea and vomiting in labour
There was no clear difference between the groups for this outcome
(RR 0.68, 95% CI 0.30 to 1.54; 59 women; Analysis 30.5).
The included study did not report any other maternal outcomes.
Neonatal
Apgar score less than seven at five minutes
There was no clear difference between the groups for this outcome
(RR 0.42, 95% CI 0.02 to 9.76; 41 infants; Analysis 30.6).
The included study did not report any other neonatal outcomes.
31. PCA fentanyl versus PCA alfentanil
One study involving 23women comparedPCA fentanyl with PCA
alfentanil (Morley-Forster 2000).
Primary outcomes
Maternal satisfaction with analgesia measured during labour
This outcome was not reported in the included study.
Maternal satisfaction with analgesia in labour measured
during the postnatal period
There was no clear difference between the groups for this out-
come, although women allocated to receive fentanyl were slightly
less likely to describe their satisfaction with their pain relief as
“adequate” or “good” within six hours of giving birth compared
with women allocated to receive alfentanil (10/11 versus 7/12; RR
1.56, 95% CI 0.93 to 2.60; Analysis 31.1).
Secondary outcomes
Maternal
Maternal pain score or pain measured in labour
There was no clear difference between the groups in pain score
measured in labour (MD -12.80, 95% CI -32.12 to 6.52; 21
women; Analysis 31.2).
No clear differences were found for any of the other secondary
outcomes reported: nausea (RR 2.73, 95% CI 0.66 to 11.30; 23
women; Analysis 31.3), caesarean section (RR 1.64, 95% CI 0.33
to 8.03; 23 women; Analysis 31.4), naloxone administration (RR
2.36, 95% CI 0.53 to 10.55; 24 women; Analysis 31.5).
The included study did not report any other maternal outcome.
Neonatal
The included study did not report any of the neonatal outcome.
32. PCA fentanyl versus PCA pethidine
One trial involving 107women comparedPCA fentanyl with PCA
pethidine (Douma 2010).
Primary outcomes
No primary outcomes were reported in this study (Douma 2010).
Secondary outcomes
Maternal
Maternal pain score or pain measured in labour
Pain scores were assessed using aVAS ranging from0 (“no pain”) to
10 cm (“worst imaginable pain”). Mean pain scores were presented
at baseline and at one, two and three hours after analgesia. There
was no clear difference in mean pain scores at one hour between
the fentanyl and pethidine groups (MD -0.65, 95% CI -1.56 to
0.26; 107 women; low-quality evidence; Analysis 32.1).
Epidural
There was moderate-quality evidence to suggest that fewer women
in the fentanyl group required epidural compared to pethidine
group (RR 0.44, 95% CI 0.21 to 0.92; Analysis 32.2).
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There was no clear difference found between groups for any of the
other secondary outcomes reported:
1. maternal sleepiness during labour (MD -0.06, 95% CI -
0.25 to 0.13; 107 women; Analysis 32.3); this outcome was
assessed using an observer sedation score (1 = awake to 5 = un-
rousable) recorded hourly;
2. nausea and vomiting (RR 0.87, 95% CI 0.55 to 1.37; 102
women; Analysis 32.4);
3. caesarean section (RR 0.25, 95% CI 0.03 to 2.34; 81
women; Analysis 32.5);
4. assisted vaginal birth (RR 0.57, 95% CI 0.22 to 1.49; 81
women; Analysis 32.6).
Neonatal
Douma 2010 only provided mean and SD values for Apgar scores
at five minutes and so these data could not be included in an
analysis.
There was no clear difference found between groups for any of the
other neonatal outcomes reported:
1. neurobehavioural score (NACS 15 minutes post delivery)
(MD -0.90, 95% CI -2.31 to 0.51; 63 infants; Analysis 32.7);
2. neurobehavioural score (NACS two hours post delivery)
(MD -0.50, 95% CI -1.95 to 0.95; 64 infants; Analysis 32.8).
33. PCA (IM) meptazinol versus PCA (IM) pethidine
One study involving 10 women examined the feasibility of IM
meptazinol versus IM pethidine with PCA administration (Li
1988).
Primary outcomes
The included study did not report any of the primary outcomes.
Secondary outcomes
Maternal
Maternal pain score or pain measured in labour
Pain scores measured one day postpartum were lower with mep-
tazinol compared with pethidine; however, there was no evidence
of a clear difference (MD -17.60, 95% CI -49.93 to 14.73; 10
women; very low-quality evidence; Analysis 33.1). All women in
both groups were satisfied with the mode of administration (very
low-quality evidence; Analysis 33.2).
There were no clear differences found between groups for any
of the other secondary outcomes reported: additional analgesia
required: epidural (RR 3.00, 95% CI 0.15 to 59.89; very low-
quality evidence;Analysis 33.3),maternal sleepiness during labour
as measured by drowsiness scores one day postpartum (MD 5.60,
95%CI -28.19 to 39.39; Analysis 33.4), nausea measured one day
postpartum (MD -8.00, 95% CI -48.70 to 32.70; Analysis 33.5).
Neonatal
There was no clear difference between groups for naloxone admin-
istration (RR 1.00, 95% CI 0.08 to 11.93; 10 infants; Analysis
33.6).
Opioids versus TENS for pain relief in labour
34. Opioids versus TENS
Four trials involving 365 women are included in this comparison.
One trial compared IV pethidine (50 mg) versus TENS to the
lower back (Neumark 1978), another IMpethidine (50mg) versus
TENS to the back (Tawfik 1982), another IM tramadol (100 mg)
versus TENS to the back (Thakur 2004), and the fourth compared
PCA IV ondansetron and tramadol versus HANS (Han’s acupoint
nerve stimulator) (Liu 2015).
Primary outcomes
Maternal satisfaction with analgesia measured during labour
or during the postnatal period
Two studies (Neumark 1978; Tawfik 1982) involving 105 women
reported on maternal satisfaction with analgesia measured post
delivery. In the study by Neumark 1978 women were asked to rate
their satisfaction with analgesia the day after the birth as having
“good”, “inadequate” or “no” analgesic effect. In the study by
Tawfik 1982 women were asked about the degree of relief they had
obtained during the whole period of delivery. This was scored as
being “excellent”, “good” or “satisfactory”. We found no evidence
of a clear difference in maternal satisfaction with analgesia rated as
“good/excellent” between the TENS and opioid groups (RR 1.23,
95% CI 0.79 to 1.92, 2 studies; 104 women; very low-quality
evidence; Analysis 34.1).
Secondary outcomes
Maternal
Maternal pain score measured in labour
Four studies (Liu 2015, Neumark 1978; Tawfik 1982; Thakur
2004) reported on maternal pain measured in labour. In the study
by Neumark 1978, pain was assessed on a six-point pain scale for
a 70-minute period (from 1, “no pain” through 6, “unbearable
pain”). However, data were reported in graphical form which we
were not able to include in the analysis. Tawfik 1982 assessed pain
relief 30 minutes after analgesia as being complete, excellent or
good versus slight relief, while Thakur 2004, assessed pain on a
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verbal response scale during labour as complete or moderate relief;
versus mild or no relief (the time of measurement was not stated).
There was no evidence of a clear difference in maternal pain scores
between the opioid and TENS groups (average RR 1.15, 95% CI
0.81 to 1.61, 2 studies; 290 women; very low-quality evidence;
Analysis 34.2). There was substantial heterogeneity for this out-
come and so a random-effects model has been used (heterogeneity
I² = 64%, Tau² = 0.04, Chi² test for heterogeneity P = 0.10).
Liu 2015 reported pain scores 30, and 60 minutes following anal-
gesia. Pain scores were lower in the opioids group compared with
the TENS group at 30 minutes (MD -20.00, 95% CI -26.09 to -
13.91; 60 women), and 60 minutes (MD -20.00, 95% CI -25.16
to -14.84; 60 women, low-quality evidence; Analysis 34.3).
Maternal sleepiness during labour
Two studies (Tawfik 1982; Thakur 2004), reported drowsiness in
labour. Women in the opioid group were more likely to report
drowsiness (RR8.96, 95%CI 1.13 to 71.07; 290women; Analysis
34.4) compared with those in the TENS group, although the 95%
CIs were very wide for this outcome.
Nausea and vomiting
Three studies (Liu 2015; Tawfik 1982; Thakur 2004) reported
nausea and vomiting in labour. Women in the opioid group were
more likely to report nausea and vomiting compared to the TENS
group (RR 13.73, 95% CI 2.72 to 69.24; 350 women; Analysis
34.5).
Caesarean section; assisted vaginal birth
Two studies reported on caesarean section and assisted vaginal
birth rates (Liu 2015; Thakur 2004). There were no caesarean
sections reported in either the opioid or TENS groups in Thakur
2004. There was no evidence of a clear difference in the number of
caesarean sections (RR 2.00, 95% CI 0.19 to 20.90; 260 women;
Analysis 34.6), or assisted vaginal births between groups (RR 1.80,
95% CI 0.40 to 8.18; 260 women; Analysis 34.7).
No other maternal outcomes were reported.
Neonatal
Fetal heart rate changes in labour (persistent decelerations or
tachycardia)
One study reported on “fetal distress” (Thakur 2004) and found
no evidence of a clear difference between groups (RR 5.00, 95%
CI 0.24 to 102.85; 200 women; Analysis 34.8).
Two studies reported on Apgar scores (Tawfik 1982; Thakur
2004). However, both studies reported mean scores and these data
are very difficult to interpret. None of the studies reported infor-
mation on the number of babies with Apgar scores less than seven
at five minutes (prespecified outcome).
No other neonatal outcomes were reported.
Subgroup analysis
We did not carry out planned subgroup analysis because most
meta-analyses included data from only one or two studies and
separate breakdown on subgroup categories were rarely provided.
We therefore did not think that examining outcomes for subgroups
would affect the conclusions of the reviewor offer any other helpful
insights.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
OUTCOME N STUDIES (n women) EFFECT CERTAINTY OF EVIDENCE
Relative
(95% CI)
Absolute
(95% CI)
IM pethidine 50 mg/100 mg versus placebo
Maternal sat isfact ion with anal-
gesia measured during labour
(number of women sat isf ied or
very sat isf ied af ter 30 minutes)
1 (50) RR 7.00
(0.38 to 128.87)
0 fewer per 1000
(f rom 0 fewer to 0 fewer)
⊕©©©
VERY LOW a,b
Maternal pain score or pain mea-
sured in labour (described as
good or fair af ter 1 hour)
1 (118) RR 1.75
(1.24 to 2.47)
310 more per 1000
(f rom 99 more to 608 more)
⊕⊕©©
LOW a,c
Maternal pain score or pain mea-
sured in labour (reduct ion in VAS
of at least 40 mm af ter 30 min-
utes)
1 (50) RR 25.00
(1.56 to 400.54)
0 fewer per 1000
(f rom 0 fewer to 0 fewer)
⊕⊕©©
LOW a,d
Addit ional analgesia required 1 (50) RR 0.71
(0.54 to 0.94)
278 fewer per 1000
(f rom 58 fewer to 442 fewer)
⊕⊕©©
LOW a,c
Epidural 1 (50) RR 0.50
(0.14 to 1.78)
120 fewer per 1000
(f rom 187 more to 206 fewer)
⊕©©©
VERY LOW a,b
IM pentazocine versus placebo
Maternal pain score measured
during labour
1 (89) - MD 3.60 lower
(9.91 lower to 2.71 higher)
⊕⊕©©
LOW e
IM tramadol versus no treatment
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Maternal sat isfact ion with anal-
gesia (Analgesic ef fect described
as sat isfactory (not clear when
measured))
1 (60) RR 11.00
(0.64 to 190.53)
0 fewer per 1000
(f rom 0 fewer to 0 fewer)
⊕©©©
VERY LOW b,f
IM meptazinol versus pethidine
Maternal pain score or pain mea-
sured in labour (Maternal pain re-
lief poor or none (3-5 PN))
1 (801) RR 1.01
(0.91 to 1.12)
6 more per 1000
(f rom 57 fewer to 77 more)
⊕⊕©©
LOW a,g
Maternal pain score or pain mea-
sured in labour (Pain intensity 4
or 5 on 5-point scale (1 hour))
2 (239) RR 1.11
(0.69 to 1.80)
79 more per 1000
(f rom 223 fewer to 576 more)
⊕©©©
VERY LOW e,h
Addit ional analgesia required 2 (233) RR 1.03
(0.88 to 1.20)
20 more per 1000
(f rom 81 fewer to 134 more)
⊕©©©
VERY LOW e,h
Epidural 4 (788) RR 0.96
(0.71 to 1.29)
7 fewer per 1000
(f rom 52 fewer to 52 more)
⊕©©©
VERY LOW g,i
IM diamorphine + prochlorperazine versus pethidine + prochlorperazine
Maternal sat isfact ion with anal-
gesia in labour measured dur-
ing the postnatal period (Global
assessment of pain relief at 24
hours)
1 (133) RR 0.88
(0.67 to 1.16)
78 fewer per 1000
(f rom 104 more to 214 fewer)
⊕©©©
VERY LOW a,e
Maternal pain score or pain mea-
sured in labour (Pain intensity at
1 hour (moderate or severe))
1 (133) RR 0.85
(0.72 to 1.01)
130 fewer per 1000
(f rom 9 more to 243 fewer)
⊕©©©
VERY LOW a,e
Addit ional analgesia required 1 (133) RR 1.35
(0.53 to 3.40)
36 more per 1000
(f rom 48 fewer to 247 more)
⊕©©©
VERY LOW a,b
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Epidural 1 (133) RR 1.22
(0.72 to 2.07)
58 more per 1000
(f rom 74 fewer to 283 more)
⊕©©©
VERY LOW a,b
IM tramadol versus pethidine
Maternal pain score or pain mea-
sured in labour (Pain intensity:
women with poor pain relief )
4 (243) RR 1.56
(1.10 to 2.21)
142 more per 1000
(f rom 25 more to 307 more)
⊕⊕©©
LOW c,j
Addit ional analgesia required 3 (295) RR 1.07
(0.60 to 1.91)
11 more per 1000
(f rom 65 fewer to 149 more)
⊕©©©
VERY LOW e,j
IM dihydrocodeine 50 mg versus pethidine 100 mg
Maternal pain score or pain mea-
sured in labour (Maternal pain re-
lief poor at 1 hour)
1 (138) RR 1.09
(0.64 to 1.86)
25 more per 1000
(f rom 99 fewer to 237 more)
⊕©©©
VERY LOW a,e
IM pentazocine versus pethidine
Maternal sat isfact ion with anal-
gesia measured during labour
(Pain relief (good or very good) at
delivery)
2 (253) RR 1.08
(0.92 to 1.27)
51 more per 1000
(f rom 51 fewer to 171 more)
⊕©©©
VERY LOW e,h
Maternal pain score or pain mea-
sured in labour (Pain relief poor
(part ial, none or worse)) - No add-
on drugs
3 (365) Average RR 1.23
(0.74 to 2.05)
135 more per 1000
(f rom 153 fewer to 616 more)
⊕©©©
VERY LOW g,i,k
Maternal pain score or pain mea-
sured in labour (Pain relief poor
(part ial, none or worse)) - With
promazine
1 (85) RR 1.53
(0.66 to 3.58)
88 more per 1000
(f rom 57 fewer to 430 more)
⊕©©©
VERY LOW b,f
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Addit ional analgesia required -
pentazocine
1 (94) RR 0.91
(0.50 to 1.65)
30 fewer per 1000
(f rom 167 fewer to 217 more)
⊕©©©
VERY LOW b,f
Addit ional analgesia required -
pentazocine + promazine
1 (85) RR 1.67
(0.73 to 3.84)
112 more per 1000
(f rom 45 fewer to 473 more)
⊕©©©
VERY LOW b,f
IM nalbuphine versus pethidine
Maternal sat isfact ion with anal-
gesia measured during the post-
natal period (numbers dissat is-
f ied)
1 (72) RR 0.73
(0.55 to 0.96)
231 fewer per 1000
(f rom 34 fewer to 386 fewer)
⊕⊕©©
LOW a,c
Maternal sat isfact ion with anal-
gesia measured during labour
(Pain f ree)
1 (40) RR 6.00
(0.79 to 45.42)
250 more per 1000
(f rom 10 fewer to 1000 more)
⊕©©©
VERY LOW b,f
Maternal pain score or pain mea-
sured in labour (Pain intensity at
30 minutes: women with severe
pain)
1 (295) RR 0.86
(0.59 to 1.26)
40 fewer per 1000
(f rom 75 more to 118 fewer)
⊕©©©
VERY LOW a,e
Maternal pain score or pain mea-
sured in labour (VAS at 60 min-
utes (at peak of contract ion))
1 (72) - MD 8.00 lower
(18.55 lower to 2.55 higher)
⊕©©©
VERY LOW a,e
Addit ional analgesia required 1 (72) RR 1.26
(0.49 to 3.27)
45 more per 1000
(f rom 87 fewer to 389 more)
⊕©©©
VERY LOW a,b
Epidural 1 (307) RR 1.65
(0.55 to 4.94)
21 more per 1000
(f rom 14 fewer to 126 more)
⊕⊕©©
LOW l
IM phenazocine versus pethidine
Epidural 1 (212) RR 1.31
(0.58 to 2.97)
27 more per 1000
(f rom 36 fewer to 169 more)
⊕©©©
VERY LOW a,b
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IM diamorphine/morphine versus pethidine
Maternal sat isfact ion with anal-
gesia (number of women sat is-
f ied or very sat isf ied)
1 (484) RR 1.13
(1.02 to 1.26)
92 more per 1000
(f rom 14 more to 184 more)
⊕⊕⊕⊕
HIGH
Maternal sat isfact ion with anal-
gesia measured during labour or
during the postnatal period (Pain
relief described as poor)
1 (90) RR 1.22
(0.56 to 2.66)
44 more per 1000
(f rom 88 fewer to 332 more)
⊕©©©
VERY LOW a,b
Addit ional analgesia required 2 (574) RR 1.00
(0.92 to 1.10)
0 fewer per 1000
(f rom 57 fewer to 71 more)
⊕⊕⊕©
MODERATE g
Maternal pain relief at 30 mins 1 (484) - MD 0.80 lower
(1.24 lower to 0.36 lower)
⊕⊕⊕⊕
HIGH
Maternal pain relief at 60 mins 1 (484) - MD 0.80 lower
(1.26 lower to 0.34 lower)
⊕⊕⊕⊕
HIGH
IM butorphanol versus pethidine
Addit ional analgesia required 1 (80) RR 0.89
(0.55 to 1.45)
52 fewer per 1000
(f rom 214 fewer to 214 more)
⊕©©©
VERY LOW a,b
IM pethidine versus Entonox
Maternal pain score or pain mea-
sured in labour (af ter 30 mins)
1 (100) - MD 1.66 higher
(1.17 higher to 2.15 higher)
⊕©©©
VERY LOW c,f
Maternal pain score or pain mea-
sured in labour (af ter 60 mins)
1 (100) - MD 0.36 lower
(0.85 lower to 0.13 higher)
⊕©©©
VERY LOW e,f
IV pethidine versus placebo
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Maternal pain score or pain mea-
sured in labour (Pain score 30
mins post analgesia)
1 (240) - MD 4.10 lower
(4.56 lower to 3.64 lower)
⊕⊕⊕©
MODERATE c
IV fentanyl versus no treatment
Maternal pain score or pain mea-
sured in labour (Pain score 1 hour
post-analgesia)
1 (70) - MD 5.00 lower
(5.47 lower to 4.53 lower)
⊕©©©
VERY LOW d,f
Maternal pain score or pain mea-
sured in labour (Pain intensity (Se-
vere) af ter 1 hour)
1 (70) RR 0.02
(0.00 to 0.25)
868 fewer per 1000
(f rom 664 fewer to 886 fewer)
⊕©©©
VERY LOW d,f
IV fentanyl versus IV pethidine
Maternal pain score or pain mea-
sured in labour (Pain score 1 hour
af ter drug administrat ion)
1 (105) - MD 0.20 lower
(1.18 lower to 0.78 higher)
⊕⊕©©
LOW a,c
Mean doses of analgesia (non
pre-specif ied)
1 (105) - MD 0.40 higher
(0.14 higher to 0.66 higher)
⊕⊕©©
LOW a,c
IV phenazocine versus IV pethidine
Maternal sat isfact ion with anal-
gesia measured during labour
(women with fair or poor relief )
1 (194) RR 0.72
(0.48 to 1.10)
104 fewer per 1000
(f rom 37 more to 193 fewer)
⊕©©©
VERY LOW a,b
IV butorphanol versus IV pethidine
Maternal pain score or pain mea-
sured in labour (Pain relief score)
1 (80) - MD 0.67 higher
(0.25 higher to 1.09 higher)
⊕⊕©©
LOW a,c
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Maternal pain score or pain mea-
sured in labour (Pain score (1 hour
af ter drug administrat ion))
1 (80) - MD 0.60 lower
(1.02 lower to 0.18 lower)
⊕⊕©©
LOW a,c
Addit ional analgesia required 1 (100) RR 0.96
(0.63 to 1.45)
19 fewer per 1000
(f rom 178 fewer to 216 more)
⊕©©©
VERY LOW a,e
Epidural 1 (200) RR 1.00
(0.30 to 3.35)
0 fewer per 1000
(f rom 35 fewer to 118 more)
⊕©©©
VERY LOW a,b
IV morphine versus pethidine
Maternal sat isfact ion with anal-
gesia (assessed 3 days postpar-
tum)
1 (141) RR 0.87
(0.78 to 0.98)
124 fewer per 1000
(f rom 19 fewer to 210 fewer)
⊕⊕©©
LOW a,c
Addit ional analgesia required 1 (143) RR 3.41
(1.90 to 6.12)
373 more per 1000
(f rom 139 more to 793 more)
⊕⊕©©
LOW a,d
IV Nisentil versus IV pethidine
Maternal sat isfact ion with anal-
gesia, maternal pain score or pain
measured in labour, addit ional
analgesia, epidural
1 (395) - - No trial reported these outcomes.
PCA pentazocine versus PCA pethidine
Maternal pan score or pain mea-
sured in labour
1 (23) - SMD 0.76 lower
(1.62 lower to 0.09 higher)
⊕©©©
VERY LOW a,e
Maternal pan score or pain mea-
sured in labour (rated as good one
day af ter birth)
1 (28) RR 0.82
(0.51 to 1.32)
141 fewer per 1000
(f rom 251 more to 385 fewer)
⊕©©©
VERY LOW a,e
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Epidural 1 (28) RR 1.50
(0.29 to 7.65)
71 more per 1000
(f rom 101 fewer to 950 more)
⊕©©©
VERY LOW a,e
PCA remifentanil versus PCA pethidine
Maternal pain score in labour 2 (122) - MD 8.59 lower
(27.61 lower to 10.44 higher)
⊕⊕©©
LOW e
Addit ional analgesia required 2 (56) RR 0.86
(0.69 to 1.08)
124 fewer per 1000
(f rom 71 more to 276 fewer)
⊕©©©
VERY LOW e,h
Epidural 2 (122) RR 0.42
(0.20 to 0.89)
181 fewer per 1000
(f rom 34 fewer to 249 fewer)
⊕⊕⊕©
MODERATE d
PCA nalbuphine versus PCA pethidine
Maternal sat isfact ion with anal-
gesia in labour measured during
the postnatal period (rated good
or excellent)
1 (60) RR 1.29
(0.88 to 1.89)
164 more per 1000
(f rom 68 fewer to 504 more)
⊕©©©
VERY LOW a,e
Maternal sat isfact ion with anal-
gesia in labour measured during
the postnatal period (Would use
the same pain relief again)
1 (59) RR 1.06
(0.79 to 1.43)
43 more per 1000
(f rom 152 fewer to 311 more)
⊕©©©
VERY LOW a,e
Maternal pain score or pain mea-
sured in labour
1 (60) - MD 0.40 lower
(0.79 lower to 0.01 lower)
⊕⊕©©
LOW a,c
Addit ional analgesia required 1 (59) RR 0.83
(0.46 to 1.48)
82 fewer per 1000
(f rom 232 more to 261 fewer)
⊕©©©
VERY LOW a,b
PCA fentanyl versus PCA pethidine
Maternla pain score measured in
labour
1 (107) - MD 0.65 lower
(1.56 lower to 0.26 higher)
⊕⊕©©
LOW e
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Epidural 1 (107) RR 0.44
(0.21 to 0.92)
190 fewer per 1000
(f rom 27 fewer to 268 fewer)
⊕⊕⊕©
MODERATE d
PCA (IM ) meptazinol versus PCA (IM ) pethidine
Maternal pain score or pain mea-
sured in labour (measured 1 day
af ter delivery)
1 (10) - MD 17.60 lower
(49.93 lower to 14.73 higher)
⊕©©©
VERY LOW a,b
Satisf ied with mode of adminis-
trat ion (PCA IM)
1 (10) RR 1.00
(0.71 to 1.41)
0 fewer per 1000
(f rom 290 fewer to 410 more)
⊕©©©
VERY LOW a,b
Epidural 1 (10) RR 3.00
(0.15 to 59.89)
0 fewer per 1000
(f rom 0 fewer to 0 fewer)
⊕©©©
VERY LOW a,b
Opioids versus TENS
Maternal sat isfact ion with anal-
gesia measured post delivery
(rated as good)
2 (104) RR 1.23
(0.79 to 1.92)
89 more per 1000
(f rom 81 fewer to 355 more)
⊕©©©
VERY LOW b,h
Maternal pain score measured
during labour
2 (290) Average RR 1.15
(0.81 to 1.61)
97 more per 1000
(f rom 122 fewer to 393 more)
⊕©©©
VERY LOW a,e,k
Maternal pain score measured
during labour (af ter 30 minutes)
1 (60) - MD 20 lower
(26.09 lower to 13.91 lower)
⊕⊕©©
LOW a,c
Maternal pain score measured
during labour (af ter 60 minutes)
1 (60) - MD 20.00 lower
(25.16 lower to 14.84 lower)
⊕⊕©©
LOW a,c
CI: conf idence interval; RR: risk rat io; MD: mean dif ference
a Risk of bias: serious (Ef fect est imate f rom single study with design lim itat ions)
b Imprecision: very serious (Wide conf idence interval crossing the line of no ef fect, few events, and small sample size)
c Imprecision: serious (Small sample size)
d Imprecision: serious (Small sample size and few events)
e Imprecision: very serious (Wide conf idence interval crossing the line of no ef fect, and small sample size)
f Risk of bias: very serious (Ef fect est imate f rom single study with serious design lim itat ions)46
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g Imprecision: serious (Wide conf idence interval crossing the line of no ef fect)
h Risk of bias: serious (Pooled ef fect provided by studies with design lim itat ions)
i Risk of bias: very serious (Pooled ef fect provided by studies with serious design lim itat ions)
jRisk of bias: serious (Pooled ef fect est imate mainly f rom studies with design lim itat ions)
k Inconsistency: serious (unexplained substant ial heterogeneity)
l Imprecision: very serious (Wide conf idence interval crossing the line of no ef fect, and few events)
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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D I S C U S S I O N
Summary of main results
We set out to answer the question of the effectiveness of parenteral
opioids and their adverse effects for women and babies. We in-
cluded a total of 70 studies, with 61 studies involving more than
8000 women contributing data. This updated review includes
34 different comparisons, where an opioid was compared with
placebo, no treatment, with another opioid, or with transcuta-
neous electrical nerve stimulation (TENS). Formany comparisons
there was a lack of consistency in what outcomes were measured,
how they were measured, and when they were recorded. For most
comparisons, and many outcomes, only one or two studies con-
tributed data, and there were few opportunities to pool data in
meta-analysis. For many comparisons, data were not reported for
many of our prespecified outcomes. The quality of the evidence
was mainly assessed as low or very low for pain outcomes. Evi-
dence was downgraded for study design limitations (most of the
studies were not blinded), many of the studies had relatively small
sample sizes and were underpowered to detect differences between
groups and so results were downgraded for imprecision of effect
estimates.
All of the studies were conducted in hospital settings, on healthy
women with uncomplicated pregnancies at 37 to 42 weeks’ gesta-
tion. We excluded studies focusing on women with pre-eclampsia
or pre-existing conditions or with a compromised fetus.
Summary of results
1. Parenteral opioids provided some pain relief during labour
as indicated in eight out of the 24 comparisons that reported
maternal pain scores or pain measured in labour. The remainder
did not report clear differences between the groups.
2. Satisfaction with analgesia was not reported under most
comparisons, and was variable where reported.
3. Opioid drugs were associated with nausea, vomiting and
drowsiness, although different types of opioids were associated
with different adverse effects.
4. For most outcomes there was no good quality evidence of
differences between treatment groups.
5. There was insufficient evidence to assess the safety of
opioids in labour.
6. The quality of the evidence for pain and pain relief
outcomes was predominantly poor or very poor.
Intramuscular (IM) administration
1. For pethidine versus placebo, there was better pain relief
with pethidine measured by women describing pain relief as
good or fair after one hour, or a reduction in visual analogue
scale (VAS) of at least 40 mm after 30 minutes, with maternal
sleepiness in labour as the main adverse effect. There was no
evidence of clear differences in other adverse effects on the
woman or on the neonate.
2. For pentazocine versus placebo, there was no clear evidence
of differences between groups for any of the outcomes reported.
3. For tramadol versus no treatment, there was no clear
difference in maternal satisfaction with analgesia. No other
outcomes were reported.
4. For meptazinol versus pethidine, there was no clear
evidence of a difference in maternal satisfaction with analgesia or
pain measured in labour whether assessed either early or late
during labour, although more women had vomiting with
meptazinol. There was no clear evidence of a difference in
outcomes for the neonate.
5. For diamorphine versus pethidine, when an antiemetic was
given as co-therapy to both groups, there was no clear evidence
of difference in maternal satisfaction, pain scores in labour, or
maternal sleepiness in labour. Vomiting occurred more
frequently in women given pethidine. Whilst more babies had an
Apgar score less than seven at one minute with pethidine, by five
minutes there was no difference between groups, and no clear
evidence of differences in other neonatal outcomes.
6. For diamorphine versus pethidine, without an antiemetic,
more women in the diamorphine group reported to be satisfied
or very satisfied with their analgesia compared with the pethidine
group. There was no clear difference between groups for number
of women requesting additional analgesia, but women reported
less pain at 30 and 60 minutes following administration of
diamorphine compared with pethidine. This was high-quality
evidence. No clear differences were seen between groups for
adverse effects or neonatal outcomes.
7. For tramadol versus pethidine, maternal pain scores in
labour were better with pethidine than tramadol, and there was
no evidence of a difference in adverse effects on mother or baby.
8. For dihydrocodeine versus pethidine, only one study
contributed data and there was no evidence of a clear difference
in maternal pain scores in labour or adverse effects. More babies
had Apgar scores less than seven at one minute with pethidine
compared with dihydrocodeine, but the difference was not
apparent by five minutes, and there was no evidence of other
differences in neonatal adverse effects.
9. Other IM comparisons, most of which were tested in only
one study, provided few clear differences in their findings. For
pentazocine versus pethidine (six studies, one with antiemetic
addition to opioid), phenazocine versus pethidine, morphine
versus pethidine, butorphanol versus pethidine, and tramadol
versus no treatment, there was no evidence of a clear difference
in maternal or neonatal outcomes between groups.
10. For nalbuphine versus pentazocine, one study found a clear
difference in maternal satisfaction with analgesia, in favour of
nalbuphine. Fewer women who received nalbuphine experienced
nausea or vomiting.
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Intravenous (IV) administration including patient-controlled
anaesthesia (PCA)
1. For most comparisons very few studies contributed data,
and for most outcomes there was no clear evidence of differences
between groups. Several IV opioids (including fentanyl,
butorphanol and morphine) appeared to perform better than
pethidine in terms of analgesic effect (either satisfaction with
analgesia or pain scores). Pethidine was associated with worse
side effects. Compared with pethidine, maternal sleepiness in
labour was lower with fentanyl (one study), and nausea was less
with butorphanol and morphine (one study for each
comparison). When fentanyl and butorphanol were compared,
butorphanol was associated with fewer requests for additional
analgesia, a reduced need for neonatal resuscitation, and fewer
babies required naloxone (one study).
Opioids versus transcutaneous electrical nerve stimulation
(TENS)
1. For most outcomes there was no evidence of clear
differences between groups (maternal satisfaction with analgesia;
maternal pain scores; caesarean section; assisted vaginal birth;
fetal distress). The only clear finding was that women in the
opioid group were more likely to experience drowsiness and
nausea and vomiting than women in the TENS group.
Overall completeness and applicability of
evidence
This review is one of a series of Cochrane reviews examining pain
management in labour; other reviews have examined pharmaco-
logical and non-pharmacological methods of pain management
in labour including biofeedback (Barragán 2011), aromatherapy
(Smith 2011a), relaxation techniques (Smith 2018a), acupunc-
ture (Smith 2011b), manual methods (Smith 2018b), TENS
(Dowswell 2009), epidural analgesia (Anim-Somuah 2018), and
a range of other methods of pain management. Smith 2011b is
currently being updated. No studies were identified that compared
an opioid with hypnosis, biofeedback, intracutaneous or subcuta-
neous sterile water injection, immersion in water, aromatherapy,
relaxation techniques (yoga, music, audio), acupuncture or acu-
pressure, or manual methods (massage, reflexology).
Studies included in the review were carried out over a long time
period (1958 to 2017), during which time there have been ma-
jor changes in women’s and clinicians’ expectations and views of
childbirth and analgesia during labour. Some drugs commonly
used in the 1950s and 1960s may no longer be available in some
countries. The increasing use of epidural analgesia in resource-rich
countries means that opioids are now less likely to be the drugs
of choice in these settings. However, in many parts of the world
epidural analgesia is not available to all women, and parenteral
opioids are still widely used. It is important for all women to make
an informed choice about pain relief options available to them;
however, providing clear information on the effectiveness and sa-
fety of parenteral opioids is a challenge in the light of the findings
from this review.
With so many different comparisons and outcomes, we are not
able to provide clear information on the acceptability, effective-
ness and adverse outcomes associated with different opioids. In
this review, we have not compared the effectiveness of parenteral
opioids as a co-therapy although in many of the studies we looked
at, women were in fact able to have other analgesia, and this may
or may not have been reported. The use of other analgesia and
co-interventions may have differed by randomisation group, and
may have had an independent or synergistic effect on outcomes for
women and babies which we were not able to detect. For example,
women’s use of nitrous oxide was not consistently reported; the
fact that it was not mentioned in a study does not necessarily mean
that it was not used by the women involved. It was also difficult to
determine equivalence in terms of dosages of different trial drugs
used, their duration of effect and speed of metabolism. Studies also
varied in terms of number of doses available to women, and the
stage of labour at which further doses were not allowed in order
to avoid detrimental effects on the baby.
There was considerable heterogeneity between studies in the out-
comes measured and how they were reported. In some of the older
studies (pre-1970), maternal sedation may have been regarded as
a desired effect of opioid drugs, and pain relief was sometimes
reported by carers rather than by women themselves. There were
varied definitions of similar outcomes such as nausea, vomiting
(or both), sleepiness, drowsiness, etc. and even greater variation in
the way pain and pain relief were measured, and the time points
at which measurements were made.
Despite including 70 studies and including data from 61, there
were relatively few clear results.Many of the studies had small sam-
ples and most did not have the statistical power (singly or pooled)
to detect differences between groups for intended or unintended
effects that occur infrequently or rarely. In view of the large num-
ber of comparisons and outcomes, it is likely that some of the
findings where we have reported a difference between groups this
may have occurred by chance. On the other hand, for some less
frequent outcomes (e.g. low Apgar scores or the need for neonatal
resuscitation), some findings suggested that there may have been a
difference between groups but the studies often had small sample
sizes, and differences between groups were not clear. In addition,
we are aware that statistical and clinical significance may not be
the same thing. For example, it is difficult to know what a 0.6
cm difference in scores on a 10 cm VAS means in relation to a
difference in actual pain.
We were surprised by the number of studies where women’s views
of pain relief, or their assessments of pain in labour, were not mea-
sured at all.We were also surprised at the paucity of data on breast-
feeding outcomes. Even more recent studies did not generally col-
lect data on this important outcome, even though observational
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studies have suggested that opioids are associated with sedation
in babies and suppression of sucking in the minutes and hours
after birth. We had also hoped to collect information on the costs
associated with using opioid drugs; none of the included studies
provided data on the costs incurred by health service providers.
It is known that opioids cross the placental barrier, and short-term
effects such as the impact of opioids on fetal heart rate patterns
and very early neurological scores have been well documented in
observational and randomised studies. It is not clear that these ef-
fects have any clinical significance or lasting impact on infant well-
being. It has also been suggested that exposure to opioids during
labour may predispose children to serious long-term effects; how-
ever,muchmore research is needed to confirm or refute these find-
ings from observational studies (Jacobson 1990; Nyberg 2000).
None of the studies included in the review followed up women
and babies for more than a few hours or days so we are not able to
contribute to these debates.
All of the included studies examined IV or IM administration; two
excluded studies examined the subcutaneous administration of
opioids (Cahal 1960; De Kornfeld 1964); three studies compared
opioids with TENS (Neumark 1978; Tawfik 1982; Thakur 2004).
Two trials compared an opioid with no treatment (Jahani 2013;
Li 1988). The lack of placebo in these two trials confound the
comparison as the placebo effect from the IM/IV administration
cannot be separated out from the effect of the investigated opioid.
Further updates of this review will exclude such trials.
Quality of the evidence
Overall we found the evidence to be of low quality regarding
the analgesic effect of opioids and satisfaction with analgesia, and
poorly reported regarding adverse effects to women and babies.
Risk of bias was variable in all the studies. Most studies reported
post-randomisation exclusions for varying reasons such as women
having an instrumental or caesarean birth, protocol violations, and
birth happening within a certain time of the study drug being ad-
ministered. Most studies did not give reasons for withdrawals or
exclusions. Generally, study reporting was poor and assessing risk
or bias was challenging.
The quality of the evidence assessed using GRADE ranged from
very low to high (Summary of findings for the main comparison;
Summary of findings 2), but the majority of evidence was down-
graded and generally the evidence was assessed as low- or very
low-quality. The reasons for downgrading included study design
limitations and some heterogeneity, and for most comparisons
few studies contributed data and results were frequently impre-
cise. Due to the large number of comparisons and small amounts
of data for each, we produced one Summary of Findings table
(Summary of findings for the main comparison) and one addi-
tional table (Summary of findings 2) displaying all the outcomes
relating to pain for each comparison. These outcomes included
maternal satisfaction with analgesia measured during labour, ma-
ternal satisfaction with analgesia in labour measured during the
postnatal period, maternal pain score or pain measured in labour,
additional analgesia required, and epidural.
In some studies women were not included in the analysis if they
received the study drug within 30 to 60 minutes of giving birth
or more than four hours before giving birth. Such exclusions are
likely to introduce serious bias; we do not know whether these
women had different outcomes from the rest of the sample, and
it is possible that outcomes may have differed by randomisation
group.
The review’s primary outcomes, maternal satisfaction with anal-
gesia reported during labour and postnatally, were reported in dif-
ferent ways (for example, reports of satisfaction, global assessment
of pain relief ) and were often poorly reported. It was not always
clearly stated to whomwomen reported their pain levels; indeed in
some cases clinicians may have made assessments. These method-
ological problems may mean there was serious response bias in
some studies.
Potential biases in the review process
We are aware that the possibility of introducing bias was present
at every stage of the reviewing process. We attempted to minimise
bias in a number of ways; two review authors carried out data
extraction and assessed risk of bias. Each worked independently.
Nevertheless, the process of assessing risk of bias, for example, is
not an exact science and includes many personal judgements.
We are also aware that publication bias is a possibility, as the review
includes several small studies which reported a number of large
results. Although we did attempt to assess reporting bias, lack of
trial protocols meant that this assessment relied on information
available in the published trial report so reporting bias was not
usually apparent.
In previous updates, wemay have introduced somebias by convert-
ing three-, four- and five-point categorical scales for the measure-
ment of pain or pain relief into binary outcomes. We attempted
to be consistent across studies, but this was not always possible as
the wording of categories varied in different studies. We have tried
to indicate in the results section, and in forest plots, what event
rates in treatment groups signify.
Agreements and disagreements with other
studies or reviews
The findings and recommendations of this review are similar to
other reviews on this topic (Bricker 2002; NICE 2014) and to an
earlier Cochrane review looking at IM opioids (Elbourne 2006).
Clinical practice guidelines in the UK recommend that women
should be informed of the risks of IV and IM opioids and of their
limitations; NICE 2014 guidelines suggest that IM and IV opi-
oids should be available for women to choose, women should be
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informed of the alternatives, and should be made aware that par-
enteral opioids may have side effects (such as nausea and drowsi-
ness) and may interfere with breastfeeding.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Though most evidence is of low or very-low quality, for healthy
women with an uncomplicated pregnancy who are giving birth at
37 to 42 weeks, parenteral opioids appear to provide some relief
from pain in labour but are associated with drowsiness, nausea,
and vomiting in the woman. Effects on the newborn are unclear.
Maternal satisfactionwith opioid analgesia was largely unreported.
The review needs to be examined alongside related Cochrane re-
views. More research is needed to determine which analgesic in-
tervention is most effective, and provides greatest satisfaction to
women with acceptable adverse effects for mothers and their new-
born.
Implications for research
The question many women would like answered is how opioids
compare with other forms of pain relief available for use during
labour, in terms of analgesic effectiveness and the risk of adverse
effects for both women and babies. Given the paucity of useful
information from the current review, it is likely that the evidence
underlying this further question is also limited. It is important that
this evidence is reviewed, however, so that women can be provided
with information that is as complete and accurate as possible,
and so that remaining gaps in knowledge can be identified and
addressed through further research.
A large pragmatic randomised controlled trial (RCT) could be un-
dertaken to compare pain relief that includes an opioid with a pain
relief regimen not including an opioid, that collects data prospec-
tively on all important prognostic factors such as co-interventions.
These factors include additional analgesia and anti-emetics, labour
augmentation by means of artificial rupture of membranes or in-
travenous (IV) infusion of oxytocin, and use of electronic fetal
monitoring. Outcomes for women and their babies in the short
and longer term are also required. Future studies could also be in
the form of multi-armed/and/or adaptive designs to try and focus
in on the most effective interventions more quickly.
Maternal outcomes that would be important to guide practice are
actual pain relief and maternal satisfaction with analgesia, and im-
portant unintended effects such as nausea, vomiting and sedation.
For the neonate, Apgar scores at five and 10 minutes, resuscitation
including use of naloxone, neonatal intensive care unit admission,
initial effective suckling and establishment of breastfeeding, seda-
tion and irritability. Future updates of this review should include
all of these maternal and neonatal outcomes.
With respect to measuring the effectiveness of an opioid for labour
pain, there are a number of issues. Assessment of pain should be
measured in the pause between contractions. In order to minimise
response bias, it is important that maternal pain assessment be
recorded by the woman herself and not by the woman’s caregiver.
Lastly, it is important to assess maternal satisfaction to encompass
more than just the effects on pain but include other central ner-
vous system (CNS) effects. It would be important to measure sat-
isfaction in the short term (within 24 hours of delivery) and again
several days postpartum. In addition, it is known that maintaining
control in labour is important to women and this relates to pain
and pain control; formal assessment of sense of control in labour
would therefore be useful such as the use of the Labour Agentry
Scale (Hodnett 1987).
Stratification at baseline of two important predictors of outcome
should includematernal parity and spontaneous or induced labour
onset.
All studies were conducted on women labouring in hospital set-
tings exclusively. Many women labour and give birth in commu-
nity settings, the proportion of which is likely to increase due to
the international initiative to normalise birth, and reduce inter-
ventions associated with complications. Therefore, more research
in midwifery-led units and at home would inform practitioners
using opioids in these settings.
If recruitment of women to RCTs is hampered due to strong ma-
ternal preferences for pain relief, then a prospective observational
study, across different care settings, which collects data on impor-
tant predictors and outcomes as described for the RCT would also
be informative.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Atkinson 1994
Methods RCT 2-arm parallel-group design
Participants Setting: (not clear) hospital in Oklahoma, USA
100 women in early active labour (with regular contractions and cervical dilatation 3 cm
to 4 cm); at term (at or > 37 weeks’ gestation); no medical or obstetric complications
or evidence of fetal distress; requesting a “pain shot” rather than an epidural (all women
were offered epidural)
Interventions Both groups had continuous electronic fetal monitoring and intrauterine pressure
catheters
Experimental: IV fentanyl 50 µg to 100 µg every 1 to 2 hrs to a max of 5 doses
Control: IV butorphanol 1 mg to 2 mg every 1 to 2 hrs to a max 5 doses
(Doses of drugs were approximately equivalent in both arms of the trial.)
Outcomes Maternal uterine activity; adverse effects and side effects (including vomiting and seda-
tion); pain scored using 10-point VAS (0 = no pain, 10 = excruciating pain) scores were
recorded by nurses; Apgar scores at 1 and 5 mins; infant neurological exam 2 to 4 hrs
and 24 to 36 hrs after birth
Notes Start and end date: December 1992 - June 1993
Power calculation: unclear
Baseline imbalances between groups: unclear
Funding source: not specified
Conflicts of interest: not specified
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation schedule
Allocation concealment (selection bias) Low risk Pharmacy prepared identical unlabelled, coded sy-
ringes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical syringes. Described as double-blind.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors reported as blinded
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Atkinson 1994 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk It was not clear at what point women were ran-
domised.155 women enrolled; 24 decided to have
an epidural and were excluded (it was not clear
whether or not this was after randomisation); 19
women delivered within 1 hr of first dose and 12
did not request analgesia and were not included in
the analysis. Data available for 100 women; if loss
occurred after randomisation this represents a very
high level of attrition
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Low risk None apparent
Bitsch 1980
Methods RCT, 2-arm parallel groups
Participants Setting: hospital, Germany
45 women, in labour, cephalic presentation
Interventions Experimental: IM tramadol 50 mg (N = 23)
Control: IM pethidine 50 mg (N = 22)
Outcomes Primary outcome: maternal analgesia. Pain assessed as good, not good relief 5 to 10 mins
after injection
Secondary outcomes: maternal side effects and fetal heart changes
Notes German language paper, translation obtained. Tramadol 100 mg plus antiemetic arm
not extracted
If additional analgesia required, repeat doses could be administered within < 1 hr
Tramadol: could have up to 3 repeat doses, 50 mg
Pethidine: could have up to 3 repeat doses, 25 mg
Start and end date: August 1978 - December 1978
Power calculation: unclear
Baseline imbalances between groups: unclear
Funding source: unclear
Conflicts of interest: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
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Bitsch 1980 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessor was described as unaware of treatment assign-
ment.
Incomplete outcome data (attrition bias)
All outcomes
High risk Women not having a normal birth were excluded from
analyses. No information on pain relief was available for
7/45 women
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Unclear risk Unclear
Blair 2005
Methods RCT, 2-arm parallel groups
Participants Setting: Belfast hospital, UK
40 women (healthy and well) in labour, ASA I or II
Exclusion criteria: women planning to have epidural analgesia, with pre-eclampsia, mul-
tiple pregnancy, premature labour, allergy to study medications
Interventions Experimental: PCA remifentanil 40 µg with lock-out of 2 mins
Control: PCA pethidine 15 mg with lock-out of 10 mins
Nitrous oxide was available to all women and women were free to choose an epidural at
any stage
Outcomes Maternal sedation score (1 to 5 fully awake to unrousable); VAS 0 to 10 for pain and
satisfaction with pain relief; nausea; anxiety; Apgar scores at 1 min and 5 mins; infant
neurological adaptive capacity score (2 hrs and 24 hrs after birth)
Notes VAS scores were reported as median with inter-quartile range. We were not able to enter
data into RevMan tables but have described findings briefly in the text
Start and end date: not reported.
Power calculation: “prospective power calculation showed that a sample size of 20 would
give 85% power for detecting a difference of 20 mm on the VAS for overall pain, with
SD 21.2 from previous work”
Baseline imbalances between groups: “The two groups were similar as to characteristics
and duration, stage of labour and use of PCA”
Funding source: not specified
Conflicts of interest: not declared
Risk of bias
Bias Authors’ judgement Support for judgement
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Blair 2005 (Continued)
Random sequence generation (selection
bias)
Unclear risk Quote: “women were randomly allocated.”
Allocation concealment (selection bias) Unclear risk Not clear when randomisation occurred or how it was
carried out
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as double-blind study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It was reported that for some outcomes assessment was
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 40 women were randomised, 1 women was not included
in the analysis because of a “protocol violation”. 1 woman
that withdrew from the study was included in the analysis
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Low risk No baseline imbalance apparent
Borglin 1971
Methods RCT, 2-arm parallel groups
Participants Hospital setting
199 women: in labour, at term gestation, following normal pregnancy
No inclusion or exclusion criteria reported
Interventions Experimental: IM pentazocine 20 mg to 40 mg (N = 91)
Control: IM pethidine 50 mg to 100 mg (N = 89)
Outcomes Primary: analgesic and sedative effects. Pain assessed at time of birth or when second
injection administered, as very good, good, moderate or none
Secondary: maternal and neonatal side effects
Notes If additional analgesia required opioid repeated once after 3 or > hrs of first injection.
Actual dose received by women not reported
Start and end date: unclear
Power calculation: unclear
Baseline imbalances between groups: unclear
Funding source: not specified
Conflicts of interest: not specified
Risk of bias
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Borglin 1971 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Ampoules numbered and in random order
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Reported as double-blind, but no description of how
achieved. Identical volume but appearance not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants analysed, but missing data for some out-
come
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Low risk Balanced at baseline for age, parity, blood pressure, pulse,
frequency contractions, FHR, augmented labour, inten-
sity of labour, membranes intact or ruptured
Campbell 1961
Methods RCT, 3-arm parallel-group design
Participants Setting: hospital in Baltimore, USA
212 women randomised (141 included in the analyses in this review)
Inclusion criteria: women admitted to hospital for planned vaginal birth, at term, re-
questing analgesia (birth under regional anaesthesia)
Exclusions: imminent birth, allergy to any study medication or requiring birth under
general anaesthesia
Interventions Interventions at 3 cm to 4 cm dilatation for primiparous, and 4 cm to 5 cm for multi-
parous women
Group 1: pentobarbital IV (initial dose 200 mg) dosage varied
Group 2: pethidine IV (initial dose 100 mg), (69 women)
Group 3: morphine IV (initial dose 8 mg), (72 women)
All 3 groups also received 0.4 mg of scopolamine. If further analgesia was required,
women were given a half of the initial dose and 0.2 mg of scopolamine. If more than 2
additional doses were required analgesia was at the discretion of the attending doctor
In this review we have included groups 2 and 3 only in the analyses; pentobarbital (a
barbiturate) is no longer used for pain relief in labour
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Campbell 1961 (Continued)
Outcomes Length of labour, amount of analgesia required, obstetric complications and neonatal
condition (Apgar score at 1 min). Maternal perceptions were recorded 3 days after birth
(satisfaction and amnesia). A focus of this paper was the perception of staff on whether
women were “manageable”. Unmanageable women were those who were “possibly dan-
gerous to others or themselves, perhaps by leaving her bed”. Staff had the option of
removing unmanageable women from the study and prescribing whatever medication
was deemed suitable
Notes All women included delivered under regional anaesthesia.
Start and end date: not reported
Power calculation: not specified
Baseline imbalances between groups: unclear
Funding source: not specified
Conflicts of interest: not specified
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “in a random manner.”
Allocation concealment (selection bias) Low risk Coded vials containing study drugs were provided
by pharmacy
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “None of the personnel concerned with the
administration of the drugs or the evaluation of the
patients’ reaction had access to themaster list at any
time.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “None of the personnel concerned with the
administration of the drugs or the evaluation of the
patients’ reaction had access to themaster list at any
time.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk All women appear to be accounted for in the anal-
ysis and there were few missing data. The data re-
garding babies were less clear, denominators were
not provided
Selective reporting (reporting bias) High risk Results were not provided for babies. There was a
statement in the text “there were few infant com-
plications in the neonatal period; none of these ap-
peared related to the drugs”
Other bias Unclear risk Baseline characteristics described as similar.
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De Boer 1987
Methods RCT, 2-arm parallel groups
Participants Setting: hospital, UK
46 women (20 primiparous and 14 multiparous women included in the analyses). Un-
complicated pregnancy
Exclusions: first stage of labour > 12 hr, second stage > 1 hr, body weight < 45 kg, multiple
pregnancy, non-vertex presentation, preterm or postmature labour, previous caesarean
section, birthweight outside the 5th and 95th centiles for gestational age, congenital fetal
abnormality
Interventions Experimental: IM meptazinol 1.5 mg/kg body weight plus 10 mg metoclopramide hy-
drochloride (N = 17)
Control: IM pethidine 1.5 mg/kg body weight plus 10 mg metoclopramide hydrochlo-
ride (N = 17)
Outcomes Neonatal acid-base balance. Maternal pH pre injection, repeated at head crowning,
neonatal pH at 10 and 60 mins PN
Notes If additional analgesia required opioid repeated > 3-hourly. Actual dose received by
women not reported
Start and end date: not reported
Power calculation: not specified
Baseline imbalances between groups: unclear
Funding source: not specified
Conflicts of interest: not specified
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk States double-blind but not described.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk States double-blind but not described.
Incomplete outcome data (attrition bias)
All outcomes
High risk 12 women excluded from analysis, reasons for all exclu-
sions not explained
Selective reporting (reporting bias) High risk Reasons why some participant data excluded not ex-
plained. 3/12 excluded because problemwith pHanalyser
(meptazinol group)
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De Boer 1987 (Continued)
Other bias Low risk No baseline imbalances
Direkvand-Moghadam 2014
Methods Randomised clinical trial using individual randomisation.
Participants Setting: hospital in Iran
90 women randomised: nulli-parous, aged between 18 and 35 years, singleton preg-
nancy, spontaneous active labour, cervical dilation between 4 cm and 5 cm, gestational
age between 38 and 40 weeks, normal FHR tracings, intact membranes, and vertex pre-
sentation
Exclusion criteria: elective labour induction, emergency caesarean delivery, known
cephalopelvic disproportion, diagnosed pre eclampsia, chorioamnionitis, pyelonephri-
tis, maternal cardiac, renal disease, intrauterine growth restriction and cervical dilation
greater than 5 cm
Interventions Experimental group: pethidine 50 mg IM - no further detail given. Not clear if it was
given as requested or to all women or whether women could request a subsequent dose.
(N = 45)
Control group: normal saline IV same volume as pethidine. (N = 45)
Amniotomy was performed by a trained midwife when cervical dilation reached 5 cm if
the membranes had not ruptured spontaneously
Outcomes Mode of birth
Duration of active phase
Notes Start and end date: December 2012 to March 2014
Funding: not stated
CoI: reported no conflicts of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was carried out in the ob-
stetric triage unit using a random-number
chart
Allocation concealment (selection bias) Unclear risk Method of concealment not described.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Equal volumes of normal saline and pethi-
dine given but by different routes. Likely
that caregiver would realise allocation. Par-
ticipants likely to be aware of treatment
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Labour outcomes were collected by care-
giver.
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Direkvand-Moghadam 2014 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Reported that none of the 90 enrolled
women withdrew for any reason. Data re-
ported for all women. However not all data
are reported in absolute numbers and de-
nominators and results are not clear for Ap-
gar scores or neonatal admission to inten-
sive care
Selective reporting (reporting bias) Unclear risk Protocol not available. Outcomes are not
clearly pre-specified. It was not clear which
outcomes the power calculation related to.
Important outcomes were not reported
Other bias Unclear risk Similar baseline characteristics. Generally
poorly reported.
Douma 2010
Methods RCT, 3-arm parallel groups
Participants Setting: the Netherlands, Department of Obstetrics and Gynaecology
180 enrolled, 159 completed the study.
Inclusion criteria: healthy ASA physical status I or II term parturients in an active stage
of labour, with singleton cephalic presentation, without prior administration of opioid
analgesics
Exclusion criteria: obesity (BMI ≥ 40 kg m−2), opioid allergy, substance abuse history,
and high-risk patients (pre-eclampsia, severe asthma, insulin-dependent diabetes melli-
tus, hepatic insufficiency, or renal failure)
Interventions 1. Remifentanil, patient controlled IV, 40 µg loading dose, remifentanil 40 µg per
bolus with a lockout of 2 mins and max dose limit of 1200 µg h−1
2. Meperidine, patient controlled IV, 49.5 mg loading dose and 5 mg bolus with
lockout of 10 mins and max dose limit of 200 mg
3. Fentanyl, patient controlled IV, 50 µg loading dose and 20 µg bolus with lockout
of 5 mins and a max dose limit of 240 µg h−1
Outcomes Outcomes: pain scores (VAS) every hr; sedation score (1 awake, 2 sleepy, 3 eyes closed,
4 eyes closed but rousable, 5 unrousable; overall satisfaction on 10-point scale 2 hrs
after delivery; side effects - nausea,vomiting, itching; Apgar scores at 1 min, 5 mins;
cord blood gas analysis; NACS scores at 15 mins and 2 hrs after delivery; oxytocin use;
instrumental delivery; CS; spontaneous delivery
Notes Quote: “All women received similar instructions on how to use the PCA device: all
parturients were instructed to press the bolus button whenever they needed pain relief.”
Start and end date: not reported
Power calculation: ’For sample size calculation, we hypothesized that average pain scores
in the remifentanil or fentanyl group would differ at least 10% from the meperidine
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Douma 2010 (Continued)
group. Assuming an SD of 15 mm based on the previous studies, we calculated a sample
size of 60 parturients per group for a power of 0.95 and a two-sided a level of 0.05 to
detect this difference’
Baseline imbalances between groups: ’The characteristics of the parturients did not differ
statistically.’
Funding source: Bronovo Research Fund
Conflicts of interest: not specified
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Established using a computer generated random
sequence in numbered envelopes.”
Allocation concealment (selection bias) Low risk Quote: “Study medication was prepared and blinded by
hospital pharmacy.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Observants and medical personnel attending to
the parturient were unaware of the drug assignment.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “with exception of baseline data, all observations
and measurements were made by blinded observers.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 180 enrolled, 159 completed the study:
52 R group;
53 M group;
54 F group;
21 excluded because delivered within 1 hr after randomi-
sation
Quote: “Data analysis was per-protocol.”
Selective reporting (reporting bias) Unclear risk All outcomes discussed in methods appear to have been
reported uponwithin results.However, the study protocol
was not evaluated
Other bias Low risk Baseline characteristics similar
Duncan 1969
Methods RCT, 2-arm parallel groups
Participants Setting: hospital, UK
200 women. 66% primips, 34% multips, > 35 weeks’ gestation. Singleton, uncompli-
cated pregnancy
Exclusions: toxaemia, chronic medical disease, isoimmunisation, obstetric complication
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Duncan 1969 (Continued)
Interventions Experimental: IM pentazocine 48 mg (N = 100)
Control: IM pethidine 120 mg (N = 100)
Nalorphine hydrobromide + methylphenidate given if opioid administered within 2/24
of second stage diagnosis and, or fetal distress
Outcomes Primary outcome: analgesic effects: pain assessed at time of injection and every 30 mins
for 4 hrs. Severe or moderate pain. Pain relief complete, partial or none
Secondary outcomes: maternal: vomiting, blood pressure and pulse. Neonatal: Apgar at
1 min in babies born within 4 hrs of opioid
Notes If additional analgesia required opioid repeated after 4 hrs. As inclusion criteria > 35
weeks’ gestation, may include preterm infants
Start and end date: not reported
Power calculation: not specified
Baseline imbalances between groups: the 100 women given each drug was comparable
in respect of age, parity, height, last antenatal weight and blood pressure, attendance at
preparation classes, and infant weight
Funding source: drug - Pentazocine was supplied by Bayer products
Conflicts of interest: not specified
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk States “double blind” but does not report how achieved.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk States “double blind” but does not report how achieved.
Incomplete outcome data (attrition bias)
All outcomes
High risk 200 women randomised. Exclusion of women from anal-
yses if inadequacy of records, reached second stage before
analgesic assessment, operative birth or another interven-
tion. Exclusion of babies from Apgar analysis if additional
analgesia given, GA, antidote given to mother pre-birth
or clinical explanation for depressed baby. Denominators
for outcomes not clear
Selective reporting (reporting bias) Unclear risk Unclear
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Duncan 1969 (Continued)
Other bias Unclear risk Balanced at baseline for age, parity, height, weight, blood
pressure, attendance at antenatal classes and infant weight
El-Refaie 2012
Methods RCT, 2-arm parallel groups
Participants Setting: Ain Shams University Maternity Hospital, Egypt
240 women randomised
Inclusion criteria: healthy, nulliparous, women aged between 18 and 30 years, at term
(37-42 weeks of gestation) with a single fetus in vertex presentation, and diagnosed with
prolonged labour due to uterine dystocia during the first stage of labour with a cervical
dilatation of 4 cm to 6 cm. (Uterine dystocia was defined as crossing of the alert line on
the partogram without abnormal fetal presentation or cephalopelvic disproportion.)
Exclusion criteria: meperidine allergy, any contraindication for vaginal delivery, labour
induction, use of oxytocin or any type of analgesia prior to randomisation, maternal
request of pain relief, fetal death, or evidence of fetal distress
Interventions Experimental: Meperidine - single dose of 50 mg meperidine in 10 mL of isotonic saline
by slow intravenous administration over 2 mins (50 mg pethidine, 2-mL solution; Misr
Pharmaceutics, Cairo, Egypt) (N = 120)
Control: placebo - 10 mL of isotonic saline supplied in identical vials. (N = 120)
Outcomes Primary outcomes: (i) duration of labour (from the time of the beginning of the inter-
vention to the time of expulsion of the fetal head) and (ii) neonatal acid-base balance in
arterial and venous.
umbilical cord blood samples at birth.
Secondary outcomes: severity of labour pain, as assessed by the 10-cm visual analogue
scale (VAS) score (0 defined as no pain) before the intervention and 15, 30, and 60 mins
after drug or placebo administration, and during the second stage of labour; maternal
adverse effects; requirement for oxytocin augmentation after intervention; mode of de-
livery; and Apgar score at 1 and 5 mins
Notes When labour crossed the alert line on partograph, women were randomised and oxytocin
commenced
Start and end date: July 2007 and October 2009
Power calculation: ’The sample size was calculated using a power of 80%, an alpha of 0.
05, expected 60-min reduction in the length of labour, and assumed standard deviation
of 158 mins based on a previous report of the length of labor in a population of women
similar to our population. A sample size of 220 women was calculated to be necessary
on the basis of these assumptions.’
Baseline imbalances between groups: ’There were no significant differences between the
two groups with regard to maternal age, body mass index, gestational age at delivery,
cervical dilatation and length before intervention, and VAS score before drug or placebo
administration’
Funding source: not reported
Conflicts of interest: not reported
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El-Refaie 2012 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated sequence
Allocation concealment (selection bias) Low risk Randomisation codes were placed in sequentially-num-
bered, opaque, sealed envelopes to be opened at time of
enrolment by a nurse who prepared the study drug and
had no further involvement with the care of the partici-
pants
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study is described as double-blind, placebo trial. If
the neonatologists needed to know the administered in-
tervention to manage a neonatal side effect, they would
call a nurse to obtain such information
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk There was no loss to follow-up and all women reportedly
received their allocated intervention
Selective reporting (reporting bias) Unclear risk All outcomes described in methods appear to be reported.
Other bias Unclear risk Similar baseline characteristics. Some lack of clarity in
results, e.g. unclear if labour durations include women
who had a caesarean
Erskine 1985
Methods RCT 2-arm parallel-group design
Participants Setting: Cape Town, South Africa
29 women in established labour, not clear howmany primips, mean age 24 years, women
were expected to have a vaginal birth and have no antenatal medical or obstetric problems
Interventions Experimental: pethidine, IV PCA 10-min lock out, 0.3 mg per kg
Control: pentazocine, IV PCA 10-min lock out, 0.15 mg per kg
Outcomes Pain relief in labour (assessed bymidwife); pain relief (measured immediately after labour
(10 cmVAS) and 24 hrs postpartum frommother); satisfaction with pain relief; maternal
and neonatal serum samples; Apgar score at 1 min and 5 mins; infant weight; neuro-
behavioural examination on 1st and 5th day
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Erskine 1985 (Continued)
Notes The study also included a non-randomised control group; we have not included this
group in the analysis
Start and end date: not reported
Power calculation: not specified
Baseline imbalances between groups: unclear
Funding source: not specified
Conflicts of interest: not specified
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk It was reported that women were attended by the
same midwife throughout labour who was not in-
formed what medication women received. It is not
clear whether this blinding was achieved for all staff
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessors of neonatal outcomes were re-
ported to be blind to group allocation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Overall attrition not clear, there were some missing
data for some outcomes. Denominators were not
provided in all of the results tables
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Unclear risk No baseline imbalance apparent
Fairlie 1999
Methods RCT 2-arm parallel-group design
Participants Setting: hospital, UK
161 women randomised, data available for 133 women. 52% primips, 48% multips,
cx at least 3 cm dilated, 37 or > weeks’ gestation in spontaneous or induced labour
(induction by amniotomy and IV infusion oxytocin)
Interventions Experimental: IMdiamorphine 7.5mg (primips), 5mg (multips) plus 12.5mg prochlor-
perazine (N = 65)
Control: IM pethidine 150 mg (primips), 100 mg (multips) plus 12.5 mg prochlorper-
azine (N = 68)
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Fairlie 1999 (Continued)
Outcomes Primary outcome: maternal pain at 1 hr VAS (0-100), pain intensity (0 = no pain, 1 =
mild pain, 2 = moderate pain, 3 = severe pain), pain relief (0 = none, 1 = slight, 2 =
moderate, 3 = good, 4 = complete)
Secondary outcomes: maternal: vomiting, sedation, global analgesia assessment at 24 hr
(good or poor). Neonatal: Apgar at 1 min and 5 mins, resuscitation, naloxone adminis-
tration, SCBU admission, significant morbidity (seizures, respiratory distress, intraven-
tricular haemorrhage, necrotising enterocolitis)
Notes Second dose at maternal request: her choice of drug or epidural. Stratified by maternal
parity. Trial stopped early after recruitment of 150 women. Planned sample size was 200
women
Start and end date: May 1990 - February 1992
Power calculation: not specified
Baseline imbalances between groups: unclear
Funding source: not specified
Conflicts of interest: not specified
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Block sizes of 6
Allocation concealment (selection bias) Low risk Coded drug containers, randomisation code not
broken until analysis
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk States double-blind, drug containers identical in ap-
pearance
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk It was stated that the randomisation code was not
broken until the analysis stage
Incomplete outcome data (attrition bias)
All outcomes
High risk 28 (17%) excluded as delivered within 1 hr of ad-
ministration of study drug
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Low risk Balanced at baseline
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Fieni 2000
Methods RCT 2-arm parallel-group design
Participants Italy: hospital care setting
40 women. Full-term pregnancy, cx≥ 4 cm, in spontaneous active labour and requiring
analgesia
Interventions Experimental: IM tramadol 100 mg (N = 20)
Control: IM pethidine 75 mg (N = 20)
Outcomes Primary outcome: maternal pain relief and acceptability. Pain assessed hourly up to 5
hrs, VAS 1-3
Secondary outcomes: maternal: observations (pulse, BP, respiratory rate, arterial oxygen
saturation). Neonatal: Apgar at 1 min and 5 mins. Umbilcal cord pH
Notes Second dose of study drug allowed after 2 hrs as required. Italian language, translation
obtained. Data were presented in a way in which we were not able to incorporate them
into data tables in RevMan
Start and end date: unclear
Power calculation: unclear
Baseline imbalances between groups: unclear
Funding source: unclear
Conflicts of interest: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear how many women analysed as only per-
centages reported
Selective reporting (reporting bias) Unclear risk Unclear
Other bias High risk No baseline characteristics table - unclear re mater-
nal parity
Likely response bias as no information on whom
women reported to about their pain post injection
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Frank 1987
Methods RCT 2-arm parallel-group design
Participants Setting: London hospital, UK
60 healthy women at term (38-42 weeks) requiring pain relief in labour
Women requesting epidural, that had already received opioid analgesia, were receiving
treatment for depression or where the fetus was at risk were excluded
Interventions Experimental: (30 women) nalbuphine, 3 mg with 3 mg increments to a max of 18 mg
per hr; lockout time 10 mins (total max dose = 42 mg)
Control: (30 women) pethidine, 15 mg, 15 mg increments to a max of 90 mg per hr;
lockout time 10 mins (total max dose = 210 mg)
Entonox ® was available to women in both groups but was withheld for 30 mins for
analgesia assessment. Analgesia was stopped in the 2nd stage if there were side effects or
if the woman requested an alternative method
Outcomes Pain (measured on 5-point scale from 1- no pain to 5 - very severe); pain relief (assessed
1 day after birth; pain relief rated as good or excellent and women saying they would use
the same method again); sedation (1 awake, 3 asleep); neuro-behavioural assessment 6
to 10 hrs after birth; FHR
Notes Start and end date: not reported
Power calculation: not specified
Baseline imbalances between groups: unclear
Funding source: Dupont (UK) Ltd
Conflicts of interest: not specified
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomly allocated.”
Allocation concealment (selection bias) Unclear risk Described as double-blind but allocation conceal-
ment was not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Very little information. Described as double-blind.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk There were some outcome data for all but one of
the women randomised, but there were high levels
of missing data for some neonatal outcomes (e.g.
neurological infant assessments 40/60 babies avail-
able for analysis)
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Frank 1987 (Continued)
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Unclear risk There was some baseline imbalance; 6/30 in the
nalbuphine groupweremultiparous comparedwith
12/30 in the pethidine group. The authors report
that they took this into account in the analysis. In
this review data have not been adjusted for baseline
imbalance
Giannina 1995
Methods RCT, 2-arm parallel groups
Participants New Jersey USA, hospital setting, 1994
28 women in labour (36 randomised) with uncomplicated pregnancies, singleton, ver-
tex presentation, at term (37 to 41 weeks), 4 cm or less cervical dilatation, at least 3
contractions in 10 mins, no known maternal or fetal conditions that would affect FHR
tracings, fetal reactive, no medications that would affect FHR in the previous 2 weeks
Exclusions criteria: meconium staining, pregnancy-induced hypertension, fetal tachy- or
brady-cardia, arrhythmias or decelerations, chorioamnionitis, FGR, abnormal placenta,
maternal fever, fetal chromosomal disorder of structural abnormality
Interventions Experimental: IV nalbuphine10 mg
Control: IV pethidine 50 mg
Both groups had continuous fetal monitoring for 1 hr following medication
Outcomes FHR (accelerations, high and low variation); Apgar scores < 8 at 1 min and 5 mins;
mode of birth; cord pH < 7.15
Notes Start and end date: March 1994 - August 1994.
Power calculation: ’Using the normal reference ranges for long-term variation and ac-
celeration of ten beats per minute for a 15-second duration, the study would require 28
women to achieve a power of 90% to detect a change from values at the 50th percentiles
to values below the fifth percentile at an alpha error of 0.05.’
Baseline imbalances between groups: there was statistical difference between the groups
Funding source: not specified
Conflicts of interest: not specified
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random number table
Allocation concealment (selection bias) Low risk Sequentially-numbered, sealed envelopes
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Giannina 1995 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not specified
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not specified
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 36 women were enrolled. 8 women did not have sufficient
FHR tracings and were not included in the analysis (22%
attrition)
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Low risk No apparent baseline imbalance
Gillam 1958
Methods RCT, 2-arm parallel-group design
Participants Setting: hospital in USA
500 women admitted to hospital in labour. Little information provided
Interventions Experimental: (185 women) alphaprodine (Nisentil), initial dose 40 mg IV, subsequent
doses IM
Control: (210 women) pethidine, initial dose 100 mg IV, subsequent doses IM
Both groups received scopolamine. Analgesia was for the first stage of labour, birth
was carried out “with rare exception” under “saddle block or pudendal block terminal
anesthesia”
Outcomes Pain relief (rated just before leaving the room for childbirth); side effects and length of
labour
Notes Start and end date: not reported
Power calculation: not reported
Baseline imbalances between groups: unclear
Funding source: not reported
Conflicts of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information
Allocation concealment (selection bias) Low risk Coded drug containers
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Gillam 1958 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Drugs were prepared by pharmacy in coded con-
tainers and the codes were not revealed until after
birth
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Drugs were prepared by pharmacy in coded con-
tainers and the codes were not revealed until after
birth
Incomplete outcome data (attrition bias)
All outcomes
High risk 500 women were randomised, 55 women received
no analgesia andwere excluded, 22women received
more than1dose of opioid (not necessarily the same
drug) and were excluded, 21 women who were in
preterm labour or had a CS were excluded and 1
woman was excluded because she was sensitive to
study medication. Data available for 395 women
(21% attrition)
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Unclear risk Study medication was for pain relief in the first
stage of labour, most women received a pudendal
block for birth so outcomes relating to birth may
not be attributable to study medication alone
Grant 1970
Methods RCT 2-arm parallel-group design
Participants Setting: hospital, UK
212 women in spontaneous or induced labour with cephalic presentation at > 36 weeks’
gestation. Recruited to the trial at 36 week antenatal clinic visit
Interventions Experimental: IM phenazocine 3 mg (N = 107)
Control: IM pethidine 150 mg (N = 105)
Outcomes Primary outcome: maternal analgesia assessed in labour as poor, fair, good, very good.
Pain relief also assessed in postnatal questionnaire within 36 hrs of birth
Secondary outcomes: maternal: amnesia, restlessness, anxiety, vomiting. Neonatal: Apgar
at 1 min and 5 mins
Notes Epidural available if further analgesia required.
Start and end date: not reported
Power calculation: not reported
Baseline imbalances between groups: ’There was no significant difference between the
two groups with respect to age, parity, height, weight, pelvic size, incidence of induced
labour or cervical dilation at the time of first dose of analgesia’
Funding source: Smith and Nephew (Pharmaceutics) Ltd provided the marked drug
ampoules
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Grant 1970 (Continued)
Conflicts of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Low risk Code kept by hospital pharmacist and remained
unbroken until trial completed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk States double-blind, coded ampoules but no further
description given
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Code kept by hospital pharmacist and remained
unbroken until trial completed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 212 women randomised. Number of women anal-
ysed is not reported
Selective reporting (reporting bias) Unclear risk MW assessed maternal side effects in labour.
Other bias Unclear risk Although baseline characteristics described as simi-
lar - proportion of primips to multips not provided.
Balanced for age, parity, height, weight, cx dilata-
tion
PN maternal recollection of pain within 36 hr and
unclear to whom women reported ratings
Hamann 1972
Methods RCT. 2-arm parallel-group design
Participants 185 randomised. analysis for 160 women in labour.
Inclusion criteria: primiparous, no pregnancy complications.
Exclusions: women with hypertension or pre-eclampsia. It appeared that women who
had any complications during birth (e.g. CS) were excluded after randomisation
Interventions Intervention group: Avacan ® 25 mg IM (a spasmolytic)
Control group: Fortral ® 20 mg IM (pentazocine)
Outcomes Number of requests for analgesia, infant birthweight, Apgar score (at birth)
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Hamann 1972 (Continued)
Notes Data extraction was done from translation notes.
Start and end date: June 1969 - January 1971
Power calculation: unclear
Baseline imbalances between groups: unclear
Funding source: unclear
Conflicts of interest: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Table of random numbers
Allocation concealment (selection bias) Unclear risk Described as a double-blind trial but methods were
not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as double-blind.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear
Incomplete outcome data (attrition bias)
All outcomes
High risk 185 women approached, 25 were excluded and re-
sults suggest that any women who had CS were ex-
cluded from the analysis along with women who
had long labours (> 24 hrs) or where no injections
were given
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Unclear risk Assessment of risk of bias done using translation
notes.
Hodgkinson 1979
Methods RCT 4-arm parallel-group design
Participants Setting not clear, USA
200 women admitted to hospital in the 1st stage of normal labour, mean age 24 years,
women received medication if they complained of moderate or severe pain
Interventions Experimental: (100 women) (i) IV butorphanol 1 mg (67 women) (ii) IV butorphanol
2 mg (33 women)
Control: (100 women) (i) IV pethidine 40 mg (68 women) (ii) IV pethidine 80 mg (32
women)
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Hodgkinson 1979 (Continued)
Outcomes Pain intensity (graphs with hourly readings); pain relief (4-point scale); neuro-be-
havioural assessment 1 day after birth (Scanlon scale)
Notes Start and end date: not reported
Power calculation: not reported
Baseline imbalances between groups: unclear
Funding source: not reported
Conflicts of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information
Allocation concealment (selection bias) Unclear risk No information. Described as “double-blind”.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as double-blind but little detail of meth-
ods of allocation concealment or blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Described as double-blind but little detail of meth-
ods of allocation concealment or blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up apparent
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Unclear risk Very little information on study methods.
Husslein 1987
Methods RCT 2-arm parallel-group design
Participants Setting: hospital, Austria
40 women with no pregnancy complications, in spontaneous and induced labour, cx 3
cm to 5 cm dilated. 72.5% primips, 27.5% multips
Interventions Experimental: IM tramadol 100 mg (N = 20)
Control: IM pethidine 100 mg (N = 20)
Outcomes Primary: pain relief, assessed 10, 30, 60, 120 mins after injection using VAS 0-100, 0 =
pain free to 100 strongest pain experienced
Secondary: side effects, augmentation and type of birth.
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Husslein 1987 (Continued)
Notes Not stated in 1 dose only
Start and end date: unclear
Power calculation: unclear
Baseline imbalances between groups: unclear
Funding source: unclear
Conflicts of interest: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk All women analysed
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Unclear risk Baseline characteristics stated as similar
Jackson 1983
Methods RCT 2-arm parallel-group design
Participants Setting: hospital, UK
100 women in labour at term gestation with uncomplicated pregnancy
Interventions Experimental: Meptazinol 1.8 mg/kg body weight (N = 50)
Control: pethidine 1.8 mg/kg body weight (N = 50)
All participants received promethazine 12.5 mg with first injection
Outcomes Primary: newborn effects: Apgar score at 1 min and 3 mins
Notes If additional analgesia required, a repeat injection could be administered 3-hourly
6/50 women from each arm received a second dose at a 3-hourly interval
Start and end date: not reported
Power calculation: not reported
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Jackson 1983 (Continued)
Baseline imbalances between groups: unclear
Funding source: not reported
Conflicts of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk States double-blind but method not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk States double-blind but method not described
Incomplete outcome data (attrition bias)
All outcomes
High risk 5 babies excluded from analysis due to heart defects
and fetal distress
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Unclear risk Balanced for parity, weight and size of baby at base-
line.
Jahani 2013
Methods RCT 2-arm parallel-group design
Participants Setting: Maternity Unit, Tamin Ejtemai Hospital, Iran
70 women randomised
Inclusion criteria: multiparous pregnant women (gravida 2-7); term singleton pregnancy;
cephalic presentation; low-risk pregnancy with no history of drug tolerance (addiction)
, medical or mental diseases
Exclusion criteria: respiratory rate < 8 or maternal bradycardia (pulse rate less than 60)
and severe congenital anomalies in neonate after birth
Interventions Experimental: Fentanyl - 50 mcg fentanyl was prescribed in 2 doses with an interval of
1 hr after being diluted in 4 cc normal saline (total volume 5 cc - 25 µg/5 mL during 10
mins infusion and repeated second dose an hr later 25 µg/5 mL) at zero and 60 mins
Control: no analgesia
Outcomes Outcomes: pain score, blood pressure, heart rate, FHR andmaternal respiratory rate, du-
ration of labour, maternal side effects drowsiness, dizziness, nausea/vomiting, respiratory
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Jahani 2013 (Continued)
depression, hypotension (BP < 90 mmHg or less than < 20% of baseline), bradycardia
(HR < 60 beats min-1), and pruritus.Neonatal outcomes included Apgar scores at 1 min
and 5 mins and resuscitation efforts (if any)
Notes Power calculation: ’based on results from a pilot study on 10 parturients (and mean
duration of the active phase), effect size was obtained at 0.4 hours with power 80% and
confidence level of 95%, the sample size was then calculated to be 70 parturients’
Baseline imbalances between groups: ‘There was no statistically significant difference in
mean age between the two groups. There were no significant differences in gravidity,
parity, fetal heart rate, contraction duration or HR between the two groups’
Funding source: not reported
Conflicts of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk A coin was tossed to determine the participants
comprising the control and case groups (35 women
per group). It was not reported if this was at the
point of randomisation but no information on al-
location concealment
Allocation concealment (selection bias) High risk Coin toss to determine group. If this was at the
point of randomisation this is a high-risk method.
There was no indication of allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not feasible
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcome assessor likely to be aware of allocation.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No reported loss to follow-up, no denominators
given in tables and no details of women requesting
further analgesia and changing groups. Not clear if
there was loss to follow-up or not
Selective reporting (reporting bias) High risk Protocol not seen, outcomes listed in methods but
are not well reported. Apgar results described nar-
ratively, resuscitation measures not mentioned
Other bias Low risk Baseline characteristics were balanced across
groups.
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Kainz 1992
Methods RCT 3-arm parallel-group design
Participants Setting: hospital, Germany
66 women. 38-41 weeks’ gestation, free of complications, in active labour and requiring
analgesia, excluded if analgesia received within 4 hrs of randomisation
Parity: not reported
Interventions Experimental: IM tramadol 100 mg (N = 20); IM tramadol 100 mg + triflupromazine
10 mg (N = 25)
Control: IM pethidine 50 mg + triflupromazine 10 mg (N = 21)
Unclear if single or multiple doses administered, and if additional analgesia administered
Outcomes Maternal outcomes: maternal pain intensity VAS (0 to 10 cm) 30, 60, 120 and 180
mins, vomiting, drowsiness, BP, HR, cardiotocogram
Notes Tramadol 100 mg only group (A) not included in our analyses. German language,
translation obtained
Start and end date: unclear
Power calculation: unclear
Baseline imbalances between groups: unclear
Funding source: unclear
Conflicts of interest: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “zulfallszahlentafel” coincidence number table.
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Stated as double-blind but methods not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Stated as double-blind but methods not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 2/66 women excluded due to giving birth within 1
hr of study drug administration
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Unclear risk Unclear
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Kamyabi 2003
Methods RCT 2-arm parallel-group design
Participants Setting: hospital in Iran
88 primiparous women in spontaneous labour, gestation ≥ 37 weeks, and cervix 5 cm
dilated
Excluded if high-risk pregnancy, narcotic addiction.
Interventions Experimental: IM (placebo) normal saline 1.5 mL (N = 44)
Control: IM pethidine 75 mg (N = 44)
Outcomes Primary: analgesic effect. Pain assessed pre and post injection using Likert Scale VAS: 10
cm line, 0% = minimum effect, 100% = maximum effect
Secondary: side effects on uterine contractions (contraction duration and interval
recorded 3 times 15 to 60 mins post injection) and neonatal Apgar score at 1 min and
5 mins
Notes Timing of maternal pain assessment not reported.
Start and end date: not reported
Power calculation: the required number of women was based on a pilot study and
considering a power of 90%, d 7%, and error 5%, 44 women were needed in each group
Baseline imbalances between groups: unclear
Funding source: not reported
Conflicts of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States ’divided randomly’.
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study agents were of identical volume and appear-
ance
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Study agents were of identical volume and appear-
ance
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number of participants analysed and planned anal-
ysis not reported
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Unclear risk The number of women allocated to each group is
not reported and unclear if there are baseline im-
balances in prognostic factors
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Kermani 2015
Methods RCT, individual randomisation - difficult to assess abstract only
Participants Setting: not clear, Iran
48 women with term pregnancies in active labour.
Exclusion criteria: not stated
Interventions Experimental group: pethidine (n = not clear) route and dose not stated
Control group: acupressure (n = not clear) acupressure at spleen point 6 (SP6)
Outcomes No data - abstract only
Notes Dates of study: not stated
Funding: not stated
Conflicts of interest: not stated
15th June 2017 - email to 2nd author. Awaiting response.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Subjects were randomly selected
and divided”. No further description
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not mentioned but not possible to blind
intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcomes probably assessed by caregiver
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear due to lack of information in ab-
stract
Selective reporting (reporting bias) Unclear risk Unable to assess
Other bias Unclear risk Unable to assess
Keskin 2003
Methods RCT 2-arm parallel-group design
Participants Setting: hospital, Turkey
59 primiparous women with uncomplicated pregnancy at term gestation, in labour with
cervix 3 cm to 5 cm dilated and reporting a pain score 4 - 5 according to Wong-Baker
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Keskin 2003 (Continued)
Faces Pain Rating Scales with 0 = no pain, 5 = most intense pain
Exclusions: maternal medical disorders, history of drug or alcohol abuse
Interventions Experimental: IM tramadol 100 mg, single dose (N = 30)
Control: IM pethidine 100 mg, single dose (N = 29)
Outcomes Primary: analgesic effect assessed 30, 60 and 120 mins following injection using Wong-
Baker Faces Pain Rating Scales with 0 = no pain, 5 = most intense pain
Secondary: side effects: nausea, vomiting, drowsiness, fatigue and neonatal effects (Apgar
score at 1 min and 5 mins)
Notes Start and end date: not reported
Power calculation: not reported
Baseline imbalances between groups: unclear
Funding sources: not reported
Conflicts of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported. “randomly divided into two groups”.
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessor unaware of treatment group
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses to follow-up not explained and no ITT anal-
ysis.
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Unclear risk Unclear
Khooshideh 2009
Methods RCT 2-arm parallel-group design
Participants Setting: hospital, Iran
160 women. Free of complications, spontaneous and induced onset, cx 4 cm dilated, in
active labour and requiring analgesia. Women excluded if cx dilated > 5 cm
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Khooshideh 2009 (Continued)
Parity: not reported
Interventions Experimental: IM tramadol 100 mg (N = 80)
Control: IM pethidine 50 mg (N = 80)
2nd dose on maternal request after 4 hrs but pethidine withheld if cx dilated > 8 cm and
tramadol given instead
Outcomes Maternal outcomes: maternal pain intensity VAS (0 to 10 cm) 10 mins , 30 mins and
1-hourly intervals until birth, maternal satisfaction 24 hrs postpartum 5-point scale (ex-
cellent, very good, good, fair, poor), drowsiness, nausea, vomiting. Neonatal outcomes:
Apgar score at 1 min and 5 mins, naloxone administration, respiratory depression
Notes Start and end date: 2004
Power calculation: based on the assumption that a difference of 30 mins in duration of
labour would be clinically significant, 53 women was needed in each group 80% power
on a 5% significance (α = 0.05, β = 0.2)
Baseline imbalances between groups: ’The two groups were comparable regarding age,
parity, height, weight, period of gestation, fetal weight, cervical dilatation at initiation
of analgesia and need for oxytocin use’
Funding source: not specified
Conflicts of interest: not specified
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated codes
Allocation concealment (selection bias) Low risk Sequentially-numbered, sealed opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Drugs administered by clinician blind to group al-
location, but does not state how this was achieved
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Women fed back theirmaternal pain score to anaes-
thetist.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Flow chart addresses all data.
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Unclear risk Baseline characteristics similar
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Kuti 2008
Methods Reported to be randomised clinical trial. Individual women randomised
Participants Setting: labour ward of Wesley Guild Hospital, Ilesa Nigeria
100womenwhowere admitted in active spontaneous labour at termwith uncomplicated
singleton pregnancies requesting analgesia
Exclusion criteria: mothers with chronic medical diseases.
Interventions Experimental group: IM injection of Pentazocine 30 mg (Laborate Pharmaceuticals,
India) (N = 50, 44 following exclusions)
Control group: IM tramadol 100 mg.(P.T Interbat, Indonesia) (n = 50, 42 following
exclusions)
Outcomes Satisfaction with analgesia
Pain in labour
Mode of birth
Maternal side effects
Neonatal admission to special care
Apgar scores
Notes Start and end dates: June 2005 - May 2006
Funding and COI: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers in
blocks of 4
Allocation concealment (selection bias) Low risk Randomisation codes were placed in se-
quentially-numbered, opaque, sealed en-
velope. Envelope was opened when the
woman requested pain relief and the drug
administered by the randomising midwife
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk It is reported that the trial is double-blind.
When each woman requested pain relief,
the next numbered envelope was opened
and the appropriate drug administered by
the randomising midwife. Not clear if this
midwife cared for woman in labour. Both
given IM so women should be unaware
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The labour ward resident doctor, unaware
of the type of injection given, recorded the
clinical data and assess the analgesic efficacy
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Kuti 2008 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 14 women (6 in the pentazocine group and
8 in the tramadol group) delivered within 1
hr of drug administration and were there-
fore excluded from further analysis. Out-
come data are available for the remaining
women in the respective groups. Giving
birth within the hr, the drug administered
could have affected the neonate
Selective reporting (reporting bias) Unclear risk All essential outcomes are reported. Proto-
col not seen.
Other bias Unclear risk Women had similar characteristics at trial
entry. Some lack of clarity in reporting out-
comes
Lalooha 2017
Methods Reported to be randomised clinical trial. Individual women randomised
Participants Setting: hospital in Iran
120 women randomised, nulliparous women with term singleton pregnancy who had
induction of labour (reasons for and methods of induction not stated in abstract)
Exclusion criteria: not stated
Interventions Experimental group: single dose of 50 mg IV pethidine at 4 cm dilatation (it was not
clear whether this was at maternal request or whether all women received it) (N = 60)
Control group: IV normal saline (placebo) (N = 60)
Outcomes Duration of labour
Notes Start and end dates: unclear
Conflict of interest: not stated
Funding not stated
Translation requested 15th June 2017 - no data used in this review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information “randomly assigned”
Allocation concealment (selection bias) Unclear risk No information “randomly assigned”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants: placebo-controlled trial.
Caregiver: placebo-controlled trial. Staff
may have been aware of allocation if there
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Lalooha 2017 (Continued)
was sedation or other side effects
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not clear when group assignment revealed
and staff providing care recorded outcomes
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 120 women included. No information on
dropouts or missing data. Not clear
Selective reporting (reporting bias) Unclear risk This was a very brief abstract. Key out-
comes not reported.
Other bias Unclear risk Assessment from abstract. Full paper in
Arabic. Very little information onmethods.
Full translation requested
Lardizabal 1999
Methods RCT 2-arm parallel-group design
Participants Argentina: 2 hospitals
310 women of mixed parity, in labour 37-42 weeks’ gestation with cervix 4 cm to 6 cm
dilated, cephalic presentation and requiring analgesia
Exclusions: maternal medical condition, evidence of fetal distress, previous caesarean
section
Interventions Experimental: IM nalbuphine 20 mg, single dose (N = 152)
Control: IM pethidine 100 mg, single dose (N = 158)
Outcomes Primary: neonatal Apgar score < 7 at 1 min
Secondary: maternal pain assessed using VAS pre-injection, and 30 mins and 120 mins
afterwards (severe pain 75 or >), nausea, vomiting and type of birth.Neonatal side effects:
condition over first 24 hrs, admission to neonatal intensive care nursery
Notes Stratified by hospital.
Start and end date: June 1991 - September 1993
Power calculation: based on previous literature, mean incidence of low Apgar score was
12% in women receiving meperidine and 3% in women receiving nalbuphine, α = 0.
05, β = 0.20, 152 women in each group is needed for a 75% relative risk reduction in
the primary endpoint
Baseline imbalances between groups: the groups were balanced across various prognostic
variables such as age, nulliparity, weeks of gestation, maternal weight, cervical dilatation
at randomisation, uterine activity, number of women with induced labour, severe pain,
nausea, vomiting, dizziness, and dry mouth
Funding source: not reported
Conflicts of interest: not reported
Risk of bias
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Lardizabal 1999 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated code
Allocation concealment (selection bias) Low risk Coded ampoules, sealed and prepared by indepen-
dent pharmacist and identical in appearance
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical ampoules
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Few losses to follow-up
Selective reporting (reporting bias) Unclear risk Not mentioned if women reported pain to their
caregiver
Other bias Unclear risk Data analyst unaware of coding. Balanced at base-
line.
Levy 1971
Methods RCT 2-arm parallel-group design
Participants USA: hospital setting
93 primiparous women in labour, uncomplicated pregnancy at 37 or more weeks’ ges-
tation and in pain described as moderate or severe
Interventions Experimental: IM pentazocine 60 mg (N = 38)
Control: IM pethidine 100 mg (N = 45)
Outcomes Primary: pain relief assessed at 1 hr, as good or poor.
Secondary: maternal side effects, nausea or vomiting, labour progress. Neonatal Apgar
score at 1 min and 5 mins
Notes If additional analgesia was required, a second injection could be administered at the
discretion of medic. Not stated if IOL onset included
Start and end date: not reported
Power calculation: not reported
Baseline imbalances between groups: unclear
Funding sources: Sterling drug company and NIH Grant RR 00404
Conflicts of interest: not reported
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Levy 1971 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Identical vials with code number but no further
information given
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical vials with code number
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No-one involved with the immediate care of the
woman knew the drug identity
Incomplete outcome data (attrition bias)
All outcomes
High risk 83/93women analysed and reasons formissing data
not reported
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Unclear risk Unclear how many women randomised to each
group and balance at baseline unclear
Li 1988
Methods (Feasibility study) RCT, 2-arm parallel-group design
Participants 10 primiparous women in labour requesting pain relief, and who had no made any
request for alternative analgesia
Interventions Intervention group: meptazinol (PCA IM) up to 600 mg (75 mg per mL)
Comparison group: pethidine (PCA IM) up to 400 mg (50 mg per mL)
Doses described as equivalent. Nitrous oxide available to women in both groups
Outcomes Pain, drowsiness and nausea on a 100 mm VAS (0 = no pain) during labour and also
rated on the day after birth; Apgar score and neonatal weight gain over 3 days
Notes Feasibility study focusing on PCA IM administration of opioids
Start and end date: not reported
Power calculation: not reported
Baseline imbalances between groups: unclear
Funding sources: not reported
Conflicts of interest: not reported
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Li 1988 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described, “randomly allocated”.
Allocation concealment (selection bias) Unclear risk Described as a double-blind comparison
but methods not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as a double-blind comparison
but methods not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Described as a double-blind comparison
but methods not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk 10 women randomised and all accounted
for in the analysis.
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Unclear risk No baseline imbalance apparent.
Li 1994
Methods RCT. 2-arm parallel groups.
Participants Setting: Beijing hospital, China
60 women in early labour (cervical dilatation 2 cm to 3 cm) at term, with singleton
pregnancy, vertex presentation, with no pregnancy complications
Interventions Intervention group: 100 mg IM tramadol
Comparison group: no analgesia
Outcomes Analgesic effect (not clear when measured); satisfactory, some effect or no effect
Notes Data extraction from translation notes.
Start and end date: August 1993 - October 1993
Power calculation: unclear
Baseline imbalances between groups: unclear
Funding sources: unclear
Conflicts of interest: unclear
Risk of bias
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Li 1994 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Women were divided “at random” into groups.
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Women in the control arm received no treatment.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Women in the control arm received no treatment.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Denominators not clear. No apparent loss to follow-up.
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Unclear risk It was not clear whether or not women in the comparison
group were given any analgesia or whether they requested
any
Lisboa 1997
Methods RCT 2-arm parallel-group design
Participants Setting: hospital, Brazil
56 women
No information in abstract about participant inclusion criteria or characteristics
Interventions Experimental: IM nalbuphine 10 mg
Control: IM pethidine 100 mg
Outcomes Analgesia and side effects.
Neonatal: Apgar score
Notes Abstract only: insufficient information about participants.
Not reported if > 1 dose given or anti-emetic.
Start and end date: not reported
Power calculation: not reported
Baseline imbalances between groups: not reported
Funding sources: not reported
Conflicts of interest: not reported
Risk of bias
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Lisboa 1997 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as “randomly selected” but not explained
how.
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not mentioned
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not mentioned
Selective reporting (reporting bias) Unclear risk Impossible to decipher.
Other bias Unclear risk Impossible to decipher.
Liu 2015
Methods Randomised controlled trial with individual randomisation.
Participants Setting: Beijing Obstetrics and Gynecology Hospital, China.
120 women randomised who had no previous poor obstetrical outcome; no experience
in Han’s Acupoint Nerve Stimulator and TENS for other reasons; term pregnancy (> 37
weeks of gestation); at active phase of the first stage of labour with cervical dilatation 3
cm
Exclusion criteria: had the history of experimental drug allergy; had been diagnosed with
other diseases such as preoperative presence of maternal mental, neurological diseases,
affecting evaluation of pains and disease conditions; had combined with gestational
hypertension, gestational diabetes, gestational thyroid diseases; had taken analgesic drugs
or with a history of long-term use of analgesic drugs; had used diazepam, piperazine
hydrochloride or other sedative, analgesic drugs in the stages of labour; were overweight
or low pregnancy weight, BMI < 18.5 or BMI > 25 kg/m2; were not agreeable to receive
painless labour and not sign the informed consent form
Interventions Experimental group 1: HANS (Han’s acupoint nerve stimulator) group (N= 30) received
DCpulse stimulus at acupoints of Jiaji points (T 10-L 3) andCiliao (BL 32)The stimulus
was 100 Hz with a burst frequency of 2 Hz (dense dispersed waveform) The intensity
was 15 mA to 30 mA. The pulse duration was used for 30 mins
Experimental group 2: PCIA (Patient-controlled intravenous analgesia) group (N = 30)
IV infused ondansetron 8 mg; 5 mins later, 1.5 mg/kg tramadol injection was slowly
dripped, connected to Baxter AP electronic pump with 50 mL of 0.70% tramadol +
ondansetron 8 mg, background infusion 2 mL/hr, PCA dose of 2 mL, lockout interval
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of 10 mins
Experimental group 3: PCEA (patient-controlled epidural analgesia) group (N = 30) L2-
3 combined spinal- epidural puncture, intrathecal injection of 3mg ropivacaine, epidural
catheter connected to Baxter AP electronic pump, with 100 mL 0.1% ropivacaine and
50 ug sufentanil, background infusion 5 mL, PCA dose of 5 mL, lockout interval of 10
mins when the cervix was fully dilated (10 cm). N =30
All treatments were stopped at the point of complete cervical dilatation
Control group (N = 30) did not receive analgesia.
Only experimental groups 1 and 2 are included in this review as per methods
Outcomes Outcomes
Mode of birth
Maternal side effects
Oxytocin use
Neonatal asphyxia
Pain scores
Duration of labour
Apgar (mean, SD)
Notes Trial dates: August 2010 - November 2013
Funding: The Scientific Achievement and Appropriate Technology Extension Project of
Beijing Municipal Commission of Health and Family Planning (TG-2014-12)
Conflict of interest: not reported
120 women were randomised, so the number of women in each group should be 30,
this is what reported in tables 1-4, but different in trial profile
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table method
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk It is not feasible to implement blinding.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk It is not feasible to implement blinding.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No reports of loss to follow-up or women
requesting other analgesia and changing
groups. Not clear if women in the control
group requested analgesia at all. Denomi-
nators given in the tables are lower than in
flowchart
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Selective reporting (reporting bias) Unclear risk All outcomes from methods are reported.
Protocol not seen.
Other bias Unclear risk There was no statistical difference in the
basic information between 4 groups (P> 0.
05). Generally reporting is unclear.
Maduska 1978
Methods RCT 2-arm parallel-group design
Participants Setting: hospital, USA
80 women at term gestation, in spontaneous and induced labour with moderate to severe
pain
Exclusions: drug abuse history, systemic disease and women who planned to breastfeed
their babies
Interventions Experimental: IM butorphanol 1 or 2 mg (N = 40)
Control: IM pethidine 40 or 80 mg (N = 40)
Outcomes Primary: pain intensity assessed 30 and 60 mins post injection. Described as 1 = slight
relief, 2 = moderate relief, 3 = good relief, 4 = complete relief. Maternal satisfaction of
overall drug effect assessed postnatally as 1 = poor, 2 = fair, 3 = very good, 4 = excellent
Secondary: neonatal Apgar score at 1 and 5 mins, resuscitation. Maternal nausea and
vomiting
Notes If additional analgesia was required, a second dose of original drug could be administered
Maternal parity not reported but different drug dosage depending on parity
Almost all (77/80) participants were non-Caucasion and all were delivered with local or
regional anaesthesia
Start and end date: not reported
Power calculation: not reported
Baseline imbalances between groups: Quote: ”There was little difference among test
groups with respect to type of labour, age, sex, type of delivery, and anaesthetic agent
administered. Butorphanol 1 mg group slightly lower mean body weight.”
Funding source: Bristol laboratories, Syracuse, New York
Conflicts of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Low risk Drugs in consecutively-numbered, identical vials
prepared by independent laboratory
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Maduska 1978 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk States double-blind, drugs in identical vials.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk All women analysed.
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Unclear risk Balanced at baseline for type of labour, weight, age,
type of birth and anaesthetic agent
Mitterschiffthaler 1991
Methods RCT 2-arm parallel-group design
Participants Setting: Germany
40 women. Term pregnancy, cx dilated 2 cm to 3 cm, spontaneous labour onset, in active
labour and requiring analgesia
Parity: not reported
Interventions Experimental: IM nalbuphine 0.1 mg/kg (N = 20)
Control: IM pethidine 0.8 mg/kg (N = 20)
States dosing was ’on demand’. Unclear if single or multiple doses administered, and if
additional analgesia administered
Outcomes Maternal outcomes: maternal pain relief VAS (0 cm to 20 cm) 30, 60, 90 and 120 mins,
opinion of pain relief 12 hrs postpartum, sedation 4-point scale (awake, tired, sleeping
but will wake if spoken to, sleeping but will wake if shaken, asleep not possible to wake
up) 30, 60, 90 and 120 mins, ’side effects’, blood pressure, heart rate, CTG. Neonatal
outcomes: Apgar score at 10 mins, respiratory depression
Notes German language - translation obtained
Start and end date: unclear
Power calculation: unclear
Baseline imbalances between groups: unclear
Funding source: unclear
Conflicts of interest: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk 4/40women excludeddue to insufficient pain relief.
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Unclear risk Unclear
Mobaraki 2016
Methods Randomised clinical trial, individually randomised
Participants Setting: hospital in Iran.
100 women randomised in spontaneous labour pain along with appropriate maternal
and fetal indications for vaginal delivery
Exclusion criteria: presence of a personality disorder, an addiction, a complicated preg-
nancy, diabetes mellitus, macrosomia, chronic obstructive pulmonary disease, an uncon-
fident fetal heart rate, valvular heart disease, an upper respiratory tract infection or sinus
obstruction, a history of asthma, and contraindications for Entonox and pethidine usage
Interventions Experimental group: pethidine (50 women)
The pethidine group received an intramuscular injection of 0.5 mg/kg of pethidine. If a
patient’s pain rated higher than 5 VAS, 0.25 mg/kg of pethidine was injected. Not clear
if pethidine was limited to 2 doses
Control group: Entonox (50 women)
Patients were taught to use an Entonox facemask at the beginning of uterine contractions
and to continue deep inspirations at times when there was pain and cramps. Use of
Entonox could be started or cut at any moment during labour according to the needs
and preferences of the woman
Outcomes Pain scores after analgesia.
Duration of first and second stage of labour.
Notes Dates: 2015
Funding: Ardabil Medical Sciences University
Conflict of interest: not stated
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk By using randomnumbers, the participants
were randomly allocated into 2 groups.
Equal groups and no further detail
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Infeasible to blind.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not mentioned, but likely to be caregiver
carrying out assessment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No loss to follow-up reported, and no de-
nominators given in results tables. Demo-
graphic data do not add up to total number
of participants. Difficult to assess due to re-
porting. Also not clear if anyone changed
intervention
Selective reporting (reporting bias) Unclear risk No protocol seen and few outcomes pre-
specified in the methods
Other bias Unclear risk Parity is not reported in each group. There
were 16/50 under 20 year olds in the
Entonox group and 9/50 in the pethidine
group. These could be more likely to be
nulliparous
Moore 1970
Methods RCT 2-arm parallel-group design
Participants Setting: hospital, UK
206 mixed parity healthy women, in spontaneous or induced labour, at > 35 weeks’
gestation, cephalic presentation and in pain described as severe, moderate or slight
Interventions Experimental: IM pentazocine 40 mg (N = 73)
Control: IM pethidine 100 mg or 50 mg (N = 133)
Outcomes Primary: pain intensity assessed at 30, 60 and 90 mins post injection, described as severe,
moderate or slight. Asked at 12 to 24 hr postnatal if drug had helped
Secondary: neonatal Apgar score at 1 min and 5 mins, maternal side effects of nausea or
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vomiting
Notes If additional analgesia required, a maximum of 3 further doses of study drug could be
administered at 2- to 3-hourly intervals. Women could also use nitrous oxide and some
had a paracervical block
> 35 weeks’ gestation therefore preterm babies may be included
Start and end date: not reported
Power calculation: not reported
Baseline imbalances between groups: the age, physical and obstetric characteristics were
similar between groups except in fetal presentation
Funding source: not reported
Conflicts of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Coded ampoules but no further information given.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk States double-blind.Coded ampoules but not stated
if identical in appearance
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk States double-blind.Coded ampoules but not stated
if identical in appearance
Incomplete outcome data (attrition bias)
All outcomes
High risk 29/206 excluded because delivered or had paracer-
vical block.
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Unclear risk Unclear
Morley-Forster 2000
Methods RCT, 2-arm parallel-group design
Participants Setting: labour ward of a university health centre in Canada
23 women randomised when they requested analgesia, 83% primips, gestational age >
32 weeks, weight < 100 kg or > 50 kg, able to speak English, no history of opioid abuse
and normal FHR tracing
(Women recruited to the study had medical contraindications to epidural although it
was no specified what these were.)
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Morley-Forster 2000 (Continued)
Interventions Experimental: fentanyl, PCA 10 mcg per mL, initial bolus dose 1 mL, basal infusion
rate of 2 mL per hr with PCA bolus 2 mL
Control: alfentanil, PCA 100 micro g per mL, initial bolus dose 1 mL, basal infusion
rate of 2 mL per hr with PCA bolus 2 mL
Doses described as equivalent. Drugs were discontinued in both groups when the at-
tending midwife estimated that birth was likely to take place within 15 mins
Outcomes Pain (rated on a 100 mm VAS, recorded at baseline and every 30 mins thereafter);
sedation (nurse rated hourly); side effects; satisfaction with pain relief (good, adequate,
inadequate); Apgar scores at 5 and 10 mins; cord blood gases; naloxone dose; neonatal
neuro-behavioural score at 4 and 24 hrs
Notes Start and end date: not reported
Power calculation: not reported
Baseline imbalances between groups: quote: “The two groups were similar in age, weight,
gestational age, parity, inductions, type of delivery, baseline pain scores, rate of cervical
dilatation, duration of PCA use. The only difference was that the opioid dose- to delivery
time was shorter in the alfentanil group.”
Funding sources: not reported
Conflicts of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation schedule prepared by pharmacy.
Allocation concealment (selection bias) Low risk Plain, numbered vials prepared by pharmacy.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Plain vials prepared by pharmacy.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Stated that assessment was carried out by staff blind
to group assignment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 25 women were randomised. 2 did not follow the
protocol and were not followed up. There were
missing data for some variables
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Unclear risk Small sample size and the onset of analgesia varied.
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Morrison 1987
Methods RCT 2-arm parallel-group design
Participants Setting: hospital, UK
1100 women. 37-42 weeks’ gestation, in active labour and requiring analgesia
Parity: 44% primips, 56% multips.
Interventions Experimental: IM meptazinol 100 mg ≤ 70 kg, 150 mg > 70 kg (N = 513)
Control: IM pethidine 1100 mg ≤ 70 kg, 150 mg > 70 kg (N = 522)
Second dose, epidural or inhalation analgesia at maternal request
Outcomes Maternal outcomes: maternal pain at 30, 60, 90 and 120 mins VAS (0 to 100 mm),
nausea, vomiting, sleepiness, use of supplementary analgesia, method of birth, opinion
of analgesic effect assessed 3-5 days postpartum (rated excellent, good, poor but just able
to cope, no effect and required additional analgesia). Neonatal outcomes: Apgar at 1min
and 5 mins, resuscitation, naloxone administration, fetal distress, type of feeding
Notes Start and end date: not reported
Power calculation: not reported
Baseline imbalances between groups: ’The groups were comparable with regard to age,
maternal weight, parity and gestation’
Funding source: not reported
Conflicts of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Low risk Coded drug containers prepared at a site remote
from the trial
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk States double-blind and used coded drug contain-
ers.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk States double-blind and used coded drug contain-
ers.
Incomplete outcome data (attrition bias)
All outcomes
High risk 65 women excluded due to clerical errors or admin-
istration of wrong drug
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Unclear risk Women were balanced at baseline for age, weight,
parity and gestation
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Mowat 1970
Methods RCT 2-arm parallel-group design
Participants Setting: hospital, UK
94 women. > 35 weeks’ gestation, age ≥ 18 years, excluded if diabetic, history of renal
or hepatic impairment or taking monoamine oxidase inhibitors, in active labour and
requiring analgesia
Parity: ≤ 3
Interventions Experimental: IM pentazocine 60 ≤ mg (N = 46)
Control: IM pethidine 15 ≤ 0 mg (N = 48)
Up to 3 injections > 3 hrs apart at maternal request.
Outcomes Maternal outcomes: satisfied with analgesia, nausea, vomiting, sleepiness, use of addi-
tional analgesia (study drug), method of birth. Neonatal outcomes: Apgar at 1 min and
5 mins
Notes Data for some outcomes available after first dose.
Start and end date: not reported
Power calculation: not reported
Baseline imbalances between groups: the groups were similar with respect to age, and
number of previous pregnancies
Funding source: Sterling Winthrop Research Division supplied the drugs
Conflicts of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk States double-blind but how achieved not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk States double-blind but how achieved not reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk Exclusions from most analyses.
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Low risk Balanced at baseline for age, parity, induced labour
onset.
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Nel 1981
Methods RCT 2-arm parallel-group design
Participants Setting: hospital, South Africa
75 women. Healthy with no clinically detectable abnormality, in active labour, sponta-
neous and induced, and requiring analgesia. Excluded if history of hypersensitivity to
any drug, previous caesarean, preterm labour, cardiac, pulmonary or renal disease and
significant hypertension
Parity: mixed
Interventions Experimental: IM meptazinol 100 mg (N = 37)
Control: IM pethidine 100 mg (N = 38)
No concomitant analgesia given, metoclopramide 10 mg as required for nausea
Outcomes Maternal outcomes: pain at 1 hr 5-point VAS scale, drug-related side effects. Neonatal
outcomes: Apgar at 1 min and 5 mins, paediatrician assessment at 24 hrs
Notes Start and end date: not reported
Power calculation: not reported
Baseline imbalances between groups: unclear
Funding source: not reported
Conflicts of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk States double-blind but does not describe how
blinding achieved
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk States double-blind but does not describe how
blinding achieved
Incomplete outcome data (attrition bias)
All outcomes
High risk Number of women randomised not reported only
number analysed, not same numbers analysed for
all outcomes
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Unclear risk Women requiring caesarean or epidural were ex-
cluded from further study, unclear if this is pre- or
post-randomisation
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Nelson 2005
Methods RCT, 3-arm parallel-group design
Participants Setting: hospital in North Carolina USA.
45 healthy women with singleton pregnancies requesting analgesia
Women with allergies to the study medication, those that had already had medication
and those taking opioids for chronic conditions were excluded, along with those with
any signs of fetal distress
Interventions Experimental: (15 women) IV butorphanol, 1 mg bolus
Control: (15 women) IV pethidine, 50 mg bolus
(A second control group received IV pethidine 25 mg plus 0.5 mg butorphanol; this
group has not been included in the analyses in this review.)
Outcomes Pain (measured on a 0 -10 numerical rating scale); sedation and nausea, Apgar scores at
1 min and 5 mins
Notes Results for pain outcomes were reported on bar charts and are difficult to interpret. We
have not included these results in the analyses in this review
Start and end date: not reported
Power calculation: ’the study was powered based on the increased variability in pain’
Baseline imbalances between groups: ’Groups did not differ in demographic or labor
characteristics’
Funding source:National Institutes ofHealth, Bethesda,Maryland (grantNo.NS41386)
Conflicts of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “computer generated balanced block de-
sign”. Block size not stated
Allocation concealment (selection bias) Unclear risk Study described as double-blind but not details on
allocation concealment provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “drug was prepared by an anaesthesiologist
not involved with the treatment of the patient or
obtaining study measures”. Described as double-
blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
High risk It was not clear how many women were ran-
domised. Any women undergoing ARM, com-
mencing oxytocin or requesting epidural were
excluded after randomisation and were replaced
Quote: “their randomization was re-entered for an-
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Nelson 2005 (Continued)
other patient”. Women who reached 10 cm dila-
tion within 1 hr of drug administration were also
excluded from the analysis
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Unclear risk Unclear
Neumark 1978
Methods Randomised trial (methods unclear)
Participants 30 women
Inclusion criteria: Quote: ”co-operative patients“ with no drug dependency. Various ages
and social groups
Exclusion criteria: unclear
Interventions 5 study groups:
1. TENS group - TENS to lower back (10 women);
2. 50 mg IV pethidine (5 women);
3. placebo TENS (no current) (5 women);
4. ”Wrong“ TENS (electrodes applied to wrong positions) (5 women);
5. no analgesia or intervention (5 women).
Outcomes Pain intensity (grades 1 - 6 - no pain, light, bearable, heavy, very heavy, unbearable) over
70-min period. Satisfaction with analgesia 1 day after the birth ”Reaction of the subjects
the day after the birth to analgesia - rated as “good”, “inadequate analgesia” or “none” -
table 2. Progress in labour
Notes Paper in German. Translation notes used for data extraction.
We were unable to use the data from this paper in the review. We had intended com-
paring outcomes for women receiving IV pethidine versus no treatment. The only out-
come reported in the paper was the amount of relief obtained from the analgesia and no
outcomes were reported for the control group (no treatment). 5 women received pethi-
dine and 5 women no treatment. It was reported that 2/5 women receiving pethidine
had “good relief ”, 3 had insufficient or no relief. All women in the control group were
reported as having an increase in pain
Results - categories for pain relief (good, insufficient, none) do not correspond with pain
scale - 6 perceptions reported in the translation
Start and end date: not reported
Power calculation: unclear
Baseline imbalances between groups: unclear
Funding source: unclear
Conflicts of interest: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
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Neumark 1978 (Continued)
Random sequence generation (selection
bias)
Unclear risk Not described - “randomly divided”.
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk 1 group received no treatment. TENS groups -
1 without current and 1 where it was applied
to wrong positions were blinded to the TENS
intervention. Pethidine group presumably were
not blinded. blinding of personnel is unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not clear
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 1 woman was lost to follow-up.
Selective reporting (reporting bias) Unclear risk Small study and results were difficult to interpret.
Other bias Unclear risk Translation, so difficult to evaluate other bias.
Nicholas 1982
Methods RCT 2-arm parallel-group design
Participants Setting: hospital, UK
450 women. Healthy women with no obstetric complications, full-term pregnancy, in
active labour and requiring analgesia. Excluded if history of hypersensitivity to any drug,
previous caesarean, preterm labour, cardiac, pulmonary or renal disease and significant
hypertension
Parity: not reported
Interventions Experimental: IM meptazinol (N = 186 analysed).
Control: IM pethidine (N = 172 analysed).
Both given according to body weight. 75 mg if 38 kg to 50 kg, 100 mg if 51 kg to 69
kg or 150 mg if 70-85 kg. Each patient received up to 2 injections of study drug, and if
analgesia still inadequate epidural given
Outcomes Maternal outcomes: maternal assessment of pain relief at 15, 30, 45, 60, 90 and 120mins
(rated none, poor, satisfactory, good, very good or complete), type of birth, epidural,
sleepiness, nausea and vomiting. Neonatal outcomes: Apgar at 1min and 5mins, apnoea,
resuscitation, and lethargy, muscle tone, irritability success of feeding within first 24-hr
period
Notes Does not report number randomised to each group.
Start and end date:not reported
Power calculation: not reported
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Nicholas 1982 (Continued)
Baseline imbalances between groups: not reported
Funding source: not reported
Conflicts of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk States double-blind but does not describe methods
used.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk States double-blind but does not describe methods
used.
Incomplete outcome data (attrition bias)
All outcomes
High risk 79.5% follow-up but no ITT analysis.
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Unclear risk Unclear
O’Dwyer 1971
Methods RCT 2-arm parallel-group design
Participants Setting: hospital, UK
100 women. Age > 18 years, > 35 weeks’ gestation, uncomplicated singleton, vaginal
birth expected, in active labour and requiring analgesia
Parity: 9% primips, 76% multips, 15% grand multips.
Interventions Experimental: IM pentazocine 30 mg (N = 48 analysed)
Control: IM Pethilorfan ®100 mg (N = 50 analysed)
Second injection possible after 2 hr, each patient could receive up to 4 injections of study
drug, and nitrous oxide or trilene to supplement analgesia if required
Outcomes Maternal outcomes: maternal assessment of pain relief (numbers obtaining or not ob-
taining pain relief ), type of birth, additional analgesia required (study drug). Neonatal
outcomes: Apgar at 1 min and 5 mins, naloxone administration
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O’Dwyer 1971 (Continued)
Notes Does not state actual number randomised to each group.
Start and end date: not reported
Power calculation: not reported
Baseline imbalances between groups: the group was balanced in most of the variables
such as age, number of previous pregnancies, and cervical dilatation
Funding source: not reported
Conflicts of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk States double-blind but does not describe methods
used.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk States double-blind but does not describe methods
used.
Incomplete outcome data (attrition bias)
All outcomes
High risk 31/98 excluded from primary outcome as delivered
within 1 hr of administration of study drug, and
16 babies excluded from Apgar assessment as study
drug administered more than 4 hrs before birth
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Unclear risk Balanced at baseline for age, parity, contractions and
vital signs
Olofsson 1996
Methods RCT 2-arm parallel-group design
Participants Setting: hospital, Stockholm, Sweden
20 healthy nulliparous women in active labour after spontaneous rupture of the mem-
branes, cephalic presentation. No exclusion criteria specified
Interventions Experimental: 0.05 mg/kg IV morphine up to 3 doses (max 0.15 mg/kg body weight)
Control: 0.5 mg/kg IV pethidine up to 3 doses (max 1.5 mg/kg body weight)
Both groups had continuous FHR monitoring.
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Olofsson 1996 (Continued)
Outcomes Sedation rates; CS, nausea and vomiting.
Notes Start and end date: not reported
Power calculation: not reported
Baseline imbalances between groups: the demographic variables were balanced between
the groups
Funding source: Karolinska Institute foundations and the Swedish Medical Research
Council
Conflicts of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “assigned at random.”
Allocation concealment (selection bias) Low risk Coded ampoules provided by pharmacy.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind; pharmacy provided
identical coded ampoules
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk No apparent loss to follow-up.
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Unclear risk Small sample and no clear information that groups
were comparable at baseline. Range of cervical di-
lations at recruitment between 4 cm and 9 cm
Olson 1964
Methods RCT, 2-arm parallel-group design
Participants Setting: Washington, USA
194 women in established labour. Analgesia was given at approximately 4 cm to 5 cm
cervical dilatation
Interventions Experimental: IV phenazocine 1 mg
Control: IV pethidine 50 mg
Both groups received promethazine 50 mg, and for both groups “birth was accomplished
under pudendal nerve block anaesthesia with terminal self-administered trichloroethy-
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Olson 1964 (Continued)
lene”
Outcomes Pain relief (recorded by women on the first postpartum day); nausea and vomiting;
adverse effects; progress in labour; Apgar scores at 1 min and 5 mins
Notes Start and end date: not reported
Power calculation: not reported
Baseline imbalances between groups: unclear
Funding source: not reported
Conflicts of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Low risk Drugs were prepared by pharmacy in identical
coded vials and the code was not broken by the
pharmacist until the study had been completed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Drugs in identical vials.Pharmacy prepared identi-
cal coded drugs
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data for some outcomes (approximately
5% for maternal postpartum outcomes, and 10%
for nurse recorded evaluations in labour)
Selective reporting (reporting bias) Unclear risk None apparent, protocol not seen.
Other bias Low risk None apparent
Osler 1987
Methods RCT 2-arm parallel-group design
Participants Setting: hospital, Denmark
199 women. Spontaneous or induced labour onset, in active labour and requiring anal-
gesia
Parity: 78% nullips, 22% multips
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Osler 1987 (Continued)
Interventions Experimental: IM meptazinol 100 mg (N = 100). Control: IM pethidine 750 mg (N =
99). Each patient could receive up to 3 injections of study drug with an interval of not
less than 2 hrs between doses
Outcomes Maternal outcomes: maternal assessment of pain relief 5, 15, 30, 60, 90, 120 mins (rated
complete, good, satisfactory, unsatisfactory), type of birth, additional analgesia required,
epidural, adverse effects. Neonatal outcomes: Apgar at 1 min and 5 mins, neonatal
distress, admission to SCBU
Notes Start and end date: not reported
Power calculation: not reported
Baseline imbalances between groups: ’There were no differences between the two groups
in age, body weight or height, or number of previous deliveries
Funding source: not reported
Conflicts of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as double-blind but no methods de-
scribed.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Described as double blind but no methods de-
scribed.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All women analysed.
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Unclear risk No baseline imbalance in age, weight, height or
number of previous deliveries
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Prasertsawat 1986
Methods RCT 3-arm parallel-group design
Participants Setting: hospital, Thailand
135women. 37 to 42weeks’ gestation, cx≥ 3 cm, in active labour and requiring analgesia
Parity: not reported
Interventions Experimental: IM tramadol 100 mg (N = 45); IMmorphine 100 mg (N = 45). Control:
IM pethidine 100 mg (N = 45). Second injection possible after 1 hr of half original study
dose, each participant could receive maximum of 2 doses
Outcomes Maternal outcomes: pain severity/relief 30 mins, 1, 2, 3, and 4 hrs (rated good, satisfac-
tory, no response), drowsiness, nausea, vomiting. Neonatal outcomes: Apgar at 1 min
and 5 mins, neonatal resuscitation
Notes Start and end date: 1 February 1986 - 28 February 1986
Power calculation: not reported
Baseline imbalances between groups: unclear
Funding sources: not reported
Conflicts of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk States blind but does not describe the method.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Medical students unaware of group allocation as-
sessed outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants analysed.
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Low risk Age and maternal weight balanced at baseline.
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Quilligan 1980
Methods RCT, 2-arm parallel-group design
Participants Setting not clear (hospital in USA)
100 women in good health in active labour, with no addiction to or tolerance to drugs
and complaining of moderate to severe pain. Women who “planned to nurse” were
excluded
Interventions Experimental: (50 women) IV butorphanol 1 mg to 2 mg (44 women had an initial
dose of 1 mg and 6 an initial dose of 2 mg, after 1 hr or more a 2nd dose was given if
requested)
Control: (50 women) IV pethidine 40 mg to 80 mg (45 women had an initial dose of 40
mg and 5 an initial dose of 80 mg, a 2nd dose was given after 1 hr or more if requested)
Outcomes Pain (5-point scale 0 - no pain, 4 - very severe pain); pain relief (5-point scale 0 - none,
4 - complete relief ); FHR; Apgar scores at 1 min and 5 mins
Notes Start and end date: not reported
Power calculation: not reported
Baseline imbalances between groups: unclear
Funding sources: not reported
Conflicts of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as double-blind study but no details pro-
vided.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Outcome data were available for all women ran-
domised.
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Unclear risk No baseline imbalance was apparent although 8
women in the butorphanol group were induced
compared with 1 woman in the pethidine group
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Rayburn 1989a
Methods RCT. 2-arm parallel groups
Participants Setting: Nebraska university hospital, USA
105 women in early active labour (3 cm to 4 cm cervical dilation); at or beyond 37
weeks’ gestation with nomedical or obstetric complications, with no signs of fetal distress
and requesting narcotic analgesia rather than an epidural. (Intervention group: 55%
nulliparous, 71% non-white race, mean age 23 years; control group: 48% nulliparous,
70% non-white race, mean age 23 years.)
Interventions Experimental: (49 women) IV fentanyl 50 µg to 100 µg per hr
Control: (56 women) IV pethidine 25 mg to 50 mg per hr
Outcomes Pain (measured on 10-point VAS recorded by labour ward nurses); nausea and vomiting;
sedation; itching; FHR changes
Notes Women were recruited only between 8 am and 3 pm on weekdays.
Start and end date: January 1988 - August 1988
Power calculation: not reported
Baseline imbalances between groups: ’There were no statistically significant differences
in maternal demographic characteristics and need for oxytocin augmentation.’
Funding source: not reported
Conflicts of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Pharmacy randomisation table.
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Staff not blinded to group allocation.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Staff not blinded to group allocation.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All women randomised seem to be included in the results.
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Unclear risk Women were recruited only on weekdays between 8am
and 3pm so may not represent the population attending
the study hospital
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Refstad 1980
Methods RCT, 2-arm parallel-group design
Participants Setting: hospital, Norway
85 women. Healthy women at term, expected to have a normal birth in active labour
and requiring analgesia
Parity: not reported
Interventions Experimental: IM pentazocine 45 mg (N = 43)
Control: IM pethidine 100 mg (N = 42)
Half dose repeated after 1 hr if required and further full dose after 3 hrs if labour
prolonged. All women received promazine 25 mg IM before 1st injection, nitrous oxide
or pudendal block or both allowed at end of 2nd stage
Outcomes Maternal outcomes: pain relief at 1 hr (0 = no pain, 1 = slight pain, 2 = moderate pain,
3 = severe pain), type of birth, additional analgesia required. Neonatal outcomes: Apgar
at 1 min and 5 mins, naloxone administration, FHR changes
Notes Start and end date: not reported
Power calculation: not reported
Baseline imbalances between groups: unclear
Funding source: Sterling-Winthrop company supplied trial drugs
Conflicts of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk 25/85 women excluded from analysis as delivered
within 1 hr of 1st dose of study drug
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Unclear risk Nitrous oxide or pudendal block permitted during
second stage
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Sekhavat 2009
Methods Reported to be a randomised clinical trial with individual randomisation
Participants Setting: hospital in Iran
150 women
Healthy women, with singleton cephalic presentation pregnancy in spontaneous labour,
3 cm or more cervical dilatation requesting analgesia
Exclusion criteria: pethidine allergy, contraindication to vaginal delivery, fetal death or
distress, fetal congenital heart malformation or obstetric complications such as antepar-
tum haemorrhage
Interventions Experimental group: pethidine IM 50 mg, with 25 mg after 4 hrs if women requested.
(N = 75)
Control group: placebo, IM saline. (N = 75)
Women in both groups received routine care which included FHR surveillance and 2-
hourly vaginal examinations, with a protocol for oxytocin augmentation for delay
Outcomes Apgar scores
Fetal heart rate changes
Oxytocin administration
Notes Start and end date: October 2004 to September 2005
It was reported that the study was not supported by any pharmaceutical company
Conflicts of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk It was reported that women were allocated
“randomly (using a randomized consecu-
tive numbered chart)”. It was not clear
whether the chart had random numbers or
that numbers were ordered consecutively
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants: study was placebo controlled.
Caregiver: study was placebo controlled -
staff may have been aware of allocation as
some women received no analgesia
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Reported to be blind to allocation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 150 women were randomised, 75 in each
group. There was no mention of dropouts
or any missing data
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Sekhavat 2009 (Continued)
Selective reporting (reporting bias) High risk There was little information. The outcome
reportedwere FHRonly.Mode of birthwas
not reported, some outcomeswere reported
to be “no different” but raw data were not
reported. No protocol available. No power
calculation
Other bias Unclear risk There was little information onmethods so
it was not possible to assess whether other
risk of bias was present
Sheikh 1986
Methods RCT, 2-arm parallel-group design
Participants Setting: hospital, UK
205 women. Healthywomen 38 to 41 weeks’ gestation, uncomplicated pregnancy, spon-
taneous or induced labour onset, in active labour and requiring analgesia. Excluded if
epidural or forceps birth likely
Parity: mixed
Interventions Experimental: IM meptazinol 100 mg (N = 98)
Control: IM pethidine 100 mg (N = 99)
Additional doses of test drug allowed at intervals no less than 2 hrs if required to a maxi-
mum of 3 doses. All women could receive nitrous oxide if required and prochlorperazine
12.5 mg IM for nausea and vomiting. Epidural at midwife discretion
Outcomes Maternal outcomes: pain intensity 30 mins and then hourly intervals until birth (rated
none, mild, moderate, severe), pain relief (rated none, slight, moderate, strong or com-
plete), type of birth, additional analgesia required, nausea and vomiting. Neonatal out-
comes: Apgar at 1 min and 5 mins, resuscitation. Within 72 hrs postpartum feeding
problems, irritability and muscle tone
Notes Start and end date: not reported
Power calculation: not reported
Baseline imbalances between groups: both the groupswere balanced for age, bodyweight,
and parity
Funding sources: Wyeth laboratories supplied the coded ampoules of the trial drugs
Conflicts of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
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Sheikh 1986 (Continued)
Allocation concealment (selection bias) Low risk Coded ampoules kept at a site remote from trial.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind, used coded ampoules
and states that identity of drug unknown
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blind outcome assessor for all bar 15% of women.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 8women excluded fromanalysis as deliveredwithin
30 mins of administration
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Unclear risk Balanced at baseline for age and weight, but im-
balance in parity. 43/98 multip meptazinol group
versus 34/99 in pethidine group
Sliom 1970
Methods RCT, 3-arm parallel-group design
Participants Setting: hospital, South Africa
196 women. Healthy women at term, uncomplicated labour, in active labour expected
to deliver in next 4 hrs and requiring analgesia. Excluded if likely to deliver within 30
mins and had received analgesia within previous 6 hrs
Parity: mixed
Interventions Experimental: IM dihydrocodeine 50 mg (N = 80)
Control: IM pethidine 100 mg (N = 58), placebo (saline) (N = 58)
Single dose of study drug.
Outcomes Maternal outcomes: pain relief at 1 hr (rated good, fair, poor), sedation (rated drowsy,
alert but calm, restless), nausea, vomiting. Neonatal outcomes: Modified Apgar at 1 min
and 5 mins (minus colour)
Notes Women excluded after randomisation if deliveredmore than 4 hrs after injection of study
drug
Start and end date: not reported
Power calculation: not reported
Baseline imbalances between groups: all the groups were balanced for age, race, and
parity
Funding sources: BDH (South Africa) Pty Ltd supplied dihydrocodeine bitartrate
Conflicts of interest: not reported
Risk of bias
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Sliom 1970 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk States double-blind. Not reported how blinding
was achieved.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk States double-blind. Not reported how blinding
was achieved.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number of women randomised not reported, au-
thors only report the number of women analysed
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Unclear risk Unequal number of women in each treatment
group due to post-randomisation exclusions. Ex-
clusions included women who delivered < 30 mins
or > 4 hrs after administration of study agents
Tawfik 1982
Methods RCT: methods not clear
Participants Setting: Egypt
90 primiparous women with normal presentation and position and expected to deliver
normally
Interventions Intervention: pethidine 50 mg IM 4- to 5-hourly
Comparison: TENS applied to back. The position arranged to suit the mother and
moved to lower abdomen if preferred
Both groups were given 10 mg diazepam IM. Both groups had artificial rupture of
membranes at 5 cm and oxytocin augmentation
Outcomes Pain intensity (scored as being: severe = 3; moderate = 2; mild = 1) - only measured
before intervention; pain relief scored (complete = 4, excellent = 3, good = 2, slight
(satisfactory) = 1) at 30 mins, 5 cm and at full cervical dilatation; patient’s opinion on
the technique - satisfaction (during whole period of delivery), scored as (excellent = 3,
good = 2, satisfactory = 1); Apgar score; side effects (drowsiness, nausea, vomiting)
Notes Start and end date:
Funding sources:
Conflicts of interest:
131Parenteral opioids for maternal pain management in labour (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Tawfik 1982 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly divided between 2 groups.”
Allocation concealment (selection bias) Unclear risk No information provided.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not reported - but not feasible with nature of interventions
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not reported - but not feasible with nature of interventions
Incomplete outcome data (attrition bias)
All outcomes
Low risk No apparent loss to follow-up.
Selective reporting (reporting bias) Unclear risk All outcomes describedwithin themethods are reported upon
within the results. However, the study protocol was not eval-
uated
Other bias Unclear risk Unbalanced groups; 35 in the intervention group and 55 in
the comparison group
Thakur 2004
Methods RCT
Participants Setting: Indore, India
300women in established labour attending for care in a hospital in India. The participants
were described as being predominantly from low socio-economic groups and from urban
areas
Inclusion criteria: term pregnancy (37 to 42 weeks), vertex presentation, cervical dilata-
tion 3 cm or more with contractions
Exclusion criteria: previous uterine scar, malpresentation, multiple pregnancy, cephalo-
pelvic disproportion, antepartum haemorrhage, pre-eclampsia or othermedical disorders
Interventions Interventions group: TENS to back
Comparison group 1: 100 mg IM tramadol
Comparison group 2: no intervention
Outcomes Maternal pain score measured on a verbal response scale during labour “degree of anal-
gesia” (degree of pain relief: no relief, mild relief, moderate relief, complete relief - di-
chotomised as a percentage); mean time for onset and duration of analgesia; duration of
stages of labour; mode of delivery (normal, forceps, CS); mean Apgar score of neonates;
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Thakur 2004 (Continued)
side effects for mothers
Notes Start and end date: not reported in translation.
Funding sources: not reported in translation.
Conflicts of interest: not reported in translation.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as “randomly allocated” but groups were of identi-
cal size with identical numbers of primiparous and multiparous
women in each group
Allocation concealment (selection bias) Unclear risk Method of randomisation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding reported - but not possible due to nature of inter-
vention
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding reported - but not possible due to nature of inter-
vention
Incomplete outcome data (attrition bias)
All outcomes
Low risk Apparently there was no loss to follow-up.
Selective reporting (reporting bias) Unclear risk All outcomes described within the methods are reported upon
within the results.However, the study protocol was not evaluated
Other bias Unclear risk Groups were unusually similar and it was not clear that there
had been stratification to achieve such balanced groups
Tharamas 1999
Methods RCT. 2-arm parallel groups
Participants 200 nulliparous women in labour.
Inclusion criteria: at term (37 to 42 weeks) spontaneous labour, in active labour, vertex
presentation
Exclusions: age < 16 or > 35, weight < 50 kg or > 75 kg, infant birthweight estimated <
2500 g or > 4000 g, medical or surgical complication or unable to understand VAS
Interventions Intervention group: IM buprenorphine 300 µg
Comparison group: IM pethidine 75 mg
Outcomes Analgesic effect at 1, 2, 3, 4 hrs, side effects (nausea, drowsiness, use of antidote)
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Tharamas 1999 (Continued)
Notes Data extraction from translation notes.
Start and end date: January 1996 - December 1996
Power calculation: unclear
Baseline imbalances between groups: unclear
Funding source: unclear
Conflicts of interest: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Treatment described as blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Denominators in tables not clear.
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Unclear risk Unclear
Tsui 2004
Methods RCT, 2-arm parallel-group design
Participants Setting: hospital, Hong Kong
50women.Healthywomen in early active labour and requiring analgesia.Uncomplicated
singleton term pregnancy, cephalic presentation. Spontaneous and induced labour onset.
Excluded if epidural already requested
Parity: 3:2 nullip:multip ratio
Interventions Experimental: IM pethidine 100 mg (N = 25)
Control: placebo (saline) (N = 25)
Single dose of study drug.
Rescue analgesia allowed after 30 mins nitrous oxide or epidural for women in pethidine
group and pethidine for women in placebo group
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Tsui 2004 (Continued)
Outcomes Maternal outcomes: pain intensity at 15 mins and 30 mins VAS (0 to 100), maternal
assessment of sedation at 15 mins and 30 mins VAS (0 to 100), type of birth, additional
analgesia required, vomiting, maternal satisfaction at 30 mins 5-point scale (1 = totally
dissatisfied to 5 = very satisfied). Neonatal outcomes: Apgar at 1 min and 5 mins,
resuscitation and admission to SCBU
Notes Study terminated after 50 women recruited as interim analysis demonstrated benefit for
pethidine. Stratified by parity
Start and end date: September 2000 to May 2001.
Power calculation: Using published and unpublished data, a sample size of 56 women per
group was needed to have 90% power at 5% significant level to detect a mean difference
of 13 mm in VAS pain score between groups
Baseline imbalances between groups: Table 1 provides this information, but it is unclear
if the groups were balanced or not
Funding source: not reported
Conflicts of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated in blocks of 10.
Allocation concealment (selection bias) Low risk Sequentially-numbered, opaque sealed envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk States double-blind and women blind to contents
of syringe.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk States double-blind and women blind to contents
of syringe. No further detail given
Incomplete outcome data (attrition bias)
All outcomes
Low risk All women accounted for in the analysis.
Selective reporting (reporting bias) Unclear risk Unclear
Other bias High risk 20/25 women in pethidine group versus 12/25
women in placebo group had labour inducedwhich
may affect maternal and neonatal outcomes
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Viegas 1993
Methods RCT, 3-arm parallel-group design
Participants Setting: hospital, Singapore
90women.Women aged18 to35 years in active labour and requiring analgesia, cx 3 cm to
5 cm, uncomplicated term pregnancy with uncomplicated birth expected, spontaneous
or induced labour onset. Excluded if preterm labour
Parity: 100% nullips
Interventions Experimental: IM tramadol 50 mg (N = 30), tramadol 100 mg (N = 30)
Control: IM pethidine 75 mg (N = 30)
Single dose of study drug.
Outcomes Maternal outcomes: pain relief at 10, 20, 30, 45 mins and 1 hr 4-point scale (0 = none, 1
= insufficient, 2 = sufficient, 3 = complete pain relief ), type of birth, drowsiness, nausea,
vomiting. Neonatal outcomes: Apgar at 1 min and 5 mins, resuscitation and admission
to SCBU
Notes Start and end date: not reported
Power calculation: not reported
Baseline imbalances between groups: Table 1 suggests that the groups were balanced
Funding source: not reported
Conflicts of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk States double-blind, identical syringes prepared
separately from clinical observer
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk States double-blind, identical syringes prepared
separately from clinical observer
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants analysed.
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Unclear risk Unclear
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Volikas 2001
Methods RCT, 2-arm parallel-group design
Participants Setting: hospital in Surrey, UK
17healthywomen 36 to 40weeks’ gestation requesting pethidine for pain relief in labour,
ASA I or II. Women with a contraindication to pethidine or remifentanil or requesting
epidural were excluded
Interventions Experimental: IV PCA remifentanil, 0.5 µg bolus per kg (based on antenatal booking
weight) with 2 mins lock-out, no hourly max
Control: IV PCA pethidine, 10 mg bolus, 5 mins lock-out, 100 mg hourly max
All women were given 10 mg metoclopramide IV over 8 hrs.
Outcomes Maternal: pain on 10 cmVAS recorded hourly; nausea recorded on a 10 cmVAS; itching;
BP pulse and resps
Neonate: 1 min and 5 mins Apgar scores.
Notes Start and end date: not reported
Power calculation: ’Power analysis (β = 0.2) revealed that 17 women would be required
in each group, assuming 10 mm change in visual analogue pain score to be clinically
significant.’
Baseline imbalances between groups: the groupswere balanced for baseline characteristics
Funding source: not reported
Conflicts of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described “randomly allocated”.
Allocation concealment (selection bias) Low risk Quote: “by selecting the next in a series of sealed
envelopes prepared by pharmacy.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Women were described as blinded. Quote: “One
investigator selected the envelope and prepared the
PCApump. the pumpwas covered so that the other
investigator, the observer, was unable to see which
drug the woman was receiving.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “One investigator selected the envelope and
prepared the PCA pump. the pump was covered so
that the other investigator, the observer, was unable
to see which drug the woman was receiving.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up apparent although for some
outcomes it was not clear what the denominators
were
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Volikas 2001 (Continued)
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Low risk None apparent
Wahab 1988
Methods RCT. 4-arm parallel groups
Start and end date: May 1984 to November 1985
Participants Setting: hospital in Cairo, Egypt
80 multiparous women at term (39 to 41 weeks), 19 to 27 years (parity 2 to 6), in the
first stage of labour following uncomplicated pregnancies, spontaneous labour
Women with respiratory or cardiac disease were excluded.
Interventions Group 1: IM nalbuphine 0.13 mg/kg
Group 2: IM butorphanol 0.16 mg/kg
Group 3: IM pentazocine 0.4 mg/kg
Group 4: IM placebo
Outcomes Pain relief 0 = complete relief, 3 = no relief. Apgar score at 1 min and 5 mins. Maternal
and fetal blood gases
Notes Data were reported as means and have not been included in data tables. We describe
findings briefly in the text
Start and end date: May 1984 - September 1985
Power calculation: not reported
Baseline imbalances between groups: the groupswere balanced for baseline characteristics
Funding source: not reported
Conflicts of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described “randomly divided”.
Allocation concealment (selection bias) Unclear risk Not described “four equal groups”.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear
138Parenteral opioids for maternal pain management in labour (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Wahab 1988 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear
Selective reporting (reporting bias) Unclear risk Not clear when randomisation took place
and denominators in tables not clear
Other bias Unclear risk The equal division into groups suggests that
there may not have been true random allo-
cation
Wali 2012
Methods Double-blind randomised trial
Participants 231 women with term, singleton pregnancy in cephalic position in the active stage of
labour
Interventions IM 100 mg tramadol (114 women) versus IM 30 mg pentazocine (117 women)
Outcomes Pain at 30 and 60 mins, maternal satisfaction, side effects, neonatal outcomes
Notes No raw data were reported in this brief abstract. We have contacted the author for more
information (27th June 2017). No data are included in the analyses
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Reported to be double-blind.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Reported to be double-blind.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information to assess (not clear how many
women were randomised or if there weremissing data)
Selective reporting (reporting bias) Unclear risk Brief abstract so unable to assess.
Other bias Unclear risk Unable to assess. The trial author has been contacted
to provide more information on methods
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Wee 2014
Methods Prospective, parallel-arm 2-centre RCT.
Block randomisation. Blocks of 2 to 10. Women randomised individually
Participants Setting: 2 large hospitals in the UK.
484 women
Nulliparous and multiparous women aged 16 years or older who had given written
informed consent, who were in active labour defined as regular uterine contractions of
at least 2 in 10 mins, with a singleton pregnancy, cervical dilatation of at least 3 cm, with
gestation of 37to 42 weeks, and weight between 60 kg and 120 kg. The weight eligibility
criterion was reduced from 70 kg to 60 kg with a substantial amendment in June 2009
approximately 3 months after the start of recruitment
Exclusion criteria: allergy or previous adverse reaction to opioids or opioid dependency,
use of parenteral opioids within the previous 24 hrs or presence of severe systemic disease
Interventions Experimental group 1: diamorphine 7.5 mg group
Given into the muscles of the gluteus or lateral thigh by the midwife looking after the
women from the trial syringes provided by the research midwife. IM. (244 women)
Experimental group 2: pethidine 150 mg group
Given into the muscles of the gluteus or lateral thigh by the midwife looking after the
women from the trial syringes provided by the research midwife. IM. (240 women)
A maximum of 2 doses of opioid were given with a minimum interval of 2 hrs if the
women requested additional analgesia. Women also received metoclopramide 10 mg
with the first dose. Regional analgesia or Entonox were available as rescue analgesia
Outcomes Satisfaction with analgesia
Severe pain
Mode of birth
Additional analgesia required
Naloxone admin
Neonatal resuscitation
Admission to special care
Breastfeeding problems
Apgar scores
Abnormal CTG
Umbilical cord gases
Notes Dates of study: not stated
Funding: independent research funded by the National Institute for Health Research
(NIHR) under its Research for Patient Benefit (RfPB) Programme (Grant Reference
Number PB-PG-0407-13170) with additional support costs funded by the Western
Comprehensive Local Research Network. The views expressed are those of the authors
and not necessarily those of the NHS, the NIHR or the Department of Health
Conflict of interest: all authors have completed the Unified Competing Interest form
and there are no competing interests. 3 authors received travel expenses for meetings in
relation to the trial
Risk of bias
Bias Authors’ judgement Support for judgement
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Wee 2014 (Continued)
Random sequence generation (selection
bias)
Low risk The trial statistician provided the com-
puter-generated block randomisationusing
block sizes between 2 and 10 to ensure ap-
proximately equal group sizes, and strati-
fied by centre
Allocation concealment (selection bias) Low risk The pharmacies of both trial centres pre-
pared batches of 2 identical syringes la-
belled only with the trial number to con-
ceal group allocation and to ensure that if
2 doses were given, the same opioid was
given both times
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Women, researchers, maternity unit staff
and trial statistician were blinded to alloca-
tion. The actual identities of the 2 groups
were not revealed until after full analysis
and discussion of the results
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Women, researchers, maternity unit staff
and trial statistician were blinded to alloca-
tion. The actual identities of the 2 groups
were not revealed until after full analysis
and discussion of the results
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No loss to follow-up reported except
Quote: “from the 60-minute measurement
onwards there was significantly more miss-
ing data in the pethidine group than the
diamorphine group (for example 19% ver-
sus 10% at 60 minutes, 53% versus 34%
at 120 minutes). The difference in quan-
tity of missing data was largely because the
women in the pethidine group tended to
deliver earlier.”. The study recruited over
their target recruitment to account for the
missing data
ITT analysis adhered to. Not all denomi-
nators reported in tables
Selective reporting (reporting bias) Low risk All outcomes reported as per protocol
Other bias Low risk Similar baseline characteristics
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Wheble 1988
Methods RCT, 2-arm parallel-group design
Participants Setting: hospital, UK
47 women. Women in active labour and requiring analgesia, 37 to 42 weeks’ gestation,
singleton pregnancies with no known disorders, spontaneous or induced labour onset
Parity: mixed
Interventions Experimental: IM meptazinol (N = 17).
Control: IM pethidine (N = 17).
Study dose dependent on woman’s weight: 100 mg if weight < 70 kg, 150 mg if weight
≥ 70 kg. Additional analgesia at discretion of caregiver, either 2nd dose of study drug,
epidural or nitrous oxide, metoclopramide as required for nausea and vomiting
Outcomes Maternal outcomes: type of birth, additional analgesia, epidural. Neonatal outcomes:
Apgar at 1 min and 5 mins, FHR changes
Notes Open non-randomised control arm
Start and end date: not reported
Power calculation: not reported
Baseline imbalances between groups: unclear
Funding source: Medical Research Council and Wyeth Research (UK)
Conflicts of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as double-blind but methods not de-
scribed.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Described as double-blind but methods not de-
scribed.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All patients analysed in an ITT analysis.
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Unclear risk Balanced at baseline for height, weight, age, socioe-
conomic group, gestation, cervical dilation, parity
and smoking
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Wilson 1986
Methods RCT, 2-arm parallel-group design
Participants Setting: hospital, UK
80 women. Healthy women in active labour and requiring analgesia, ≥ 38 weeks’ gesta-
tion, uncomplicated pregnancy
Parity: 4 or less
Interventions Experimental: IM nalbuphine 20 mg (N = 37). Control: IM pethidine 100 mg (N =
35). Additional doses of test drug allowed at intervals no less than 2 hrs if required to
a maximum of 3 doses. Epidural if analgesia inadequate at discretion of caregiver and
subsequently removed from trial
Outcomes Maternal outcomes: pain intensity at peak of contraction at 30, 60 and90mins (rated very
severe, severe, moderate, slight) and with VAS (0 to 100), type of birth, sleepiness, nausea
and vomiting. Neonatal outcomes: Apgar at 1min and 5 mins, naloxone administration,
Scanlon score (neuro-behavioural score) at 2 to 4 hrs and 24 hrs
Notes Start and end date: not reported
Power calculation: not reported
Baseline imbalances between groups: unclear
Funding source: not reported
Conflicts of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk States double-blind and study drugswere dispensed
in coded ampoules
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk 8/80 excluded fromanalyses due to inadequate pain
relief.
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Unclear risk Does not report actual number randomised per
group. Broadly comparable at baseline with respect
to physical and obstetric characteristics
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Zafar 2016
Methods RCT with individual randomisation.
Participants Setting: Islamic International Medical college trust - Rawalpindi (Punjab province) and
Islamabad, Pakistan
150 women in early labour (3 cm to 6 cm) (spontaneous or induced) with uncomplicated
singleton term pregnancy and cephalic presentation
Exclusion criteria: women, who requested for other forms of analgesia, had a complicated
pregnancy (e.g. pre-eclampsia, antepartum haemorrhage)/pre-existing medical disease,
had any contraindication to vaginal delivery, or contraindication to opioids
Interventions Experimental group 1 (n = 50) (conventional group) received a single intramuscular
injection of 1 mL of pentazocine (30 mg) and oral placebo
Experimental group 2 (n = 50) (homeopathy group) received 1 mL of saline injection
and oral homeopathic medicine prescribed by a qualified homeopath. The homeopathic
medicine used wasChamomilla recutita with strength of 1 M, manufactured by William
Schwabe Karlsruhe (Schwabe) and origin was from Germany. It was used in a dose of 3
drops. This medicine comes in a dilution of 30, 200 and 1 M
Control group (n = 50) (placebo group) received oral placebo and 1mL of saline injection
Outcomes Mode of birth
Side effects
Pain intensity
Duration of labour
Notes Start and end dates: August 2008 to September 2009
Funding: the funding for this project was provided by theHigher EducationCommission
Pakistan
Conflict of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation codes were generated through
computer.
Allocation concealment (selection bias) Low risk Randomisation codes were placed in sequen-
tial numbers in sealed envelopes. Women were
asked to pick from a shuffled deck of cards with
a number that was assigned to an envelope. The
selected envelope containing the treatment was
opened up by a health worker who prepared
the study drugs and had no further involvement
with women’s assessment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study drugs and the placebowere dispensed
in similar packing to ensure blinding of patients
as well as dispensers
Caregiver: a health worker, who was blinded to
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Zafar 2016 (Continued)
the contents of the drug injected the medicine
and dispensed oral preparation of small, white
sugar pellets
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not mentioned though if caregiver recorded
outcomes, assessors were blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 1 women in placebo group opted for epidural
and was withdrawn from the study
3 women form conventional group, 8 women
from homeopathy group, and 8 women from
placebo group were lost to follow-up. It is re-
ported that ‘the missing values were observed
as some women delivered before any pain as-
sessment or the observations were not recorded.
’ There were no further reasons provided
Selective reporting (reporting bias) Unclear risk All essential outcomes are reported, protocol not
seen and outcomes not clearly specified in text
Other bias Unclear risk The baseline demographic characteristics, age,
weight and height, were similar in the 3 groups.
However Camomilla group had fewer prim-
ips, and fewer > para 3. Denominators not
clearly specified. Abstract reports 99 women
randomised, full-text reports 150 before exclu-
sions
Zhu 2013
Methods Randomised trial with individual randomisation.
Participants 150 full-term primiparous women intending to have normal vaginal birth
No exclusion criteria (abstract only)
Interventions Group1 (50women): fentanyl-droperidolmixed liquor via acupoint injection at different
time stages: BL 23 in active phase and BL 32 in second stage
Group 2 (50 women): fentanyl-droperidol mixed liquor via subcutaneous injection
Group 3 (50 women): NaCl 0.9% via subcutaneous injection
Outcomes VAS score
level or norepinephrine
Blood pressure
Notes Dates: not in abstract
Funding: not reported
Conflict of interest: not reported
ABSTRACT ONLY - no data. Full text in Chinese
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Zhu 2013 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly divided”. Method not de-
scribed
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Women receiving the subcutaneous injec-
tions may have been blinded, unlikely that
blinding would have been maintained for
staff
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not mentioned, likely to have outcomes
collected by staff.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unable to assess - abstract only
Selective reporting (reporting bias) Unclear risk Unable to assess - abstract only
Other bias Unclear risk Unable to assess - abstract only
ARM: artificial rupture of the membranes
ASA: American Society of Anesthesiologists Classification
BMI: body mass index
BP: blood pressure
CS: caesarean section
CTG: cardiotocograph
cx: cervix
FGR: fetal growth restriction
FHR: fetal heart rate
GA: gestational age
HR: heart rate
IM: intramuscular
IOL: induction of labour
ITT: intention-to-treat
hr(s): hour(s)
IV: intravenous
min(s): minute(s)
multips: multiparous women
MW: midwife
NACS: Neurologic and Adaptive Capacity Score
nullips: nulliparous women
PCA: patient controlled analgesia
PN: postnatal
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primips: primiparous women
RCT: randomised controlled trial
resps: respirations
SC: subcutaneous
SCBU: special care baby unit
SD: standard deviation
TENS: transcutaneous electrical nerve stimulation
VAS: visual analogue scale
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abd-El-Maeboud 2014 The intervention was IV paracetamol, which is not an opiate.
Abdollahi 2014 IM pethidine was compared with IV paracetamol. The comparison of opiates with non-opioid drugs is
not a relevant comparison for this review
Aiken 1971 This study compares the use of diazepam versus a placebo. Both groups had pethidine
Alhashemi 2011 IM pethidine was compared with IV paracetamol. The comparison of opiates with non-opioid drugs is
not a relevant comparison for this review
Ankumah 2016 IV morphine was compared with IV paracetamol. The comparison of opiates with non-opioid drugs is not
a relevant comparison for this review
Balcioglu 2007 In this study group allocation was by order of hospital admission (alternate allocation). Not an RCT
Balki 2007 In this study both groups received the same drug (remifentanil) by PCA. The focus of the study was on
variation in the bolus size versus variation in the background infusion rate. Studies that examine variation
in mode of administration will be considered in a separate related Cochrane review
Balki 2012 In this study both groups had opioids (remifentanil administration in the form of either an infusion or
PCA demand bolus (intravenous injection of a single dose over a short period of time)
Ballas 1976 There was no evidence that this study was an RCT. There were 3 study groups and all 3 received pethidine
(1 after 1-hour delay). The aim of the study was to monitor uterine activity over 60 minutes
Bare 1962 This study examined the effects of hydroxine hydrochloride, an antihistamine. None of the study groups
received an opioid analgesic drug
Bhatia 2013 IM tramadol was compared with IV paracetamol. The comparison of opiates with non-opioid drugs is not
a relevant comparison for this review
Bredow 1992 This study was not an RCT. Alternate allocation to groups.
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Brelje 1966 This was a quasi-randomised study with group allocation by month of birth. The aim of the study was to
look at hydroxine as an adjunct to pethidine. both study groups had pethidine
Brookes 2013 This trial compares different routes of administration as well as different drugs
Busacca 1982 In this study, 1 group received pethidine with promethazine and 1 received no treatment. As the opioid
group received a combination of drugs any differences between groups may have been due to the effect of
the add-on drug
Cahal 1960 This study had 3 groups: SC pethidine, SC benzethidine and SC flurethidine. We are not aware that, apart
from pethidine, these drugs are used any longer for pain relief in labour
Calderon 2006 In this study, 1 group received IV remifentanil and 1 group received IM pethidine with haloperidol. With
1 group receiving an add-on drug it would not be possible to compare the effects of the 2 opioids
Callaghan 1966 In this study pethidine was compared with the use of a sedative. It was not clear that this was an RCT
Camann 1992 This study compared IV sufentanil with epidural analgesia. Epidural analgesia in labour is covered in a
related Cochrane review
Castro 2004 This study was for pain relief during second trimester labour for termination of pregnancy and so not for
pain relief for labour of childbirth
Cavanagh 1966 This study had 4 groups: pethidine IM, anileridine IM, pethidine + perphenazine IM and anileridine +
perphenazine IM. We are not aware that anileridine is used any longer in obstetric practice
Chandnani 2013 It was not clear whether or not this was a randomised trial. Women were divided into 2 equal-sized groups
but there was no indication that allocation was random
Chang 1976 It was not clear that participants in this trial were all in labour. The aim of the study was to examine fetal
acid balance, with maternal and fetal blood sampling 30 and 60 minutes after administering the drugs. No
other outcomes were recorded
Cincadze 1978 Brief conference abstract. It was not clear that this was an RCT. We attempted to trace the authors for
more information without success
Cullhed 1961 This was not an RCT. Groups were divided into groups according to date of hospital attendance
Dahiya 2015 IM tramadol was compared with IV paracetamol. The comparison of opiates with non-opioid drugs is not
a relevant comparison for this review
Dan 1991 In this study 1 group received IV nalbuphine and the other pethidine with promethazine, as the pethidine
group had an add-on drug it is not possible to compare the 2 opioids
De Kornfeld 1964 This study was excluded for methodological reasons; there was extremely high attrition for some outcomes
(> 50%). SC pethidine and placebo were compared in this study; however, it appeared that the drugs were
administered very late in labour.Of 224women included in the analysis, it appeared thatmore than half had
given birth within an hour of drug administration. There were data on pain relief for only approximately
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103 women at 1 hour. Results were very difficult to interpret
De Lamerens 1964 All study groups received pethidine. The aim of the study was to examine the effects of tranquillisers as
adjuncts to analgesics
Eames 1964 This study had 2 groups: pethidine 100 mg IM and oxymorphone 1.5 mg IM. Oxymorphone is no longer
used for pain relief in labour
Easton 2016 The trial registration refers to “crossover assignment” in the methods. Cross-over trials are not eligible for
inclusion in this review
El Kinawy 2015b This study compares pethidine with an NSAID; this is not a eligible comparison for this review
El-Kerdawy 2010 This study compared opioids with epidural analgesia. Epidural analgesia in labour is covered in a related
Cochrane review
Elbohoty 2012 IV pethidine was compared with IV paracetamol. The comparison of opiates with non-opioid drugs is not
a relevant comparison for this review
Elhalwagy 2017 This study examines ketamine which is not an opioid.
Eliot 1975 There was no evidence that there was random allocation in this study. There were 2 study groups and both
received pethidine, the aim of the study was to compare drugs administered as an adjunct to the opioid
analgesia (diazepam vs promazine)
Evron 2005 In this study 2 different drugs using different modes of administration were compared. IV pethidine (with
dummy PCA) was compared with PCA remifentanil (with dummy background IV infusion). With both
the drug and method being different in each arm of the trial results from this study are very difficult to
interpret
Evron 2007 PCA IV pethidine was compared with epidural analgesia.
Evron 2008 In this study with 4 different treatment arms, 1 group received IV remifentanil, the remaining 3 received
epidural analgesia. Epidurals are covered in a separate Cochrane review
Fernandez 2015 In this study pethidine was given with haloperidol compared with a birth ball. The addition of haloperidol
means this comparison is not relevant for this review
Fleet 2015 In this study all the 3 groups received fentanyl but in different doses and by different routes of administration
Freeman 2012 PCA remifentanil was compared with epidural (this comparison is eligible for inclusion in a related review)
Gambling 1998 This study compared IV pethidine versus a combined spinal epidural
Ginosar 2003 Study examining IV versus epidural fentanyl.
Goodlin 1988 Entry in trials register. It is not clear that this study was completed. We attempted to contact the author
and searched for any published results relating to this trial without success
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Grandjean 1979 Study examining IV versus epidural analgesia.
Greer 1988 The study evaluated the effects of the interventions on platelet function in the newborn
Gupta 2016 This study is looking at IV paracetamol ad an adjunct to PCA epidural analgesia
Hashemiyan 2014 This study examine an opioid compared with paracetamol. This is not a relevant comparison for this review
Hodgkinson 1978 In this study both randomised groups received pethidine. One group also received naloxone. A third, non-
randomised “matched” group received no narcotic drugs
Isenor 1993 In this study both groups received the same drug (pethidine). The focus of the study was on variation in
route of administration; IM was compared with PCA (IV) pethidine. Studies that examine variation in
mode of administration will be considered in a separate related Cochrane review
John 2013 Study examining cortisol levels in women receiving IV opioid vs epidural. This comparison is eligible for
a related review
Jost 2015 This was a cross-over study which is not eligible for inclusion in this review. The study was examining
different bolus doses of PCA remifentanil
Kalaskar 2007 No results were reported in this brief abstract. We attempted to contact the author without success
Kaltreider 1967 Only women in preterm labour were recruited to this study. This study was excluded for methodological
reasons: there was no information about the number of women randomised and women who received any
additional non-study medications were excluded post randomisation. Under these circumstances interpret-
ing the findings of this study are very difficult
Karadjova 2016 IV PCA opioid vs epidural. This comparison is eligible for inclusion in a related review
Kaur 2015 IM opioid (tramadol) was compared with non opioid (IV paracetamol). This comparison is not eligible
for inclusion in this review
Khooshideh 2015 Intervention and control were both IV remifentanil, comparing different regimens
Krins 1969 Study participants were not women in labour.
Lallar 2015 IM opioid (tramadol) was compared with non opioid (IV paracetamol). This comparison is not eligible
for inclusion in this review
Li 1995 In this study, 2 opioid drugs were compared (tramadol and dihydroetorphine hydrochloride).However, the
drugs were administered by different routes (sublingual versus oral) and results are therefore very difficult
to interpret
Logtenberg 2017 This study compared PCA remifentanil with epidural; this comparison is not eligible for this review
MacVicar 1960 Not an RCT; consecutive allocation to groups. Study examining the sedative effects of drugs and their
effects on memory
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Malkasian 1967 In this study both groups received pethidine. The focus of the trial was on the use of promethazine versus
hydroxyzine as add-on drugs
Marshalov 2012 This study compared and opiate (not clear what drug, route or dose) with epidural. This comparison is
not eligible for this review
McDonald 1964 This study included 5 study arms and focused specifically on neonatal serum bilirubin, an outcome not
relevant to this review
McGrath 1992 A study examining epidural versus IV analgesia.
McInnes 2004 In this study both groups received the same drug (diamorphine) either by PCA or IM. Studies that examine
variation in mode of administration will be considered in a separate related Cochrane review
McQuitty 1967 This study focused on promethazine, promazine and propiomazine ad adjuncts to pethidine. All study
groups received pethidine
Moore 1974 It was not clear that this was a randomised trial. Women were paired and then allocated in sequence to 4
study arms
Morgan 2004 This was a pilot study reported as an abstract only and there was too little information on methods and
results to assess risk of bias and results did not include outcomes relevant to this review
Morris 1994 Study focusing on IV versus epidural fentanyl.
Nafisi 2006 Study comparing IV pethidine versus epidural.
Ng 2011 Although both the groups received different opioids, the mode of administration was not the same
Nikkola 2000 In this study, women in the 2 arms of the trials were given different drugs with different routes of admin-
istration. PCA IV fentanyl was compared with paracervical blockade; 10 mL 0.25% bupivacaine injected
into 4 locations in the cervix
Overton 1992 This study comparing sublingual diamorphine with IM pethidine was reported in a brief abstract; no
denominators for study groups were provided. We attempted to contact the study author for more infor-
mation without success
Pandole 2003 In this study, women received either IM tramadol or IM pethidine. It was not clear that this was an RCT
Polley 2000 This study compared IV vs epidural fentanyl (epidural analgesia is the subject of separate Cochrane reviews)
Posner 1960 In this study both groups received pethidine; the focus of the study was on a narcotic antagonist (levallor-
phan) as an adjunct to pethidine
Powe 1962 All 3 groups in this study received pethidine. The aimof the studywas to examine the effects of promethazine
and propiomazine as adjuncts to pethidine
Rabie 2006 This study compared the use of IV PCA remifentanil versus epidural
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Rahimi 2012 This was a cross-over study. This design is not eligible for inclusion in the review
Ransom 1966 This study had 2 groups: pethidine 125 mg IM and oxymorphone 1.25 mg IM
Rayburn 1989 In this study both groups received the same drug (pethidine) by PCA versus nurse administered (IV).
Studies that examine variation in mode of administration will be considered in a separate related Cochrane
review
Rayburn 1991 In this study both groups received the same drug (fentanyl) 1 group by PCA and 1 nurse administered
(IV). Studies that examine variation in mode of administration will be considered in a separate related
Cochrane review
Roberts 1957 In this study a mood-enhancing drug (methylpentonol) was compared with an analgesic (pethidine). The
outcome was not pain relief but fetal expiratory volume. There was no comparison of analgesic drugs in
labour. We are not aware that methylpentonol is any longer used during childbirth
Roberts 1960 In this study both groups received the same IM opioid analgesia (alphaprodine). The study examined the
effects of a narcotic antagonist (levallorphan) as an adjunct to the opioid
Robinson 1980 This study compared different ways of administering pethidine (IM vs IV); the IM group received an
anti-emetic the IV group did not. 386 women were randomised but there appears to have been serious
attrition with complete data for only approximately a third of women randomised. Attrition was mainly
due to protocol deviations. With these methodological problems findings from this study are very difficult
to interpret
Ron 1984 Study examining the value of promethazine as an adjunct to pethidine. The study did include a placebo
group but the only result reported was maternal blood pressure 10 minutes after injection of the drug/
placebo
Rowley 1963 This was a quasi-randomised study. The outcomes collected in this study were neonate bilirubin levels
Sabry 2011 In this study the comparison group received epidural. This comparison is examined in a related review
Samanta 2013 In this study the comparison group received epidural. This comparison is examined in a related review
Savage 1955 Quasi-randomised study with alternate allocation.
Sentnor 1966 This study had 4 groups: pethidine 50 mg, 75 mg or 100 mg IM, oxymorphone 0.75 mg, 1.125 mg or 1.
5 mg, pethidine + noroxymorphone IM and oxymorphone + noroxymorphone IM. Oxymorphone is no
longer used in clinical practice
Shahriari 2007 In this study IV remifentanil was compared with IM pethidine. As both the drug and the route were
different, we excluded this study as results are difficult to interpret
Singh 2001 Not an RCT.
Solek-Pastuszka 2009 This study compared opioids with epidural analgesia. Epidural analgesia in labour is covered in a related
Cochrane review
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Soontrapa 2002 This was a quasi-randomised study and allocation could be anticipated
Sosa 2004 This study focused onwomen with dystocia and the use of pethidine to promote progress in labour.Women
requiring pain relief were excluded
Spellacy 1966 All study groups received pethidine; the aim of the study was to look at the effects of adjuncts
Stocki 2014 In this study the comparison group received epidural. This comparison is examined in a related review
Stourac 2014 In this study the comparison group received epidural. This comparison is examined in a related review
Suvonnakote 1986 In this study comparing IM pethidine and IM tramadol the report states that the sample was randomly
selected, but there was no indication that there was random allocation to groups
Taskin 1993 In this study the focus was on the rate of cervical dilatation rather than pain relief. The study was reported
in a brief abstract; we attempted to contact the authors for more information without success
Thurlow 2002 In this study 2 different drugs with different modes of administration were compared. IM pethidine (with
an antiemetic) was compared with PCA remifentanil. In view of the different modes of administration we
decided to exclude this study as results are very difficult to interpret
Tomlin 1965 It was not clear that the women included in this study were in labour; women were recruited in the
third trimester admitted to hospital following complications or “awaiting caesarean section or the birth of
multiple pregnancies”
Tournaire 1980 This study, otherwise eligible for the review, focused on the effect of pethidine on the frequency and
intensity of uterine contractions and the rate of cervical dilatation; no other outcomes were reported
Treisser 1981 This study did not focus on pain relief in labour; rather, it examined the effects of different drugs on progress
in labour for women with dystocia (oxytocin, chlorpromazine, ritodine and pethidine were compared)
Tripti 2006 Quasi-randomised study with alternate allocation.
Vavrinkova 2005 There was no evidence that this was an RCT.
Volmanen 2005 This study compares IV remifentanil with inhaled 50% nitrous oxide in a cross-over trial. Results were not
reported separately for the first stage of this trial
Volmanen 2008 This study compared IV remifentanil versus epidural analgesia
Volmanen 2009 This study reported on different regimens of IVPCA remifentanil
Von Vorherr 1963 This study focused on speeding up progress in labour. In this group study groups received oxytocin as well
as analgesics and women in the control arm received an higher dose of oxytocin
Walker 1992 In this study pethidine was compared with a NSAID ketorolac. Ketorolac is not used nowadays in obstetric
analgesia
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Wan 1965 Both study groups received pethidine; the aim of the study was to look at the effects of a sedative as an
adjuvant therapy
Weissman 2006 The comparison group in this study received epidural; this is not a relevant comparison in this review
Wiener 1979 In this study epidural analgesia was compared with IM pethidine. It was not clear that this was an RCT
Williams 1962 Both groups in this study received pethidine. The aim of the study was to examine the effects of a narcotic
antagonist (levallorphan) as an adjunct to pethidine
Wilson 2016 In this study different opioids were compared but the route of administration was also different
Wong 2005 This study is reported in a series of papers and conference abstracts. The study examined the use of an
intrathecal opioid as part of a combined spinal epidural compared to a systemic opioid. Epidural analgesia
is covered in a separate related Cochrane review
IM: intramuscular
IV: intravenous
NSAID: non-steroidal anti-inflammatory drug
PCA: patient controlled analgesia
RCT: randomised controlled trial
SC: subcutaneous
Characteristics of studies awaiting assessment [ordered by study ID]
Mohan 2015
Methods Unclear
Participants Unclear
Interventions Unclear
Outcomes Unclear
Notes This report is awaiting classification pending further investigation
Sereshti 2013
Methods RCT with individual randomisation
Participants 120 women randomised.
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Sereshti 2013 (Continued)
Interventions Group 1: massage
Group 2: intramuscular pethidine
Group 3: standard care
Outcomes Pain intensity
Duration of labour only
Notes Setting: Valiasr hospital in Broojen, Iran
Abstract only, full-text awaiting translation.
RCT: randomised controlled trial
Characteristics of ongoing studies [ordered by study ID]
Kokki 2015
Trial name or title The effect of oxycodone to placental and fetal circulation during the phase I of labour and the efficacy, safety
and neonatal effects of oxycodone
Methods Clinical trial (methods not clear)
Participants Women at the onset of labour
Interventions IV oxycodone versus placebo
Outcomes Fetal circulation and condition of the newborn.
Starting date Not clear
Contact information Dr Kokki at Kuopio University Hospital, Finland. Merja.Kokki@kuh.fi
Author contacted 26th June 2017.
Notes
Raheja 2016
Trial name or title Tramadol for labour analgesia in low-risk women: a placebo controlled randomised trial
Methods Placebo controlled RCT with parallel assignment
Participants 86 women in labour
Interventions 50 mg IM tramadol vs placebo (IV water)
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Raheja 2016 (Continued)
Outcomes Pain (VAS), satisfaction (1-5 Likert), fetal distress, mode of birth, duration of labour
Starting date December 2018 (completion planned for May 2018
Contact information aastha raheja2000@yahoo.com Dr Aastha Raheja, Maulana Azad Medical College
Notes
Reyes 2013
Trial name or title Tramadol for labour analgesia in low-risk primiparous women
Methods Double-blind randomised trial
Participants Primiparous women with singleton pregnancy in labour with intact membranes
Interventions Subcutaneous 100 mg tramadol vs placebo
Outcomes Pain in labour, duration of labour, neonatal outcomes, side effects, oxytocin
Starting date October 2012. (Reported to be completed by June 2013)
Contact information Osvaldo A. Reyes T., Saint Thomas Hospital, Panama
Notes No email address and unable to contact author.
Sahin 2012
Trial name or title Study of the effectiveness of administration of meperidine on the length of active phase of labour in women
Methods Clinical trial
Participants Not clear
Interventions Not clear
Outcomes Not clear
Starting date The recruitment status of this study is unknown. The completion date has passed and the status has not been
verified in more than 2 years
Contact information This study was due for completion in 2012. There is no email address.Orhan SAHIN, M.D., Kanuni Sultan
Suleyman Training and Research
Notes
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Shen 2008
Trial name or title Intravenous Remifentanil for Labour Analgesia (IRELAN)
Methods Reported to be parallel RCT.
Participants Planned enrolment 1000 nulliparous women in spontaneous labour requesting analgesia
Interventions IV PCA remifentanil versus IV intermittent hydromorphone 1 mg (on request)
Outcomes Pain (VAS) during labour, mode of birth, maternal satisfaction with analgesia, use of other analgesia, use of
oxytocin, breastfeeding at 6 weeks, neonatal outcomes
Starting date July 2008, planned completion September 2009. There is no evidence that this study was completed. No
email address. The record has not been updated since 2009
Contact information XiaoFeng Shen, Nanjing Medical University
Notes ClinicalTrials.gov: NCT00710086
IV: intravenous
RCT: randomised controlled trial:
PCA: patient-controlled analgesia
VAS: visual analogue scale
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D A T A A N D A N A L Y S E S
Comparison 1. IM pethidine 50 mg/100 mg versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal satisfaction with
analgesia measured during
labour (number of women
satisfied or very satisfied after
30 minutes)
1 50 Risk Ratio (M-H, Fixed, 95% CI) 7.0 [0.38, 128.87]
2 Maternal pain score or pain
measured in labour (described
as good or fair after 1 hour)
1 116 Risk Ratio (M-H, Fixed, 95% CI) 1.75 [1.24, 2.47]
3 Maternal pain score or pain
measured in labour (reduction
in VAS of at least 40 mm after
30 minutes)
1 50 Risk Ratio (M-H, Fixed, 95% CI) 25.0 [1.56, 400.54]
4 Additional analgesia required 1 50 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.54, 0.94]
5 Epidural 1 50 Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.14, 1.78]
6 Nausea and vomiting 2 166 Risk Ratio (M-H, Fixed, 95% CI) 1.47 [0.65, 3.31]
7 Maternal sleepiness 2 166 Risk Ratio (M-H, Fixed, 95% CI) 4.67 [2.43, 8.95]
8 Assisted vaginal delivery 1 50 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.34, 2.19]
9 Caesarean section 2 140 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.36, 1.37]
10 Neonatal resuscitation 1 50 Risk Ratio (M-H, Fixed, 95% CI) 1.67 [0.45, 6.24]
11 Low Apgar score (≤ 7) at 1 and
5 minutes
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
11.1 Low scores at 1 minute 2 166 Risk Ratio (M-H, Random, 95% CI) 1.64 [0.52, 5.18]
11.2 Low scores at 5 minutes 2 200 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
12 Admission to NICU 1 50 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 15.12]
Comparison 2. IM pentazocine versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal pain score measured
during labour
1 89 Mean Difference (IV, Fixed, 95% CI) -3.60 [-9.91, 2.71]
2 Nausea and vomiting 1 89 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Caesarean section 1 89 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.24, 3.35]
4 Assisted vaginal birth 1 89 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.10, 3.39]
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Comparison 3. IM tramadol versus no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal satisfaction with
analgesia (Analgesic effect
described as satisfactory (not
clear when measured))
1 60 Risk Ratio (M-H, Fixed, 95% CI) 11.0 [0.64, 190.53]
Comparison 4. IM meptazinol versus pethidine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal pain score or pain
measured in labour (Maternal
pain relief poor or none (3-5
PN))
1 801 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.91, 1.12]
2 Maternal pain score or pain
measured in labour (Pain
intensity 4 or 5 on 5-point
scale (1 hour))
2 239 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.69, 1.80]
3 Additional analgesia required 2 233 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.88, 1.20]
4 Epidural 4 788 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.71, 1.29]
5 Maternal sleepiness 3 1590 Risk Ratio (M-H, Random, 95% CI) 0.55 [0.28, 1.07]
6 Nausea and vomiting 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Nausea 3 1590 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.95, 1.28]
6.2 Vomiting 3 1589 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [1.06, 1.47]
7 Caesarean section 3 1266 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.16, 2.00]
8 Assisted vaginal birth 3 1266 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.81, 1.22]
9 Breastfeeding at discharge
(problems)
1 197 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.17, 3.30]
10 Fetal heart rate changes
(decelerations)
1 34 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [0.92, 1.64]
11 Naloxone administration 1 998 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.77, 1.02]
11.1 < 36 weeks’ gestation 1 23 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.49, 1.89]
11.2 ≥ 36 weeks’ gestation 1 975 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.77, 1.02]
12 Neonatal resuscitation (by
gestation)
2 1356 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.95, 1.05]
12.1 < 36 weeks’ gestation 1 23 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.69, 1.16]
12.2 ≥ 36 weeks’ gestation 2 1333 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.95, 1.05]
13 Neonatal resuscitation 1 100 Risk Ratio (M-H, Fixed, 95% CI) 1.5 [0.26, 8.60]
14 Apgar score ≤ 7 at 1 minute 6 791 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.56, 1.11]
15 Apgar score ≤ 7 at 5 minutes 3 616 Risk Ratio (M-H, Fixed, 95% CI) 0.50 [0.05, 5.37]
16 Admission to NICU 1 199 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.48, 1.63]
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Comparison 5. IM diamorphine + prochlorperazine versus pethidine + prochlorperazine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal satisfaction with
analgesia in labour measured
during the postnatal period
(Global assessment of pain
relief at 24 hours)
1 133 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.67, 1.16]
2 Maternal pain score or pain
measured in labour (Pain
intensity at 1 hour (moderate
or severe))
1 133 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.72, 1.01]
3 Additonal analgesia required 1 133 Risk Ratio (M-H, Fixed, 95% CI) 1.35 [0.53, 3.40]
4 Epidural 1 133 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.72, 2.07]
5 Maternal sleepiness during
labour
1 133 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.52, 1.66]
6 Vomiting in labour 1 133 Risk Ratio (M-H, Fixed, 95% CI) 0.39 [0.17, 0.86]
7 Caesarean section 1 133 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.10, 2.76]
8 Assisted vaginal birth 1 133 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.46, 2.02]
9 Neonatal resuscitation 1 133 Risk Ratio (M-H, Fixed, 95% CI) 1.21 [0.73, 2.02]
10 Apgar < 7 at 1 minute 1 133 Risk Ratio (M-H, Fixed, 95% CI) 0.41 [0.18, 0.91]
11 Apgar < 7 at 5 minutes 1 133 Risk Ratio (M-H, Fixed, 95% CI) 0.35 [0.04, 3.27]
12 Admission to NICU 1 133 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.21, 1.64]
Comparison 6. IM tramadol versus pethidine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal pain score or pain
measured in labour (Pain
intensity: women with poor
pain relief )
4 243 Risk Ratio (M-H, Fixed, 95% CI) 1.56 [1.10, 2.21]
2 Additional analgesia required 3 295 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.60, 1.91]
3 Maternal sleepiness in labour 5 409 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.33, 0.97]
4 Nausea and vomiting in labour 6 454 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.34, 2.76]
5 Caesarean section 3 260 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.23, 2.18]
6 Assisted vaginal birth 3 260 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.12, 2.56]
7 Neonatal resuscitation 1 90 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Apgar scores ≤ 7 at 1 and 5
minutes
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 Less than 7 at 1 minute 2 250 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.2 Less than 7 at 5 minutes 1 160 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Neonatal respiratory distress 1 59 Risk Ratio (M-H, Fixed, 95% CI) 2.26 [0.64, 7.89]
10 Admission to NICU 1 59 Risk Ratio (M-H, Fixed, 95% CI) 2.26 [0.64, 7.89]
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Comparison 7. IM tramadol + triflupromazine versus pethidine + triflupromazine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal sleepiness in labour 1 40 Risk Ratio (M-H, Fixed, 95% CI) 2.86 [0.68, 12.12]
2 Nausea and vomiting in labour 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Nausea 1 40 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.13, 5.25]
2.2 Vomiting 1 40 Risk Ratio (M-H, Fixed, 95% CI) 0.40 [0.02, 9.35]
Comparison 8. IM dihydrocodeine 50 mg versus pethidine 100 mg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal pain score or pain
measured in labour (Maternal
pain relief poor at 1 hour)
1 138 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.64, 1.86]
2 Maternal sleepiness in labour 1 138 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.43, 1.04]
3 Nausea and vomiting in labour 1 138 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.40, 1.88]
4 Apgar ≤ 7 at 1 minute 1 138 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.39, 0.84]
Comparison 9. IM pentazocine versus pethidine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal satisfaction with
analgesia measured during
labour (Pain relief (good or
very good) at delivery)
2 253 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.92, 1.27]
2 Maternal pain score or pain
measured in labour (Pain relief
poor (partial, none or worse))
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 No add-on drugs 3 365 Risk Ratio (M-H, Random, 95% CI) 1.23 [0.74, 2.05]
2.2 With promazine 1 85 Risk Ratio (M-H, Random, 95% CI) 1.53 [0.66, 3.58]
3 Additional analgesia required 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Pentazocine 1 94 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.50, 1.65]
3.2 Pentazocine + promazine 1 85 Risk Ratio (M-H, Fixed, 95% CI) 1.67 [0.73, 3.84]
4 Maternal sleepiness in labour 3 391 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.89, 1.12]
5 Nausea and vomiting in labour 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Nausea 3 391 Risk Ratio (M-H, Fixed, 95% CI) 0.46 [0.24, 0.90]
5.2 Vomiting 1 73 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.27, 3.14]
6 Assisted vaginal birth 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 No add-on drugs 1 94 Risk Ratio (M-H, Fixed, 95% CI) 5.22 [0.63, 42.97]
6.2 With promazine 1 85 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.23, 2.71]
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7 Naloxone administration 1 85 Risk Ratio (M-H, Fixed, 95% CI) 0.49 [0.09, 2.53]
7.1 With promazine 1 85 Risk Ratio (M-H, Fixed, 95% CI) 0.49 [0.09, 2.53]
8 Apgar score ≤ 7 at 1 minute 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 No add-on drugs 2 242 Risk Ratio (M-H, Random, 95% CI) 1.39 [0.06, 32.97]
8.2 With promazine 1 66 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.07, 17.30]
9 Apgar score ≤ 7 at 5 minutes 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
9.1 No add-on drugs 1 62 Risk Ratio (M-H, Fixed, 95% CI) 0.23 [0.01, 4.54]
9.2 With promazine 1 66 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.02, 8.88]
Comparison 10. IM nalbuphine versus pethidine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal satisfaction with
analgesia measured during the
postnatal period (numbers
dissatisfied)
1 72 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.55, 0.96]
2 Maternal satisfaction with
analgesia measured during
labour (Pain free)
1 40 Risk Ratio (M-H, Fixed, 95% CI) 6.0 [0.79, 45.42]
3 Maternal pain score or pain
measured in labour (Pain
intensity at 30 minutes: women
with severe pain)
1 295 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.59, 1.26]
4 Maternal pain score or pain
measured in labour (VAS
at 60 minutes (at peak of
contraction))
1 72 Mean Difference (IV, Fixed, 95% CI) -8.0 [-18.55, 2.55]
5 Additional analgesia required 1 72 Risk Ratio (M-H, Fixed, 95% CI) 1.26 [0.49, 3.27]
6 Epidural 1 307 Risk Ratio (M-H, Fixed, 95% CI) 1.65 [0.55, 4.94]
7 Maternal sleepiness in labour 1 72 Risk Ratio (M-H, Fixed, 95% CI) 3.78 [0.86, 16.60]
8 Nausea and vomiting in labour 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 Nausea 1 301 Risk Ratio (M-H, Fixed, 95% CI) 0.62 [0.42, 0.91]
8.2 Vomiting 1 301 Risk Ratio (M-H, Fixed, 95% CI) 0.41 [0.22, 0.76]
8.3 Nausea and vomiting 1 72 Risk Ratio (M-H, Fixed, 95% CI) 0.41 [0.18, 0.94]
9 Caesarean section 1 310 Risk Ratio (M-H, Fixed, 95% CI) 0.45 [0.12, 1.69]
10 Assisted vaginal birth 2 382 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.25, 3.85]
11 Naloxone administration 1 72 Risk Ratio (M-H, Fixed, 95% CI) 6.63 [0.35, 123.93]
12 Apgar score ≤ 7 at 1 and 5
minutes
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
12.1 Low score at 1 minute 2 382 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.72, 1.95]
12.2 Low score at 5 minutes 1 72 Risk Ratio (M-H, Random, 95% CI) 0.47 [0.04, 4.99]
13 Admission to NICU 1 299 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.61, 1.89]
14 Neonatal neurobehavioural
(Scanlon) 2-4 hours PN
1 72 Mean Difference (IV, Fixed, 95% CI) -3.70 [-6.14, -1.26]
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Comparison 11. IM phenazocine versus pethidine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Epidural 1 212 Risk Ratio (M-H, Fixed, 95% CI) 1.31 [0.58, 2.97]
2 Vomiting 1 212 Risk Ratio (M-H, Fixed, 95% CI) 0.39 [0.20, 0.78]
Comparison 12. IM diamorphine/morphine versus pethidine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal satisfaction with
analgesia (number of women
satisfied or very satisfied)
1 484 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [1.02, 1.26]
2 Maternal satisfaction with
analgesia measured during
labour or during the postnatal
period (Pain relief described as
poor)
1 90 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.56, 2.66]
3 Maternal pain score or pain
measured in labour (pain relief
at 30 mins)
1 484 Mean Difference (IV, Fixed, 95% CI) -0.80 [-1.24, -0.36]
4 Maternal pain score or pain
measured in labour (pain relief
at 60 mins)
1 484 Mean Difference (IV, Fixed, 95% CI) -0.80 [-1.26, -0.34]
5 Additional analgesia required 2 574 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.92, 1.10]
6 Maternal sleepiness 1 90 Risk Ratio (M-H, Fixed, 95% CI) 0.6 [0.29, 1.23]
7 Nausea and vomiting 1 90 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.21, 4.69]
8 Caesarean section 1 484 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.66, 1.35]
9 Assisted vaginal birth 1 484 Risk Ratio (M-H, Fixed, 95% CI) 1.28 [0.91, 1.80]
10 Naloxone administration 1 484 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.20, 4.83]
11 Neonatal resuscitation 2 574 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.66, 1.41]
12 Apgar < 7 at 1 minute 2 574 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.76, 1.73]
13 Admission to NICU 1 484 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.34, 2.23]
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Comparison 13. IM butorphanol versus pethidine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Additional analgesia required 1 80 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.55, 1.45]
2 Nausea 1 80 Risk Ratio (M-H, Fixed, 95% CI) 0.2 [0.01, 4.04]
3 Vomiting 1 80 Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.05, 5.30]
4 Neonatal resuscitation 1 80 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.95]
5 Naloxone administration
(neonatal)
1 80 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.95]
Comparison 14. IM Avacan® versus IM pentazocine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Additional analgesia required -
Entonox
1 160 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.53, 1.63]
2 Additional analgesia required -
pudendal-paracervical block
1 160 Risk Ratio (M-H, Fixed, 95% CI) 2.02 [1.16, 3.53]
3 Caesarean section 1 184 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.21, 1.84]
4 Low Apgar score (< 7) ”at birth” 1 160 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.27, 1.26]
Comparison 15. IM pentazocine versus IM Pethilorfan®
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal pain score measured
during labour (Pain relief
(women NOT obtaining pain
relief ) at 1 hour)
1 69 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.77, 1.95]
2 Additional analgesia required 1 98 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.10, 2.71]
3 Assisted vaginal birth 1 98 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.07, 16.19]
4 Apgar < 8 at 1 minute (non
pre-specified)
1 82 Risk Ratio (M-H, Fixed, 95% CI) 5.71 [0.72, 45.39]
5 Apgar < 8 at 5 minutes (non
pre-specified)
1 82 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 16. IM pentazocine versus complementary and alternate medicine (CAM)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal pain score measured
during labour
1 89 Mean Difference (IV, Fixed, 95% CI) -0.40 [-7.61, 6.81]
2 Nausea and vomiting 1 89 Risk Ratio (M-H, Fixed, 95% CI) 0.30 [0.01, 7.14]
3 Caesarean section 1 89 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.24, 3.35]
4 Assisted vaginal delivery 1 89 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.13, 6.07]
Comparison 17. IM pentazocine versus IM tramadol
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal satisfaction with
analgesia measured during
labour (pain relief after 30
mins)
1 100 Risk Ratio (M-H, Fixed, 95% CI) 2.4 [1.28, 4.48]
2 Maternal satisfaction with
analgesia measured during
labour (pain after 60 mins)
1 100 Risk Ratio (M-H, Fixed, 95% CI) 1.62 [0.91, 2.86]
3 Maternal pain score or pain
measured in labour (moderate
or severe at 30 mins)
1 100 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.55, 1.02]
4 Maternal pain score or pain
measured in labour (moderate
or severe at 60 mins)
1 100 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.60, 1.08]
5 Maternal sleepiness during
labour
1 100 Risk Ratio (M-H, Fixed, 95% CI) 1.67 [0.66, 4.24]
6 Nausea and vomiting 1 100 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.06, 15.55]
7 Caesarean section 1 100 Risk Ratio (M-H, Fixed, 95% CI) 1.5 [0.45, 4.99]
8 Assisted vaginal delivery 1 100 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.19, 21.36]
9 Apgar score < 7 at 1 minute 1 100 Risk Ratio (M-H, Fixed, 95% CI) 1.67 [0.42, 6.60]
10 Apgar score < 7 at 5 minutes 1 100 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.13, 71.92]
11 Admission to NICU 1 86 Risk Ratio (M-H, Fixed, 95% CI) 2.87 [0.12, 68.47]
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Comparison 18. IM pethidine versus Entonox
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal pain score or pain
measured in labour (after 30
mins)
1 100 Mean Difference (IV, Fixed, 95% CI) 1.66 [1.17, 2.15]
2 Maternal pain score or pain
measured in labour (after 60
mins)
1 100 Mean Difference (IV, Fixed, 95% CI) -0.36 [-0.85, 0.13]
Comparison 19. IV pethidine versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal pain score or pain
measured in labour (Pain score
30 mins post analgesia)
1 240 Mean Difference (IV, Fixed, 95% CI) -4.1 [-4.56, -3.64]
2 Nausea and vomiting 1 240 Risk Ratio (M-H, Fixed, 95% CI) 2.43 [1.05, 5.64]
3 Caesarean section 1 240 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.46, 1.68]
4 Assisted vaginal birth 1 240 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.33, 1.71]
5 Admission to NICU 1 240 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.11, 3.92]
Comparison 20. IV fentanyl versus no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal pain score or pain
measured in labour (Pain score
1 hour post-analgesia)
1 70 Mean Difference (IV, Fixed, 95% CI) -5.0 [-5.47, -4.53]
2 Maternal pain score or pain
measured in labour (Pain
intensity (Severe) after 1 hour)
1 70 Risk Ratio (M-H, Fixed, 95% CI) 0.02 [0.00, 0.25]
3 Caesarean section 1 70 Risk Ratio (M-H, Fixed, 95% CI) 1.5 [0.27, 8.43]
166Parenteral opioids for maternal pain management in labour (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Comparison 21. IV fentanyl versus IV pethidine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal pain score or pain
measured in labour (Pain
score 1 hour after drug
administration)
1 105 Mean Difference (IV, Fixed, 95% CI) -0.20 [-1.18, 0.78]
2 Mean doses of analgesia (non
pre-specified)
1 105 Mean Difference (IV, Fixed, 95% CI) 0.40 [0.14, 0.66]
3 Maternal sleepiness in labour
(sedation)
1 105 Risk Ratio (M-H, Fixed, 95% CI) 0.05 [0.00, 0.82]
4 Nausea and/or vomiting 1 105 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.17, 1.55]
5 Anti-emetic required (non
pre-specified)
1 105 Risk Ratio (M-H, Fixed, 95% CI) 0.09 [0.01, 1.52]
6 Caesarean section 1 105 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [0.24, 5.40]
7 Naloxone administered 1 105 Risk Ratio (M-H, Fixed, 95% CI) 0.16 [0.02, 1.28]
8 Babies requiring
resuscitation/ventilatory
support
1 105 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.46, 2.32]
9 Apgar score < 7 at 1 minute 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
10 Apgar score < 7 at 5 minutes 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
11 Neurobehavioural score (1 - 2
hours after delivery)
1 105 Mean Difference (IV, Fixed, 95% CI) 1.30 [0.15, 2.45]
12 Neurobehavioural score (2
hours - 24 hours)
1 105 Mean Difference (IV, Fixed, 95% CI) 0.90 [-0.42, 2.22]
Comparison 22. IV nalbuphine versus IV pethidine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Caesarean section 1 28 Risk Ratio (M-H, Fixed, 95% CI) 5.0 [0.26, 95.61]
2 Apgar score < 7 at 1 minute 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3 Apgar score < 7 at 5 minutes 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
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Comparison 23. IV phenazocine versus IV pethidine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal satisfaction with
analgesia measured during
labour (women with fair or
poor relief )
1 194 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.48, 1.10]
2 Nausea with vomiting 1 194 Risk Ratio (M-H, Fixed, 95% CI) 0.4 [0.08, 2.01]
3 Perinatal death 1 194 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Apgar score < 7 at 1 minute 1 194 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 24. IV butorphanol versus IV pethidine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal pain score or pain
measured in labour (Pain relief
score)
1 80 Mean Difference (IV, Fixed, 95% CI) 0.67 [0.25, 1.09]
2 Maternal pain score or pain
measured in labour (Pain
score (1 hour after drug
administration))
1 80 Mean Difference (IV, Fixed, 95% CI) -0.60 [-1.02, -0.18]
3 Additional analgesia required 1 100 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.63, 1.45]
4 Epidural 1 200 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.30, 3.35]
5 Nausea and/or vomiting 1 200 Risk Ratio (M-H, Fixed, 95% CI) 0.04 [0.00, 0.67]
6 Caesarean section 1 200 Risk Ratio (M-H, Fixed, 95% CI) 0.8 [0.22, 2.89]
7 Assisted vaginal birth 1 200 Risk Ratio (M-H, Fixed, 95% CI) 1.3 [0.60, 2.83]
8 Apgar score < 7 at 1 minute 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
9 Apgar score < 7 at 5 minutes 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
Comparison 25. IV morphine versus IV pethidine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal satisfaction with
analgesia (assessed 3 days
postpartum)
1 141 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.78, 0.98]
2 Additional analgesia required 1 143 Risk Ratio (M-H, Fixed, 95% CI) 3.41 [1.90, 6.12]
3 Nausea and vomiting 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Nausea 1 20 Risk Ratio (M-H, Fixed, 95% CI) 0.17 [0.02, 1.14]
3.2 Vomiting 1 20 Risk Ratio (M-H, Fixed, 95% CI) 0.25 [0.03, 1.86]
4 Caesarean section 1 20 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 26. IV Nisentil versus IV pethidine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Nausea and vomiting 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Nausea 1 395 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.33, 1.52]
1.2 Vomiting 1 395 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.22, 0.66]
2 Neonatal
resuscitation/ventilatory
support
1 395 Risk Ratio (M-H, Fixed, 95% CI) 1.99 [0.85, 4.63]
Comparison 27. IV fentanyl versus IV butorphanol
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Additional analgesia required 1 100 Risk Ratio (M-H, Fixed, 95% CI) 1.39 [1.05, 1.85]
2 Epidural 1 100 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [1.00, 4.02]
3 Matenal sleepiness (required
tactile rousing)
1 100 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.64, 14.16]
4 Caesarean section 1 100 Risk Ratio (M-H, Fixed, 95% CI) 0.8 [0.23, 2.81]
5 Naloxone required 1 100 Risk Ratio (M-H, Fixed, 95% CI) 1.75 [0.81, 3.80]
6 Neonatal resuscitation (Babies
requiring ventilatory support)
1 100 Risk Ratio (M-H, Fixed, 95% CI) 11.0 [0.62, 193.80]
7 Apgar score < 7 at 5 minutes 1 100 Risk Ratio (M-H, Fixed, 95% CI) 1.2 [0.39, 3.68]
8 Newborn neurobehavioural
score at 2-4 hours
1 100 Mean Difference (IV, Fixed, 95% CI) 0.0 [-1.61, 1.61]
9 Newborn neurobehavioural
score at 24-36 hours
1 100 Mean Difference (IV, Fixed, 95% CI) -0.50 [-1.62, 0.62]
Comparison 28. PCA pentazocine versus PCA pethidine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal pan score or pain
measured in labour
1 23 Mean Difference (IV, Fixed, 95% CI) -1.45 [-2.96, 0.06]
2 Maternal pan score or pain
measured in labour (rated as
good one day after birth)
1 28 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.51, 1.32]
3 Epidural 1 28 Risk Ratio (M-H, Fixed, 95% CI) 1.5 [0.29, 7.65]
4 Nausea and vomiting 1 29 Risk Ratio (M-H, Fixed, 95% CI) 0.10 [0.01, 1.61]
5 Maternal sleepiness during
labour (Sedation)
1 29 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.01, 4.09]
6 Caesarean section 1 29 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.02, 8.07]
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7 Breastfeeding at discharge 1 23 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.85, 1.17]
8 Apgar score < 7 at 5 minutes 1 29 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 29. PCA remifentanil versus PCA pethidine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal pain score in labour 2 122 Mean Difference (IV, Random, 95% CI) -8.59 [-27.61, 10.
44]
2 Additional analgesia required 2 56 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.69, 1.08]
3 Epidural 2 122 Risk Ratio (M-H, Fixed, 95% CI) 0.42 [0.20, 0.89]
4 Maternal sleepiness during
labour
1 105 Mean Difference (IV, Fixed, 95% CI) 0.40 [0.14, 0.66]
5 Nausea and vomiting 2 119 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.61, 1.49]
6 Caesarean section 2 97 Risk Ratio (M-H, Fixed, 95% CI) 1.81 [0.60, 5.46]
7 Assisted vaginal birth 2 97 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.46, 2.00]
8 Satisfaction with childbirth
experience
1 68 Mean Difference (IV, Fixed, 95% CI) 1.10 [0.46, 1.74]
9 Naloxone administered 2 56 Risk Ratio (M-H, Fixed, 95% CI) 0.3 [0.01, 6.47]
10 Apgar score < 7 at 5 minutes 1 17 Risk Ratio (M-H, Fixed, 95% CI) 0.13 [0.01, 2.16]
11 Admission to NICU 1 17 Risk Ratio (M-H, Fixed, 95% CI) 0.3 [0.01, 6.47]
12 Newborn neurobehavioural
score (15 minutes post delivery)
1 56 Mean Difference (IV, Fixed, 95% CI) 0.20 [-0.93, 1.33]
13 Newborn neurobehavioural
score (2 hours post delivery)
1 56 Mean Difference (IV, Fixed, 95% CI) 0.60 [-0.66, 1.86]
Comparison 30. PCA nalbuphine versus PCA pethidine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal satisfaction with
analgesia in labour measured
during the postnatal period
(rated good or excellent)
1 60 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.88, 1.89]
2 Maternal satisfaction with
analgesia in labour measured
during the postnatal period
(Would use the same pain relief
again)
1 59 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.79, 1.43]
3 Maternal pain score or pain
measured in labour
1 60 Mean Difference (IV, Fixed, 95% CI) -0.40 [-0.79, -0.01]
4 Additional analgesia required 1 59 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.46, 1.48]
5 Nausea and vomiting 1 59 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.30, 1.54]
6 Apgar score < 7 at 5 minutes 1 41 Risk Ratio (M-H, Fixed, 95% CI) 0.42 [0.02, 9.76]
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Comparison 31. PCA fentanyl versus PCA alfentanil
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal satisfaction with
analgesia in labour measured
during the postnatal period
(described as adequate)
1 23 Risk Ratio (M-H, Fixed, 95% CI) 1.56 [0.93, 2.60]
2 Maternal pain score or pain
measured in labour (Pain score
at 4-6 cm cervical dilatation)
1 21 Mean Difference (IV, Fixed, 95% CI) -12.80 [-32.12, 6.
52]
3 Nausea 1 23 Risk Ratio (M-H, Fixed, 95% CI) 2.73 [0.66, 11.30]
4 Caesarean section 1 23 Risk Ratio (M-H, Fixed, 95% CI) 1.64 [0.33, 8.03]
5 Naloxone required 1 24 Risk Ratio (M-H, Fixed, 95% CI) 2.36 [0.53, 10.55]
Comparison 32. PCA fentanyl versus PCA pethidine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternla pain score measured in
labour
1 107 Mean Difference (IV, Fixed, 95% CI) -0.65 [-1.56, 0.26]
2 Epidural 1 107 Risk Ratio (M-H, Fixed, 95% CI) 0.44 [0.21, 0.92]
3 Maternal sleepiness during
labour
1 107 Mean Difference (IV, Fixed, 95% CI) -0.06 [-0.25, 0.13]
4 Nausea and vomiting 1 102 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.55, 1.37]
5 Caesarean section 1 81 Risk Ratio (M-H, Fixed, 95% CI) 0.25 [0.03, 2.34]
6 Assisted vaginal birth 1 81 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.22, 1.49]
7 Newborn neurobehavioural
score (15 minutes post delivery)
1 63 Mean Difference (IV, Fixed, 95% CI) -0.90 [-2.31, 0.51]
8 Newborn neurobehavioural
score (2 hours post delivery)
1 64 Mean Difference (IV, Fixed, 95% CI) -0.5 [-1.95, 0.95]
Comparison 33. PCA (IM) meptazinol versus PCA (IM) pethidine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal pain score or pain
measured in labour (measured
1 day after delivery)
1 10 Mean Difference (IV, Fixed, 95% CI) -17.60 [-49.93, 14.
73]
2 Satisfied with mode of
administration (PCA IM) (non
pre-specified)
1 10 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.71, 1.41]
3 Epidural 1 10 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.15, 59.89]
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4 Maternal sleepiness in labour
(Drowsiness score in labour
rated 1 day after delivery)
1 10 Mean Difference (IV, Fixed, 95% CI) 5.60 [-28.19, 39.39]
5 Nausea (score in labour rated 1
day after delivery)
1 10 Mean Difference (IV, Fixed, 95% CI) -8.0 [-48.70, 32.70]
6 Naloxone administered 1 10 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.08, 11.93]
Comparison 34. Opioids versus TENS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal satisfaction with
analgesia measured post
delivery (rated as good)
2 104 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [0.79, 1.92]
2 Maternal pain score measured
during labour
2 290 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.81, 1.61]
3 Maternal pain score in labour 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 Pain score (after 30
minutes)
1 60 Mean Difference (IV, Fixed, 95% CI) -20.0 [-26.09, -13.
91]
3.2 Pain score (after 60
minutes)
1 60 Mean Difference (IV, Fixed, 95% CI) -20.0 [-25.16, -14.
84]
4 Maternal sleepiness during
labour (Drowsiness)
2 290 Risk Ratio (M-H, Fixed, 95% CI) 8.96 [1.13, 71.07]
5 Nausea and vomiting 3 350 Risk Ratio (M-H, Fixed, 95% CI) 13.73 [2.72, 69.24]
6 Caesarean section 2 260 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.19, 20.90]
7 Assisted vaginal birth 2 260 Risk Ratio (M-H, Fixed, 95% CI) 1.8 [0.40, 8.18]
8 Fetal heart rate changes in labour
(Fetal distress)
1 200 Risk Ratio (M-H, Fixed, 95% CI) 5.0 [0.24, 102.85]
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Analysis 1.1. Comparison 1 IM pethidine 50 mg/100 mg versus placebo, Outcome 1 Maternal satisfaction
with analgesia measured during labour (number of women satisfied or very satisfied after 30 minutes).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 1 IM pethidine 50 mg/100 mg versus placebo
Outcome: 1 Maternal satisfaction with analgesia measured during labour (number of women satisfied or very satisfied after 30 minutes)
Study or subgroup Pethidine IM Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tsui 2004 (1) 3/25 0/25 100.0 % 7.00 [ 0.38, 128.87 ]
Total (95% CI) 25 25 100.0 % 7.00 [ 0.38, 128.87 ]
Total events: 3 (Pethidine IM), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours placebo Favours pethidine
(1) Maternal satisfaction rated as 4 or 5 on rating scale 0-5 where 0 = very disatisfied to 5= very satisfied
Analysis 1.2. Comparison 1 IM pethidine 50 mg/100 mg versus placebo, Outcome 2 Maternal pain score or
pain measured in labour (described as good or fair after 1 hour).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 1 IM pethidine 50 mg/100 mg versus placebo
Outcome: 2 Maternal pain score or pain measured in labour (described as good or fair after 1 hour)
Study or subgroup Pethidine IM Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sliom 1970 42/58 24/58 100.0 % 1.75 [ 1.24, 2.47 ]
Total (95% CI) 58 58 100.0 % 1.75 [ 1.24, 2.47 ]
Total events: 42 (Pethidine IM), 24 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.18 (P = 0.0015)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Favours placebo Favours pethidine
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Analysis 1.3. Comparison 1 IM pethidine 50 mg/100 mg versus placebo, Outcome 3 Maternal pain score or
pain measured in labour (reduction in VAS of at least 40 mm after 30 minutes).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 1 IM pethidine 50 mg/100 mg versus placebo
Outcome: 3 Maternal pain score or pain measured in labour (reduction in VAS of at least 40 mm after 30 minutes)
Study or subgroup Pethidine IM Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tsui 2004 12/25 0/25 100.0 % 25.00 [ 1.56, 400.54 ]
Total (95% CI) 25 25 100.0 % 25.00 [ 1.56, 400.54 ]
Total events: 12 (Pethidine IM), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.27 (P = 0.023)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours placebo Favours pethidine
Analysis 1.4. Comparison 1 IM pethidine 50 mg/100 mg versus placebo, Outcome 4 Additional analgesia
required.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 1 IM pethidine 50 mg/100 mg versus placebo
Outcome: 4 Additional analgesia required
Study or subgroup Pethidine IM Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tsui 2004 (1) 17/25 24/25 100.0 % 0.71 [ 0.54, 0.94 ]
Total (95% CI) 25 25 100.0 % 0.71 [ 0.54, 0.94 ]
Total events: 17 (Pethidine IM), 24 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.41 (P = 0.016)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours pethidine Favours placebo
(1) Epidural, pethidine, and Entonox
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Analysis 1.5. Comparison 1 IM pethidine 50 mg/100 mg versus placebo, Outcome 5 Epidural.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 1 IM pethidine 50 mg/100 mg versus placebo
Outcome: 5 Epidural
Study or subgroup Pethidine IM Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tsui 2004 3/25 6/25 100.0 % 0.50 [ 0.14, 1.78 ]
Total (95% CI) 25 25 100.0 % 0.50 [ 0.14, 1.78 ]
Total events: 3 (Pethidine IM), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours pethidine Favours placebo
Analysis 1.6. Comparison 1 IM pethidine 50 mg/100 mg versus placebo, Outcome 6 Nausea and vomiting.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 1 IM pethidine 50 mg/100 mg versus placebo
Outcome: 6 Nausea and vomiting
Study or subgroup Pethidine IM Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sliom 1970 10/58 8/58 94.1 % 1.25 [ 0.53, 2.94 ]
Tsui 2004 (1) 2/25 0/25 5.9 % 5.00 [ 0.25, 99.16 ]
Total (95% CI) 83 83 100.0 % 1.47 [ 0.65, 3.31 ]
Total events: 12 (Pethidine IM), 8 (Placebo)
Heterogeneity: Chi2 = 0.78, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours pethidine Favours placebo
(1) Figures for vomiting only
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Analysis 1.7. Comparison 1 IM pethidine 50 mg/100 mg versus placebo, Outcome 7 Maternal sleepiness.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 1 IM pethidine 50 mg/100 mg versus placebo
Outcome: 7 Maternal sleepiness
Study or subgroup Pethidine IM Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sliom 1970 26/58 6/58 66.7 % 4.33 [ 1.93, 9.74 ]
Tsui 2004 16/25 3/25 33.3 % 5.33 [ 1.77, 16.05 ]
Total (95% CI) 83 83 100.0 % 4.67 [ 2.43, 8.95 ]
Total events: 42 (Pethidine IM), 9 (Placebo)
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 4.63 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours pethidine Favours placebo
Analysis 1.8. Comparison 1 IM pethidine 50 mg/100 mg versus placebo, Outcome 8 Assisted vaginal delivery.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 1 IM pethidine 50 mg/100 mg versus placebo
Outcome: 8 Assisted vaginal delivery
Study or subgroup Pethidine IM Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tsui 2004 6/25 7/25 100.0 % 0.86 [ 0.34, 2.19 ]
Total (95% CI) 25 25 100.0 % 0.86 [ 0.34, 2.19 ]
Total events: 6 (Pethidine IM), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours pethidine Favours placebo
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Analysis 1.9. Comparison 1 IM pethidine 50 mg/100 mg versus placebo, Outcome 9 Caesarean section.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 1 IM pethidine 50 mg/100 mg versus placebo
Outcome: 9 Caesarean section
Study or subgroup Pethidine IM Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Direkvand-Moghadam 2014 7/45 11/45 64.7 % 0.64 [ 0.27, 1.49 ]
Tsui 2004 5/25 6/25 35.3 % 0.83 [ 0.29, 2.38 ]
Total (95% CI) 70 70 100.0 % 0.71 [ 0.36, 1.37 ]
Total events: 12 (Pethidine IM), 17 (Placebo)
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours pethidine Favours placebo
Analysis 1.10. Comparison 1 IM pethidine 50 mg/100 mg versus placebo, Outcome 10 Neonatal
resuscitation.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 1 IM pethidine 50 mg/100 mg versus placebo
Outcome: 10 Neonatal resuscitation
Study or subgroup Pethidine IM Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tsui 2004 5/25 3/25 100.0 % 1.67 [ 0.45, 6.24 ]
Total (95% CI) 25 25 100.0 % 1.67 [ 0.45, 6.24 ]
Total events: 5 (Pethidine IM), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours pethidine Favours placebo
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Analysis 1.11. Comparison 1 IM pethidine 50 mg/100 mg versus placebo, Outcome 11 Low Apgar score (≤
7) at 1 and 5 minutes.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 1 IM pethidine 50 mg/100 mg versus placebo
Outcome: 11 Low Apgar score (≤ 7) at 1 and 5 minutes
Study or subgroup Pethidine IM Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low scores at 1 minute
Sliom 1970 33/58 13/58 64.4 % 2.54 [ 1.50, 4.31 ]
Tsui 2004 3/25 4/25 35.6 % 0.75 [ 0.19, 3.01 ]
Subtotal (95% CI) 83 83 100.0 % 1.64 [ 0.52, 5.18 ]
Total events: 36 (Pethidine IM), 17 (Placebo)
Heterogeneity: Tau2 = 0.46; Chi2 = 2.59, df = 1 (P = 0.11); I2 =61%
Test for overall effect: Z = 0.85 (P = 0.39)
2 Low scores at 5 minutes
Sekhavat 2009 0/75 0/75 Not estimable
Tsui 2004 0/25 0/25 Not estimable
Subtotal (95% CI) 100 100 Not estimable
Total events: 0 (Pethidine IM), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.01 0.1 1 10 100
Favours pethidine Favours placebo
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Analysis 1.12. Comparison 1 IM pethidine 50 mg/100 mg versus placebo, Outcome 12 Admission to NICU.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 1 IM pethidine 50 mg/100 mg versus placebo
Outcome: 12 Admission to NICU
Study or subgroup Pethidine IM Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tsui 2004 1/25 1/25 100.0 % 1.00 [ 0.07, 15.12 ]
Total (95% CI) 25 25 100.0 % 1.00 [ 0.07, 15.12 ]
Total events: 1 (Pethidine IM), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours pethidine Favours placebo
Analysis 2.1. Comparison 2 IM pentazocine versus placebo, Outcome 1 Maternal pain score measured
during labour.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 2 IM pentazocine versus placebo
Outcome: 1 Maternal pain score measured during labour
Study or subgroup Pentazocine Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Zafar 2016 47 81.5 (17.8247) 42 85.1 (12.3134) 100.0 % -3.60 [ -9.91, 2.71 ]
Total (95% CI) 47 42 100.0 % -3.60 [ -9.91, 2.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours pentazocine Favours placebo
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Analysis 2.2. Comparison 2 IM pentazocine versus placebo, Outcome 2 Nausea and vomiting.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 2 IM pentazocine versus placebo
Outcome: 2 Nausea and vomiting
Study or subgroup Pentazocine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Zafar 2016 0/47 0/42 Not estimable
Total (95% CI) 47 42 Not estimable
Total events: 0 (Pentazocine), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours pentazocine Favours placebo
Analysis 2.3. Comparison 2 IM pentazocine versus placebo, Outcome 3 Caesarean section.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 2 IM pentazocine versus placebo
Outcome: 3 Caesarean section
Study or subgroup Pentazocine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Zafar 2016 4/47 4/42 100.0 % 0.89 [ 0.24, 3.35 ]
Total (95% CI) 47 42 100.0 % 0.89 [ 0.24, 3.35 ]
Total events: 4 (Pentazocine), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.87)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours pentazocine Favours placebo
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Analysis 2.4. Comparison 2 IM pentazocine versus placebo, Outcome 4 Assisted vaginal birth.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 2 IM pentazocine versus placebo
Outcome: 4 Assisted vaginal birth
Study or subgroup Pentazocine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Zafar 2016 2/47 3/42 100.0 % 0.60 [ 0.10, 3.39 ]
Total (95% CI) 47 42 100.0 % 0.60 [ 0.10, 3.39 ]
Total events: 2 (Pentazocine), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours pentazocine Favours placebo
Analysis 3.1. Comparison 3 IM tramadol versus no treatment, Outcome 1 Maternal satisfaction with
analgesia (Analgesic effect described as satisfactory (not clear when measured)).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 3 IM tramadol versus no treatment
Outcome: 1 Maternal satisfaction with analgesia (Analgesic effect described as satisfactory (not clear when measured))
Study or subgroup Tramadol No analgesia Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Li 1994 5/30 0/30 100.0 % 11.00 [ 0.64, 190.53 ]
Total (95% CI) 30 30 100.0 % 11.00 [ 0.64, 190.53 ]
Total events: 5 (Tramadol), 0 (No analgesia)
Heterogeneity: not applicable
Test for overall effect: Z = 1.65 (P = 0.099)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours no analgesia Favours tramadol
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Analysis 4.1. Comparison 4 IM meptazinol versus pethidine, Outcome 1 Maternal pain score or pain
measured in labour (Maternal pain relief poor or none (3-5 PN)).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 4 IM meptazinol versus pethidine
Outcome: 1 Maternal pain score or pain measured in labour (Maternal pain relief poor or none (3-5 PN))
Study or subgroup Meptazinol Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Morrison 1987 (1) 255/394 260/407 100.0 % 1.01 [ 0.91, 1.12 ]
Total (95% CI) 394 407 100.0 % 1.01 [ 0.91, 1.12 ]
Total events: 255 (Meptazinol), 260 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours meptazinol Favours pethidine
(1) Post partum assessment of analgesia 3-5 postpartum
Analysis 4.2. Comparison 4 IM meptazinol versus pethidine, Outcome 2 Maternal pain score or pain
measured in labour (Pain intensity 4 or 5 on 5-point scale (1 hour)).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 4 IM meptazinol versus pethidine
Outcome: 2 Maternal pain score or pain measured in labour (Pain intensity 4 or 5 on 5-point scale (1 hour))
Study or subgroup Meptazinol Pethidine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Nel 1981 11/34 6/30 22.5 % 1.62 [ 0.68, 3.84 ]
Sheikh 1986 78/87 79/88 77.5 % 1.00 [ 0.90, 1.10 ]
Total (95% CI) 121 118 100.0 % 1.11 [ 0.69, 1.80 ]
Total events: 89 (Meptazinol), 85 (Pethidine)
Heterogeneity: Tau2 = 0.08; Chi2 = 1.77, df = 1 (P = 0.18); I2 =43%
Test for overall effect: Z = 0.43 (P = 0.66)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours meptazinol Favours pethidine
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Analysis 4.3. Comparison 4 IM meptazinol versus pethidine, Outcome 3 Additional analgesia required.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 4 IM meptazinol versus pethidine
Outcome: 3 Additional analgesia required
Study or subgroup Meptazinol Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Osler 1987 (1) 79/100 76/99 97.4 % 1.03 [ 0.89, 1.19 ]
Wheble 1988 2/17 2/17 2.6 % 1.00 [ 0.16, 6.30 ]
Total (95% CI) 117 116 100.0 % 1.03 [ 0.88, 1.20 ]
Total events: 81 (Meptazinol), 78 (Pethidine)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours meptazinol Favours pethidine
(1) For Osler 1987 additional analgesia relates to a pudendal, whereas for Wheble it relates to a second dose of study drug.
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Analysis 4.4. Comparison 4 IM meptazinol versus pethidine, Outcome 4 Epidural.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 4 IM meptazinol versus pethidine
Outcome: 4 Epidural
Study or subgroup Meptazinol Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nicholas 1982 36/186 37/172 53.9 % 0.90 [ 0.60, 1.35 ]
Osler 1987 11/100 9/99 12.7 % 1.21 [ 0.52, 2.79 ]
Sheikh 1986 17/98 20/99 27.9 % 0.86 [ 0.48, 1.54 ]
Wheble 1988 6/17 4/17 5.6 % 1.50 [ 0.51, 4.38 ]
Total (95% CI) 401 387 100.0 % 0.96 [ 0.71, 1.29 ]
Total events: 70 (Meptazinol), 70 (Pethidine)
Heterogeneity: Chi2 = 1.20, df = 3 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.26 (P = 0.79)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours meptazinol Favours pethidine
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Analysis 4.5. Comparison 4 IM meptazinol versus pethidine, Outcome 5 Maternal sleepiness.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 4 IM meptazinol versus pethidine
Outcome: 5 Maternal sleepiness
Study or subgroup Meptazinol Pethidine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Morrison 1987 147/513 202/522 63.3 % 0.74 [ 0.62, 0.88 ]
Nicholas 1982 4/186 14/172 23.9 % 0.26 [ 0.09, 0.79 ]
Sheikh 1986 2/98 4/99 12.8 % 0.51 [ 0.09, 2.69 ]
Total (95% CI) 797 793 100.0 % 0.55 [ 0.28, 1.07 ]
Total events: 153 (Meptazinol), 220 (Pethidine)
Heterogeneity: Tau2 = 0.18; Chi2 = 3.57, df = 2 (P = 0.17); I2 =44%
Test for overall effect: Z = 1.75 (P = 0.080)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours meptazinol Favours pethidine
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Analysis 4.6. Comparison 4 IM meptazinol versus pethidine, Outcome 6 Nausea and vomiting.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 4 IM meptazinol versus pethidine
Outcome: 6 Nausea and vomiting
Study or subgroup Meptazinol Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Nausea
Morrison 1987 189/513 169/522 73.5 % 1.14 [ 0.96, 1.35 ]
Nicholas 1982 39/186 39/172 17.8 % 0.92 [ 0.62, 1.37 ]
Sheikh 1986 24/98 20/99 8.7 % 1.21 [ 0.72, 2.05 ]
Subtotal (95% CI) 797 793 100.0 % 1.11 [ 0.95, 1.28 ]
Total events: 252 (Meptazinol), 228 (Pethidine)
Heterogeneity: Chi2 = 1.03, df = 2 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.34 (P = 0.18)
2 Vomiting
Morrison 1987 184/513 141/522 74.3 % 1.33 [ 1.11, 1.59 ]
Nicholas 1982 36/186 31/171 17.2 % 1.07 [ 0.69, 1.65 ]
Sheikh 1986 15/98 16/99 8.5 % 0.95 [ 0.50, 1.81 ]
Subtotal (95% CI) 797 792 100.0 % 1.25 [ 1.06, 1.47 ]
Total events: 235 (Meptazinol), 188 (Pethidine)
Heterogeneity: Chi2 = 1.64, df = 2 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 2.69 (P = 0.0071)
0.1 0.2 0.5 1 2 5 10
Favours meptazinol Favours pethidine
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Analysis 4.7. Comparison 4 IM meptazinol versus pethidine, Outcome 7 Caesarean section.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 4 IM meptazinol versus pethidine
Outcome: 7 Caesarean section
Study or subgroup Meptazinol Pethidine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Morrison 1987 33/512 25/521 46.8 % 1.34 [ 0.81, 2.23 ]
Osler 1987 5/100 13/99 38.7 % 0.38 [ 0.14, 1.03 ]
Wheble 1988 0/17 5/17 14.6 % 0.09 [ 0.01, 1.53 ]
Total (95% CI) 629 637 100.0 % 0.56 [ 0.16, 2.00 ]
Total events: 38 (Meptazinol), 43 (Pethidine)
Heterogeneity: Tau2 = 0.84; Chi2 = 7.85, df = 2 (P = 0.02); I2 =75%
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours meptazinol Favours pethidine
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Analysis 4.8. Comparison 4 IM meptazinol versus pethidine, Outcome 8 Assisted vaginal birth.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 4 IM meptazinol versus pethidine
Outcome: 8 Assisted vaginal birth
Study or subgroup Meptazinol Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Morrison 1987 97/512 107/521 75.7 % 0.92 [ 0.72, 1.18 ]
Osler 1987 36/100 28/99 20.1 % 1.27 [ 0.85, 1.91 ]
Wheble 1988 6/17 6/17 4.3 % 1.00 [ 0.40, 2.48 ]
Total (95% CI) 629 637 100.0 % 1.00 [ 0.81, 1.22 ]
Total events: 139 (Meptazinol), 141 (Pethidine)
Heterogeneity: Chi2 = 1.76, df = 2 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours meptazinol Favours pethidine
Analysis 4.9. Comparison 4 IM meptazinol versus pethidine, Outcome 9 Breastfeeding at discharge
(problems).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 4 IM meptazinol versus pethidine
Outcome: 9 Breastfeeding at discharge (problems)
Study or subgroup Meptazinol Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sheikh 1986 3/98 4/99 100.0 % 0.76 [ 0.17, 3.30 ]
Total (95% CI) 98 99 100.0 % 0.76 [ 0.17, 3.30 ]
Total events: 3 (Meptazinol), 4 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 4.10. Comparison 4 IM meptazinol versus pethidine, Outcome 10 Fetal heart rate changes
(decelerations).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 4 IM meptazinol versus pethidine
Outcome: 10 Fetal heart rate changes (decelerations)
Study or subgroup Meptazinol Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Boer 1987 16/17 13/17 100.0 % 1.23 [ 0.92, 1.64 ]
Total (95% CI) 17 17 100.0 % 1.23 [ 0.92, 1.64 ]
Total events: 16 (Meptazinol), 13 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours meptazinol Favours pethidine
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Analysis 4.11. Comparison 4 IM meptazinol versus pethidine, Outcome 11 Naloxone administration.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 4 IM meptazinol versus pethidine
Outcome: 11 Naloxone administration
Study or subgroup Meptazinol Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 < 36 weeks’ gestation
Morrison 1987 9/15 5/8 2.8 % 0.96 [ 0.49, 1.89 ]
Subtotal (95% CI) 15 8 2.8 % 0.96 [ 0.49, 1.89 ]
Total events: 9 (Meptazinol), 5 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.91)
2≥ 36 weeks’ gestation
Morrison 1987 198/479 231/496 97.2 % 0.89 [ 0.77, 1.02 ]
Subtotal (95% CI) 479 496 97.2 % 0.89 [ 0.77, 1.02 ]
Total events: 198 (Meptazinol), 231 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
Total (95% CI) 494 504 100.0 % 0.89 [ 0.77, 1.02 ]
Total events: 207 (Meptazinol), 236 (Pethidine)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 1.64 (P = 0.10)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.82), I2 =0.0%
0.01 0.1 1 10 100
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Analysis 4.12. Comparison 4 IM meptazinol versus pethidine, Outcome 12 Neonatal resuscitation (by
gestation).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 4 IM meptazinol versus pethidine
Outcome: 12 Neonatal resuscitation (by gestation)
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 < 36 weeks’ gestation
Morrison 1987 13/15 8/8 2.3 % 0.89 [ 0.69, 1.16 ]
Subtotal (95% CI) 15 8 2.3 % 0.89 [ 0.69, 1.16 ]
Total events: 13 (Experimental), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
2≥ 36 weeks’ gestation
Morrison 1987 429/479 441/496 92.6 % 1.01 [ 0.96, 1.05 ]
Nicholas 1982 (1) 21/186 23/172 5.1 % 0.84 [ 0.49, 1.47 ]
Subtotal (95% CI) 665 668 97.7 % 1.00 [ 0.95, 1.05 ]
Total events: 450 (Experimental), 464 (Control)
Heterogeneity: Chi2 = 0.50, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
Total (95% CI) 680 676 100.0 % 1.00 [ 0.95, 1.05 ]
Total events: 463 (Experimental), 472 (Control)
Heterogeneity: Chi2 = 1.24, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.15 (P = 0.88)
Test for subgroup differences: Chi2 = 0.66, df = 1 (P = 0.42), I2 =0.0%
0.5 0.7 1 1.5 2
Favours meptazinol Favours pethidine
(1) Nicholas = apnoea interpreted as requirement for resuscitation
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Analysis 4.13. Comparison 4 IM meptazinol versus pethidine, Outcome 13 Neonatal resuscitation.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 4 IM meptazinol versus pethidine
Outcome: 13 Neonatal resuscitation
Study or subgroup Meptazinol Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Jackson 1983 3/50 2/50 100.0 % 1.50 [ 0.26, 8.60 ]
Total (95% CI) 50 50 100.0 % 1.50 [ 0.26, 8.60 ]
Total events: 3 (Meptazinol), 2 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.65)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours meptazinol Favours pethidine
Analysis 4.14. Comparison 4 IM meptazinol versus pethidine, Outcome 14 Apgar score ≤ 7 at 1 minute.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 4 IM meptazinol versus pethidine
Outcome: 14 Apgar score≤ 7 at 1 minute
Study or subgroup Meptazinol Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Boer 1987 3/17 4/17 6.4 % 0.75 [ 0.20, 2.86 ]
Jackson 1983 11/47 12/48 19.0 % 0.94 [ 0.46, 1.91 ]
Nel 1981 (1) 3/35 3/36 4.7 % 1.03 [ 0.22, 4.76 ]
Nicholas 1982 (2) 15/186 18/172 29.9 % 0.77 [ 0.40, 1.48 ]
Osler 1987 (3) 15/100 20/99 32.1 % 0.74 [ 0.40, 1.37 ]
Wheble 1988 (4) 3/17 5/17 8.0 % 0.60 [ 0.17, 2.12 ]
Total (95% CI) 402 389 100.0 % 0.79 [ 0.56, 1.11 ]
Total events: 50 (Meptazinol), 62 (Pethidine)
Heterogeneity: Chi2 = 0.57, df = 5 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 1.35 (P = 0.18)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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(1) Nel = Apgar < 7
(2) Nicholas = Apgar < 7
(3) Osler <= 7
(4) Wheble Apgar < 7
Analysis 4.15. Comparison 4 IM meptazinol versus pethidine, Outcome 15 Apgar score ≤ 7 at 5 minutes.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 4 IM meptazinol versus pethidine
Outcome: 15 Apgar score≤ 7 at 5 minutes
Study or subgroup Meptazinol Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nel 1981 0/35 0/35 Not estimable
Nicholas 1982 0/181 0/166 Not estimable
Osler 1987 (1) 1/100 2/99 100.0 % 0.50 [ 0.05, 5.37 ]
Total (95% CI) 316 300 100.0 % 0.50 [ 0.05, 5.37 ]
Total events: 1 (Meptazinol), 2 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours meptazinol Favours pethidine
(1) Osler Apgar =< 7
193Parenteral opioids for maternal pain management in labour (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.16. Comparison 4 IM meptazinol versus pethidine, Outcome 16 Admission to NICU.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 4 IM meptazinol versus pethidine
Outcome: 16 Admission to NICU
Study or subgroup Meptazinol Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Osler 1987 16/100 18/99 100.0 % 0.88 [ 0.48, 1.63 ]
Total (95% CI) 100 99 100.0 % 0.88 [ 0.48, 1.63 ]
Total events: 16 (Meptazinol), 18 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 5.1. Comparison 5 IM diamorphine + prochlorperazine versus pethidine + prochlorperazine,
Outcome 1 Maternal satisfaction with analgesia in labour measured during the postnatal period (Global
assessment of pain relief at 24 hours).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 5 IM diamorphine + prochlorperazine versus pethidine + prochlorperazine
Outcome: 1 Maternal satisfaction with analgesia in labour measured during the postnatal period (Global assessment of pain relief at 24 hours)
Study or subgroup
Diamorphine
cotherapy IM
Pethidine
cotherapy
IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fairlie 1999 (1) 37/65 44/68 100.0 % 0.88 [ 0.67, 1.16 ]
Total (95% CI) 65 68 100.0 % 0.88 [ 0.67, 1.16 ]
Total events: 37 (Diamorphine cotherapy IM), 44 (Pethidine cotherapy IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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(1) Pain relief as rated as poor or fair
Analysis 5.2. Comparison 5 IM diamorphine + prochlorperazine versus pethidine + prochlorperazine,
Outcome 2 Maternal pain score or pain measured in labour (Pain intensity at 1 hour (moderate or severe)).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 5 IM diamorphine + prochlorperazine versus pethidine + prochlorperazine
Outcome: 2 Maternal pain score or pain measured in labour (Pain intensity at 1 hour (moderate or severe))
Study or subgroup
Diamorphine
cotherapy IM
Pethidine
cotherapy
IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fairlie 1999 48/65 59/68 100.0 % 0.85 [ 0.72, 1.01 ]
Total (95% CI) 65 68 100.0 % 0.85 [ 0.72, 1.01 ]
Total events: 48 (Diamorphine cotherapy IM), 59 (Pethidine cotherapy IM)
Heterogeneity: not applicable
Test for overall effect: Z = 1.84 (P = 0.066)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours diamorphine + pro Favours pethidine + pro
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Analysis 5.3. Comparison 5 IM diamorphine + prochlorperazine versus pethidine + prochlorperazine,
Outcome 3 Additonal analgesia required.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 5 IM diamorphine + prochlorperazine versus pethidine + prochlorperazine
Outcome: 3 Additonal analgesia required
Study or subgroup
Diamorphine
cotherapy IM
Pethidine
cotherapy
IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fairlie 1999 (1) 9/65 7/68 100.0 % 1.35 [ 0.53, 3.40 ]
Total (95% CI) 65 68 100.0 % 1.35 [ 0.53, 3.40 ]
Total events: 9 (Diamorphine cotherapy IM), 7 (Pethidine cotherapy IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours diamorphine + pro Favours pethidine + pro
(1) Second dose of study drug
Analysis 5.4. Comparison 5 IM diamorphine + prochlorperazine versus pethidine + prochlorperazine,
Outcome 4 Epidural.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 5 IM diamorphine + prochlorperazine versus pethidine + prochlorperazine
Outcome: 4 Epidural
Study or subgroup
Diamorphine
cotherapy IM
Pethidine
cotherapy
IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fairlie 1999 (1) 21/65 18/68 100.0 % 1.22 [ 0.72, 2.07 ]
Total (95% CI) 65 68 100.0 % 1.22 [ 0.72, 2.07 ]
Total events: 21 (Diamorphine cotherapy IM), 18 (Pethidine cotherapy IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours diamorphine + pro Favours pethidine + pro
196Parenteral opioids for maternal pain management in labour (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(1) 2nd dose of study drug
Analysis 5.5. Comparison 5 IM diamorphine + prochlorperazine versus pethidine + prochlorperazine,
Outcome 5 Maternal sleepiness during labour.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 5 IM diamorphine + prochlorperazine versus pethidine + prochlorperazine
Outcome: 5 Maternal sleepiness during labour
Study or subgroup
Diamorphine
cotherapy IM
Pethidine
cotherapy
IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fairlie 1999 (1) 16/65 18/68 100.0 % 0.93 [ 0.52, 1.66 ]
Total (95% CI) 65 68 100.0 % 0.93 [ 0.52, 1.66 ]
Total events: 16 (Diamorphine cotherapy IM), 18 (Pethidine cotherapy IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours diamorphine + pro Favours pethidine + pro
(1) Moderately drowsy or asleep at 60 minutes post-injection
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Analysis 5.6. Comparison 5 IM diamorphine + prochlorperazine versus pethidine + prochlorperazine,
Outcome 6 Vomiting in labour.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 5 IM diamorphine + prochlorperazine versus pethidine + prochlorperazine
Outcome: 6 Vomiting in labour
Study or subgroup
Diamorphine
cotherapy IM
Pethidine
cotherapy
IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fairlie 1999 (1) 7/65 19/68 100.0 % 0.39 [ 0.17, 0.86 ]
Total (95% CI) 65 68 100.0 % 0.39 [ 0.17, 0.86 ]
Total events: 7 (Diamorphine cotherapy IM), 19 (Pethidine cotherapy IM)
Heterogeneity: not applicable
Test for overall effect: Z = 2.34 (P = 0.019)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours diamorphine + pro Favours pethidine + pro
(1) 1 hour post-adminstration
Analysis 5.7. Comparison 5 IM diamorphine + prochlorperazine versus pethidine + prochlorperazine,
Outcome 7 Caesarean section.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 5 IM diamorphine + prochlorperazine versus pethidine + prochlorperazine
Outcome: 7 Caesarean section
Study or subgroup
Diamorphine
cotherapy IM
Pethidine
cotherapy
IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fairlie 1999 2/65 4/68 100.0 % 0.52 [ 0.10, 2.76 ]
Total (95% CI) 65 68 100.0 % 0.52 [ 0.10, 2.76 ]
Total events: 2 (Diamorphine cotherapy IM), 4 (Pethidine cotherapy IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours diamorphine + pro Favours pethidine + pro
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Analysis 5.8. Comparison 5 IM diamorphine + prochlorperazine versus pethidine + prochlorperazine,
Outcome 8 Assisted vaginal birth.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 5 IM diamorphine + prochlorperazine versus pethidine + prochlorperazine
Outcome: 8 Assisted vaginal birth
Study or subgroup
Diamorphine
cotherapy IM
Pethidine
cotherapy
IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fairlie 1999 11/65 12/68 100.0 % 0.96 [ 0.46, 2.02 ]
Total (95% CI) 65 68 100.0 % 0.96 [ 0.46, 2.02 ]
Total events: 11 (Diamorphine cotherapy IM), 12 (Pethidine cotherapy IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.11 (P = 0.91)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours diamorphine + pro Favours pethidine + pro
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Analysis 5.9. Comparison 5 IM diamorphine + prochlorperazine versus pethidine + prochlorperazine,
Outcome 9 Neonatal resuscitation.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 5 IM diamorphine + prochlorperazine versus pethidine + prochlorperazine
Outcome: 9 Neonatal resuscitation
Study or subgroup
Diamorphine
cotherapy IM
Pethidine
cotherapy
IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fairlie 1999 22/65 19/68 100.0 % 1.21 [ 0.73, 2.02 ]
Total (95% CI) 65 68 100.0 % 1.21 [ 0.73, 2.02 ]
Total events: 22 (Diamorphine cotherapy IM), 19 (Pethidine cotherapy IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours diamorphine + pro Favours pethidine + pro
Analysis 5.10. Comparison 5 IM diamorphine + prochlorperazine versus pethidine + prochlorperazine,
Outcome 10 Apgar < 7 at 1 minute.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 5 IM diamorphine + prochlorperazine versus pethidine + prochlorperazine
Outcome: 10 Apgar < 7 at 1 minute
Study or subgroup
Diamorphine
cotherapy IM
Pethidine
cotherapy
IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fairlie 1999 7/65 18/68 100.0 % 0.41 [ 0.18, 0.91 ]
Total (95% CI) 65 68 100.0 % 0.41 [ 0.18, 0.91 ]
Total events: 7 (Diamorphine cotherapy IM), 18 (Pethidine cotherapy IM)
Heterogeneity: not applicable
Test for overall effect: Z = 2.19 (P = 0.028)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours diamorphine + pro Favours pethidine + pro
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Analysis 5.11. Comparison 5 IM diamorphine + prochlorperazine versus pethidine + prochlorperazine,
Outcome 11 Apgar < 7 at 5 minutes.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 5 IM diamorphine + prochlorperazine versus pethidine + prochlorperazine
Outcome: 11 Apgar < 7 at 5 minutes
Study or subgroup
Diamorphine
cotherapy IM
Pethidine
cotherapy
IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fairlie 1999 1/65 3/68 100.0 % 0.35 [ 0.04, 3.27 ]
Total (95% CI) 65 68 100.0 % 0.35 [ 0.04, 3.27 ]
Total events: 1 (Diamorphine cotherapy IM), 3 (Pethidine cotherapy IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours diamorphine + pro Favours pethidine + pro
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Analysis 5.12. Comparison 5 IM diamorphine + prochlorperazine versus pethidine + prochlorperazine,
Outcome 12 Admission to NICU.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 5 IM diamorphine + prochlorperazine versus pethidine + prochlorperazine
Outcome: 12 Admission to NICU
Study or subgroup
Diamorphine
cotherapy IM
Pethidine
cotherapy
IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fairlie 1999 5/65 9/68 100.0 % 0.58 [ 0.21, 1.64 ]
Total (95% CI) 65 68 100.0 % 0.58 [ 0.21, 1.64 ]
Total events: 5 (Diamorphine cotherapy IM), 9 (Pethidine cotherapy IM)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours diamorphine + pro Favours pethidine + pro
Analysis 6.1. Comparison 6 IM tramadol versus pethidine, Outcome 1 Maternal pain score or pain
measured in labour (Pain intensity: women with poor pain relief).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 6 IM tramadol versus pethidine
Outcome: 1 Maternal pain score or pain measured in labour (Pain intensity: women with poor pain relief)
Study or subgroup Tramadol IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bitsch 1980 9/23 3/22 10.0 % 2.87 [ 0.89, 9.23 ]
Keskin 2003 (1) 21/23 13/25 40.8 % 1.76 [ 1.18, 2.61 ]
Prasertsawat 1986 (2) 10/45 9/45 29.5 % 1.11 [ 0.50, 2.47 ]
Viegas 1993 (3) 7/30 6/30 19.7 % 1.17 [ 0.44, 3.06 ]
Total (95% CI) 121 122 100.0 % 1.56 [ 1.10, 2.21 ]
Total events: 47 (Tramadol IM), 31 (Pethidine IM)
Heterogeneity: Chi2 = 2.42, df = 3 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 2.51 (P = 0.012)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours tramadol Favours pethidine
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(1) Keskin 4 or 5 at 60 mins; Bitsch 5-10 mins post-admin
(2) Prasertsawat Poor response after 1st dose.
(3) Viegas none or insufficient relief
Analysis 6.2. Comparison 6 IM tramadol versus pethidine, Outcome 2 Additional analgesia required.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 6 IM tramadol versus pethidine
Outcome: 2 Additional analgesia required
Study or subgroup Tramadol IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bitsch 1980 (1) 16/23 17/22 69.0 % 0.90 [ 0.63, 1.28 ]
Khooshideh 2009 (2) 0/80 0/80 Not estimable
Prasertsawat 1986 (3) 11/45 7/45 31.0 % 1.57 [ 0.67, 3.69 ]
Total (95% CI) 148 147 100.0 % 1.07 [ 0.60, 1.91 ]
Total events: 27 (Tramadol IM), 24 (Pethidine IM)
Heterogeneity: Tau2 = 0.10; Chi2 = 1.86, df = 1 (P = 0.17); I2 =46%
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours tramadol Favours pethidine
(1) Second and third doses of study drug
(2) Second dose
(3) Second dose of study drug, half dose
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Analysis 6.3. Comparison 6 IM tramadol versus pethidine, Outcome 3 Maternal sleepiness in labour.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 6 IM tramadol versus pethidine
Outcome: 3 Maternal sleepiness in labour
Study or subgroup Tramadol IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Husslein 1987 6/20 10/20 17.9 % 0.60 [ 0.27, 1.34 ]
Keskin 2003 (1) 16/30 14/29 23.7 % 1.10 [ 0.67, 1.83 ]
Khooshideh 2009 23/80 64/80 26.4 % 0.36 [ 0.25, 0.52 ]
Prasertsawat 1986 10/45 15/45 20.0 % 0.67 [ 0.34, 1.32 ]
Viegas 1993 3/30 10/30 12.0 % 0.30 [ 0.09, 0.98 ]
Total (95% CI) 205 204 100.0 % 0.57 [ 0.33, 0.97 ]
Total events: 58 (Tramadol IM), 113 (Pethidine IM)
Heterogeneity: Tau2 = 0.24; Chi2 = 14.15, df = 4 (P = 0.01); I2 =72%
Test for overall effect: Z = 2.08 (P = 0.037)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours tramadol Favours pethidine
(1) Keskin - assessed at 60 mins.
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Analysis 6.4. Comparison 6 IM tramadol versus pethidine, Outcome 4 Nausea and vomiting in labour.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 6 IM tramadol versus pethidine
Outcome: 4 Nausea and vomiting in labour
Study or subgroup Tramadol IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bitsch 1980 0/23 6/22 9.0 % 0.07 [ 0.00, 1.24 ]
Husslein 1987 (1) 2/20 2/20 14.3 % 1.00 [ 0.16, 6.42 ]
Keskin 2003 (2) 9/30 1/29 13.3 % 8.70 [ 1.18, 64.41 ]
Khooshideh 2009 12/80 28/80 24.0 % 0.43 [ 0.23, 0.78 ]
Prasertsawat 1986 (3) 10/45 3/45 19.2 % 3.33 [ 0.98, 11.32 ]
Viegas 1993 (4) 4/30 7/30 20.1 % 0.57 [ 0.19, 1.75 ]
Total (95% CI) 228 226 100.0 % 0.97 [ 0.34, 2.76 ]
Total events: 37 (Tramadol IM), 47 (Pethidine IM)
Heterogeneity: Tau2 = 1.09; Chi2 = 17.89, df = 5 (P = 0.003); I2 =72%
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours tramadol Favours pethidine
(1) Husslein is nausea only or vomiting only as the data are identical
(2) Keskin: nausea at 60 mins - vomiting 1 case in pathidine group.
(3) nausea - vomiting in 2/45 tramadol and 2/45 pethidine.
(4) Viegas vomiting 3/30 Tramadol 100 mg and 7/30 Pethidine. Nausea in FP.
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Analysis 6.5. Comparison 6 IM tramadol versus pethidine, Outcome 5 Caesarean section.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 6 IM tramadol versus pethidine
Outcome: 5 Caesarean section
Study or subgroup Tramadol IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Husslein 1987 0/20 0/20 Not estimable
Khooshideh 2009 4/80 5/80 71.4 % 0.80 [ 0.22, 2.87 ]
Viegas 1993 1/30 2/30 28.6 % 0.50 [ 0.05, 5.22 ]
Total (95% CI) 130 130 100.0 % 0.71 [ 0.23, 2.18 ]
Total events: 5 (Tramadol IM), 7 (Pethidine IM)
Heterogeneity: Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.55)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours tramadol Favours pethidine
Analysis 6.6. Comparison 6 IM tramadol versus pethidine, Outcome 6 Assisted vaginal birth.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 6 IM tramadol versus pethidine
Outcome: 6 Assisted vaginal birth
Study or subgroup Tramadol IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Husslein 1987 0/20 1/20 33.3 % 0.33 [ 0.01, 7.72 ]
Khooshideh 2009 0/80 2/80 55.6 % 0.20 [ 0.01, 4.10 ]
Viegas 1993 1/30 0/30 11.1 % 3.00 [ 0.13, 70.83 ]
Total (95% CI) 130 130 100.0 % 0.56 [ 0.12, 2.56 ]
Total events: 1 (Tramadol IM), 3 (Pethidine IM)
Heterogeneity: Chi2 = 1.63, df = 2 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.75 (P = 0.45)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours tramadol Favours pethidine
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Analysis 6.7. Comparison 6 IM tramadol versus pethidine, Outcome 7 Neonatal resuscitation.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 6 IM tramadol versus pethidine
Outcome: 7 Neonatal resuscitation
Study or subgroup Tramadol IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Prasertsawat 1986 0/45 0/45 Not estimable
Total (95% CI) 45 45 Not estimable
Total events: 0 (Tramadol IM), 0 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours tramadol Favours pethidine
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Analysis 6.8. Comparison 6 IM tramadol versus pethidine, Outcome 8 Apgar scores ≤ 7 at 1 and 5 minutes.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 6 IM tramadol versus pethidine
Outcome: 8 Apgar scores≤ 7 at 1 and 5 minutes
Study or subgroup Tramadol IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Less than 7 at 1 minute
Khooshideh 2009 0/80 0/80 Not estimable
Prasertsawat 1986 0/45 0/45 Not estimable
Subtotal (95% CI) 125 125 Not estimable
Total events: 0 (Tramadol IM), 0 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Less than 7 at 5 minutes
Khooshideh 2009 0/80 0/80 Not estimable
Subtotal (95% CI) 80 80 Not estimable
Total events: 0 (Tramadol IM), 0 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.01 0.1 1 10 100
Favours tramadol Favours pethidine
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Analysis 6.9. Comparison 6 IM tramadol versus pethidine, Outcome 9 Neonatal respiratory distress.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 6 IM tramadol versus pethidine
Outcome: 9 Neonatal respiratory distress
Study or subgroup Tramadol IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Keskin 2003 7/30 3/29 100.0 % 2.26 [ 0.64, 7.89 ]
Total (95% CI) 30 29 100.0 % 2.26 [ 0.64, 7.89 ]
Total events: 7 (Tramadol IM), 3 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.20)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours tramadol Favours pethidine
Analysis 6.10. Comparison 6 IM tramadol versus pethidine, Outcome 10 Admission to NICU.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 6 IM tramadol versus pethidine
Outcome: 10 Admission to NICU
Study or subgroup Tramadol IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Keskin 2003 7/30 3/29 100.0 % 2.26 [ 0.64, 7.89 ]
Total (95% CI) 30 29 100.0 % 2.26 [ 0.64, 7.89 ]
Total events: 7 (Tramadol IM), 3 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.20)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours tramadol Favours pethidine
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Analysis 7.1. Comparison 7 IM tramadol + triflupromazine versus pethidine + triflupromazine, Outcome 1
Maternal sleepiness in labour.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 7 IM tramadol + triflupromazine versus pethidine + triflupromazine
Outcome: 1 Maternal sleepiness in labour
Study or subgroup Tramadol IM+tri Pethidine IM+tri Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kainz 1992 7/22 2/18 100.0 % 2.86 [ 0.68, 12.12 ]
Total (95% CI) 22 18 100.0 % 2.86 [ 0.68, 12.12 ]
Total events: 7 (Tramadol IM+tri), 2 (Pethidine IM+tri)
Heterogeneity: not applicable
Test for overall effect: Z = 1.43 (P = 0.15)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours tramadol + tri Favours pethidine + tri
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Analysis 7.2. Comparison 7 IM tramadol + triflupromazine versus pethidine + triflupromazine, Outcome 2
Nausea and vomiting in labour.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 7 IM tramadol + triflupromazine versus pethidine + triflupromazine
Outcome: 2 Nausea and vomiting in labour
Study or subgroup Tramadol IM+tri Pethidine IM+tri Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Nausea
Kainz 1992 (1) 2/22 2/18 100.0 % 0.82 [ 0.13, 5.25 ]
Subtotal (95% CI) 22 18 100.0 % 0.82 [ 0.13, 5.25 ]
Total events: 2 (Tramadol IM+tri), 2 (Pethidine IM+tri)
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.83)
2 Vomiting
Kainz 1992 0/18 1/22 100.0 % 0.40 [ 0.02, 9.35 ]
Subtotal (95% CI) 18 22 100.0 % 0.40 [ 0.02, 9.35 ]
Total events: 0 (Tramadol IM+tri), 1 (Pethidine IM+tri)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
0.01 0.1 1 10 100
Favours tramadol + tri Favours pethidine + tri
(1) assessment at 60 minutes
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Analysis 8.1. Comparison 8 IM dihydrocodeine 50 mg versus pethidine 100 mg, Outcome 1 Maternal pain
score or pain measured in labour (Maternal pain relief poor at 1 hour).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 8 IM dihydrocodeine 50 mg versus pethidine 100 mg
Outcome: 1 Maternal pain score or pain measured in labour (Maternal pain relief poor at 1 hour)
Study or subgroup Dihydrocodeine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sliom 1970 24/80 16/58 100.0 % 1.09 [ 0.64, 1.86 ]
Total (95% CI) 80 58 100.0 % 1.09 [ 0.64, 1.86 ]
Total events: 24 (Dihydrocodeine IM), 16 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours dihydrocodeine Favours pethidine
Analysis 8.2. Comparison 8 IM dihydrocodeine 50 mg versus pethidine 100 mg, Outcome 2 Maternal
sleepiness in labour.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 8 IM dihydrocodeine 50 mg versus pethidine 100 mg
Outcome: 2 Maternal sleepiness in labour
Study or subgroup Dihydrocodeine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sliom 1970 24/80 26/58 100.0 % 0.67 [ 0.43, 1.04 ]
Total (95% CI) 80 58 100.0 % 0.67 [ 0.43, 1.04 ]
Total events: 24 (Dihydrocodeine IM), 26 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 1.79 (P = 0.074)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours dihydrocodeine Favours pethidine
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Analysis 8.3. Comparison 8 IM dihydrocodeine 50 mg versus pethidine 100 mg, Outcome 3 Nausea and
vomiting in labour.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 8 IM dihydrocodeine 50 mg versus pethidine 100 mg
Outcome: 3 Nausea and vomiting in labour
Study or subgroup Dihydrocodeine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sliom 1970 12/80 10/58 100.0 % 0.87 [ 0.40, 1.88 ]
Total (95% CI) 80 58 100.0 % 0.87 [ 0.40, 1.88 ]
Total events: 12 (Dihydrocodeine IM), 10 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours dihydrocodeine Favours pethidine
Analysis 8.4. Comparison 8 IM dihydrocodeine 50 mg versus pethidine 100 mg, Outcome 4 Apgar ≤ 7 at 1
minute.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 8 IM dihydrocodeine 50 mg versus pethidine 100 mg
Outcome: 4 Apgar≤ 7 at 1 minute
Study or subgroup Dihydrocodeine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sliom 1970 26/80 33/58 100.0 % 0.57 [ 0.39, 0.84 ]
Total (95% CI) 80 58 100.0 % 0.57 [ 0.39, 0.84 ]
Total events: 26 (Dihydrocodeine IM), 33 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 2.83 (P = 0.0046)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours dihydrocodeine Favours pethidine
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Analysis 9.1. Comparison 9 IM pentazocine versus pethidine, Outcome 1 Maternal satisfaction with
analgesia measured during labour (Pain relief (good or very good) at delivery).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 9 IM pentazocine versus pethidine
Outcome: 1 Maternal satisfaction with analgesia measured during labour (Pain relief (good or very good) at delivery)
Study or subgroup Pentazocine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Borglin 1971 74/91 65/89 81.5 % 1.11 [ 0.95, 1.31 ]
Mowat 1970 (1) 13/34 16/39 18.5 % 0.93 [ 0.53, 1.65 ]
Total (95% CI) 125 128 100.0 % 1.08 [ 0.92, 1.27 ]
Total events: 87 (Pentazocine IM), 81 (Pethidine IM)
Heterogeneity: Chi2 = 0.40, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours pethidine Favours pentazocine
(1) Obtained relief after 1st injection.
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Analysis 9.2. Comparison 9 IM pentazocine versus pethidine, Outcome 2 Maternal pain score or pain
measured in labour (Pain relief poor (partial, none or worse)).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 9 IM pentazocine versus pethidine
Outcome: 2 Maternal pain score or pain measured in labour (Pain relief poor (partial, none or worse))
Study or subgroup Pentazocine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 No add-on drugs
Duncan 1969 (1) 77/83 73/77 42.6 % 0.98 [ 0.90, 1.06 ]
Levy 1971 (2) 14/38 9/45 23.2 % 1.84 [ 0.90, 3.77 ]
Moore 1970 (3) 33/65 23/57 34.2 % 1.26 [ 0.85, 1.87 ]
Subtotal (95% CI) 186 179 100.0 % 1.23 [ 0.74, 2.05 ]
Total events: 124 (Pentazocine IM), 105 (Pethidine IM)
Heterogeneity: Tau2 = 0.16; Chi2 = 11.59, df = 2 (P = 0.003); I2 =83%
Test for overall effect: Z = 0.81 (P = 0.42)
2 With promazine
Refstad 1980 11/43 7/42 100.0 % 1.53 [ 0.66, 3.58 ]
Subtotal (95% CI) 43 42 100.0 % 1.53 [ 0.66, 3.58 ]
Total events: 11 (Pentazocine IM), 7 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
0.01 0.1 1 10 100
Favours pentazocine Favours pethidine
(1) After 1st injection only.
(2) Unclear when pain assessed but following first dose.
(3) Severe pain at 60 minutes.
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Analysis 9.3. Comparison 9 IM pentazocine versus pethidine, Outcome 3 Additional analgesia required.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 9 IM pentazocine versus pethidine
Outcome: 3 Additional analgesia required
Study or subgroup Pentazocine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Pentazocine
Mowat 1970 (1) 14/46 16/48 100.0 % 0.91 [ 0.50, 1.65 ]
Subtotal (95% CI) 46 48 100.0 % 0.91 [ 0.50, 1.65 ]
Total events: 14 (Pentazocine IM), 16 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.76)
2 Pentazocine + promazine
Refstad 1980 (2) 12/43 7/42 100.0 % 1.67 [ 0.73, 3.84 ]
Subtotal (95% CI) 43 42 100.0 % 1.67 [ 0.73, 3.84 ]
Total events: 12 (Pentazocine IM), 7 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
0.01 0.1 1 10 100
Favours pentazocine Favours pethidine
(1) Additional doses of study drug.
(2) 2nd dose of study drug
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Analysis 9.4. Comparison 9 IM pentazocine versus pethidine, Outcome 4 Maternal sleepiness in labour.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 9 IM pentazocine versus pethidine
Outcome: 4 Maternal sleepiness in labour
Study or subgroup Pentazocine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Borglin 1971 (1) 82/91 80/89 62.7 % 1.00 [ 0.91, 1.11 ]
Moore 1970 21/73 19/65 15.6 % 0.98 [ 0.58, 1.66 ]
Mowat 1970 (2) 26/34 30/39 21.7 % 0.99 [ 0.77, 1.28 ]
Total (95% CI) 198 193 100.0 % 1.00 [ 0.89, 1.12 ]
Total events: 129 (Pentazocine IM), 129 (Pethidine IM)
Heterogeneity: Chi2 = 0.01, df = 2 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours pentazocine Favours pethidine
(1) Borglin 1971 - Sedating and relaxing effects
(2) After 1st injection
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Analysis 9.5. Comparison 9 IM pentazocine versus pethidine, Outcome 5 Nausea and vomiting in labour.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 9 IM pentazocine versus pethidine
Outcome: 5 Nausea and vomiting in labour
Study or subgroup Pentazocine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Nausea
Borglin 1971 1/91 1/89 4.3 % 0.98 [ 0.06, 15.40 ]
Moore 1970 (1) 7/73 15/65 67.8 % 0.42 [ 0.18, 0.96 ]
Mowat 1970 (2) 3/34 7/39 27.9 % 0.49 [ 0.14, 1.75 ]
Subtotal (95% CI) 198 193 100.0 % 0.46 [ 0.24, 0.90 ]
Total events: 11 (Pentazocine IM), 23 (Pethidine IM)
Heterogeneity: Chi2 = 0.36, df = 2 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 2.26 (P = 0.024)
2 Vomiting
Mowat 1970 (3) 4/34 5/39 100.0 % 0.92 [ 0.27, 3.14 ]
Subtotal (95% CI) 34 39 100.0 % 0.92 [ 0.27, 3.14 ]
Total events: 4 (Pentazocine IM), 5 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
0.01 0.1 1 10 100
Favours pentazocine Favours pethidine
(1) Nausea or vomiting
(2) After 1st injection.
(3) After 1st injection.
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Analysis 9.6. Comparison 9 IM pentazocine versus pethidine, Outcome 6 Assisted vaginal birth.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 9 IM pentazocine versus pethidine
Outcome: 6 Assisted vaginal birth
Study or subgroup Pentazocine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No add-on drugs
Mowat 1970 5/46 1/48 100.0 % 5.22 [ 0.63, 42.97 ]
Subtotal (95% CI) 46 48 100.0 % 5.22 [ 0.63, 42.97 ]
Total events: 5 (Pentazocine IM), 1 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 1.54 (P = 0.12)
2 With promazine
Refstad 1980 4/43 5/42 100.0 % 0.78 [ 0.23, 2.71 ]
Subtotal (95% CI) 43 42 100.0 % 0.78 [ 0.23, 2.71 ]
Total events: 4 (Pentazocine IM), 5 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
0.01 0.1 1 10 100
Favours pentazocine Favours pethidine
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Analysis 9.7. Comparison 9 IM pentazocine versus pethidine, Outcome 7 Naloxone administration.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 9 IM pentazocine versus pethidine
Outcome: 7 Naloxone administration
Study or subgroup Pentazocine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 With promazine
Refstad 1980 2/43 4/42 100.0 % 0.49 [ 0.09, 2.53 ]
Total (95% CI) 43 42 100.0 % 0.49 [ 0.09, 2.53 ]
Total events: 2 (Pentazocine IM), 4 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.39)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours pentazocine Favours pethidine
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Analysis 9.8. Comparison 9 IM pentazocine versus pethidine, Outcome 8 Apgar score ≤ 7 at 1 minute.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 9 IM pentazocine versus pethidine
Outcome: 8 Apgar score≤ 7 at 1 minute
Study or subgroup Pentazocine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 No add-on drugs
Borglin 1971 6/91 1/89 55.6 % 5.87 [ 0.72, 47.76 ]
Levy 1971 (1) 0/29 2/33 44.4 % 0.23 [ 0.01, 4.54 ]
Subtotal (95% CI) 120 122 100.0 % 1.39 [ 0.06, 32.97 ]
Total events: 6 (Pentazocine IM), 3 (Pethidine IM)
Heterogeneity: Tau2 = 3.56; Chi2 = 3.04, df = 1 (P = 0.08); I2 =67%
Test for overall effect: Z = 0.20 (P = 0.84)
2 With promazine
Refstad 1980 (2) 1/31 1/35 100.0 % 1.13 [ 0.07, 17.30 ]
Subtotal (95% CI) 31 35 100.0 % 1.13 [ 0.07, 17.30 ]
Total events: 1 (Pentazocine IM), 1 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
0.01 0.1 1 10 100
Favours pentazocine Favours pethidine
(1) Apgar is for babies that had 1 dose only and does not include data for 1st dose of women who had 2 doses
(2) After 1 dose only
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Analysis 9.9. Comparison 9 IM pentazocine versus pethidine, Outcome 9 Apgar score ≤ 7 at 5 minutes.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 9 IM pentazocine versus pethidine
Outcome: 9 Apgar score≤ 7 at 5 minutes
Study or subgroup Pentazocine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No add-on drugs
Levy 1971 (1) 0/29 2/33 100.0 % 0.23 [ 0.01, 4.54 ]
Subtotal (95% CI) 29 33 100.0 % 0.23 [ 0.01, 4.54 ]
Total events: 0 (Pentazocine IM), 2 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
2 With promazine
Refstad 1980 (2) 0/31 1/35 100.0 % 0.38 [ 0.02, 8.88 ]
Subtotal (95% CI) 31 35 100.0 % 0.38 [ 0.02, 8.88 ]
Total events: 0 (Pentazocine IM), 1 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
0.01 0.1 1 10 100
Favours pentazocine Favours pethidine
(1) Apgar is for babies that had 1 dose only and does not include data for 1st dose of women who had 2 doses
(2) After 1st dose only
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Analysis 10.1. Comparison 10 IM nalbuphine versus pethidine, Outcome 1 Maternal satisfaction with
analgesia measured during the postnatal period (numbers dissatisfied).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 10 IM nalbuphine versus pethidine
Outcome: 1 Maternal satisfaction with analgesia measured during the postnatal period (numbers dissatisfied)
Study or subgroup Nalbuphine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wilson 1986 (1) 23/37 30/35 100.0 % 0.73 [ 0.55, 0.96 ]
Total (95% CI) 37 35 100.0 % 0.73 [ 0.55, 0.96 ]
Total events: 23 (Nalbuphine IM), 30 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 2.21 (P = 0.027)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours nalbuphine Favours pethidine
(1) Rated as minimally effective.
Analysis 10.2. Comparison 10 IM nalbuphine versus pethidine, Outcome 2 Maternal satisfaction with
analgesia measured during labour (Pain free).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 10 IM nalbuphine versus pethidine
Outcome: 2 Maternal satisfaction with analgesia measured during labour (Pain free)
Study or subgroup Nalbuphine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mitterschiffthaler 1991 (1) 6/20 1/20 100.0 % 6.00 [ 0.79, 45.42 ]
Total (95% CI) 20 20 100.0 % 6.00 [ 0.79, 45.42 ]
Total events: 6 (Nalbuphine IM), 1 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 1.73 (P = 0.083)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours pethidine Favours nalbuphine
(1) Unclear when pain assessed
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Analysis 10.3. Comparison 10 IM nalbuphine versus pethidine, Outcome 3 Maternal pain score or pain
measured in labour (Pain intensity at 30 minutes: women with severe pain).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 10 IM nalbuphine versus pethidine
Outcome: 3 Maternal pain score or pain measured in labour (Pain intensity at 30 minutes: women with severe pain)
Study or subgroup Nalbuphine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lardizabal 1999 37/149 42/146 100.0 % 0.86 [ 0.59, 1.26 ]
Total (95% CI) 149 146 100.0 % 0.86 [ 0.59, 1.26 ]
Total events: 37 (Nalbuphine IM), 42 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours nalbuphine Favours pethidine
Analysis 10.4. Comparison 10 IM nalbuphine versus pethidine, Outcome 4 Maternal pain score or pain
measured in labour (VAS at 60 minutes (at peak of contraction)).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 10 IM nalbuphine versus pethidine
Outcome: 4 Maternal pain score or pain measured in labour (VAS at 60 minutes (at peak of contraction))
Study or subgroup Nalbuphine IM Pethidine IM
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Wilson 1986 37 66 (24.9) 35 74 (20.7) 100.0 % -8.00 [ -18.55, 2.55 ]
Total (95% CI) 37 35 100.0 % -8.00 [ -18.55, 2.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours nalbuphine Favours pethidine
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Analysis 10.5. Comparison 10 IM nalbuphine versus pethidine, Outcome 5 Additional analgesia required.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 10 IM nalbuphine versus pethidine
Outcome: 5 Additional analgesia required
Study or subgroup Nalbuphine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wilson 1986 (1) 8/37 6/35 100.0 % 1.26 [ 0.49, 3.27 ]
Total (95% CI) 37 35 100.0 % 1.26 [ 0.49, 3.27 ]
Total events: 8 (Nalbuphine IM), 6 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours nalbuphine Favours pethidine
(1) 2nd dose of study drug
Analysis 10.6. Comparison 10 IM nalbuphine versus pethidine, Outcome 6 Epidural.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 10 IM nalbuphine versus pethidine
Outcome: 6 Epidural
Study or subgroup Nalbuphine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lardizabal 1999 8/151 5/156 100.0 % 1.65 [ 0.55, 4.94 ]
Total (95% CI) 151 156 100.0 % 1.65 [ 0.55, 4.94 ]
Total events: 8 (Nalbuphine IM), 5 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours nalbuphine Favours pethidine
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Analysis 10.7. Comparison 10 IM nalbuphine versus pethidine, Outcome 7 Maternal sleepiness in labour.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 10 IM nalbuphine versus pethidine
Outcome: 7 Maternal sleepiness in labour
Study or subgroup Nalbuphine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wilson 1986 (1) 8/37 2/35 100.0 % 3.78 [ 0.86, 16.60 ]
Total (95% CI) 37 35 100.0 % 3.78 [ 0.86, 16.60 ]
Total events: 8 (Nalbuphine IM), 2 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 1.76 (P = 0.078)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours nalbuphine Favours pethidine
(1) Excessive sedation
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Analysis 10.8. Comparison 10 IM nalbuphine versus pethidine, Outcome 8 Nausea and vomiting in labour.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 10 IM nalbuphine versus pethidine
Outcome: 8 Nausea and vomiting in labour
Study or subgroup Nalbuphine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Nausea
Lardizabal 1999 30/147 51/154 100.0 % 0.62 [ 0.42, 0.91 ]
Subtotal (95% CI) 147 154 100.0 % 0.62 [ 0.42, 0.91 ]
Total events: 30 (Nalbuphine IM), 51 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 2.43 (P = 0.015)
2 Vomiting
Lardizabal 1999 12/147 31/154 100.0 % 0.41 [ 0.22, 0.76 ]
Subtotal (95% CI) 147 154 100.0 % 0.41 [ 0.22, 0.76 ]
Total events: 12 (Nalbuphine IM), 31 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 2.82 (P = 0.0048)
3 Nausea and vomiting
Wilson 1986 6/37 14/35 100.0 % 0.41 [ 0.18, 0.94 ]
Subtotal (95% CI) 37 35 100.0 % 0.41 [ 0.18, 0.94 ]
Total events: 6 (Nalbuphine IM), 14 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 2.11 (P = 0.035)
0.01 0.1 1 10 100
Favours nalbuphine Favours pethidine
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Analysis 10.9. Comparison 10 IM nalbuphine versus pethidine, Outcome 9 Caesarean section.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 10 IM nalbuphine versus pethidine
Outcome: 9 Caesarean section
Study or subgroup Nalbuphine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lardizabal 1999 3/152 7/158 100.0 % 0.45 [ 0.12, 1.69 ]
Total (95% CI) 152 158 100.0 % 0.45 [ 0.12, 1.69 ]
Total events: 3 (Nalbuphine IM), 7 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.23)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours nalbuphine Favours pethidine
Analysis 10.10. Comparison 10 IM nalbuphine versus pethidine, Outcome 10 Assisted vaginal birth.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 10 IM nalbuphine versus pethidine
Outcome: 10 Assisted vaginal birth
Study or subgroup Nalbuphine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Lardizabal 1999 13/152 9/158 72.5 % 1.50 [ 0.66, 3.41 ]
Wilson 1986 1/37 3/35 27.5 % 0.32 [ 0.03, 2.89 ]
Total (95% CI) 189 193 100.0 % 0.98 [ 0.25, 3.85 ]
Total events: 14 (Nalbuphine IM), 12 (Pethidine IM)
Heterogeneity: Tau2 = 0.50; Chi2 = 1.69, df = 1 (P = 0.19); I2 =41%
Test for overall effect: Z = 0.03 (P = 0.97)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours nalbuphine Favours pethidine
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Analysis 10.11. Comparison 10 IM nalbuphine versus pethidine, Outcome 11 Naloxone administration.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 10 IM nalbuphine versus pethidine
Outcome: 11 Naloxone administration
Study or subgroup Nalbuphine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wilson 1986 3/37 0/35 100.0 % 6.63 [ 0.35, 123.93 ]
Total (95% CI) 37 35 100.0 % 6.63 [ 0.35, 123.93 ]
Total events: 3 (Nalbuphine IM), 0 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.21)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours nalbuphine Favours pethidine
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Analysis 10.12. Comparison 10 IM nalbuphine versus pethidine, Outcome 12 Apgar score ≤ 7 at 1 and 5
minutes.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 10 IM nalbuphine versus pethidine
Outcome: 12 Apgar score≤ 7 at 1 and 5 minutes
Study or subgroup Nalbuphine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low score at 1 minute
Lardizabal 1999 16/152 10/158 29.8 % 1.66 [ 0.78, 3.55 ]
Wilson 1986 (1) 26/37 24/35 70.2 % 1.02 [ 0.75, 1.39 ]
Subtotal (95% CI) 189 193 100.0 % 1.18 [ 0.72, 1.95 ]
Total events: 42 (Nalbuphine IM), 34 (Pethidine IM)
Heterogeneity: Tau2 = 0.07; Chi2 = 1.77, df = 1 (P = 0.18); I2 =44%
Test for overall effect: Z = 0.66 (P = 0.51)
2 Low score at 5 minutes
Wilson 1986 1/37 2/35 100.0 % 0.47 [ 0.04, 4.99 ]
Subtotal (95% CI) 37 35 100.0 % 0.47 [ 0.04, 4.99 ]
Total events: 1 (Nalbuphine IM), 2 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.53)
0.01 0.1 1 10 100
Favours nalbuphine Favours pethidine
(1) Apgar modified: minus colour score
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Analysis 10.13. Comparison 10 IM nalbuphine versus pethidine, Outcome 13 Admission to NICU.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 10 IM nalbuphine versus pethidine
Outcome: 13 Admission to NICU
Study or subgroup Nalbuphine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lardizabal 1999 21/148 20/151 100.0 % 1.07 [ 0.61, 1.89 ]
Total (95% CI) 148 151 100.0 % 1.07 [ 0.61, 1.89 ]
Total events: 21 (Nalbuphine IM), 20 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours nalbuphine Favours pethidine
Analysis 10.14. Comparison 10 IM nalbuphine versus pethidine, Outcome 14 Neonatal neurobehavioural
(Scanlon) 2-4 hours PN.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 10 IM nalbuphine versus pethidine
Outcome: 14 Neonatal neurobehavioural (Scanlon) 2-4 hours PN
Study or subgroup Nalbuphine IM Pethidine IM
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Wilson 1986 (1) 37 21.6 (4.9) 35 25.3 (5.6) 100.0 % -3.70 [ -6.14, -1.26 ]
Total (95% CI) 37 35 100.0 % -3.70 [ -6.14, -1.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.98 (P = 0.0029)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Lower with nalbuphine Lower with pethidine
(1) Lower scores on Scanlon scale = poorer outcome
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Analysis 11.1. Comparison 11 IM phenazocine versus pethidine, Outcome 1 Epidural.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 11 IM phenazocine versus pethidine
Outcome: 1 Epidural
Study or subgroup Phenazocine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Grant 1970 12/107 9/105 100.0 % 1.31 [ 0.58, 2.97 ]
Total (95% CI) 107 105 100.0 % 1.31 [ 0.58, 2.97 ]
Total events: 12 (Phenazocine IM), 9 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours phenazocine Favours pethidine
Analysis 11.2. Comparison 11 IM phenazocine versus pethidine, Outcome 2 Vomiting.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 11 IM phenazocine versus pethidine
Outcome: 2 Vomiting
Study or subgroup Phenazocine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Grant 1970 10/107 25/105 100.0 % 0.39 [ 0.20, 0.78 ]
Total (95% CI) 107 105 100.0 % 0.39 [ 0.20, 0.78 ]
Total events: 10 (Phenazocine IM), 25 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 2.69 (P = 0.0072)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours phenazocine Favours pethidine
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Analysis 12.1. Comparison 12 IM diamorphine/morphine versus pethidine, Outcome 1 Maternal satisfaction
with analgesia (number of women satisfied or very satisfied).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 12 IM diamorphine/morphine versus pethidine
Outcome: 1 Maternal satisfaction with analgesia (number of women satisfied or very satisfied)
Study or subgroup Morphine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wee 2014 196/244 170/240 100.0 % 1.13 [ 1.02, 1.26 ]
Total (95% CI) 244 240 100.0 % 1.13 [ 1.02, 1.26 ]
Total events: 196 (Morphine IM), 170 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 2.41 (P = 0.016)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours pethidine Favours morphine
Analysis 12.2. Comparison 12 IM diamorphine/morphine versus pethidine, Outcome 2 Maternal satisfaction
with analgesia measured during labour or during the postnatal period (Pain relief described as poor).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 12 IM diamorphine/morphine versus pethidine
Outcome: 2 Maternal satisfaction with analgesia measured during labour or during the postnatal period (Pain relief described as poor)
Study or subgroup Morphine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Prasertsawat 1986 (1) 11/45 9/45 100.0 % 1.22 [ 0.56, 2.66 ]
Total (95% CI) 45 45 100.0 % 1.22 [ 0.56, 2.66 ]
Total events: 11 (Morphine IM), 9 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours morphine Favours pethidine
(1) Poor response after 1st dose.
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Analysis 12.3. Comparison 12 IM diamorphine/morphine versus pethidine, Outcome 3 Maternal pain score
or pain measured in labour (pain relief at 30 mins).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 12 IM diamorphine/morphine versus pethidine
Outcome: 3 Maternal pain score or pain measured in labour (pain relief at 30 mins)
Study or subgroup Morphine IM Pethidine IM
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Wee 2014 244 5.9 (2.3) 240 6.7 (2.6) 100.0 % -0.80 [ -1.24, -0.36 ]
Total (95% CI) 244 240 100.0 % -0.80 [ -1.24, -0.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.58 (P = 0.00034)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours morphine Favours pethidine
Analysis 12.4. Comparison 12 IM diamorphine/morphine versus pethidine, Outcome 4 Maternal pain score
or pain measured in labour (pain relief at 60 mins).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 12 IM diamorphine/morphine versus pethidine
Outcome: 4 Maternal pain score or pain measured in labour (pain relief at 60 mins)
Study or subgroup Morphine IM Pethidine IM
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Wee 2014 244 5.9 (2.5) 240 6.7 (2.7) 100.0 % -0.80 [ -1.26, -0.34 ]
Total (95% CI) 244 240 100.0 % -0.80 [ -1.26, -0.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.38 (P = 0.00072)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours morphine Favours pethidine
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Analysis 12.5. Comparison 12 IM diamorphine/morphine versus pethidine, Outcome 5 Additional analgesia
required.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 12 IM diamorphine/morphine versus pethidine
Outcome: 5 Additional analgesia required
Study or subgroup Morphine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Prasertsawat 1986 (1) 8/45 7/45 3.4 % 1.14 [ 0.45, 2.89 ]
Wee 2014 (2) 198/244 195/240 96.6 % 1.00 [ 0.92, 1.09 ]
Total (95% CI) 289 285 100.0 % 1.00 [ 0.92, 1.10 ]
Total events: 206 (Morphine IM), 202 (Pethidine IM)
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.94)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours morphine Favours pethidine
(1) 2nd dose of study drug but half initial amount
(2) Entonox
Analysis 12.6. Comparison 12 IM diamorphine/morphine versus pethidine, Outcome 6 Maternal sleepiness.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 12 IM diamorphine/morphine versus pethidine
Outcome: 6 Maternal sleepiness
Study or subgroup Morphine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Prasertsawat 1986 9/45 15/45 100.0 % 0.60 [ 0.29, 1.23 ]
Total (95% CI) 45 45 100.0 % 0.60 [ 0.29, 1.23 ]
Total events: 9 (Morphine IM), 15 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours morphine Favours pethidine
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Analysis 12.7. Comparison 12 IM diamorphine/morphine versus pethidine, Outcome 7 Nausea and
vomiting.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 12 IM diamorphine/morphine versus pethidine
Outcome: 7 Nausea and vomiting
Study or subgroup Morphine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Prasertsawat 1986 (1) 3/45 3/45 100.0 % 1.00 [ 0.21, 4.69 ]
Total (95% CI) 45 45 100.0 % 1.00 [ 0.21, 4.69 ]
Total events: 3 (Morphine IM), 3 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours morphine Favours pethidine
(1) Prasertsawat nausea - vomiting in 1/45 morphine and 2/45 pethidine.
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Analysis 12.8. Comparison 12 IM diamorphine/morphine versus pethidine, Outcome 8 Caesarean section.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 12 IM diamorphine/morphine versus pethidine
Outcome: 8 Caesarean section
Study or subgroup Morphine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wee 2014 47/244 49/240 100.0 % 0.94 [ 0.66, 1.35 ]
Total (95% CI) 244 240 100.0 % 0.94 [ 0.66, 1.35 ]
Total events: 47 (Morphine IM), 49 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours morphine Favours pethidine
Analysis 12.9. Comparison 12 IM diamorphine/morphine versus pethidine, Outcome 9 Assisted vaginal
birth.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 12 IM diamorphine/morphine versus pethidine
Outcome: 9 Assisted vaginal birth
Study or subgroup Morphine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wee 2014 60/244 46/240 100.0 % 1.28 [ 0.91, 1.80 ]
Total (95% CI) 244 240 100.0 % 1.28 [ 0.91, 1.80 ]
Total events: 60 (Morphine IM), 46 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 1.44 (P = 0.15)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours morphine Favours pethidine
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Analysis 12.10. Comparison 12 IM diamorphine/morphine versus pethidine, Outcome 10 Naloxone
administration.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 12 IM diamorphine/morphine versus pethidine
Outcome: 10 Naloxone administration
Study or subgroup Morphine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wee 2014 3/244 3/240 100.0 % 0.98 [ 0.20, 4.83 ]
Total (95% CI) 244 240 100.0 % 0.98 [ 0.20, 4.83 ]
Total events: 3 (Morphine IM), 3 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours morphine Favours pethidine
Analysis 12.11. Comparison 12 IM diamorphine/morphine versus pethidine, Outcome 11 Neonatal
resuscitation.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 12 IM diamorphine/morphine versus pethidine
Outcome: 11 Neonatal resuscitation
Study or subgroup Morphine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Prasertsawat 1986 0/45 0/45 Not estimable
Wee 2014 43/244 44/240 100.0 % 0.96 [ 0.66, 1.41 ]
Total (95% CI) 289 285 100.0 % 0.96 [ 0.66, 1.41 ]
Total events: 43 (Morphine IM), 44 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours morphine Favours pethidine
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Analysis 12.12. Comparison 12 IM diamorphine/morphine versus pethidine, Outcome 12 Apgar < 7 at 1
minute.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 12 IM diamorphine/morphine versus pethidine
Outcome: 12 Apgar < 7 at 1 minute
Study or subgroup Morphine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Prasertsawat 1986 0/45 0/45 Not estimable
Wee 2014 42/244 36/240 100.0 % 1.15 [ 0.76, 1.73 ]
Total (95% CI) 289 285 100.0 % 1.15 [ 0.76, 1.73 ]
Total events: 42 (Morphine IM), 36 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours morphine Favours pethidine
Analysis 12.13. Comparison 12 IM diamorphine/morphine versus pethidine, Outcome 13 Admission to
NICU.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 12 IM diamorphine/morphine versus pethidine
Outcome: 13 Admission to NICU
Study or subgroup Morphine IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wee 2014 8/244 9/240 100.0 % 0.87 [ 0.34, 2.23 ]
Total (95% CI) 244 240 100.0 % 0.87 [ 0.34, 2.23 ]
Total events: 8 (Morphine IM), 9 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours morphine Favours pethidine
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Analysis 13.1. Comparison 13 IM butorphanol versus pethidine, Outcome 1 Additional analgesia required.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 13 IM butorphanol versus pethidine
Outcome: 1 Additional analgesia required
Study or subgroup Butorphanol IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Maduska 1978 (1) 17/40 19/40 100.0 % 0.89 [ 0.55, 1.45 ]
Total (95% CI) 40 40 100.0 % 0.89 [ 0.55, 1.45 ]
Total events: 17 (Butorphanol IM), 19 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours butorphanol Favours pethidine
(1) 2nd dose of study drug
Analysis 13.2. Comparison 13 IM butorphanol versus pethidine, Outcome 2 Nausea.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 13 IM butorphanol versus pethidine
Outcome: 2 Nausea
Study or subgroup Butorphanol IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Maduska 1978 (1) 0/40 2/40 100.0 % 0.20 [ 0.01, 4.04 ]
Total (95% CI) 40 40 100.0 % 0.20 [ 0.01, 4.04 ]
Total events: 0 (Butorphanol IM), 2 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours butorphanol Favours pethidine
(1) Unclear when assessed
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Analysis 13.3. Comparison 13 IM butorphanol versus pethidine, Outcome 3 Vomiting.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 13 IM butorphanol versus pethidine
Outcome: 3 Vomiting
Study or subgroup Butorphanol IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Maduska 1978 (1) 1/40 2/40 100.0 % 0.50 [ 0.05, 5.30 ]
Total (95% CI) 40 40 100.0 % 0.50 [ 0.05, 5.30 ]
Total events: 1 (Butorphanol IM), 2 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours butorphanol Favours pethidine
(1) Unclear when assessed
Analysis 13.4. Comparison 13 IM butorphanol versus pethidine, Outcome 4 Neonatal resuscitation.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 13 IM butorphanol versus pethidine
Outcome: 4 Neonatal resuscitation
Study or subgroup Butorphanol IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Maduska 1978 (1) 0/40 1/40 100.0 % 0.33 [ 0.01, 7.95 ]
Total (95% CI) 40 40 100.0 % 0.33 [ 0.01, 7.95 ]
Total events: 0 (Butorphanol IM), 1 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours butorphanol Favours pethidine
(1) received 2 doses of pethidine (40 mg x 2)
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Analysis 13.5. Comparison 13 IM butorphanol versus pethidine, Outcome 5 Naloxone administration
(neonatal).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 13 IM butorphanol versus pethidine
Outcome: 5 Naloxone administration (neonatal)
Study or subgroup Butorphanol IM Pethidine IM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Maduska 1978 (1) 0/40 1/40 100.0 % 0.33 [ 0.01, 7.95 ]
Total (95% CI) 40 40 100.0 % 0.33 [ 0.01, 7.95 ]
Total events: 0 (Butorphanol IM), 1 (Pethidine IM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours butorphanol Favours pethidine
(1) received 2 doses of pethidine (40 mg x 2)
Analysis 14.1. Comparison 14 IM Avacan® versus IM pentazocine, Outcome 1 Additional analgesia required
- Entonox.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 14 IM Avacan versus IM pentazocine
Outcome: 1 Additional analgesia required - Entonox
Study or subgroup Avacan Pentazocine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hamann 1972 18/81 19/79 100.0 % 0.92 [ 0.53, 1.63 ]
Total (95% CI) 81 79 100.0 % 0.92 [ 0.53, 1.63 ]
Total events: 18 (Avacan), 19 (Pentazocine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.78)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Favours Avacan Favours pentazocine
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Analysis 14.2. Comparison 14 IM Avacan® versus IM pentazocine, Outcome 2 Additional analgesia required
- pudendal-paracervical block.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 14 IM Avacan versus IM pentazocine
Outcome: 2 Additional analgesia required - pudendal-paracervical block
Study or subgroup Avacan Pentazocine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hamann 1972 29/81 14/79 100.0 % 2.02 [ 1.16, 3.53 ]
Total (95% CI) 81 79 100.0 % 2.02 [ 1.16, 3.53 ]
Total events: 29 (Avacan), 14 (Pentazocine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.47 (P = 0.013)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Avacan Favours pentazocine
Analysis 14.3. Comparison 14 IM Avacan® versus IM pentazocine, Outcome 3 Caesarean section.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 14 IM Avacan versus IM pentazocine
Outcome: 3 Caesarean section
Study or subgroup Avacan Pentazocine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hamann 1972 (1) 5/92 8/92 100.0 % 0.63 [ 0.21, 1.84 ]
Total (95% CI) 92 92 100.0 % 0.63 [ 0.21, 1.84 ]
Total events: 5 (Avacan), 8 (Pentazocine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.39)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Avacan Favours pentazocine
(1) Denominators not clear (women having CS were excluded from analyses in study report).
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Analysis 14.4. Comparison 14 IM Avacan® versus IM pentazocine, Outcome 4 Low Apgar score (< 7) “at
birth”.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 14 IM Avacan versus IM pentazocine
Outcome: 4 Low Apgar score (< 7) ”at birth”
Study or subgroup Avacan Pentazocine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hamann 1972 9/81 15/79 100.0 % 0.59 [ 0.27, 1.26 ]
Total (95% CI) 81 79 100.0 % 0.59 [ 0.27, 1.26 ]
Total events: 9 (Avacan), 15 (Pentazocine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Avacan Favours pentazocine
Analysis 15.1. Comparison 15 IM pentazocine versus IM Pethilorfan®, Outcome 1 Maternal pain score
measured during labour (Pain relief (women NOT obtaining pain relief) at 1 hour).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 15 IM pentazocine versus IM Pethilorfan
Outcome: 1 Maternal pain score measured during labour (Pain relief (women NOT obtaining pain relief) at 1 hour)
Study or subgroup Pentazocine Pethilorfan Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
O’Dwyer 1971 (1) 18/32 17/37 100.0 % 1.22 [ 0.77, 1.95 ]
Total (95% CI) 32 37 100.0 % 1.22 [ 0.77, 1.95 ]
Total events: 18 (Pentazocine), 17 (Pethilorfan)
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.39)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours pentazocine Favours pethilorfan
(1) After 1st dose only
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Analysis 15.2. Comparison 15 IM pentazocine versus IM Pethilorfan®, Outcome 2 Additional analgesia
required.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 15 IM pentazocine versus IM Pethilorfan
Outcome: 2 Additional analgesia required
Study or subgroup Pentazocine Pethilorfan Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
O’Dwyer 1971 (1) 2/48 4/50 100.0 % 0.52 [ 0.10, 2.71 ]
Total (95% CI) 48 50 100.0 % 0.52 [ 0.10, 2.71 ]
Total events: 2 (Pentazocine), 4 (Pethilorfan)
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours pentazocine Favours pethilorfan
(1) 2nd dose of study drug
Analysis 15.3. Comparison 15 IM pentazocine versus IM Pethilorfan®, Outcome 3 Assisted vaginal birth.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 15 IM pentazocine versus IM Pethilorfan
Outcome: 3 Assisted vaginal birth
Study or subgroup Pentazocine Pethilorfan Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
O’Dwyer 1971 1/48 1/50 100.0 % 1.04 [ 0.07, 16.19 ]
Total (95% CI) 48 50 100.0 % 1.04 [ 0.07, 16.19 ]
Total events: 1 (Pentazocine), 1 (Pethilorfan)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours pentazocine Favours pethilorfan
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Analysis 15.4. Comparison 15 IM pentazocine versus IM Pethilorfan®, Outcome 4 Apgar < 8 at 1 minute
(non pre-specified).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 15 IM pentazocine versus IM Pethilorfan
Outcome: 4 Apgar < 8 at 1 minute (non pre-specified)
Study or subgroup Pentazocine Pethilorfan Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
O’Dwyer 1971 6/42 1/40 100.0 % 5.71 [ 0.72, 45.39 ]
Total (95% CI) 42 40 100.0 % 5.71 [ 0.72, 45.39 ]
Total events: 6 (Pentazocine), 1 (Pethilorfan)
Heterogeneity: not applicable
Test for overall effect: Z = 1.65 (P = 0.099)
Test for subgroup differences: Not applicable
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Analysis 15.5. Comparison 15 IM pentazocine versus IM Pethilorfan®, Outcome 5 Apgar < 8 at 5 minutes
(non pre-specified).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 15 IM pentazocine versus IM Pethilorfan
Outcome: 5 Apgar < 8 at 5 minutes (non pre-specified)
Study or subgroup Pentazocine Pethilorfan Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
O’Dwyer 1971 0/42 0/40 Not estimable
Total (95% CI) 42 40 Not estimable
Total events: 0 (Pentazocine), 0 (Pethilorfan)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 16.1. Comparison 16 IM pentazocine versus complementary and alternate medicine (CAM),
Outcome 1 Maternal pain score measured during labour.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 16 IM pentazocine versus complementary and alternate medicine (CAM)
Outcome: 1 Maternal pain score measured during labour
Study or subgroup Pentazocaine CAM
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Zafar 2016 47 81.5 (17.82) 42 81.9 (16.8499) 100.0 % -0.40 [ -7.61, 6.81 ]
Total (95% CI) 47 42 100.0 % -0.40 [ -7.61, 6.81 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.11 (P = 0.91)
Test for subgroup differences: Not applicable
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Analysis 16.2. Comparison 16 IM pentazocine versus complementary and alternate medicine (CAM),
Outcome 2 Nausea and vomiting.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 16 IM pentazocine versus complementary and alternate medicine (CAM)
Outcome: 2 Nausea and vomiting
Study or subgroup Pentazocaine CAM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Zafar 2016 0/47 1/42 100.0 % 0.30 [ 0.01, 7.14 ]
Total (95% CI) 47 42 100.0 % 0.30 [ 0.01, 7.14 ]
Total events: 0 (Pentazocaine), 1 (CAM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.46)
Test for subgroup differences: Not applicable
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Analysis 16.3. Comparison 16 IM pentazocine versus complementary and alternate medicine (CAM),
Outcome 3 Caesarean section.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 16 IM pentazocine versus complementary and alternate medicine (CAM)
Outcome: 3 Caesarean section
Study or subgroup Pentazocaine CAM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Zafar 2016 4/47 4/42 100.0 % 0.89 [ 0.24, 3.35 ]
Total (95% CI) 47 42 100.0 % 0.89 [ 0.24, 3.35 ]
Total events: 4 (Pentazocaine), 4 (CAM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.87)
Test for subgroup differences: Not applicable
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Analysis 16.4. Comparison 16 IM pentazocine versus complementary and alternate medicine (CAM),
Outcome 4 Assisted vaginal delivery.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 16 IM pentazocine versus complementary and alternate medicine (CAM)
Outcome: 4 Assisted vaginal delivery
Study or subgroup Pentazocaine CAM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Zafar 2016 2/47 2/42 100.0 % 0.89 [ 0.13, 6.07 ]
Total (95% CI) 47 42 100.0 % 0.89 [ 0.13, 6.07 ]
Total events: 2 (Pentazocaine), 2 (CAM)
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.91)
Test for subgroup differences: Not applicable
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Analysis 17.1. Comparison 17 IM pentazocine versus IM tramadol, Outcome 1 Maternal satisfaction with
analgesia measured during labour (pain relief after 30 mins).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 17 IM pentazocine versus IM tramadol
Outcome: 1 Maternal satisfaction with analgesia measured during labour (pain relief after 30 mins)
Study or subgroup Pentazocine Tramadol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kuti 2008 24/50 10/50 100.0 % 2.40 [ 1.28, 4.48 ]
Total (95% CI) 50 50 100.0 % 2.40 [ 1.28, 4.48 ]
Total events: 24 (Pentazocine), 10 (Tramadol)
Heterogeneity: not applicable
Test for overall effect: Z = 2.75 (P = 0.0060)
Test for subgroup differences: Not applicable
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Analysis 17.2. Comparison 17 IM pentazocine versus IM tramadol, Outcome 2 Maternal satisfaction with
analgesia measured during labour (pain after 60 mins).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 17 IM pentazocine versus IM tramadol
Outcome: 2 Maternal satisfaction with analgesia measured during labour (pain after 60 mins)
Study or subgroup Pentazocine Tramadol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kuti 2008 21/50 13/50 100.0 % 1.62 [ 0.91, 2.86 ]
Total (95% CI) 50 50 100.0 % 1.62 [ 0.91, 2.86 ]
Total events: 21 (Pentazocine), 13 (Tramadol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.65 (P = 0.099)
Test for subgroup differences: Not applicable
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Analysis 17.3. Comparison 17 IM pentazocine versus IM tramadol, Outcome 3 Maternal pain score or pain
measured in labour (moderate or severe at 30 mins).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 17 IM pentazocine versus IM tramadol
Outcome: 3 Maternal pain score or pain measured in labour (moderate or severe at 30 mins)
Study or subgroup Pentazocine Tramadol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kuti 2008 27/50 36/50 100.0 % 0.75 [ 0.55, 1.02 ]
Total (95% CI) 50 50 100.0 % 0.75 [ 0.55, 1.02 ]
Total events: 27 (Pentazocine), 36 (Tramadol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.83 (P = 0.068)
Test for subgroup differences: Not applicable
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Analysis 17.4. Comparison 17 IM pentazocine versus IM tramadol, Outcome 4 Maternal pain score or pain
measured in labour (moderate or severe at 60 mins).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 17 IM pentazocine versus IM tramadol
Outcome: 4 Maternal pain score or pain measured in labour (moderate or severe at 60 mins)
Study or subgroup Pentazocine Tramadol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kuti 2008 29/50 36/50 100.0 % 0.81 [ 0.60, 1.08 ]
Total (95% CI) 50 50 100.0 % 0.81 [ 0.60, 1.08 ]
Total events: 29 (Pentazocine), 36 (Tramadol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 17.5. Comparison 17 IM pentazocine versus IM tramadol, Outcome 5 Maternal sleepiness during
labour.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 17 IM pentazocine versus IM tramadol
Outcome: 5 Maternal sleepiness during labour
Study or subgroup Pentazocine Tramadol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kuti 2008 10/50 6/50 100.0 % 1.67 [ 0.66, 4.24 ]
Total (95% CI) 50 50 100.0 % 1.67 [ 0.66, 4.24 ]
Total events: 10 (Pentazocine), 6 (Tramadol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
Test for subgroup differences: Not applicable
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Analysis 17.6. Comparison 17 IM pentazocine versus IM tramadol, Outcome 6 Nausea and vomiting.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 17 IM pentazocine versus IM tramadol
Outcome: 6 Nausea and vomiting
Study or subgroup Pentazocine Tramadol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kuti 2008 1/50 1/50 100.0 % 1.00 [ 0.06, 15.55 ]
Total (95% CI) 50 50 100.0 % 1.00 [ 0.06, 15.55 ]
Total events: 1 (Pentazocine), 1 (Tramadol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 17.7. Comparison 17 IM pentazocine versus IM tramadol, Outcome 7 Caesarean section.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 17 IM pentazocine versus IM tramadol
Outcome: 7 Caesarean section
Study or subgroup Pentazocine Tramadol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kuti 2008 6/50 4/50 100.0 % 1.50 [ 0.45, 4.99 ]
Total (95% CI) 50 50 100.0 % 1.50 [ 0.45, 4.99 ]
Total events: 6 (Pentazocine), 4 (Tramadol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
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Analysis 17.8. Comparison 17 IM pentazocine versus IM tramadol, Outcome 8 Assisted vaginal delivery.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 17 IM pentazocine versus IM tramadol
Outcome: 8 Assisted vaginal delivery
Study or subgroup Pentazocine Tramadol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kuti 2008 2/50 1/50 100.0 % 2.00 [ 0.19, 21.36 ]
Total (95% CI) 50 50 100.0 % 2.00 [ 0.19, 21.36 ]
Total events: 2 (Pentazocine), 1 (Tramadol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Not applicable
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Analysis 17.9. Comparison 17 IM pentazocine versus IM tramadol, Outcome 9 Apgar score < 7 at 1 minute.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 17 IM pentazocine versus IM tramadol
Outcome: 9 Apgar score < 7 at 1 minute
Study or subgroup Pentazocine Tramadol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kuti 2008 5/50 3/50 100.0 % 1.67 [ 0.42, 6.60 ]
Total (95% CI) 50 50 100.0 % 1.67 [ 0.42, 6.60 ]
Total events: 5 (Pentazocine), 3 (Tramadol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
Test for subgroup differences: Not applicable
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Analysis 17.10. Comparison 17 IM pentazocine versus IM tramadol, Outcome 10 Apgar score < 7 at 5
minutes.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 17 IM pentazocine versus IM tramadol
Outcome: 10 Apgar score < 7 at 5 minutes
Study or subgroup Pentazocine Tramadol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kuti 2008 1/50 0/50 100.0 % 3.00 [ 0.13, 71.92 ]
Total (95% CI) 50 50 100.0 % 3.00 [ 0.13, 71.92 ]
Total events: 1 (Pentazocine), 0 (Tramadol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 17.11. Comparison 17 IM pentazocine versus IM tramadol, Outcome 11 Admission to NICU.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 17 IM pentazocine versus IM tramadol
Outcome: 11 Admission to NICU
Study or subgroup Pentazocine Tramadol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kuti 2008 1/44 0/42 100.0 % 2.87 [ 0.12, 68.47 ]
Total (95% CI) 44 42 100.0 % 2.87 [ 0.12, 68.47 ]
Total events: 1 (Pentazocine), 0 (Tramadol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
Test for subgroup differences: Not applicable
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Analysis 18.1. Comparison 18 IM pethidine versus Entonox, Outcome 1 Maternal pain score or pain
measured in labour (after 30 mins).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 18 IM pethidine versus Entonox
Outcome: 1 Maternal pain score or pain measured in labour (after 30 mins)
Study or subgroup Pethidine Entonox
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Mobaraki 2016 50 5.6 (1.1) 50 3.94 (1.4) 100.0 % 1.66 [ 1.17, 2.15 ]
Total (95% CI) 50 50 100.0 % 1.66 [ 1.17, 2.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.59 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 18.2. Comparison 18 IM pethidine versus Entonox, Outcome 2 Maternal pain score or pain
measured in labour (after 60 mins).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 18 IM pethidine versus Entonox
Outcome: 2 Maternal pain score or pain measured in labour (after 60 mins)
Study or subgroup Pethidine Entonox
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Mobaraki 2016 50 4.7 (1.1) 50 5.06 (1.4) 100.0 % -0.36 [ -0.85, 0.13 ]
Total (95% CI) 50 50 100.0 % -0.36 [ -0.85, 0.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.43 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 19.1. Comparison 19 IV pethidine versus placebo, Outcome 1 Maternal pain score or pain
measured in labour (Pain score 30 mins post analgesia).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 19 IV pethidine versus placebo
Outcome: 1 Maternal pain score or pain measured in labour (Pain score 30 mins post analgesia)
Study or subgroup Pethidine IM Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
El-Refaie 2012 120 4.1 (1.9) 120 8.2 (1.7) 100.0 % -4.10 [ -4.56, -3.64 ]
Total (95% CI) 120 120 100.0 % -4.10 [ -4.56, -3.64 ]
Heterogeneity: not applicable
Test for overall effect: Z = 17.62 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 19.2. Comparison 19 IV pethidine versus placebo, Outcome 2 Nausea and vomiting.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 19 IV pethidine versus placebo
Outcome: 2 Nausea and vomiting
Study or subgroup Pethidine IM Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
El-Refaie 2012 17/120 7/120 100.0 % 2.43 [ 1.05, 5.64 ]
Total (95% CI) 120 120 100.0 % 2.43 [ 1.05, 5.64 ]
Total events: 17 (Pethidine IM), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.06 (P = 0.039)
Test for subgroup differences: Not applicable
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Analysis 19.3. Comparison 19 IV pethidine versus placebo, Outcome 3 Caesarean section.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 19 IV pethidine versus placebo
Outcome: 3 Caesarean section
Study or subgroup Pethidine IM Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
El-Refaie 2012 15/120 17/120 100.0 % 0.88 [ 0.46, 1.68 ]
Total (95% CI) 120 120 100.0 % 0.88 [ 0.46, 1.68 ]
Total events: 15 (Pethidine IM), 17 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.70)
Test for subgroup differences: Not applicable
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Analysis 19.4. Comparison 19 IV pethidine versus placebo, Outcome 4 Assisted vaginal birth.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 19 IV pethidine versus placebo
Outcome: 4 Assisted vaginal birth
Study or subgroup Pethidine IM Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
El-Refaie 2012 9/120 12/120 100.0 % 0.75 [ 0.33, 1.71 ]
Total (95% CI) 120 120 100.0 % 0.75 [ 0.33, 1.71 ]
Total events: 9 (Pethidine IM), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 19.5. Comparison 19 IV pethidine versus placebo, Outcome 5 Admission to NICU.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 19 IV pethidine versus placebo
Outcome: 5 Admission to NICU
Study or subgroup Pethidine IM Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
El-Refaie 2012 2/120 3/120 100.0 % 0.67 [ 0.11, 3.92 ]
Total (95% CI) 120 120 100.0 % 0.67 [ 0.11, 3.92 ]
Total events: 2 (Pethidine IM), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Not applicable
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Analysis 20.1. Comparison 20 IV fentanyl versus no treatment, Outcome 1 Maternal pain score or pain
measured in labour (Pain score 1 hour post-analgesia).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 20 IV fentanyl versus no treatment
Outcome: 1 Maternal pain score or pain measured in labour (Pain score 1 hour post-analgesia)
Study or subgroup Fentanyl No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Jahani 2013 35 3 (1) 35 8 (1) 100.0 % -5.00 [ -5.47, -4.53 ]
Total (95% CI) 35 35 100.0 % -5.00 [ -5.47, -4.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 20.92 (P < 0.00001)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours Fentanyl Favours no treatment
Analysis 20.2. Comparison 20 IV fentanyl versus no treatment, Outcome 2 Maternal pain score or pain
measured in labour (Pain intensity (Severe) after 1 hour).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 20 IV fentanyl versus no treatment
Outcome: 2 Maternal pain score or pain measured in labour (Pain intensity (Severe) after 1 hour)
Study or subgroup Fentanyl No treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Jahani 2013 0/35 31/35 100.0 % 0.02 [ 0.00, 0.25 ]
Total (95% CI) 35 35 100.0 % 0.02 [ 0.00, 0.25 ]
Total events: 0 (Fentanyl), 31 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 2.95 (P = 0.0032)
Test for subgroup differences: Not applicable
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Analysis 20.3. Comparison 20 IV fentanyl versus no treatment, Outcome 3 Caesarean section.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 20 IV fentanyl versus no treatment
Outcome: 3 Caesarean section
Study or subgroup Fentanyl No treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Jahani 2013 3/35 2/35 100.0 % 1.50 [ 0.27, 8.43 ]
Total (95% CI) 35 35 100.0 % 1.50 [ 0.27, 8.43 ]
Total events: 3 (Fentanyl), 2 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.65)
Test for subgroup differences: Not applicable
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Analysis 21.1. Comparison 21 IV fentanyl versus IV pethidine, Outcome 1 Maternal pain score or pain
measured in labour (Pain score 1 hour after drug administration).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 21 IV fentanyl versus IV pethidine
Outcome: 1 Maternal pain score or pain measured in labour (Pain score 1 hour after drug administration)
Study or subgroup Fentanyl Pethidine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Rayburn 1989a (1) 49 5.9 (2.8) 56 6.1 (2.245) 100.0 % -0.20 [ -1.18, 0.78 ]
Total (95% CI) 49 56 100.0 % -0.20 [ -1.18, 0.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Not applicable
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(1) Pain score at 4-7cm dilatation (SD/SE not clear)
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Analysis 21.2. Comparison 21 IV fentanyl versus IV pethidine, Outcome 2 Mean doses of analgesia (non pre-
specified).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 21 IV fentanyl versus IV pethidine
Outcome: 2 Mean doses of analgesia (non pre-specified)
Study or subgroup Fentanyl Pethidine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Rayburn 1989a 49 2.3 (0.8) 56 1.9 (0.5) 100.0 % 0.40 [ 0.14, 0.66 ]
Total (95% CI) 49 56 100.0 % 0.40 [ 0.14, 0.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.02 (P = 0.0025)
Test for subgroup differences: Not applicable
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Analysis 21.3. Comparison 21 IV fentanyl versus IV pethidine, Outcome 3 Maternal sleepiness in labour
(sedation).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 21 IV fentanyl versus IV pethidine
Outcome: 3 Maternal sleepiness in labour (sedation)
Study or subgroup Fentanyl Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rayburn 1989a 0/49 11/56 100.0 % 0.05 [ 0.00, 0.82 ]
Total (95% CI) 49 56 100.0 % 0.05 [ 0.00, 0.82 ]
Total events: 0 (Fentanyl), 11 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.10 (P = 0.036)
Test for subgroup differences: Not applicable
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Analysis 21.4. Comparison 21 IV fentanyl versus IV pethidine, Outcome 4 Nausea and/or vomiting.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 21 IV fentanyl versus IV pethidine
Outcome: 4 Nausea and/or vomiting
Study or subgroup Fentanyl Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rayburn 1989a 4/49 9/56 100.0 % 0.51 [ 0.17, 1.55 ]
Total (95% CI) 49 56 100.0 % 0.51 [ 0.17, 1.55 ]
Total events: 4 (Fentanyl), 9 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 21.5. Comparison 21 IV fentanyl versus IV pethidine, Outcome 5 Anti-emetic required (non pre-
specified).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 21 IV fentanyl versus IV pethidine
Outcome: 5 Anti-emetic required (non pre-specified)
Study or subgroup Fentanyl Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rayburn 1989a 0/49 6/56 100.0 % 0.09 [ 0.01, 1.52 ]
Total (95% CI) 49 56 100.0 % 0.09 [ 0.01, 1.52 ]
Total events: 0 (Fentanyl), 6 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.67 (P = 0.094)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours fentanyl Favours pethidine
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Analysis 21.6. Comparison 21 IV fentanyl versus IV pethidine, Outcome 6 Caesarean section.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 21 IV fentanyl versus IV pethidine
Outcome: 6 Caesarean section
Study or subgroup Fentanyl Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rayburn 1989a 3/49 3/56 100.0 % 1.14 [ 0.24, 5.40 ]
Total (95% CI) 49 56 100.0 % 1.14 [ 0.24, 5.40 ]
Total events: 3 (Fentanyl), 3 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.87)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours fentanyl Favours pethidine
Analysis 21.7. Comparison 21 IV fentanyl versus IV pethidine, Outcome 7 Naloxone administered.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 21 IV fentanyl versus IV pethidine
Outcome: 7 Naloxone administered
Study or subgroup Fentanyl Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rayburn 1989a 1/49 7/56 100.0 % 0.16 [ 0.02, 1.28 ]
Total (95% CI) 49 56 100.0 % 0.16 [ 0.02, 1.28 ]
Total events: 1 (Fentanyl), 7 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.72 (P = 0.085)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours fentanyl Favours pethidine
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Analysis 21.8. Comparison 21 IV fentanyl versus IV pethidine, Outcome 8 Babies requiring
resuscitation/ventilatory support.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 21 IV fentanyl versus IV pethidine
Outcome: 8 Babies requiring resuscitation/ventilatory support
Study or subgroup Experimental Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rayburn 1989a 9/49 10/56 100.0 % 1.03 [ 0.46, 2.32 ]
Total (95% CI) 49 56 100.0 % 1.03 [ 0.46, 2.32 ]
Total events: 9 (Experimental), 10 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.95)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours pethidine
Analysis 21.9. Comparison 21 IV fentanyl versus IV pethidine, Outcome 9 Apgar score < 7 at 1 minute.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 21 IV fentanyl versus IV pethidine
Outcome: 9 Apgar score < 7 at 1 minute
Study or subgroup Fentanyl Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rayburn 1989a 5/49 9/56 0.63 [ 0.23, 1.77 ]
0.01 0.1 1 10 100
Favours fentanyl Favours pethidine
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Analysis 21.10. Comparison 21 IV fentanyl versus IV pethidine, Outcome 10 Apgar score < 7 at 5 minutes.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 21 IV fentanyl versus IV pethidine
Outcome: 10 Apgar score < 7 at 5 minutes
Study or subgroup Fentanyl Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rayburn 1989a 0/49 1/56 0.38 [ 0.02, 9.12 ]
0.01 0.1 1 10 100
Favours fentanyl Favours pethidine
Analysis 21.11. Comparison 21 IV fentanyl versus IV pethidine, Outcome 11 Neurobehavioural score (1 - 2
hours after delivery).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 21 IV fentanyl versus IV pethidine
Outcome: 11 Neurobehavioural score (1 - 2 hours after delivery)
Study or subgroup Fentanyl Pethidine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Rayburn 1989a (1) 49 33.2 (2.9) 56 31.9 (3.1) 100.0 % 1.30 [ 0.15, 2.45 ]
Total (95% CI) 49 56 100.0 % 1.30 [ 0.15, 2.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.22 (P = 0.026)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Lower with fentanyl Lower with pethidine
(1) Neurologic and Adaptive Capacity Score - 40 maximum score, >30 reassuring. High scores = positive result
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Analysis 21.12. Comparison 21 IV fentanyl versus IV pethidine, Outcome 12 Neurobehavioural score (2
hours - 24 hours).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 21 IV fentanyl versus IV pethidine
Outcome: 12 Neurobehavioural score (2 hours - 24 hours)
Study or subgroup Fentanyl Pethidine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Rayburn 1989a (1) 49 35.7 (3.4) 56 34.8 (3.5) 100.0 % 0.90 [ -0.42, 2.22 ]
Total (95% CI) 49 56 100.0 % 0.90 [ -0.42, 2.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Lower with fentanyl Lower with pethidine
(1) Neurologic and Adaptive Capacity Score - 40 maximum score, >30 reassuring. High scores = positive result
Analysis 22.1. Comparison 22 IV nalbuphine versus IV pethidine, Outcome 1 Caesarean section.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 22 IV nalbuphine versus IV pethidine
Outcome: 1 Caesarean section
Study or subgroup Nalbuphine Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Giannina 1995 2/14 0/14 100.0 % 5.00 [ 0.26, 95.61 ]
Total (95% CI) 14 14 100.0 % 5.00 [ 0.26, 95.61 ]
Total events: 2 (Nalbuphine), 0 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.29)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours nalbuphine Favours pethidine
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Analysis 22.2. Comparison 22 IV nalbuphine versus IV pethidine, Outcome 2 Apgar score < 7 at 1 minute.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 22 IV nalbuphine versus IV pethidine
Outcome: 2 Apgar score < 7 at 1 minute
Study or subgroup Nalbuphine Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Giannina 1995 1/14 0/14 3.00 [ 0.13, 67.91 ]
0.01 0.1 1 10 100
Favours nalbuphine Favours pethidine
Analysis 22.3. Comparison 22 IV nalbuphine versus IV pethidine, Outcome 3 Apgar score < 7 at 5 minutes.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 22 IV nalbuphine versus IV pethidine
Outcome: 3 Apgar score < 7 at 5 minutes
Study or subgroup Nalbuphine Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Giannina 1995 0/14 0/14 Not estimable
0.01 0.1 1 10 100
Favours nalbuphine Favours pethidine
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Analysis 23.1. Comparison 23 IV phenazocine versus IV pethidine, Outcome 1 Maternal satisfaction with
analgesia measured during labour (women with fair or poor relief).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 23 IV phenazocine versus IV pethidine
Outcome: 1 Maternal satisfaction with analgesia measured during labour (women with fair or poor relief)
Study or subgroup Phenazocine Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Olson 1964 26/97 36/97 100.0 % 0.72 [ 0.48, 1.10 ]
Total (95% CI) 97 97 100.0 % 0.72 [ 0.48, 1.10 ]
Total events: 26 (Phenazocine), 36 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours phenazocine Favours pethidine
Analysis 23.2. Comparison 23 IV phenazocine versus IV pethidine, Outcome 2 Nausea with vomiting.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 23 IV phenazocine versus IV pethidine
Outcome: 2 Nausea with vomiting
Study or subgroup Phenazocine Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Olson 1964 2/97 5/97 100.0 % 0.40 [ 0.08, 2.01 ]
Total (95% CI) 97 97 100.0 % 0.40 [ 0.08, 2.01 ]
Total events: 2 (Phenazocine), 5 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours phenazocine Favours pethidine
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Analysis 23.3. Comparison 23 IV phenazocine versus IV pethidine, Outcome 3 Perinatal death.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 23 IV phenazocine versus IV pethidine
Outcome: 3 Perinatal death
Study or subgroup Phenazocine Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Olson 1964 0/97 0/97 Not estimable
Total (95% CI) 97 97 Not estimable
Total events: 0 (Phenazocine), 0 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours phenazocine Favours pethidine
Analysis 23.4. Comparison 23 IV phenazocine versus IV pethidine, Outcome 4 Apgar score < 7 at 1 minute.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 23 IV phenazocine versus IV pethidine
Outcome: 4 Apgar score < 7 at 1 minute
Study or subgroup Phenazocine Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Olson 1964 0/97 0/97 Not estimable
Total (95% CI) 97 97 Not estimable
Total events: 0 (Phenazocine), 0 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours phenazocine Favours pethidine
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Analysis 24.1. Comparison 24 IV butorphanol versus IV pethidine, Outcome 1 Maternal pain score or pain
measured in labour (Pain relief score).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 24 IV butorphanol versus IV pethidine
Outcome: 1 Maternal pain score or pain measured in labour (Pain relief score)
Study or subgroup Butorphanol Pethidine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Quilligan 1980 40 1.7 (1.01) 40 1.03 (0.89) 100.0 % 0.67 [ 0.25, 1.09 ]
Total (95% CI) 40 40 100.0 % 0.67 [ 0.25, 1.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.15 (P = 0.0016)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours pethidine Favours butorphanol
Analysis 24.2. Comparison 24 IV butorphanol versus IV pethidine, Outcome 2 Maternal pain score or pain
measured in labour (Pain score (1 hour after drug administration)).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 24 IV butorphanol versus IV pethidine
Outcome: 2 Maternal pain score or pain measured in labour (Pain score (1 hour after drug administration))
Study or subgroup Butorphanol Pethidine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Quilligan 1980 40 2.1 (1.01) 40 2.7 (0.89) 100.0 % -0.60 [ -1.02, -0.18 ]
Total (95% CI) 40 40 100.0 % -0.60 [ -1.02, -0.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.82 (P = 0.0048)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours butorphanol Favours pethidine
269Parenteral opioids for maternal pain management in labour (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 24.3. Comparison 24 IV butorphanol versus IV pethidine, Outcome 3 Additional analgesia required.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 24 IV butorphanol versus IV pethidine
Outcome: 3 Additional analgesia required
Study or subgroup Butorphanol Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Quilligan 1980 (1) 23/50 24/50 100.0 % 0.96 [ 0.63, 1.45 ]
Total (95% CI) 50 50 100.0 % 0.96 [ 0.63, 1.45 ]
Total events: 23 (Butorphanol), 24 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours butorphanol Favours pethidine
(1) 2nd dose required
Analysis 24.4. Comparison 24 IV butorphanol versus IV pethidine, Outcome 4 Epidural.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 24 IV butorphanol versus IV pethidine
Outcome: 4 Epidural
Study or subgroup Butorphanol Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hodgkinson 1979 5/100 5/100 100.0 % 1.00 [ 0.30, 3.35 ]
Total (95% CI) 100 100 100.0 % 1.00 [ 0.30, 3.35 ]
Total events: 5 (Butorphanol), 5 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours butorphanol Favours pethidine
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Analysis 24.5. Comparison 24 IV butorphanol versus IV pethidine, Outcome 5 Nausea and/or vomiting.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 24 IV butorphanol versus IV pethidine
Outcome: 5 Nausea and/or vomiting
Study or subgroup Butorphanol Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hodgkinson 1979 0/100 12/100 100.0 % 0.04 [ 0.00, 0.67 ]
Total (95% CI) 100 100 100.0 % 0.04 [ 0.00, 0.67 ]
Total events: 0 (Butorphanol), 12 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.24 (P = 0.025)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours butorphanol Favours pethidine
Analysis 24.6. Comparison 24 IV butorphanol versus IV pethidine, Outcome 6 Caesarean section.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 24 IV butorphanol versus IV pethidine
Outcome: 6 Caesarean section
Study or subgroup Butorphanol Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hodgkinson 1979 4/100 5/100 100.0 % 0.80 [ 0.22, 2.89 ]
Total (95% CI) 100 100 100.0 % 0.80 [ 0.22, 2.89 ]
Total events: 4 (Butorphanol), 5 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.73)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours butorphanol Favours pethidine
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Analysis 24.7. Comparison 24 IV butorphanol versus IV pethidine, Outcome 7 Assisted vaginal birth.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 24 IV butorphanol versus IV pethidine
Outcome: 7 Assisted vaginal birth
Study or subgroup Butorphanol Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hodgkinson 1979 13/100 10/100 100.0 % 1.30 [ 0.60, 2.83 ]
Total (95% CI) 100 100 100.0 % 1.30 [ 0.60, 2.83 ]
Total events: 13 (Butorphanol), 10 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours butorphanol Favours pethidine
Analysis 24.8. Comparison 24 IV butorphanol versus IV pethidine, Outcome 8 Apgar score < 7 at 1 minute.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 24 IV butorphanol versus IV pethidine
Outcome: 8 Apgar score < 7 at 1 minute
Study or subgroup Butorphanol Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hodgkinson 1979 3/100 7/100 0.43 [ 0.11, 1.61 ]
Nelson 2005 1/15 1/15 1.00 [ 0.07, 14.55 ]
0.01 0.1 1 10 100
Favours butorphanol Favours pethidine
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Analysis 24.9. Comparison 24 IV butorphanol versus IV pethidine, Outcome 9 Apgar score < 7 at 5 minutes.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 24 IV butorphanol versus IV pethidine
Outcome: 9 Apgar score < 7 at 5 minutes
Study or subgroup Butorphanol Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hodgkinson 1979 1/100 1/100 1.00 [ 0.06, 15.77 ]
Nelson 2005 0/15 0/15 Not estimable
0.01 0.1 1 10 100
Favours butorphanol Favours pethidine
Analysis 25.1. Comparison 25 IV morphine versus IV pethidine, Outcome 1 Maternal satisfaction with
analgesia (assessed 3 days postpartum).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 25 IV morphine versus IV pethidine
Outcome: 1 Maternal satisfaction with analgesia (assessed 3 days postpartum)
Study or subgroup Experimental Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Campbell 1961 60/72 66/69 100.0 % 0.87 [ 0.78, 0.98 ]
Total (95% CI) 72 69 100.0 % 0.87 [ 0.78, 0.98 ]
Total events: 60 (Experimental), 66 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.35 (P = 0.019)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 25.2. Comparison 25 IV morphine versus IV pethidine, Outcome 2 Additional analgesia required.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 25 IV morphine versus IV pethidine
Outcome: 2 Additional analgesia required
Study or subgroup Morphine Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Campbell 1961 (1) 38/72 11/71 100.0 % 3.41 [ 1.90, 6.12 ]
Total (95% CI) 72 71 100.0 % 3.41 [ 1.90, 6.12 ]
Total events: 38 (Morphine), 11 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 4.10 (P = 0.000041)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours morphine Favours pethidine
(1) Further dose of study analgesia required
Analysis 25.3. Comparison 25 IV morphine versus IV pethidine, Outcome 3 Nausea and vomiting.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 25 IV morphine versus IV pethidine
Outcome: 3 Nausea and vomiting
Study or subgroup Morphine Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Nausea
Olofsson 1996 1/10 6/10 100.0 % 0.17 [ 0.02, 1.14 ]
Subtotal (95% CI) 10 10 100.0 % 0.17 [ 0.02, 1.14 ]
Total events: 1 (Morphine), 6 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.82 (P = 0.068)
2 Vomiting
Olofsson 1996 1/10 4/10 100.0 % 0.25 [ 0.03, 1.86 ]
Subtotal (95% CI) 10 10 100.0 % 0.25 [ 0.03, 1.86 ]
Total events: 1 (Morphine), 4 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.35 (P = 0.18)
0.01 0.1 1 10 100
Favours morphine Favours pethidine
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Analysis 25.4. Comparison 25 IV morphine versus IV pethidine, Outcome 4 Caesarean section.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 25 IV morphine versus IV pethidine
Outcome: 4 Caesarean section
Study or subgroup Morphine Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Olofsson 1996 0/10 0/10 Not estimable
Total (95% CI) 10 10 Not estimable
Total events: 0 (Morphine), 0 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours morphine Favours pethidine
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Analysis 26.1. Comparison 26 IV Nisentil versus IV pethidine, Outcome 1 Nausea and vomiting.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 26 IV Nisentil versus IV pethidine
Outcome: 1 Nausea and vomiting
Study or subgroup Nisentil Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Nausea
Gillam 1958 10/185 16/210 100.0 % 0.71 [ 0.33, 1.52 ]
Subtotal (95% CI) 185 210 100.0 % 0.71 [ 0.33, 1.52 ]
Total events: 10 (Nisentil), 16 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
2 Vomiting
Gillam 1958 (1) 15/185 45/210 100.0 % 0.38 [ 0.22, 0.66 ]
Subtotal (95% CI) 185 210 100.0 % 0.38 [ 0.22, 0.66 ]
Total events: 15 (Nisentil), 45 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 3.46 (P = 0.00053)
0.01 0.1 1 10 100
Favours nisentil Favours pethidine
(1) Both groups also received scopolamine
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Analysis 26.2. Comparison 26 IV Nisentil versus IV pethidine, Outcome 2 Neonatal
resuscitation/ventilatory support.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 26 IV Nisentil versus IV pethidine
Outcome: 2 Neonatal resuscitation/ventilatory support
Study or subgroup Nisentil Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gillam 1958 14/185 8/210 100.0 % 1.99 [ 0.85, 4.63 ]
Total (95% CI) 185 210 100.0 % 1.99 [ 0.85, 4.63 ]
Total events: 14 (Nisentil), 8 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.59 (P = 0.11)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours nisentil Favours pethidine
Analysis 27.1. Comparison 27 IV fentanyl versus IV butorphanol, Outcome 1 Additional analgesia required.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 27 IV fentanyl versus IV butorphanol
Outcome: 1 Additional analgesia required
Study or subgroup Fentanyl Butorphanol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Atkinson 1994 (1) 39/50 28/50 100.0 % 1.39 [ 1.05, 1.85 ]
Total (95% CI) 50 50 100.0 % 1.39 [ 1.05, 1.85 ]
Total events: 39 (Fentanyl), 28 (Butorphanol)
Heterogeneity: not applicable
Test for overall effect: Z = 2.27 (P = 0.023)
Test for subgroup differences: Not applicable
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Favours fentanyl Favours butorphanol
(1) Two or more doses
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Analysis 27.2. Comparison 27 IV fentanyl versus IV butorphanol, Outcome 2 Epidural.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 27 IV fentanyl versus IV butorphanol
Outcome: 2 Epidural
Study or subgroup Fentanyl Butorphanol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Atkinson 1994 18/50 9/50 100.0 % 2.00 [ 1.00, 4.02 ]
Total (95% CI) 50 50 100.0 % 2.00 [ 1.00, 4.02 ]
Total events: 18 (Fentanyl), 9 (Butorphanol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.95 (P = 0.051)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours fentanyl Favours butorphanol
Analysis 27.3. Comparison 27 IV fentanyl versus IV butorphanol, Outcome 3 Matenal sleepiness (required
tactile rousing).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 27 IV fentanyl versus IV butorphanol
Outcome: 3 Matenal sleepiness (required tactile rousing)
Study or subgroup Fentanyl Butorphanol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Atkinson 1994 6/50 2/50 100.0 % 3.00 [ 0.64, 14.16 ]
Total (95% CI) 50 50 100.0 % 3.00 [ 0.64, 14.16 ]
Total events: 6 (Fentanyl), 2 (Butorphanol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.17)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours fentanyl Favours butorphanol
278Parenteral opioids for maternal pain management in labour (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 27.4. Comparison 27 IV fentanyl versus IV butorphanol, Outcome 4 Caesarean section.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 27 IV fentanyl versus IV butorphanol
Outcome: 4 Caesarean section
Study or subgroup Fentanyl Butorphanol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Atkinson 1994 4/50 5/50 100.0 % 0.80 [ 0.23, 2.81 ]
Total (95% CI) 50 50 100.0 % 0.80 [ 0.23, 2.81 ]
Total events: 4 (Fentanyl), 5 (Butorphanol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Not applicable
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Analysis 27.5. Comparison 27 IV fentanyl versus IV butorphanol, Outcome 5 Naloxone required.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 27 IV fentanyl versus IV butorphanol
Outcome: 5 Naloxone required
Study or subgroup Fentanyl Butorphanol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Atkinson 1994 14/50 8/50 100.0 % 1.75 [ 0.81, 3.80 ]
Total (95% CI) 50 50 100.0 % 1.75 [ 0.81, 3.80 ]
Total events: 14 (Fentanyl), 8 (Butorphanol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 27.6. Comparison 27 IV fentanyl versus IV butorphanol, Outcome 6 Neonatal resuscitation (Babies
requiring ventilatory support).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 27 IV fentanyl versus IV butorphanol
Outcome: 6 Neonatal resuscitation (Babies requiring ventilatory support)
Study or subgroup Fentanyl Butorphanol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Atkinson 1994 5/50 0/50 100.0 % 11.00 [ 0.62, 193.80 ]
Total (95% CI) 50 50 100.0 % 11.00 [ 0.62, 193.80 ]
Total events: 5 (Fentanyl), 0 (Butorphanol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
Test for subgroup differences: Not applicable
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Analysis 27.7. Comparison 27 IV fentanyl versus IV butorphanol, Outcome 7 Apgar score < 7 at 5 minutes.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 27 IV fentanyl versus IV butorphanol
Outcome: 7 Apgar score < 7 at 5 minutes
Study or subgroup Fentanyl Butorphanol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Atkinson 1994 6/50 5/50 100.0 % 1.20 [ 0.39, 3.68 ]
Total (95% CI) 50 50 100.0 % 1.20 [ 0.39, 3.68 ]
Total events: 6 (Fentanyl), 5 (Butorphanol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
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Analysis 27.8. Comparison 27 IV fentanyl versus IV butorphanol, Outcome 8 Newborn neurobehavioural
score at 2-4 hours.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 27 IV fentanyl versus IV butorphanol
Outcome: 8 Newborn neurobehavioural score at 2-4 hours
Study or subgroup Fentanyl Butorphanol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Atkinson 1994 50 28.4 (3.7) 50 28.4 (4.5) 100.0 % 0.0 [ -1.61, 1.61 ]
Total (95% CI) 50 50 100.0 % 0.0 [ -1.61, 1.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 27.9. Comparison 27 IV fentanyl versus IV butorphanol, Outcome 9 Newborn neurobehavioural
score at 24-36 hours.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 27 IV fentanyl versus IV butorphanol
Outcome: 9 Newborn neurobehavioural score at 24-36 hours
Study or subgroup Fentanyl Butorphanol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Atkinson 1994 50 31.7 (2.9) 50 32.2 (2.8) 100.0 % -0.50 [ -1.62, 0.62 ]
Total (95% CI) 50 50 100.0 % -0.50 [ -1.62, 0.62 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Not applicable
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Analysis 28.1. Comparison 28 PCA pentazocine versus PCA pethidine, Outcome 1 Maternal pan score or
pain measured in labour.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 28 PCA pentazocine versus PCA pethidine
Outcome: 1 Maternal pan score or pain measured in labour
Study or subgroup Pentazocine Pethidine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Erskine 1985 (1) 11 4.2 (1.98) 12 5.65 (1.68) 100.0 % -1.45 [ -2.96, 0.06 ]
Total (95% CI) 11 12 100.0 % -1.45 [ -2.96, 0.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.89 (P = 0.059)
Test for subgroup differences: Not applicable
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(1) Recorded just after delivery
Analysis 28.2. Comparison 28 PCA pentazocine versus PCA pethidine, Outcome 2 Maternal pan score or
pain measured in labour (rated as good one day after birth).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 28 PCA pentazocine versus PCA pethidine
Outcome: 2 Maternal pan score or pain measured in labour (rated as good one day after birth)
Study or subgroup Pentazocine Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Erskine 1985 9/14 11/14 100.0 % 0.82 [ 0.51, 1.32 ]
Total (95% CI) 14 14 100.0 % 0.82 [ 0.51, 1.32 ]
Total events: 9 (Pentazocine), 11 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours pethidine Favours pentazocine
282Parenteral opioids for maternal pain management in labour (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 28.3. Comparison 28 PCA pentazocine versus PCA pethidine, Outcome 3 Epidural.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 28 PCA pentazocine versus PCA pethidine
Outcome: 3 Epidural
Study or subgroup Pentazocine Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Erskine 1985 3/14 2/14 100.0 % 1.50 [ 0.29, 7.65 ]
Total (95% CI) 14 14 100.0 % 1.50 [ 0.29, 7.65 ]
Total events: 3 (Pentazocine), 2 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.63)
Test for subgroup differences: Not applicable
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Analysis 28.4. Comparison 28 PCA pentazocine versus PCA pethidine, Outcome 4 Nausea and vomiting.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 28 PCA pentazocine versus PCA pethidine
Outcome: 4 Nausea and vomiting
Study or subgroup Pentazocine Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Erskine 1985 0/14 5/15 100.0 % 0.10 [ 0.01, 1.61 ]
Total (95% CI) 14 15 100.0 % 0.10 [ 0.01, 1.61 ]
Total events: 0 (Pentazocine), 5 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.63 (P = 0.10)
Test for subgroup differences: Not applicable
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Analysis 28.5. Comparison 28 PCA pentazocine versus PCA pethidine, Outcome 5 Maternal sleepiness
during labour (Sedation).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 28 PCA pentazocine versus PCA pethidine
Outcome: 5 Maternal sleepiness during labour (Sedation)
Study or subgroup Pentazocine Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Erskine 1985 0/14 2/15 100.0 % 0.21 [ 0.01, 4.09 ]
Total (95% CI) 14 15 100.0 % 0.21 [ 0.01, 4.09 ]
Total events: 0 (Pentazocine), 2 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.31)
Test for subgroup differences: Not applicable
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Analysis 28.6. Comparison 28 PCA pentazocine versus PCA pethidine, Outcome 6 Caesarean section.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 28 PCA pentazocine versus PCA pethidine
Outcome: 6 Caesarean section
Study or subgroup Pentazocine Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Erskine 1985 0/14 1/15 100.0 % 0.36 [ 0.02, 8.07 ]
Total (95% CI) 14 15 100.0 % 0.36 [ 0.02, 8.07 ]
Total events: 0 (Pentazocine), 1 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours pentazocine Favours pethidine
284Parenteral opioids for maternal pain management in labour (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 28.7. Comparison 28 PCA pentazocine versus PCA pethidine, Outcome 7 Breastfeeding at
discharge.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 28 PCA pentazocine versus PCA pethidine
Outcome: 7 Breastfeeding at discharge
Study or subgroup Pentazocine Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Erskine 1985 11/11 12/12 100.0 % 1.00 [ 0.85, 1.17 ]
Total (95% CI) 11 12 100.0 % 1.00 [ 0.85, 1.17 ]
Total events: 11 (Pentazocine), 12 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours pethidine Favours pentazocine
Analysis 28.8. Comparison 28 PCA pentazocine versus PCA pethidine, Outcome 8 Apgar score < 7 at 5
minutes.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 28 PCA pentazocine versus PCA pethidine
Outcome: 8 Apgar score < 7 at 5 minutes
Study or subgroup Pentazocine Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Erskine 1985 0/14 0/15 Not estimable
Total (95% CI) 14 15 Not estimable
Total events: 0 (Pentazocine), 0 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 29.1. Comparison 29 PCA remifentanil versus PCA pethidine, Outcome 1 Maternal pain score in
labour.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 29 PCA remifentanil versus PCA pethidine
Outcome: 1 Maternal pain score in labour
Study or subgroup Remifentanil Pethidine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Douma 2010 52 4.56 (2.4) 53 6.61 (2.3) 68.8 % -2.05 [ -2.95, -1.15 ]
Volikas 2001 9 28 (28) 8 51 (25) 31.2 % -23.00 [ -48.19, 2.19 ]
Total (95% CI) 61 61 100.0 % -8.59 [ -27.61, 10.44 ]
Heterogeneity: Tau2 = 136.73; Chi2 = 2.65, df = 1 (P = 0.10); I2 =62%
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Not applicable
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Analysis 29.2. Comparison 29 PCA remifentanil versus PCA pethidine, Outcome 2 Additional analgesia
required.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 29 PCA remifentanil versus PCA pethidine
Outcome: 2 Additional analgesia required
Study or subgroup Remifentanil Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Blair 2005 (1) 18/20 19/19 79.0 % 0.90 [ 0.76, 1.07 ]
Volikas 2001 (2) 4/9 5/8 21.0 % 0.71 [ 0.29, 1.76 ]
Total (95% CI) 29 27 100.0 % 0.86 [ 0.69, 1.08 ]
Total events: 22 (Remifentanil), 24 (Pethidine)
Heterogeneity: Chi2 = 0.45, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 1.30 (P = 0.19)
Test for subgroup differences: Not applicable
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(2) Entonox
Analysis 29.3. Comparison 29 PCA remifentanil versus PCA pethidine, Outcome 3 Epidural.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 29 PCA remifentanil versus PCA pethidine
Outcome: 3 Epidural
Study or subgroup Remifentanil Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Douma 2010 7/52 18/53 94.4 % 0.40 [ 0.18, 0.87 ]
Volikas 2001 1/9 1/8 5.6 % 0.89 [ 0.07, 12.00 ]
Total (95% CI) 61 61 100.0 % 0.42 [ 0.20, 0.89 ]
Total events: 8 (Remifentanil), 19 (Pethidine)
Heterogeneity: Chi2 = 0.34, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 2.25 (P = 0.024)
Test for subgroup differences: Not applicable
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Analysis 29.4. Comparison 29 PCA remifentanil versus PCA pethidine, Outcome 4 Maternal sleepiness
during labour.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 29 PCA remifentanil versus PCA pethidine
Outcome: 4 Maternal sleepiness during labour
Study or subgroup Remifentanil Pethidine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Douma 2010 52 1.85 (0.8) 53 1.45 (0.5) 100.0 % 0.40 [ 0.14, 0.66 ]
Total (95% CI) 52 53 100.0 % 0.40 [ 0.14, 0.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.07 (P = 0.0022)
Test for subgroup differences: Not applicable
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Analysis 29.5. Comparison 29 PCA remifentanil versus PCA pethidine, Outcome 5 Nausea and vomiting.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 29 PCA remifentanil versus PCA pethidine
Outcome: 5 Nausea and vomiting
Study or subgroup Remifentanil Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Douma 2010 20/51 23/51 97.8 % 0.87 [ 0.55, 1.37 ]
Volikas 2001 (1) 2/9 0/8 2.2 % 4.50 [ 0.25, 81.76 ]
Total (95% CI) 60 59 100.0 % 0.95 [ 0.61, 1.49 ]
Total events: 22 (Remifentanil), 23 (Pethidine)
Heterogeneity: Chi2 = 1.25, df = 1 (P = 0.26); I2 =20%
Test for overall effect: Z = 0.22 (P = 0.83)
Test for subgroup differences: Not applicable
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Analysis 29.6. Comparison 29 PCA remifentanil versus PCA pethidine, Outcome 6 Caesarean section.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 29 PCA remifentanil versus PCA pethidine
Outcome: 6 Caesarean section
Study or subgroup Remifentanil Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Douma 2010 7/45 3/35 76.1 % 1.81 [ 0.51, 6.52 ]
Volikas 2001 2/9 1/8 23.9 % 1.78 [ 0.20, 16.10 ]
Total (95% CI) 54 43 100.0 % 1.81 [ 0.60, 5.46 ]
Total events: 9 (Remifentanil), 4 (Pethidine)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 1.05 (P = 0.30)
Test for subgroup differences: Not applicable
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Analysis 29.7. Comparison 29 PCA remifentanil versus PCA pethidine, Outcome 7 Assisted vaginal birth.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 29 PCA remifentanil versus PCA pethidine
Outcome: 7 Assisted vaginal birth
Study or subgroup Remifentanil Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Douma 2010 10/45 8/35 81.0 % 0.97 [ 0.43, 2.20 ]
Volikas 2001 2/9 2/8 19.0 % 0.89 [ 0.16, 4.93 ]
Total (95% CI) 54 43 100.0 % 0.96 [ 0.46, 2.00 ]
Total events: 12 (Remifentanil), 10 (Pethidine)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.91)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours remifentanil Favours pethidine
Analysis 29.8. Comparison 29 PCA remifentanil versus PCA pethidine, Outcome 8 Satisfaction with
childbirth experience.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 29 PCA remifentanil versus PCA pethidine
Outcome: 8 Satisfaction with childbirth experience
Study or subgroup Remifentanil Pethidine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Douma 2010 38 8.1 (1.1) 30 7 (1.5) 100.0 % 1.10 [ 0.46, 1.74 ]
Total (95% CI) 38 30 100.0 % 1.10 [ 0.46, 1.74 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.37 (P = 0.00076)
Test for subgroup differences: Not applicable
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Analysis 29.9. Comparison 29 PCA remifentanil versus PCA pethidine, Outcome 9 Naloxone administered.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 29 PCA remifentanil versus PCA pethidine
Outcome: 9 Naloxone administered
Study or subgroup Remifentanil Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Blair 2005 0/20 0/19 Not estimable
Volikas 2001 0/9 1/8 100.0 % 0.30 [ 0.01, 6.47 ]
Total (95% CI) 29 27 100.0 % 0.30 [ 0.01, 6.47 ]
Total events: 0 (Remifentanil), 1 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
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Analysis 29.10. Comparison 29 PCA remifentanil versus PCA pethidine, Outcome 10 Apgar score < 7 at 5
minutes.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 29 PCA remifentanil versus PCA pethidine
Outcome: 10 Apgar score < 7 at 5 minutes
Study or subgroup Remifentanil Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Volikas 2001 0/9 3/8 100.0 % 0.13 [ 0.01, 2.16 ]
Total (95% CI) 9 8 100.0 % 0.13 [ 0.01, 2.16 ]
Total events: 0 (Remifentanil), 3 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 29.11. Comparison 29 PCA remifentanil versus PCA pethidine, Outcome 11 Admission to NICU.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 29 PCA remifentanil versus PCA pethidine
Outcome: 11 Admission to NICU
Study or subgroup Remifentanil Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Volikas 2001 0/9 1/8 100.0 % 0.30 [ 0.01, 6.47 ]
Total (95% CI) 9 8 100.0 % 0.30 [ 0.01, 6.47 ]
Total events: 0 (Remifentanil), 1 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
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Analysis 29.12. Comparison 29 PCA remifentanil versus PCA pethidine, Outcome 12 Newborn
neurobehavioural score (15 minutes post delivery).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 29 PCA remifentanil versus PCA pethidine
Outcome: 12 Newborn neurobehavioural score (15 minutes post delivery)
Study or subgroup Remifentanil Pethidine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Douma 2010 31 37 (2.2) 25 36.8 (2.1) 100.0 % 0.20 [ -0.93, 1.33 ]
Total (95% CI) 31 25 100.0 % 0.20 [ -0.93, 1.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Not applicable
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Analysis 29.13. Comparison 29 PCA remifentanil versus PCA pethidine, Outcome 13 Newborn
neurobehavioural score (2 hours post delivery).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 29 PCA remifentanil versus PCA pethidine
Outcome: 13 Newborn neurobehavioural score (2 hours post delivery)
Study or subgroup Remifentanil Pethidine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Douma 2010 30 37.8 (2) 26 37.2 (2.7) 100.0 % 0.60 [ -0.66, 1.86 ]
Total (95% CI) 30 26 100.0 % 0.60 [ -0.66, 1.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
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Analysis 30.1. Comparison 30 PCA nalbuphine versus PCA pethidine, Outcome 1 Maternal satisfaction
with analgesia in labour measured during the postnatal period (rated good or excellent).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 30 PCA nalbuphine versus PCA pethidine
Outcome: 1 Maternal satisfaction with analgesia in labour measured during the postnatal period (rated good or excellent)
Study or subgroup Nalbuphine Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Frank 1987 22/30 17/30 100.0 % 1.29 [ 0.88, 1.89 ]
Total (95% CI) 30 30 100.0 % 1.29 [ 0.88, 1.89 ]
Total events: 22 (Nalbuphine), 17 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)
Test for subgroup differences: Not applicable
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Analysis 30.2. Comparison 30 PCA nalbuphine versus PCA pethidine, Outcome 2 Maternal satisfaction
with analgesia in labour measured during the postnatal period (Would use the same pain relief again).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 30 PCA nalbuphine versus PCA pethidine
Outcome: 2 Maternal satisfaction with analgesia in labour measured during the postnatal period (Would use the same pain relief again)
Study or subgroup Nalbuphine Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Frank 1987 23/30 21/29 100.0 % 1.06 [ 0.79, 1.43 ]
Total (95% CI) 30 29 100.0 % 1.06 [ 0.79, 1.43 ]
Total events: 23 (Nalbuphine), 21 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable
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Analysis 30.3. Comparison 30 PCA nalbuphine versus PCA pethidine, Outcome 3 Maternal pain score or
pain measured in labour.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 30 PCA nalbuphine versus PCA pethidine
Outcome: 3 Maternal pain score or pain measured in labour
Study or subgroup Nalbuphine Pethidine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Frank 1987 (1) 30 2.1 (0.774) 30 2.5 (0.774) 100.0 % -0.40 [ -0.79, -0.01 ]
Total (95% CI) 30 30 100.0 % -0.40 [ -0.79, -0.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.00 (P = 0.045)
Test for subgroup differences: Not applicable
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(1) SD estimated from P value 0.05
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Analysis 30.4. Comparison 30 PCA nalbuphine versus PCA pethidine, Outcome 4 Additional analgesia
required.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 30 PCA nalbuphine versus PCA pethidine
Outcome: 4 Additional analgesia required
Study or subgroup Nalbuphine Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Frank 1987 (1) 12/30 14/29 100.0 % 0.83 [ 0.46, 1.48 ]
Total (95% CI) 30 29 100.0 % 0.83 [ 0.46, 1.48 ]
Total events: 12 (Nalbuphine), 14 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Not applicable
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Favours nalbuphine Favours pethidine
(1) Entonox
Analysis 30.5. Comparison 30 PCA nalbuphine versus PCA pethidine, Outcome 5 Nausea and vomiting.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 30 PCA nalbuphine versus PCA pethidine
Outcome: 5 Nausea and vomiting
Study or subgroup Nalbuphine Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Frank 1987 7/30 10/29 100.0 % 0.68 [ 0.30, 1.54 ]
Total (95% CI) 30 29 100.0 % 0.68 [ 0.30, 1.54 ]
Total events: 7 (Nalbuphine), 10 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
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Analysis 30.6. Comparison 30 PCA nalbuphine versus PCA pethidine, Outcome 6 Apgar score < 7 at 5
minutes.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 30 PCA nalbuphine versus PCA pethidine
Outcome: 6 Apgar score < 7 at 5 minutes
Study or subgroup Nalbuphine Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Frank 1987 (1) 0/18 1/23 100.0 % 0.42 [ 0.02, 9.76 ]
Total (95% CI) 18 23 100.0 % 0.42 [ 0.02, 9.76 ]
Total events: 0 (Nalbuphine), 1 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Not applicable
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Favours nalbuphine Favours pethidine
(1) Those babies delivered within 4 hrs of medication only
Analysis 31.1. Comparison 31 PCA fentanyl versus PCA alfentanil, Outcome 1 Maternal satisfaction with
analgesia in labour measured during the postnatal period (described as adequate).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 31 PCA fentanyl versus PCA alfentanil
Outcome: 1 Maternal satisfaction with analgesia in labour measured during the postnatal period (described as adequate)
Study or subgroup Fentanyl Alfentanil Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Morley-Forster 2000 10/11 7/12 100.0 % 1.56 [ 0.93, 2.60 ]
Total (95% CI) 11 12 100.0 % 1.56 [ 0.93, 2.60 ]
Total events: 10 (Fentanyl), 7 (Alfentanil)
Heterogeneity: not applicable
Test for overall effect: Z = 1.69 (P = 0.090)
Test for subgroup differences: Not applicable
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Analysis 31.2. Comparison 31 PCA fentanyl versus PCA alfentanil, Outcome 2 Maternal pain score or pain
measured in labour (Pain score at 4-6 cm cervical dilatation).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 31 PCA fentanyl versus PCA alfentanil
Outcome: 2 Maternal pain score or pain measured in labour (Pain score at 4-6 cm cervical dilatation)
Study or subgroup Fentanyl Alfentanil
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Morley-Forster 2000 11 54.9 (24.9) 10 67.7 (20.2) 100.0 % -12.80 [ -32.12, 6.52 ]
Total (95% CI) 11 10 100.0 % -12.80 [ -32.12, 6.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 31.3. Comparison 31 PCA fentanyl versus PCA alfentanil, Outcome 3 Nausea.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 31 PCA fentanyl versus PCA alfentanil
Outcome: 3 Nausea
Study or subgroup Fentanyl Alfentanil Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Morley-Forster 2000 5/11 2/12 100.0 % 2.73 [ 0.66, 11.30 ]
Total (95% CI) 11 12 100.0 % 2.73 [ 0.66, 11.30 ]
Total events: 5 (Fentanyl), 2 (Alfentanil)
Heterogeneity: not applicable
Test for overall effect: Z = 1.38 (P = 0.17)
Test for subgroup differences: Not applicable
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Analysis 31.4. Comparison 31 PCA fentanyl versus PCA alfentanil, Outcome 4 Caesarean section.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 31 PCA fentanyl versus PCA alfentanil
Outcome: 4 Caesarean section
Study or subgroup Fentanyl Alfentanil Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Morley-Forster 2000 3/11 2/12 100.0 % 1.64 [ 0.33, 8.03 ]
Total (95% CI) 11 12 100.0 % 1.64 [ 0.33, 8.03 ]
Total events: 3 (Fentanyl), 2 (Alfentanil)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Not applicable
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Favours fentanyl Favours alfentanil
Analysis 31.5. Comparison 31 PCA fentanyl versus PCA alfentanil, Outcome 5 Naloxone required.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 31 PCA fentanyl versus PCA alfentanil
Outcome: 5 Naloxone required
Study or subgroup Fentanyl Alfentanil Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Morley-Forster 2000 4/11 2/13 100.0 % 2.36 [ 0.53, 10.55 ]
Total (95% CI) 11 13 100.0 % 2.36 [ 0.53, 10.55 ]
Total events: 4 (Fentanyl), 2 (Alfentanil)
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
Test for subgroup differences: Not applicable
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Analysis 32.1. Comparison 32 PCA fentanyl versus PCA pethidine, Outcome 1 Maternla pain score
measured in labour.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 32 PCA fentanyl versus PCA pethidine
Outcome: 1 Maternla pain score measured in labour
Study or subgroup Fentanyl Pethidine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Douma 2010 54 5.96 (2.5) 53 6.61 (2.3) 100.0 % -0.65 [ -1.56, 0.26 ]
Total (95% CI) 54 53 100.0 % -0.65 [ -1.56, 0.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 32.2. Comparison 32 PCA fentanyl versus PCA pethidine, Outcome 2 Epidural.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 32 PCA fentanyl versus PCA pethidine
Outcome: 2 Epidural
Study or subgroup Fentanyl Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Douma 2010 8/54 18/53 100.0 % 0.44 [ 0.21, 0.92 ]
Total (95% CI) 54 53 100.0 % 0.44 [ 0.21, 0.92 ]
Total events: 8 (Fentanyl), 18 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.19 (P = 0.028)
Test for subgroup differences: Not applicable
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Analysis 32.3. Comparison 32 PCA fentanyl versus PCA pethidine, Outcome 3 Maternal sleepiness during
labour.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 32 PCA fentanyl versus PCA pethidine
Outcome: 3 Maternal sleepiness during labour
Study or subgroup Fentanyl Pethidine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Douma 2010 54 1.39 (0.5) 53 1.45 (0.5) 100.0 % -0.06 [ -0.25, 0.13 ]
Total (95% CI) 54 53 100.0 % -0.06 [ -0.25, 0.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.53)
Test for subgroup differences: Not applicable
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Analysis 32.4. Comparison 32 PCA fentanyl versus PCA pethidine, Outcome 4 Nausea and vomiting.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 32 PCA fentanyl versus PCA pethidine
Outcome: 4 Nausea and vomiting
Study or subgroup Fentanyl Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Douma 2010 20/51 23/51 100.0 % 0.87 [ 0.55, 1.37 ]
Total (95% CI) 51 51 100.0 % 0.87 [ 0.55, 1.37 ]
Total events: 20 (Fentanyl), 23 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Not applicable
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Analysis 32.5. Comparison 32 PCA fentanyl versus PCA pethidine, Outcome 5 Caesarean section.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 32 PCA fentanyl versus PCA pethidine
Outcome: 5 Caesarean section
Study or subgroup Fentanyl Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Douma 2010 1/46 3/35 100.0 % 0.25 [ 0.03, 2.34 ]
Total (95% CI) 46 35 100.0 % 0.25 [ 0.03, 2.34 ]
Total events: 1 (Fentanyl), 3 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 32.6. Comparison 32 PCA fentanyl versus PCA pethidine, Outcome 6 Assisted vaginal birth.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 32 PCA fentanyl versus PCA pethidine
Outcome: 6 Assisted vaginal birth
Study or subgroup Fentanyl Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Douma 2010 6/46 8/35 100.0 % 0.57 [ 0.22, 1.49 ]
Total (95% CI) 46 35 100.0 % 0.57 [ 0.22, 1.49 ]
Total events: 6 (Fentanyl), 8 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.25)
Test for subgroup differences: Not applicable
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Analysis 32.7. Comparison 32 PCA fentanyl versus PCA pethidine, Outcome 7 Newborn neurobehavioural
score (15 minutes post delivery).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 32 PCA fentanyl versus PCA pethidine
Outcome: 7 Newborn neurobehavioural score (15 minutes post delivery)
Study or subgroup Fentanyl Pethidine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Douma 2010 (1) 38 35.9 (3.6) 25 36.8 (2.1) 100.0 % -0.90 [ -2.31, 0.51 ]
Total (95% CI) 38 25 100.0 % -0.90 [ -2.31, 0.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.25 (P = 0.21)
Test for subgroup differences: Not applicable
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(1) Neurologic and Adaptive Capacity Score - 40 maximum score, >30 reassuring. High scores = positive result
Analysis 32.8. Comparison 32 PCA fentanyl versus PCA pethidine, Outcome 8 Newborn neurobehavioural
score (2 hours post delivery).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 32 PCA fentanyl versus PCA pethidine
Outcome: 8 Newborn neurobehavioural score (2 hours post delivery)
Study or subgroup Fentanyl Pethidine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Douma 2010 (1) 38 36.7 (3.2) 26 37.2 (2.7) 100.0 % -0.50 [ -1.95, 0.95 ]
Total (95% CI) 38 26 100.0 % -0.50 [ -1.95, 0.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Not applicable
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(1) Neurologic and Adaptive Capacity Score - 40 maximum score, >30 reassuring. High scores = positive result
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Analysis 33.1. Comparison 33 PCA (IM) meptazinol versus PCA (IM) pethidine, Outcome 1 Maternal pain
score or pain measured in labour (measured 1 day after delivery).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 33 PCA (IM) meptazinol versus PCA (IM) pethidine
Outcome: 1 Maternal pain score or pain measured in labour (measured 1 day after delivery)
Study or subgroup Meptazinol Pethidine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Li 1988 5 60.2 (29) 5 77.8 (22.8) 100.0 % -17.60 [ -49.93, 14.73 ]
Total (95% CI) 5 5 100.0 % -17.60 [ -49.93, 14.73 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.29)
Test for subgroup differences: Not applicable
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Analysis 33.2. Comparison 33 PCA (IM) meptazinol versus PCA (IM) pethidine, Outcome 2 Satisfied with
mode of administration (PCA IM) (non pre-specified).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 33 PCA (IM) meptazinol versus PCA (IM) pethidine
Outcome: 2 Satisfied with mode of administration (PCA IM) (non pre-specified)
Study or subgroup Meptazinol Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Li 1988 5/5 5/5 100.0 % 1.00 [ 0.71, 1.41 ]
Total (95% CI) 5 5 100.0 % 1.00 [ 0.71, 1.41 ]
Total events: 5 (Meptazinol), 5 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 33.3. Comparison 33 PCA (IM) meptazinol versus PCA (IM) pethidine, Outcome 3 Epidural.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 33 PCA (IM) meptazinol versus PCA (IM) pethidine
Outcome: 3 Epidural
Study or subgroup Meptazinol Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Li 1988 1/5 0/5 100.0 % 3.00 [ 0.15, 59.89 ]
Total (95% CI) 5 5 100.0 % 3.00 [ 0.15, 59.89 ]
Total events: 1 (Meptazinol), 0 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Not applicable
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Analysis 33.4. Comparison 33 PCA (IM) meptazinol versus PCA (IM) pethidine, Outcome 4 Maternal
sleepiness in labour (Drowsiness score in labour rated 1 day after delivery).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 33 PCA (IM) meptazinol versus PCA (IM) pethidine
Outcome: 4 Maternal sleepiness in labour (Drowsiness score in labour rated 1 day after delivery)
Study or subgroup Meptazinol Pethidine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Li 1988 (1) 5 57.4 (38.4) 5 51.8 (3.4) 100.0 % 5.60 [ -28.19, 39.39 ]
Total (95% CI) 5 5 100.0 % 5.60 [ -28.19, 39.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
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(1) SD in pethidine group as reported in published paper (extremely small)
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Analysis 33.5. Comparison 33 PCA (IM) meptazinol versus PCA (IM) pethidine, Outcome 5 Nausea (score
in labour rated 1 day after delivery).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 33 PCA (IM) meptazinol versus PCA (IM) pethidine
Outcome: 5 Nausea (score in labour rated 1 day after delivery)
Study or subgroup Meptazinol Pethidine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Li 1988 5 30.6 (28.7) 5 38.6 (36.5) 100.0 % -8.00 [ -48.70, 32.70 ]
Total (95% CI) 5 5 100.0 % -8.00 [ -48.70, 32.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
Test for subgroup differences: Not applicable
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Analysis 33.6. Comparison 33 PCA (IM) meptazinol versus PCA (IM) pethidine, Outcome 6 Naloxone
administered.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 33 PCA (IM) meptazinol versus PCA (IM) pethidine
Outcome: 6 Naloxone administered
Study or subgroup Meptazinol Pethidine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Li 1988 1/5 1/5 100.0 % 1.00 [ 0.08, 11.93 ]
Total (95% CI) 5 5 100.0 % 1.00 [ 0.08, 11.93 ]
Total events: 1 (Meptazinol), 1 (Pethidine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 34.1. Comparison 34 Opioids versus TENS, Outcome 1 Maternal satisfaction with analgesia
measured post delivery (rated as good).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 34 Opioids versus TENS
Outcome: 1 Maternal satisfaction with analgesia measured post delivery (rated as good)
Study or subgroup Opioids TENS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Neumark 1978 2/5 2/9 7.2 % 1.80 [ 0.35, 9.16 ]
Tawfik 1982 28/55 15/35 92.8 % 1.19 [ 0.75, 1.89 ]
Total (95% CI) 60 44 100.0 % 1.23 [ 0.79, 1.92 ]
Total events: 30 (Opioids), 17 (TENS)
Heterogeneity: Chi2 = 0.23, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Not applicable
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Analysis 34.2. Comparison 34 Opioids versus TENS, Outcome 2 Maternal pain score measured during
labour.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 34 Opioids versus TENS
Outcome: 2 Maternal pain score measured during labour
Study or subgroup Opioids TENS Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Tawfik 1982 38/55 17/35 38.5 % 1.42 [ 0.97, 2.09 ]
Thakur 2004 70/100 70/100 61.5 % 1.00 [ 0.83, 1.20 ]
Total (95% CI) 155 135 100.0 % 1.15 [ 0.81, 1.61 ]
Total events: 108 (Opioids), 87 (TENS)
Heterogeneity: Tau2 = 0.04; Chi2 = 2.76, df = 1 (P = 0.10); I2 =64%
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
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Analysis 34.3. Comparison 34 Opioids versus TENS, Outcome 3 Maternal pain score in labour.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 34 Opioids versus TENS
Outcome: 3 Maternal pain score in labour
Study or subgroup Opioids TENS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Pain score (after 30 minutes)
Liu 2015 30 51 (11) 30 71 (13) 100.0 % -20.00 [ -26.09, -13.91 ]
Subtotal (95% CI) 30 30 100.0 % -20.00 [ -26.09, -13.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.43 (P < 0.00001)
2 Pain score (after 60 minutes)
Liu 2015 30 45 (8) 30 65 (12) 100.0 % -20.00 [ -25.16, -14.84 ]
Subtotal (95% CI) 30 30 100.0 % -20.00 [ -25.16, -14.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.60 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 1.00), I2 =0.0%
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Analysis 34.4. Comparison 34 Opioids versus TENS, Outcome 4 Maternal sleepiness during labour
(Drowsiness).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 34 Opioids versus TENS
Outcome: 4 Maternal sleepiness during labour (Drowsiness)
Study or subgroup Opioids TENS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tawfik 1982 9/55 0/35 54.9 % 12.21 [ 0.73, 203.45 ]
Thakur 2004 2/100 0/100 45.1 % 5.00 [ 0.24, 102.85 ]
Total (95% CI) 155 135 100.0 % 8.96 [ 1.13, 71.07 ]
Total events: 11 (Opioids), 0 (TENS)
Heterogeneity: Chi2 = 0.19, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 2.08 (P = 0.038)
Test for subgroup differences: Not applicable
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Analysis 34.5. Comparison 34 Opioids versus TENS, Outcome 5 Nausea and vomiting.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 34 Opioids versus TENS
Outcome: 5 Nausea and vomiting
Study or subgroup Opioids TENS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Liu 2015 6/30 0/30 31.1 % 13.00 [ 0.76, 220.96 ]
Tawfik 1982 6/55 0/35 37.8 % 8.36 [ 0.49, 143.87 ]
Thakur 2004 10/100 0/100 31.1 % 21.00 [ 1.25, 353.58 ]
Total (95% CI) 185 165 100.0 % 13.73 [ 2.72, 69.24 ]
Total events: 22 (Opioids), 0 (TENS)
Heterogeneity: Chi2 = 0.21, df = 2 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 3.17 (P = 0.0015)
Test for subgroup differences: Not applicable
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Analysis 34.6. Comparison 34 Opioids versus TENS, Outcome 6 Caesarean section.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 34 Opioids versus TENS
Outcome: 6 Caesarean section
Study or subgroup Opioids TENS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Liu 2015 2/30 1/30 100.0 % 2.00 [ 0.19, 20.90 ]
Thakur 2004 0/100 0/100 Not estimable
Total (95% CI) 130 130 100.0 % 2.00 [ 0.19, 20.90 ]
Total events: 2 (Opioids), 1 (TENS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable
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Analysis 34.7. Comparison 34 Opioids versus TENS, Outcome 7 Assisted vaginal birth.
Review: Parenteral opioids for maternal pain management in labour
Comparison: 34 Opioids versus TENS
Outcome: 7 Assisted vaginal birth
Study or subgroup Opioids TENS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Liu 2015 2/30 2/30 80.0 % 1.00 [ 0.15, 6.64 ]
Thakur 2004 2/100 0/100 20.0 % 5.00 [ 0.24, 102.85 ]
Total (95% CI) 130 130 100.0 % 1.80 [ 0.40, 8.18 ]
Total events: 4 (Opioids), 2 (TENS)
Heterogeneity: Chi2 = 0.81, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 34.8. Comparison 34 Opioids versus TENS, Outcome 8 Fetal heart rate changes in labour (Fetal
distress).
Review: Parenteral opioids for maternal pain management in labour
Comparison: 34 Opioids versus TENS
Outcome: 8 Fetal heart rate changes in labour (Fetal distress)
Study or subgroup Opioids TENS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Thakur 2004 2/100 0/100 100.0 % 5.00 [ 0.24, 102.85 ]
Total (95% CI) 100 100 100.0 % 5.00 [ 0.24, 102.85 ]
Total events: 2 (Opioids), 0 (TENS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Not applicable
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A P P E N D I C E S
Appendix 1. Search terms for ICTRP and ClinicalTrials.gov
(intravenous OR intramuscular OR opioids or opioid) AND (birth OR labour OR labor)
WH A T ’ S N E W
Date Event Description
11 May 2017 New search has been performed Search updated, 70 new reports assessed. ’Summary of
findings’ tables have been incorporated in this update
11 May 2017 New citation required but conclusions have not changed We included 13 new trials in this update. We also ex-
cluded a further 34 trials, identified five ongoing studies
and added two to the awaiting classification section. Al-
together, the review now includes 70 trials
H I S T O R Y
Protocol first published: Issue 4, 2008
Review first published: Issue 9, 2010
Date Event Description
21 June 2011 New search has been performed Search updated. We have included data from three new studies (Douma 2010;
Tawfik 1982; Thakur 2004). These changes have not altered the conclusions of
the review
New outcome added - see Differences between protocol and review.
C O N T R I B U T I O N S O F A U T H O R S
In this 2017 version of the review, Anna Cuthbert and Lesley Smith assessed eligibility and carried out data extraction. Lesley Smith
and Ethel Burns updated the background and discussion.
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D E C L A R A T I O N S O F I N T E R E S T
Lesley A Smith: none known.
Ethel Burns: none known.
Anna Cuthbert: is supported by a grant to her Institution from WHO to work on this review, and has received support via an NIHR
grant to her Institution to work on other Cochrane reviews.
S O U R C E S O F S U P P O R T
Internal sources
• (AC) The University of Liverpool, UK.
External sources
• National Institute for Health Research, UK.
2010 Update - NIHR NHS Cochrane Collaboration Programme Grant Scheme award for NHS-prioritised centrally-managed,
pregnancy and childbirth systematic reviews:CPGS02
• 2017 Update - WHO UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and
Research Training in Human Reproduction (HRP), Department of Reproductive Health and Research (RHR), World Health
Organization, Switzerland.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The Background section of the review has been updated and amended since publication of the protocol and has been revised for this
update.
The focus of some of the reports we identified using the search strategy was on the route of administration, rather than on the
effectiveness of opioids compared with placebo or other opioids. That is, in several trials, women in both arms received the same opioid
and the same dose but the drug was given by a different route (e.g. intravenous (staff administered) versus patient-controlled analgesia,
or intramuscular versus intravenous). Although in the original protocol we had specified that we would examine different routes, in
retrospect we thought that including such comparisons would add several more potentially large sections to the review (each report
requiring a different comparison) and would throw little light on the main review questions: whether opioids are effective for pain relief
in labour without causing unpleasant side effects or harm to mothers and babies. Studies focusing on route of administration will be
examined in the future in a separate, related Cochrane review.
For the 2017 update, we split the outcome “Additional analgesia: Epidural” into two separate outcomes: “Additional analgesia required”
and “Epidural”. This meant we were able to capture second doses of study drugs that were already reported in the previous update. The
review now includes GRADE methods and one new ‘Summary of findings’ table. Given the nature of this review, with many different
comparisons and small sample sizes, we also added an additional table with GRADE including all outcomes relating to pain.
The previous update of this review was one of a series of reviews included in an overview of reviews examining methods of pain
management in labour Jones 2012. It has been updated to follow the generic protocol developed in 2011 for reviews contributing to
the overview (Jones 2011), as a result of which we have added a new comparison (opioids versus TENS).
For the 2017 update, we added in a search of ClinicalTrials.gov and theWHO International Clinical Trials Registry Platform ( ICTRP).
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Analgesia, Obstetrical [∗methods]; Analgesics, Opioid [∗administration & dosage; adverse effects]; Injections, Intramuscular; Injec-
tions, Intravenous; Labor Pain [∗drug therapy]; Meperidine [administration & dosage]; Randomized Controlled Trials as Topic; Tran-
scutaneous Electric Nerve Stimulation
MeSH check words
Female; Humans; Pregnancy
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